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Gastrointestinal cancer is a type of disease characterized by increased cell growth combined 
with the ability of these cells to spread to or invade other parts of the body. Intestinal 
cancer is one of the leading causes of morbidity and mortality worldwide. In clinical 
practice, gastroenterologists are often confronted with premalignant tissues or cancer. As 
populations in Western countries age, the treatment options for cancer will become even 
more relevant. Therefore, it is important to understand the etiology of gastrointestinal 
cancer and identify novel avenues for the rational treatment of this disease.
Barrett’s esophagus and esophageal cancer
Esophageal cancer is the eighth most common cancer worldwide, with approximately 
398,000 people diagnosed with squamous cell carcinoma (SCC) and 52,000 with 
esophageal adenocarcinoma (EAC) in 2012. This corresponds with incidence rates of 
5.2 and 0.7 per 100,000 population, respectively (1). EACs develop from metaplastic 
Barrett’s esophagus (BE) located in the lower esophagus and SCC develops from the 
squamous epithelium (2). Both histological types have dysplasia as their precursor. Recent 
epidemiological data indicate that 79% of SCCs worldwide occur in Southeastern and 
Central Asia, whereas 46% of people with EACs are diagnosed in Northern and Western 
Europe, North America, and Oceania. In general, the incidence of esophageal cancer is 
higher in men compared to women, especially in EACs, for which the male to female ratio 
is 4.4:1, compared to 2.7:1 for SCC (1). In the past decades, developed countries have 
seen an increase in the incidence of EAC, attributed to the higher prevalence of obesity 
(3). On the other hand, the decreasing incidence of SCC in these contexts correlates 
with the decline in smoking (4). By 2030, it is predicted that 1 in each 100 men in the 
Netherlands and the United Kingdom will be diagnosed with EAC during their lifetime 
(5). SCC remains most common in low- and middle-income countries, including in 
Africa and Eastern Asia (6). Almost half of people with esophageal carcinoma have 
distant disease at the time of diagnosis and treatment of this group is at present limited 
to palliative strategies only (7).
Endoscopic therapy may be an option for early esophageal cancers. Surgical resection is 
a potentially curative treatment for esophageal cancer, but it is only feasible in people 
who are fit for surgery, have locally resectable disease, and show no signs of distant 
metastases. Unfortunately, most people develop recurrent tumor growth within the first 
few years after surgery. Palliative care is the only option for metastatic disease, with a 
five-year survival rate of less than three percent (8). Palliative therapy aims to control 
tumor growth and increase survival without significantly decreasing quality of life.
BE is a premalignant condition of the distal esophagus. In BE, the pre-existent squamous 
epithelium is replaced by columnar epithelium which develops under the influence of 
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gastroesophageal reflux disease (GERD), and frequently contains goblet cells (9-11). The 
progression from BE to EAC is a gradual process, in which intestinal metaplasia (IM) 
evolves to low-grade dysplasia (LGD), high-grade dysplasia (HGD) and eventually EAC 
(12). In Western countries, the prevalence of BE has increased dramatically since the 
1970s (13), which explains the increasing incidence of EAC. This increasing incidence 
makes it paramount to improve understanding of the etiology of this disease.
Colorectal cancer
Colorectal cancer (CRC) is one of the leading contributors to cancer mortality 
worldwide (14, 15). In the United States CRC accounts for 8% of new cancer cases 
and also for 8% of deaths due to cancer in both males and females (14). In Europe 
CRC is the second most common cancer (15). The majority of CRCs are sporadic 
rather than familial (16). Environmental factors that are involved in the pathogenesis of 
CRC include obesity, smoking, diet, and low physical activity (17). In the past decades, 
there has been a decline in the incidence rate of CRC, probably due to changes in 
occurrence of risk factors and, more importantly, screening for premalignant lesions 
with colonoscopy (18). Increased use of colonoscopy since 2000 has led to a more rapid 
decline of CRC incidence because some premalignant lesions are resected, being mostly 
colonic adenomas (19). Colonic adenomas are premalignant epithelial tumors with a 
glandular origin or with glandular characteristics. Adenomas grow in different ways, 
namely tubular, villous, or tubulovillous (20). The villous type is found in larger polyps 
and has a higher potential of malignant transformation (21, 22). About thirty years 
ago Vogelstein et al. described the importance of premalignant lesions and their role in 
the adenoma-carcinoma sequence (23). The prevalence of these premalignant lesions is 
considered 25 percent at the age of 50 years and increases up to 50 percent at the age 
of 70 years (24-27). Obviously, not all adenomas will lead to colorectal carcinomas. 
Thus, most screened patients are overtreated by removal of the adenomas. In some 
screened patients colorectal cancer will develop even though adenomas were removed 
(28). Identifying the molecular aberrations in the removed adenomas might provide 
information on the malignant potential and could lead to better understanding of 
colorectal cancer development. 
Pancreatic cancer
Pancreatic cancer is a disease affecting roughly 40,000 people each year. Survival is very 
poor, of the 15 – 20% of patients whom are eligible for curative therapy by surgery, 
5-year survival is below 20% (29-31). Pancreatic cancer has two types of precursor 
lesions, the pancreatic cystic neoplasms (PCN) and pancreatic intraepithelial neoplasias 
(PanIN). Pancreatic cystic neoplasms can be categorized into 4 types, with intraductal 
papillary mucinous neoplasms and mucinous cystic neoplasms showing a high malignant 









more favorable prognosis (32, 33). Development of pancreatic cancer can be prevented 
by resection of the cysts with high-risk malignant potential. Unfortunately, current 
imaging and diagnostic techniques have difficulty distinguishing low-risk cysts from 
high-risk and transformed cysts, which in some cases leads to unnecessary surgery. Thus, 
better diagnostic tools are urgently needed. 
HOX genes in the etiology of  GI-tract cancers
Given the large disease burden of GI-tract cancer and the limited understanding of its 
etiology, we decided to investigate its molecular etiology. In this thesis, we concentrated 
these efforts on HOX gene function in these pathologies, below we explain why.
Barrett’s esophagus
As stated above, premalignant metaplasia constitutes the precursor lesion for many 
gastrointestinal cancers. Ever since the opening lecture of Rudolph Virchow “on 
metaplasia” at the eighth International Medical Congress, in 1884 at Copenhagen, 
the field has been characterized by a lack of consensus on the definition, origin, and 
molecular biology of metaplasia. 
The most striking feature of upper GI tract metaplasia is its aberrant morphology. BE 
appears to involve the acquisition of a posterior phenotype by anterior gut epithelium 
through a process of homeotic transformation. Misinterpretation of positional 
information is likely to be involved in the pathogenesis of this disease. The same holds 
true for other types of metaplasia and heterotopias such as gastric metaplasia, Paneth 
cell metaplasia and prepyloric metaplasia in the colon, the gastric inlet patch, and gastric 
heterotopia in the Meckels diverticulum, all of which were studied in this thesis. 
In general, regulation of anterior to posterior patterning of specialized tissue is largely 
dependent on the concerted action of two evolutionary highly conserved gene systems, 
the Caudal-related Homeobox (CDX) transcription factor gene family and the genes of 
the Homeobox (HOX) cluster. The function of CDX genes has been studied extensively 
in the context of BE (34-39). In that context, HOX genes have barely been studied, but 
HOX genes have been linked to homeotic transformations in general (40).
HOX genes are grouped in the A, B, C, and D clusters. The 3’ to 5’ sequence of the 
HOX genes in a single HOX cluster, i.e. paralogues, corresponds to the sequence in 
which the paralogues act along bodies length axes. This property, termed collinearity, 
links clustering to function. HOX genes encode transcriptional regulatory proteins that 
control organogenesis, maintain tissue homeostasis and are key drivers of developmental 
processes (41, 42). In addition, HOX proteins have shown to be associated with worse 
prognosis for patients with gastric and esophageal squamous cell carcinoma (43, 44). 
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Previously, a Hox gene expression gradient was established along the murine embryonic 
gut (45). The presence of a rough HOX gradient along the adult human gut has been 
established by Yahagi et al. in 2004 (46). It is clear that ectopic expression of Hox genes 
in mice can interfere with intestinal organogenesis (47, 48). Furthermore, di Pietro 
et al. (49) explored the expression of mid cluster HOXB genes in human BE, normal 
esophagus, and other GI epithelia amongst which colon epithelium. They concluded 
that in BE the mid cluster HOXB gene expression resembled HOXB expression in the 
colon. The cluster with the highest potential for being implicated in BE seems to be 
cluster A (43, 44, 50). Additionally, it was found that conditions of GERD, mimicked in 
vitro, did not induce HOXB genes (49). These observations prompt further investigation 
into the role of HOX genes in the Barrett’s process.
Barrett’s esophagus model systems
The process of conversion of normal squamous epithelium towards Barrett’s metaplasia 
is difficult to monitor directly under clinical conditions. This has impeded the progress 
of the field. Thus, over the years, several experimental models have been published 
to investigate the mechanisms of BE pathogenesis. However, either the technical 
possibilities or the translational relevance of these models, or both, is limited. There is 
a continuing need for more and better model systems. In this thesis, several new model 
systems are described to facilitate the study of Barrett’s esophagus etiology. These are a 
cell culture based, bile and acid exposure model, a stem cell differentiation based model, 
and an ex vitro in vivo model. 
Squamous esophagus
The disease etiology of esophageal squamous cell carcinoma (ESCC) is still poorly 
understood. However, a possible role for HOX genes in ESCC development is emerging. 
HOXA13 overexpression has been detected in human ESCC tissue (51), and in other 
types of cancer like gastric cancer, cervical cancer, ovarian cancer and prostate carcinoma 
(52-55). High HOXA13 protein expression is correlated with a shorter median survival 
time in ESCC patients (56) and poor clinicopathological characteristics of patients (57). 
The expression profile of HOXA13, ANXA2 and SOD2 was suggested as predictive 
marker of the postoperative outcome of patients with ESCC (58). Expression of FGF2, 
the normal morphogen of HOXA13, also correlates with poor survival of patients with 
ESCC (59). Much is still unclear on how HOXA13 exerts these effects in ESCC. 
Colon
In acute myeloid leukemia (AML) a translocation encoding the NUP98-HOXA9 
oncogene results in overexpression of HOXA9 (60). This HOXA9 expression is the 









hematopoietic malignancies, HOXA9 has a pro-oncogenic effect in epithelial ovarian 
cancer, osteosarcoma, breast, and oral squamous cell cancer (62-65). Moreover, an 
upregulation of HOXA9 has been described in CRC (66, 67). Upregulation of HOXA9 
in premalignant colonic tissues is unclear, as well as its potential function. 
Screening and surveillance
After being informed on the etiology of GI-tract cancers, it is important to develop 
high quality screening and surveillance tools to detect patients whom are at risk, and 
estimate their risk of progression to malignancy. These tools have the potential to 
prevent malignant disease and can theoretically prevent nearly all the disease burden 
in the population. The estimated incidence of EAC in patients with BE is around 
0.12% to 0.38% per year (68-71). This relatively low annual risk reinforces the need 
for risk stratification tools to make BE surveillance more effective. BE length, male 
gender, smoking, and LGD are known risk factors for progression to HGD and EAC 
(68, 71-74). Two large population studies confirmed that patients with LGD have an 
approximately five times higher risk of progression compared to patients with non-
dysplastic BE (68, 71). Thus, surveillance that is more intensive is recommended in BE 
patients with LGD (75, 76). However, the histological diagnosis of LGD is subject to 
a considerable inter- and intra-observer variation, because of sample error and overlap 
with features of non-neoplastic regenerative changes (77-80). 
Because none of the current clinical and histologic criteria is able to accurately predict 
which patients are likely to progress to HGD or EAC, there is an increasing interest 
in (molecular) biomarkers. Many immunohistochemical (IHC) biomarkers have been 
studied in BE progression, mainly because they can be applied to standard histological 
samples. In clinical practice, IHC biomarkers are relatively easily applicable compared 
to other techniques. Currently, the addition of p53 IHC to the histological assessment 
is recommended in the guideline of the British Society of Gastroenterology as it may 
improve the diagnostic reproducibility of a histological diagnosis of LGD (75). The 
use of IHC biomarkers as independent predictor of neoplastic progression is not yet 
performed in routine clinical care, neither for p53, nor for other IHC biomarkers. 
Current guidelines recommend endoscopic surveillance in BE patients to detect HGD 
or EAC at an early stage, with the aim to improve survival rates (75, 76). Several studies 
have shown that patients diagnosed with EAC during BE surveillance have earlier staged 




Palliative care for esophageal cancer
In daily practice, clinicians often offer palliative chemotherapy to control tumor growth, 
increase quality of life, and increase life expectancy. Clinicians have the option to choose 
from cytostatic therapies, which are directed against fast dividing cells in general, or 
from targeted therapies directed against specific molecules needed for carcinogenesis 
and tumor growth. The most extensively used agents for this disease are 5-fluorouracil 
(5-FU) and cisplatin, which are included in most combination chemotherapy regimens. 
However, the chemotherapy agents used in randomized controlled trials are very 
heterogeneous. Researchers have examined targeted therapies as palliative treatment 
for a decade (85). People treated with these anti-neoplastic agents generally experience 
fewer side effects compared to people treated with classic cytotoxic chemotherapies. 
Palliative chemotherapy and/or targeted therapies are widely accepted treatment 
options. However, with the exception of ramucirumab, evidence for the efficacy of 
palliative treatment for esophageal and gastroesophageal junction cancer is lacking. 
Due to the limited availability of relevant data, summarizing the available evidence 
could increase insight into whether chemotherapy and targeted therapies are justifiably 
being prescribed to people with advanced or metastatic esophageal or gastroesophageal 
junction (GEJ) cancer.
The use of biologicals in palliative oncology is expanding at a rapid pace. These new 
therapeutic agents may improve patients’ survival and quality of life. However, the 
money spend on biologicals is expected to increase at a faster rate than the overall 
spending growth on pharmaceuticals and is projected to represent roughly one fifth 
of the total costs in 2017 (86). It would be beneficial for drug companies, policy 
makers, physicians, and patients alike when the cost-effectiveness of these biologicals 
would become apparent at an early stage of development. ESCC is a good example of a 
carcinoma for which biologicals are being studied in palliative phase II studies.
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The overall aim of this thesis is to increase our understanding of the etiology, the 
detection, and the palliative treatment of gastrointestinal (GI) cancers. This thesis is 
divided into five parts. 
Part 1 contains the introduction of this thesis. Chapter 1.1 describes the general 
introduction on intestinal cancer, focusing on Barrett’s esophagus and esophageal cancer, 
colorectal cancer, and pancreatic cancer. Additionally, it focuses on HOX genes in the 
etiology of gastrointestinal tract cancers, screening and surveillance, and palliative care. 
Chapter 1.2 describes the outline of this thesis. 
Part 2 describes investigations into the involvement of HOX genes in the etiology of 
(pre)malignant lesions of the GI tract. In Chapter 2 the involvement of HOX genes 
was studied in esophageal carcinogenesis. We show the adult gut is characterized by 
HOX collinearity. In BE, HOX expression is reprogrammed to a distal pattern in stem 
and differentiated cells, characterized by prominent HOXA13 expression. Strikingly, 
HOXA13 was found to be expressed in the adult physiological gastroesophageal junction. 
In a model of the cell of origin of BE, HOXA13 confers a relative competitive advantage 
and a pro-oncogenic expression profile. In a BE model, HOXA13 downregulates the 
epidermal differentiation complex, increases proliferation, and conveys phenotypical 
aspects of BE. We concluded, HOXA13 helps explain the etiology, phenotype, and 
oncogenic potential of BE. Chapter 3 studies the oncogenic hallmarks HOXA13 confers 
to esophageal keratinocytes. In this context, it provides a proliferation advantage to 
keratinocytes, reduces sensitivity to chemical agents, regulates MHC class I expression, 
and differentiation status, and promotes cellular migration. Chapter 4 focusses on the 
role of HOXA9 in colonic adenomas. HOXA9 levels are increased in colonic adenomas 
compared to location matched healthy tissue. It inhibits cellular migration, which appears 
to be mediated by decreased PAK activity. Strikingly, the pro-oncogenic phenotype of 
HOXA9 alteration in hematologic malignancies was also found in this study as HOXA9 
stimulates cell growth. This phenotype appears to be mediated through increased IGF1, 
FLT3, PTGS2, p-4E-BP1, and p-ERK1/2. In conjunction, these data identify HOX as 
a pivotal mediator of the etiology and behavior of malignancies in the GI-tract. 
Part 3 focusses on predicting the development of malignant lesions. Chapter 5 studies 
vitamin D receptor polymorphisms and shows these are associated with reduced 
esophageal vitamin D receptor expression and reduced esophageal adenocarcinoma risk. 
In Chapter 6.1 the existing literature is systematically reviewed regarding the value of 
immunohistochemical biomarkers for predicting neoplastic progression in BE patients 
and a meta-analysis is performed for the biomarkers investigated multiple times in 
independent studies. Aberrant p53 expression in BE patients appeared to be associated 
with a significantly increased risk of neoplastic progression for both non-dysplastic and 
LGD BE patients. Chapter 6.2 contains a letter to the editor in response to a review 
and meta-analysis in which studies were included without follow-up, which were used 
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to assess the value of p53 as a biomarker. In Chapter 7 we focus our attention on DNA-
based molecular biomarkers, and investigate whether DNA integrity may serve as a basis 
to predict malignant transformation in premalignant lesions of the pancreas. Chapter 8 
optimized and established in vitro and in vivo BE models which aid in the investigation 
of the etiology of malignant lesions.
Part 4 investigates palliative treatment of esophageal cancer. Chapter 9 studies palliative 
chemotherapy and targeted therapies for esophageal and GEJ cancer. People who receive 
more chemotherapeutic or targeted therapeutic agents have an increased overall survival 
compared to people who receive less. With the exception of ramucirumab, it remains 
unclear which other individual agents cause the survival benefit. Although treatment-
associated toxicities of grade 3 or more occurred more frequently, there is no evidence 
that palliative chemotherapy and/or targeted therapy decrease quality of life. Chapter 10 
investigates the cost-effectiveness of cetuximab for advanced esophageal squamous cell 
carcinoma, based on phase II trial data. It shows that the addition of cetuximab is not 
cost-effective. This also shows that phase II trial data can be used for cost-effectiveness 
assessments. 
Part 5 contains a summary and general discussion of the main findings of this thesis in 
Chapter 11. Chapter 12 contains a Dutch summary and Chapter 13 consists out of 
the appendices.
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Abstract
Barrett’s esophagus in gastrointestinal reflux patients constitutes a columnar epithelium 
with distal characteristics, prone to progress to esophageal adenocarcinoma. HOX 
genes are known mediators of position-dependent morphology. Here we show HOX 
collinearity in the adult gut while Barrett’s esophagus shows high HOXA13 expression in 
stem cells and their progeny. HOXA13 overexpression appears sufficient to explain both 
the phenotype (through downregulation of the epidermal differentiation complex) and 
the oncogenic potential of Barrett’s esophagus. Intriguingly, employing a mouse model 
that contains a reporter coupled to the HOXA13 promotor we identify single HOXA13-
positive cells distally from the physiological esophagus, which is mirrored in human 
physiology, but increased in BE. Additionally, we observe that HOXA13 expression 
confers a competitive advantage to cells. We thus propose that Barrett’s esophagus and 
associated esophageal adenocarcinoma is the consequence of expansion of this gastro-
esophageal HOXA13-expressing compartment following epithelial injury.
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Barrett’s esophagus (BE) and gastric intestinal metaplasia (IM) are important risk factors 
for adenocarcinoma of the esophagus and stomach. In the esophagus, the chronic 
inflammation associated with gastroesophageal reflux disease (GERD) is believed to 
lead to Barrett’s esophagus (BE), a crypt-structured columnar epithelium with distal 
gastrointestinal (GI)-tract characteristics, located just above the gastroesophageal 
junction (GEJ). BE is a precursor lesion for esophageal adenocarcinoma (EAC) (1, 2), a 
disease which has shown a strong increase in incidence in the past decades. Analogously, 
H. pylori-infection can degenerate into atrophic gastritis and gastric IM, which in turn 
can progress into gastric cancer, the third leading cause of cancer-related death (3). 
Similarly, while absolute risk is low, heterotopic tissues in Meckel’s diverticula and 
gastric inlet patches of the proximal esophagus represent relatively high-risk regions 
for adenocarcinoma comparatively to other sites of the ileum and proximal esophagus, 
respectively (4, 5). Therefore, a deeper understanding of the biology of BE and gastric 
IM is necessary for designing rational avenues for the prevention and treatment of GI 
cancers.
BE is characterized by the presence of cells with a caudal intestinal phenotype at a 
rostral location. Therefore, dysregulation of positional specification is likely involved 
in the etiology of BE. Regulation of rostral-caudal patterning of specialized tissue in 
embryology and adulthood is to a large extent dependent on the concerted action of 
two evolutionary highly conserved gene systems, the Caudal-related Homeobox (CDX) 
transcription factor gene family and the genes of the Homeobox (HOX) cluster. A 
substantial research effort has been invested in investigating the role of CDX genes 
in positional misspecification in BE (6). However, these efforts have not yielded 
convincing evidence that these genes are the principal mediators of the distal phenotype 
in this disease (7, 8). Intriguingly, however, a microarray-based gene expression study 
of BE suggested potential misregulation of the HOX gene family in BE (9). HOX genes 
are linked to morphological transformations and neoplasia (10, 11). Four clusters 
of HOX genes, HOXA to HOXD, have been defined. The 3’ to 5’ sequence of HOX 
gene paralogues corresponds to the sequence in which they act along the rostrocaudal 
axis. This property is termed collinearity and links clustering to function. Previously, 
a Hox expression gradient was found along the murine embryonic gut (12). Ectopic 
Hox expression in mice can alter intestinal differentiation (8). A HOX gradient along 
the adult human gut has also been reported (13), but that study involved pooling full 
thickness gut specimens, limiting data interpretation. Nevertheless, we feel that there 
is sufficient evidence to prompt exploring the function of HOX gene expression with 
respect to positional identity in physiology and pathology of the GI-tract in general and 




Collection of  human material 
All human tissues used in this study were obtained at the Erasmus University Medical 
Center, department of Gastroenterology & Hepatology. The use of these samples was 
approved by the Erasmus MC medical ethical committee (MEC-2015-208, MEC-
2015-209, MEC-2015-199, MEC-2010-093; tissues were handled according to the 
FEDERA code of conduct and informed consent was obtained where necessary (14). 
Biopsy specimens to investigate HOX collinearity were obtained by double balloon 
enteroscopy. Nine biopsy specimens were obtained from each patient (n=3) at different 
locations along the GI-tract. Sequentially these locations were: esophagus, stomach, 
duodenum, jejunum, proximal ileum, distal ileum, ascending colon, descending colon 
and sigmoid/rectum (Supplementary Figure S1a). Included patients had unexplained 
symptoms, mostly anemia, while inflammatory bowel disease patients were excluded. 
All biopsies for RNA isolation were stored in RNA-later at -80°C. Squamous esophageal 
biopsies (n=13) originated 5 cm above the squamocolumnar junction (SCJ). Barrett’s 
(BE) biopsies (n=13) originated caudal of the SCJ and cranial of the gastric folds (all 
patients were on PPI therapy), stomach biopsies (n=12) were from the corpus. All 
three types of biopsy specimens were derived from the same patients, (one stomach 
biopsy specimen was not obtained due to patient agitation during the gastroscopy). The 
squamous esophageal, BE, and stomach biopsies were taken in a paired fashion from 13 
patients. Where the number of samples is indicated below, this indicates the number 
of individual patients. To determine the proximal colonic HOXA13 border, biopsies 
were taken from the cecum at the appendix base, the ileocecal valve, 5 cm distal to the 
ileocecal valve, and from the transverse colon in each patient (n=5). Forceps biopsy 
specimens of EACs (n=12) were obtained. Pathological examination of simultaneously 
taken forceps biopsies around the study specimens had to be positive for EAC.
Collection of  archival pathology specimens 
FFPE material was collected from gastric IM (from the antrum, angulus, and corpus, 
i.e. not from the cardia; n=12), the gastric inlet patch (n=5), CLE (from the proximal 
esophagus; n=14), and Meckel’s diverticula (n=14). For RNAscope RNA-ISH, one FFPE 
specimen of each of these origins was used. Depending on the extent of metaplasia, 
remainder of tissues was used whole, macroscopically separated, or processed with the 
Photo-Activated Localization Microscopy with the Laser Caption Microdissection 
(PALM LCM) for mRNA isolation and subsequent qPCR. Nuclease-free membrane 
slides treated with UV light at 254 nm for 30 minutes were used to mount 10 µm 
sections, dried overnight at 56°C, deparaffinized, stained with hematoxylin and eosin, 
and dehydrated. AdhesiveCap microtubes obtained from Zeiss (Oberkochen, Germany) 
were used to collect the tissue of interest after cutting and pulsing of the PALM LCM. 







Additionally, FFPE materials or fresh pinch biopsies were collected from the squamous 
esophagus of a patient without BE, the squamous esophagus of a BE patient, BE, 
EAC, stomach (the corpus), and the ileum. Colon was used as a positive control. FFPE 
materials that were collected only for RNA-ISH were pyloric metaplasia (from the 
colon; n=5), Paneth cell metaplasia (from the colon; n=5), fetal GEJ tissue (n=2 of 
17 weeks, and n=1 of 20 weeks; this material originated from spontaneous abortions), 
and adult GEJ tissue consisting out of continuous strips of tissue containing squamous 
esophageal epithelium, GEJ, and oxyntic stomach epithelium (n=3). Two strips came 
from surgical specimens without evidence of BE, with a neuroendocrine tumor and 
decompensated achalasia (male of 71 and female of 56 years old). The third patient 
had surgery to remove an EAC (male of 63 years old). All tissues were obtained from 
the gastroenterology and pathology departments of the ErasmusMC according to the 
FEDERA code of conduct (14).
Animal studies 
For the Hoxa13 mRNA expression analysis throughout the murine gastrointestinal (GI) 
tract, four C57BL/6J wildtype mice were used between three and five months of age. 
The GI-tract was divided into 1: esophagus; 2: stomach; 3: duodenum; 4: jejunum; 
5: proximal ileum; 6: distal ileum; 7: cecum; 8: proximal colon; 9: distal colon, of 
which sections were opened and rinsed in PBS followed by storage in RNAlater at 
-80°C (Supplementary Figure S1b). For determining which cells express Hoxa13 in 
the GI-tract, tissues from a C57BL/6J-Hoxa13-GFP heterozygous mutant mouse model 
were employed, in which GFP expression is driven by the endogenous mouse Hoxa13 
promotor through the creation of a fusion protein (15). These tissues were taken out 
and embedded in O.C.T. Compound bought from Qiagen Inc. (Hilden, Germany) 
and frozen at -80°C. Cryosections were made which were mounted in fluoroshield 
mounting medium with DAPI obtained from Abcam (Cambridge, UK). Subsequently, 
the GEJ and the distal GI-tract were analyzed directly for GFP expression using the 
Zeiss confocal laser scan microscope LSM 510. Additionally, immunohistochemistry 
staining was performed with anti-GFP antibody (#AB3080, Bio-Connect BV) (see 
below). These murine experiments were approved by the Ethical Committee for Animal 
Experiments of the Erasmus MC.
Immunohistochemistry 
For immunohistochemistry, slides were blocked in 10% of normal goat serum, antigens 
were retrieved by boiling samples in citrate buffer (pH6), and samples were incubated 
overnight at 4°C with primary antibody. Dilutions and manufactures of primary 
antibodies are presented in the Supplementary Table S6. After incubation with HRP-
conjugated secondary antibody (Dako EnVision+System-HRR labeled Polymer Anti 
Mouse, Dako) endogenous peroxidase was blocked in 3% H2O2 and antibody binding 
Chapter 2
36
was visualized by DAB staining. IHC analysis for HOXA13 was tried using antibodies 
ab106503 and ab26084, however these failed to show specificity and have since been 
discontinued by the companies offering them. H&E staining was performed. For 
H&E stainings de-parafinized 4µM slides were incubated during 3 min in hematoxylin 
solution, followed by tap water washes and 15sec of incubation with eosin. For PAS 
staining, de-parafinized slides were incubated with 0.5% Periodic Acid solution for 10 
min, followed by two dH2O washes and incubation in Schiff’s reagent (Sigma Aldrich) 
for 15 min and hematoxylin for 3 minutes. 
RNA isolation 
RNA was isolated using the NucleoSpin RNA isolation kit (Macherey Nagel, Düren, 
Germany). Biopsies and animal tissues were homogenized by the TissueRuptor 
obtained from Qiagen Inc. RNA concentrations were measured using a Nanodrop 
spectrophotometer and samples were stored in RNA storage solution (Sodium Citrate 
pH 6.4), bought from Ambion (Foster City, USA) and kept at -80°C. RNA integrity 
was checked with 1% agarose gel-electrophoresis. FFPE material was deparaffinized 
with xylene and ethanol, lysed, digested with proteinase K, and RNA was isolated with 
the High Pure FFPET RNA isolation kit obtained from Roche (Basel, Switzerland). 
RNA isolation from de-differentiated KH2 mouse embryonic stem cells (mESCs) was 
done using a picopure RNA isolation kit (Thermo-Fisher Scientific, Waltham, USA). 
After RNA isolation all samples for RNA-Sequencing were tested on the Agilent 2100 
Bioanalyzer to determine RNA integrity and quantity.
cDNA and qPCR 
cDNA was made from 1 µg RNA using Primescript RT Master Mix according to 
manufacturer’s instructions (Takara, Otsu, Japan), for 15 min at 37°C and 5 sec at 
95°C, and stored at -20°C. qPCR was performed for 40 cycles in the iQ5 Real-Time 
PCR detection system that was obtained from BioRad Laboratories (Veenendaal, 
The Netherlands). For each reaction 10 µl cDNA template, 12.5 µl SYBR GreenER 
purchased from Invitrogen (Carlsbad, CA), and 2.5 µl 10 pM/µl primer were used. 
Reactions were performed in duplicate. Primers used are shown in Supplementary 
Table S4 and were ordered at Sigma-Aldrich (Darmstadt, Germany). qPCR data were 
analyzed with Microsoft Excel using the ΔΔCt method. Reference genes used for PCRs 
on human materials were RP2, β-ACTIN, and GAPDH. Reference genes used for PCRs 
on mice materials were Eef2, Rpl37, and Leng8. Differences in expression were analyzed 
with a two sided Student’s t-test using Prism 5.01, obtained from GraphPad Software 
(San Diego, USA). Values from individual samples were excluded if they deviated more 
than 2SD from the mean. Correlations between HOTTIP expression in the squamous 
esophagus and BE, and correlations between HOTTIP and HOXA13 expression levels in 
the squamous esophagus and BE were tested using nonparametric Spearman correlations. 







This is depicted in graphs by connecting lines between datapoints, also indicating the 
paired nature of the specimens, i.e. they are derived from the same patient, used for this 
analysis.
In situ hybridization by RNAscope
RNAscope was performed according to the instructions of the manufacturer of the 
probes and the reagent kit (VS Reagent Kit 320600; Advanced Cell Diagnostics), on 
proteinase K (0.1%, 10 min at 37°C) treated paraffin sections (5 µm). Subsequently, 
slides were hybridized with the RNA probe from RNAscopeVS Hs-HOXA13, (art. 
#ACDA 400226), or the control probe also from RNAscopeVS Hs-PPIB (art. #ACDA 
313901)(16). PPIB (peptidylprolyl isomerase B) is a ubiquitously expressed gene. The 
RNAscope probe Hybridization in situ Multiplex was bought from Advanced Cell 
Diagnostics (Newark, USA). Pyloric metaplasia and Paneth cell metaplasia of the colon 
were quantified using FIJI, for which a macro was made (Supplementary Macro 
S1) (17). For illustrations of RNA-Scope slides in the paper, background grey signal 
reduction was performed using Photoshop. 
Analysis of  GSE datasets
Expression profiles from clonogenic human gastro-intestinal stem cell cultures were 
obtained from Gene Expression Omnibus datasets GSE57584 (18) and GSE65013 
(19). In silico analyses were performed using the NCBI Gene Expression Omnibus 
(GEO) database. Analyses in the GEO database were performed by using the GEO2R 
tool (www.ncbi.nlm.nih.gov/geo/geo2r/), R 3.2.3., Biobase 2.30.0, GEOquery 2.40.0, 
limma 3.26.8 (20). The results were represented as a 2log-fold change (2log-FC). In 
Microsoft Excel, this 2log-FC was converted to fold change (FC). For each 2log-FC 
an empirical Bayes moderated t-statistic was calculated. P-values were corrected for 
multiple testing using the Benjamini & Hochberg false discovery rate method.
Analysis of  single cell RNA seq datasets
BE and ESMG Single Cell Experiment Matrix from supplementary Data files 6 ll three 
Experiment Matrixes have been mapped to hg38 standard human genome (‘TxDb.
Hsapiens.UCSC.hg38.knownGene’ R-package), normalized as Reads Per Kilobase per 
Million mapped reads (RPKM). Genes expressed in less than in 0.5% cells were filtered 
out. Low-quality cells were excluded based on: (1) the number of expressed genes - for 
10x Single-Cell sequence data, cells expressing less than 400 or more than 7000 genes, 
for smartSeq data cells expressing less than 1000 and more than 7000 were removed. 
Different numbers were chosen due to the different sequencing depth. (2) Boxplot 
representation of all cells – outliers, i.e. cells mapping higher or lower than 1.5x the first 
or third quartile were removed. (3) Based on % of reads - cells were removed if there 
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were more than 20% of reads mapping to mitochondrial or ribosomal genes. HOXA13-
related genes query: HOXA13-positive cells from normal esophagus were selected with 
R. Genes that were expressed in at least 70% of these HOXA13-positive cells (20445) 
were analyzed for their expression in HOXA13-negative cells of normal esophagus as 
well as HOXA13-negative and positive cells in BE tissue. For T-SNE plot, 638 cells were 
included (388 cells from Barrett’s tissue, 250 cells from normal esophagus) and plotted 
based on their location of origin (color) as well as HOXA13 expression (open vs closed 
symbols). 
Cell culture
All cells were cultured with penicillin (100u/mL) and streptomycin (100u/mL) and were 
regularly STR-verified and checked for mycoplasma by handing in samples prepared 
according to instructions at GATC Biotech (Konstanz, Germany). Primary human 
esophageal epithelial cells transformed with hTERT (EPC2-hTERT) (gift of K.K. 
Krishnadath) (21), were cultured with Keratinocyte SFM medium, supplemented with 
bovine pituitary extract at 50 µg/ml and EGF at 1 ng/ml (Thermo-Fisher Scientific). 
HET1A, the primary immortalized human squamous esophageal cell line Het-1A was 
a gift of J.W.P.M. van Baal (University Utrecht, The Netherlands). These cells were 
grown in EPM2 medium obtained from AthenaES, (Baltimore, Maryland, USA). The 
primary immortalized human BE cell line (BAR-T) was a gift of dr. J.W.P.M. van Baal 
who had, in turn, received them from dr. R.F. Souza (University of Texas Southwestern 
Medical Center, USA). These cells were grown in supplemented keratinocyte basal 
medium (KBM2), bought from Lonza (Basel, Switzerland), according to the method 
of Jaiswal et al. (22). KH2 mESCs were a gift of J. Gribnau and maintained in DMEM 
with 10% FCS, Non-Essential Amino Acids, sodium pyruvate, LIF, and β-mercapto-
ethanol (embryonic stem cell medium; Supplementary Table S5). Dishes were coated 
with attachment factor protein solution (Thermo-Fisher Scientific). Irradiated mouse 
embryonic fibroblasts (3T3-Swiss albino cells (gift of J.W.P.M. van Baal), cultured in 
DMEM with 10% FCS, and were used as feeder cells. HEK293T cells were cultured in 
DMEM with 10% FCS.
Generation of  EPC2-hTERT HOXA13 overexpression model
The human HOXA13 gene including its single intron was amplified 
using Q5 polymerase from gDNA using primers (AgeI HoxA13 F; 
GGTGGTACCGGTGCCACCATGACAGCCTCCGTGCTCCT, and XbaI 
HoxA13 R; ACCACCTCTAGATTAACTAGTGGTTTTCAGTT) and cloned into 
pEN_TmiRc3 using AgeI and XbaI restriction sites, a gift from Iain Fraser (Addgene 
(Cambridge, USA) #25748) (23). Subsequently, the HOXA13 insert was transferred 
into pSLIK-Venus, using a Gateway reaction (24). pSLIK-Venus was a gift from Iain 
Fraser (Addgene #25734) (23). A similar plasmid but without the HOXA13 insert 







served as control. Both plasmids were sequenced by LGC Genomics (Teddington, 
UK). Next, plasmids were packaged into lentiviral particles following transfection 
in HEK293T cells with third generation packaging plasmids. The supernatant was 
collected and ultracentrifuged. EPC2-hTERT cells were transduced with the virus and 
Fluorescence-Activated Cell Sorted (FACS) for YFP (pSLIK-Venus) positive cells on the 
BD FACSCantoTM II that was bought from BD Biosciences (San Jose, USA). These 
cells were grown and analyzed as a cell pool. HOXA13 was induced by the addition 
of 1.25 µg/ml doxycycline to the culture medium. Overexpression was determined by 
qPCR according to scientific standards (data not shown).
Generation of  KH2 mouse embryonic stem cells HOXA13 overexpression model
The human HOXA13 gene including its single intron was amplified using Q5 
polymerase from gDNA using primers with an added N-terminal FLAG-tag sequence 
(GACTACAAAGACGATGACGACAAG) and Kozak sequence (GCCGCCACC; 
Supplementary Table S5). Next, this PCR product was ligated into EcoRI digested 
pgk-ATG-frt (Addgene #20734) using Gibson Cloning (New England BioLabs Inc., 
Ipswich, USA). pgk-ATG-frt was a gift from Rudolf Jaenisch (25). KH2 mESCs were 
passaged the day before the electroporation and four h before electroporation medium 
was replaced. Approximately 1.5 107 KH2 cells were electroporated with 50 µg of pgk-
ATG-frt-HOXA13 and 25 µg of pCAGGS-FLPe-puro (Addgene #20733) (26). Cells 
were electroporated in 4 mm cuvettes, with two consecutive pulses (400V/250uF) using 
a Gene PulserXcell (Bio-Rad Laboratories). The next day 140 µg/ml Hygromycin B 
(Thermo-Fisher Scientific) was added for the selection of correctly targeted colonies. 
DNA from resistant colonies was isolated with the Kleargene XL blood DNA extraction 
kit (LGC, Teddington, UK) and analyzed by Q5 PCR using the following primers: 
PGK-F1 or PGK-F2 and T1E2-HygroR6 and T1E2-HygroR7 (Supplementary Table 
S5). Correctly-targeted clones were checked for proper HOXA13 induction by the 
addition of 1.25 µg/ml doxycycline to the culture medium for 3 days. Overexpression 
was determined according to scientific standards (data not shown). Three HOXA13 
overexpression versus three control biological replicates were selected and used for 
experiments.
Differentiation of  KH2 mouse embryonic stem cells 
An optimized version of the Ogaki protocol was used (27). Cells were plated on 50% 
confluent pre-cultured M15 cells, a mesoderm-derived feeder cell line (28) (gift of N. 
Hastie, University of Edinburgh, UK). Cells grew six days in differentiation medium 
consisting of ESC medium without LIF, with the addition of Activin-A, basic Fibroblast 
Growth Factor, CHIR, and Noggin (Supplementary Table S5). HOXA13-expression 
was induced on day four using doxycycline at 1.25 µg/ml. On day six, cells were analyzed 
by FACS by double staining with 0.8 µg PE Rat Anti-Mouse CD184 (CXCR4) and 
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2.0 µg Anti-CD324 Alexa Fluor® 488 (E-Cadherin) at 4°C for 45 min (Supplementary 
Table S5). The cells were analysed with a BD FACSCantoTM II (BD Biosciences, USA). 
Data were analyzed with BD FACSDiva v8.0.1 software, which was obtained from BD 
Biosciences, and processed using Microsoft Excel. Double-positive cells were sorted and 
cultured for another day with doxycycline at 1.25 µg/ml before harvesting and RNA 
isolation took place, using the picopure RNA isolation kit (Thermo-Fisher Scientific).
Generation of  the BAR-T HOXA13 knock-out model
Functional HOXA13 was removed from BAR-T cells using CRISPR/Cas9-mediated 
gene editing. A HOXA13 sgRNA targeting exon 1 was cloned into pTLCV2, by 
ligating two annealed oligonucleotides, i.e. Guide1sgRNA F and R (Supplementary 
Table S4). TLCV2 was a gift from Adam Karpf (Addgene #87360) (29). Following 
sequence verification, the pTLCV2-HOXA13sgRNA plasmid was packaged into 
lentiviral particles by cotransfection into HEK293T cells with pSPAX2 and pMD2.G, 
gifts from Didier Trono (Addgene #12260 and #12259). The supernatant was harvested 
and ultracentrifuged after which BAR-T cells were transduced. Mixed populations of 
transduced cells were plated at very low confluence, single cell clones could subsequently 
be isolated using glass cloning cylinders and low melting point agarose from Sigma-
Aldrich, followed by DNA isolation using the Kleargene kit, followed by sequence 
verification with primers TILHOXA13R3 and Pre-HOXA13-FW2 flanking the sgRNA-
site (Supplementary Table S4). Three cell lines in which both alleles were affected by 
unique out-of-frame deletions were selected along with three control cell lines (data not 
shown).
RNA-sequencing
The EPC2-hTERT samples (n=8) were treated with the TruSeq Stranded mRNA Library 
Prep Kit. Sequencing took place according to the Illumina TruSeq v3 protocol on an 
Illumina HiSeq2500 sequencer. Sample preparation and sequencing was performed at 
the Erasmus MC. Reads of 50 base-pairs were generated and mapped against reference 
genome hg19 with Tophat (version 2.0.10). Expression was quantified using HTseq-
count (0.6.1). Stranded libraries of the BAR-T (n=6), and both non-differentiated 
and differentiated KH2 mESCs (n=6 each) were prepared with the NEBNext RNA 
Ultra sample prep kit. Sequencing took place according to the Illumina NestSeq 500 
protocol on an Illumina HiSeq2500 sequencer. Sample preparation and sequencing 
was performed at GenomeScan in Leiden, The Netherlands. Reads of 75 base-pairs 
were generated, mapped against reference genome hg19 or mm9 with Tophat (version 
2.1.0), and quantified using HTSeq (version 0.6.1p1). Data were processed using R. 
version 3.2.5 (30), in combination with the module DeSeq2 (31). Generated FCs and p 
values adjusted for multiple testing, i.e. q values, were analyzed using Ingenuity Pathway 
Analysis (IPA) version 42012434, obtained from Qiagen Inc. (Hilden, Germany) (32). 







We limited the number of genes analyzed to a maximum of 1000 by eliminating genes 
with a (relatively) low fold change if differentially expressed genes number was above 
1000. The dataset cut-offs used were always a q value of 0.05, the fold change cut-off 
was set at: nondifferentiated KH2-mESCs, FC 2, 888 genes; differentiation of KH2-
mESCs, FC 5, 924 genes; differentiated KH2-mESCs, FC not restricted, 665 genes; 
BAR-T, FC not restricted, 146 genes; EPC2-hTERT, FC 1.3, 990 genes. Activity scores 
are known in IPA as “z-scores” which represents the number of standard deviations from 
the mean of a normal distribution. For analysis and visualization of gene expression in 
the epidermal differentiation complex the raw counts from both models normalized 
to total reads were used. Genes for which one of both cell models had less than ten 
reads in the control or experimental samples were excluded. Overlap in multiple testing 
corrected differentially expressed genes in the BAR-T and EPC2-hTERT datasets was 
calculated as follows; the proportion of overexpressed genes in the EPC2-hTERT dataset 
was determined. Half of the differentially expressed genes in the BAR-T dataset would 
be expected to be regulated in the same direction if regulation would be random. This 
expected overlap if regulation was random, and the observed overlap, were used as input 
for an X2 test. Information included in Supplementary Table S2 and S3 in the “known 
function” and “Detailed description” columns was obtained through non-systematic 
review and should not be considered as an exhaustive overview of the literature. 
Association of expression of molecules in the distal GI-tract with their regulation by 
HOXA13 expression was reviewed using the human proteome atlas and depicted in 
Supplementary Table S2 (33).
Acid and bile exposure
For assessment of HOXA13 mRNA expression upon acid/bile exposure, EPC2-hTERT 
and HET-1A cells were treated for 30 minutes with cell culture medium adjusted to a pH 
of 7.0 or 4.0 using HCl. Cells were subsequently washed using PBS and given standard 
medium. Acid experiments were performed four times in duplo. Cells were separately 
exposed to medium with a bile acid mixture in concentrations of 0, 200, (and 400 for 
EPC2-hTERT) µmole/L for 30 minutes at a pH of 7.0. The bile acid mixture consisted 
of 25% deoxycholic acid, 45% glycocholic acid and 30% taurochenodeoxycholic acid. 
Cells were subsequently washed using PBS and given normal medium. Bile experiments 
were performed twice in duplicate. After 24 h, the cells were harvested and RNA was 
isolated. Methods were derived from Bus et al. (34). To assess the effect of bile/adic on 
expansion of cells, EPC2-hTERT cells transduced with HOXA13 or control vector as 
described above were seeded in 96-well plate with at least 2 wells per condition. Next 
day, medium was replaced with 100 µl of bile/acid mixture in cell culture medium (50 
µM of sodium glycocholatenhydrate, 50 µM taurochenodeoxycholic acid, pH=4.95). 
After incubation for 4 days, MTT test was performed as described below. Experiment 
was performed at least five times.
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BAR-T spatial distribution experiments
These were performed with three biological replicate cell lines containing HOXA13 
knock-out and three control cell lines. 40,000 BAR-T cells were seeded in a 6 well plate 
and pictures were taken the second day after seeding. Per well three pictures were taken. 
These pictures were analyzed using FIJI, using the multipoint tool, an X and Y (pixel) 
coordinate table was generated (17). The distance between each cell and its three closest 
neighbors was quantified using Microsoft Excel and analyzed by two sided student’s 
t-test. The experiment was performed in three independent cell lines and repeated three 
times. 
MTT assay
For assessment of cell growth of EPC2 and BAR-T cells, we performed a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (35). We 
seeded 1000 cells per well in 96 well plates for each of the three wild-type and three 
HOXA13 knock-out cell lines. Per condition at least 2 wells were used. On days one, 
three, five, and seven 10 µl MTT at 5 µg/ml was added and incubated for three h, the 
medium was removed, and the precipitate was dissolved in 100 µl DMSO, which was 
incubated for five minutes under continuous shaking. For BAR-T cells, absorption was 
measured in a BioRad microplate reader Model 680 XR at 490 and 595 nm, the average 
absorption was used to process the data. For EPC2 cells it was measured with Tecan 
microplate reader Model Infinite 200 pro at 565 nm with reference wavelength 670 nm. 
The experiment was repeated three times and a two sided Student’s t-test was used to test 
for statistical significance. 
3D culture EPC2-hTERT cells
3D culturing of EPC2-hTERT cells was performed as previously described (36). 
4000 EPC2-hTERT cells in culture medium were mixed 1:1 with ice-cold Matrigel 
basement membrane matrix (Corning BV), seeded in 50 µl drops in a 24 well plate 
for cell suspension, and incubated at 37°C for 30 minutes. After solidification, 500 µL 
of culturing medium supplemented with 0.6mM CaCl2 was added. Y27632 (10 µM) 
was included in medium only the first 24 h after seeding. Medium was refreshed and 
pictures were taken every three days. The morphology of spheroids (based on number 
of extrusions, or ‘invadosomes’) was counted on day 5. The area of the spheroids was 
measured with FIJI (17). For H&E staining and IHC analysis of involucrin (see above), 
spheroids were fixed in 4% formaldehyde for 7 min on day 11, washed with PBS, put in 
2% agarose, and embedded in paraffin, then 4 µM slices were sectioned. Quantification 
was based on the percentage of positive cells and the intensity of the staining (scores 
ranged from 0, 2 to 9).







Organotypic air-liquid interface culture
Plate inserts (Sigma-Aldrich, Germany) were covered with bovine collagen I (Thermo 
Fisher Scientific, USA). The fibroblast (3T3-Swiss albino) feeder layer was embedded 
within a collagen matrix and was allowed to mature for 7 days, after which time BAR-T 
HOXA13 knock-out and control epithelial cells were seeded on top and allowed to grow 
to confluence for an additional 3 days as described (37). Then the culture media level 
of the upper well was reduced, exposing the apical side of keratinocytes to the air, while 
maintaining liquid levels at the basolateral side. On day 15, cultures were harvested 
for histologic examination. 4 µM paraffin-embedded sections were deparaffinized, and 
staining with hematoxylin and eosin, PAS staining and immunohistochemistry for 
involucrin were performed. 
Rat trachea in vivo tissue reconstitution model
500,000 parental BAR-T cells (derived from six independent clones) or HOXA13 
knock-out clones (three independent clones) in 30 µl of medium were sealed in the 
lumen of devitalized and denuded rat tracheas and implanted under the dorsal skin of 
NOD SCID gamma mice as described by Croagh et al. (38). Mice were sacrificed after 
four or six weeks. Harvested rat tracheas were formalin fixed, decalcified, embedded in 
paraffin and sectioned. Staining with hematoxylin and eosin, alcian blue, PAS staining 
and immunohistochemistry using antibodies against human mitochondria, CK7, TFF3, 
CDX2, p63, CK5, and involucrin (a gift from Prof. Pritinder Kaur, Curtin University, 
Australia or #I9018-100UL from Sigma-Aldrich) were performed (Supplementary 
Figure S6 and Table S6). These murine experiments were approved by the Peter 
MacCallum Cancer Centre Animal Experimentation Ethics Committee.
Results
HOX cluster gene expression in the gastrointestinal tract is collinear in men and 
mice
Investigating HOX gene mRNA expression in the murine and human gastrointestinal 
tract, we observed collinearity that is similar in adult humans and mice (Figure 1A 
for human HOXA, Supplementary Figure S2 for all HOX genes and Supplementary 
Figure S1 for graphical presentation of the studied HOX clusters and the locations of 
biopsies taken along the human (n=3) and mouse (n=4) GI tract). The highest HOX 
gene cluster expression was observed in the colon, except for the HOXC cluster. For 
individual paralogues, there is a higher expression of 5’ HOXA/B genes in the distal 
GI-tract from HOXA5/B5 onward. Of all HOXA paralogues, expression of HOXA13 
was highest and restricted to the colon (Figure 1A). HOXA13 expression is regulated by 
LncRNA HOTTIP, which is located 5’ to HOXA13 (39). Accordingly, HOTTIP and 
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Figure 1. HOXA cluster gene expression shows collinearity along the adult gastrointestinal tract but is 
deregulated in BE, various metaplasias and esophageal adenocarcinoma. (A) HOXA cluster genes are 
collinearly expressed along the GI-tract of adult humans (n=3). Numbers represent fold changes of mRNA 
expression relative to the esophagus, which is indicated by a black rectangle. Th us, fold changes can be 
compared within each HOXA paralogue member but not between them. (B) HOXA cluster gene expression 
in the squamous esophagus of BE patients (n=13), columnar lined esophagus (CLE) (n=14), BE (n=13), 
EAC (n=12), and gastric IM (n=12) is characterized by an upregulation of 5’ HOXA genes. Numbers 
represent fold changes of mRNA expression relative to the mRNA expression in the esophagus of healthy 
individuals. (C) HOXA13 expression quantifi ed by qPCR in BE, CLE, IM of the stomach, and heterotopias 
along the GI tract with their corresponding physiological epithelia. SQ Barrett’s and BE are derived from 
the same person. Mean±SEM, *p<0.05; **p<0.01; ***p<0.001. Gastric inlet patch (GIP; from proximal 
esophagus; n=5); squamous esophagus of a healthy control (HC) (from 5 cm proximal to the GEJ; n=12); 
squamous esophagus of BE patients (from 5 centimeter proximal to the GEJ; n=13); CLE (from below the 
GEJ and above the gastric folds in segments at least 2 centimeter in length; n=14); BE (from below the 
GEJ and above the gastric folds in segments at least 2 centimeter in length; n=13); EAC (n= 12); stomach 
(from the cardia; n=14); gastric IM (from the antrum, angulus, and corpus, i.e. not from the cardia; 
n=12); ileum (n=6); Meckel’s diverticulum with gastric heterotopia (n=14), and; colon (from ascending, 
transverse, and sigmoid; n=9). SQ: squamous epithelium. (D) Deregulation of HOXA13 expression in 
gastrointestinal tract pathology as evaluated with RNA in situ hybridization in clinical samples. HOXA13 is 
upregulated in IM and heterotopia and downregulated in pyloric and Paneth cell metaplasia in the colon. 
One sample of each tissue type was analyzed; (E) Downregulation of HOXA13 expression (corrected for 
PPIB expression) relative to adjacent non-metaplastic tissue, was observed for Paneth cell metaplasia (n=5; 
FC 0.59; p=0.0041) and pyloric metaplasia (n=5; FC 0.22; p=0.0001) (lower panels. Representative images 
of HE staining, HOXA13 RNA-scope, and PPIB reference gene RNA-scope of Paneth cell metaplasia (from 
the colon) present in two glands to the bottom right (upper panels) and pyloric metaplasia (from the colon) 
in the top left two glands (middle panels) are shown.
HOXA13 share a similar expression pattern (Supplementary Figure S2). For HOXD, all 
paralogue genes have increased expression in the distal colon, while HOXC expression is 
mainly localized in the proximal and ileal regions. Th us, HOX gene expression is linked 
to positional identity in the mammalian gut, and collinearity is particularly strong for 
the HOXA/B paralogues. 
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Subsequently, we addressed the question as to whether gastrointestinal HOX coding is 
already present at the gastrointestinal stem cell stage, or is established only upon the 
formation of differentiated derivatives. For this, we used publicly available data published 
by Wang et al. which contains the mRNA expression of human stem cells isolated from the 
GI-tract and either cultured as stem cells or differentiated in an air-liquid interface (ALI) 
(18). Analysis of this data shows that HOX gene expression patterns in stem cell and ALI 
cultures are similar. HOXA and B cluster genes have a significantly higher expression in the 
large intestine as compared to the small intestine, in particular 5’ HOXA genes including 
HOXA13 (Figure 2A for HOXA genes, for clusters HOXB, C, and D see Supplementary 
Figure S3). No clear regulation of the HOXC or D clusters is seen in this in dataset, with 
exception of an upregulation of HOXC10 in the large intestine. Hence, HOX coding is 
an inherent feature of the location-specific stem cell and is maintained in its derivatives. 
HOXA13 in BE, GI heterotopias and GI cancers
As positional phenotype is linked to HOX status in physiology, we subsequently 
characterized HOX mRNA expression in several metaplastic tissues known to assume 
the morphological phenotype of other intestinal locations, as well as their sequelae. BE 
shows upregulation of HOXA10, 11, and 13, and HOXB 6, 7, 9, and 13 mRNA by qPCR 
when compared to the normal squamous esophagus (Figure 1B and Supplementary 
Figure S4), which closely resembles colonic HOXA and B expression patterns. High 
5’ HOXA gene expression is also present in columnar-lined esophagus without goblet 
cells (CLE; a BE-related condition), esophageal adenocarcinoma (EAC), and IM of the 
stomach (Figure 1B). In accordance with a regulatory role for HOTTIP on HOXA13 
expression, we find that HOTTIP is also overexpressed in BE, and correlates with 
HOXA13 expression patterns (Supplementary Figure S5A, B, C). HOTAIR, a lncRNA 
located in the HOXC cluster and associated with chromatin reprogramming in cancer 
progression (40) is upregulated as well (Supplementary Figure S5D, E, F) (39). We 
concluded that BE, EAC and various metaplasias with caudal histo-morphological 
characteristics have HOXA and HOXB expression patterns typical of the caudal GI-
tract, with upregulation of HOXA13 expression being the most prominent feature 
(Figure 1C). Heterotopias, namely the gastric inlet patch in the proximal esophagus 
and heterotopia of the Meckel’s diverticulum, are tissues which have a physiological 
appearance, but are normally found in a different location. These heterotopias are also 
characterized by abundant HOXA13 mRNA expression (Figure 1C). One of the existing 
hypotheses on the cell of origin of BE states that BE may arise from cells with progenitor 
properties that are able to give rise to a variety of cell types (41). To investigate whether 
aberrant HOX gene expression in BE is established at the level of the epithelium-specific 
stem cell, we interrogated the publically available data of Yamamoto et al. (18, 19). 
HOX gene expression patterns in squamous esophageal and BE stem cells as well as 
their respective ALI-differentiated derivatives were retrieved. HOX gene expression in 







stem cell cultures from these locations is similar to their ALI diff erentiated counterparts 
(Figure 2B, Supplementary Figure S3). In BE stem cells, an upregulation of 5’ HOXA 
genes (Figure 2B) as well as HOXB6, 7, 13, and HOXC10 is seen (Supplementary 
Figure 2. HOXA expression in stem cells of the GI-tract and in BE. (A) HOXA cluster genes, in particular 
5’ HOXA genes including HOXA13, have a higher expression in the large intestine (n=3 in technical 
duplicate) compared to the small intestine (n=3 in technical duplicate), in both stem cells (left panel) 
and diff erentiated cells (right panel). (B) 5’ HOXA cluster gene expression in BE is higher compared to 
the squamous esophagus in stem cell and ALI diff erentiated cultures. n=12 (BE) versus n=2 (squamous 
esophagus) in technical duplicates are depicted for stem cell cultures and n=1 each for ALI diff erentiated 
samples in technical duplicates. Normalization was performed by setting mRNA expression to 1 for the 
small intestine (A) or squamous esophagus (B). *p<0.05; **p<0.01; ***p<0.001. Th is fi gure includes no 
estimate of variance as the empirical Bayes-moderated t-statistic was used which does not generate a 
standard error. Data were derived from publically available databases belonging to two studies (18, 19).
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Figure S3), reaching levels similar to those observed in the colon. Thus, alternative HOX 
coding associated with BE is established at the epithelium-specific stem cell level and is 
maintained in derivatives of the stem cells involved.
According to the collinearity theory, a paralogue group 13 member is more likely to 
confer the distal characteristics seen in BE as compared to more anterior paralogue 
group members (42). Of the paralogue group 13 members, HOXA13 and HOXB13 
are overexpressed in BE, with HOXA13 showing much higher expression compared to 
HOXB13 in BE, EAC, and IM of the stomach (Supplementary Figure S4). Therefore, 
while HOX genes such as HOXA11, B6, B9, and B13 are also potentially interesting 
candidates, here we chose to focus on the HOXA13 gene for further in-depth analysis of 
different metaplastic tissues. As immunohistochemistry for HOXA13 was unsuccessful, 
(two anti-HOXA13 antibodies were tested but lacked specificity) we resorted to in situ 
hybridization (ISH) for HOXA13 to further confirm the observed atypical expression 
of this gene in different tissues (examples shown in Figure 1D). Metaplasia is found 
throughout the GI-tract. While BE and IM acquire a more distal phenotype, distally 
located colonic pyloric and Paneth cell metaplasia, related to inflammatory bowel 
disease, acquire a more rostral phenotype (43). Accordingly, downregulation of HOXA13 
expression (corrected for PPIB expression as a reference gene) relative to adjacent non-
metaplastic tissue, was seen for these tissues (Figure 1E), again supporting a role for 
HOXA13 in positional identity. 
Binary regulation of  HOXA13 expression
To study in more detail which cells in the healthy GI-tract express Hoxa13, we employed 
a murine model in which expression of a Hoxa13-GFP fusion protein is driven by the 
endogenous mouse Hoxa13 promoter. Within the epithelial compartment, the proximal 
expression border is located at the transition from the distal to the proximal colon as can 
be seen from fluorescent images and images of anti-GFP IHC staining (Figure 3A, B and 
Supplementary Figure S6 A-D for bigger overview images). This proximal expression 
border seems to be crypt-clonal, with some crypts expressing Hoxa13 and others not 
(see arrows in Figure 3B and close-up in Figure 3C). Functional consequences of this 
clonality are unknown and, while beyond the scope of the present manuscript, present an 
interesting biological question. The distal Hoxa13-GFP expression is limited by the anal 
squamocolumnar junction (SCJ; Supplementary Figure S6E, please note this cannot 
be appreciated in Figure 3A, as this part was damaged for this mouse). To investigate 
whether these local gradients of Hoxa13 expression are also present in humans, HOXA13 
mRNA expression was assessed by qPCR in an additional set of biopsies taken from 
different colonic locations. Cecal biopsies are HOXA13-negative, while HOXA13 
expression increases from the ileocecal valve to the distal transverse colon, demonstrating 
a similar expression pattern as observed in the mouse (Figure 3D).









In addition to a Hoxa13 gradient along the GI tract, epithelial Hoxa13-GFP expression 
is also tightly regulated along the baso-luminal axis of individual crypts. Proximally, only 
apical expression is seen, while distally Hoxa13-GFP is expressed along the entire baso-
luminal axis of the crypts (Figure 3E). In addition, mesenchymal expression is observed 
in the cells just beneath the epithelium in the proximal colonic epithelium (Figure 3E). 
Within the cell, the strongest signal is co-localized with nuclei, as expected, but cytoplasmic 
staining is also seen which can be explained by ribosomal synthesis (Figure 3E). 
We concluded that spatial regulation of Hoxa13/HOXA13 expression is very precise, 
robust and colon-specific, raising questions as to the cellular origin of the HOXA13 
expression observed in BE.
Individual Hoxa13/HOXA13-positive cells in the upper GI tract
No significant expression of HOXA13 mRNA was seen in the squamous esophagus 
of BE patients by qPCR (Figure 1C, D), suggesting that GERD does not provoke 
HOXA13 expression per se. Indeed, when two primary immortalized squamous 
esophageal cell lines (EPC2-hTERT and HET-1A) were exposed to either bile or acid, 
only minor effects on HOXA13 expression were observed (two to fourfold from a low 
baseline expression; Figure 4A, B), more in agreement with cells having a relatively high 
HOXA13 expression showing better survival of the treatment rather than upregulation 
of expression per se. This was confirmed by analysis of the publicly available single 
cell RNAseq database recently published by Owen et al. (44). Results at single cell 
level demonstrate the presence of a small population of HOXA13-positive cells in the 
normal squamous esophagus of BE patients (8%). In BE tissue, the percentage of these 
HOXA13-positive cells increase to 30%, but their individual HOXA13 mRNA levels are 
not increased as compared to HOXA13-expressing cells of the normal esophagus (Figure 
4C, D). Similarly, the number of HOXA13-positive cells, but not HOXA13 expression 
per cell, is increased in IM of the stomach, early gastric cancer, and colorectal cancer 
Figure 3. Murine and human HOXA13 expression is subject to strict spatial control in colon. (A) A 
representative example of a “Swiss roll” configuration of the large intestine of the Hoxa13-GFP heterozygous 
mouse model. An asterisk indicates the most distal portion of the epithelium. Magnification of the insets 
are shown in panels B, C and E. (B) The proximal border of physiological Hoxa13 expression in the adult 
mouse is patchy and located between the proximal and distal colon, indicated by a black dashed line in the 
bottom panel (macroscopic image of an opened mouse colon). Representative images of anti-GFP IHC 
and confocal microscopy are shown. Arrows indicate crypts that are positive for Hoxa13 among Hoxa13-
negative crypts. (C) The Hoxa13 expression is crypt clonal. (D) In adult humans the cecum bottom is 
negative for HOXA13 while positivity increases distally (n=5). Mean±SEM, *p<0.05. HOXA13 mRNA 
levels were normalized to levels in the transverse colon. (E) Hoxa13 expression is tightly regulated along the 
baso-luminal axis. Distally, Hoxa13 is expressed along the entire baso-luminal axis of the colonic crypts, 
proximally only expression at the luminal side is seen. In addition, a mesenchymal expression is observed 
in the cells just beneath the epithelium, predominantly in the proximal colon. (Ei) anti-GFP IHC, (Eii) 
confocal images.

































































































































































































































































































































































































































































































































(Figure 4C, D). Th us, we further investigated Hoxa13 at cellular level in our samples. 
Although Hoxa13 mRNA expression was detectable in only one of four mice in the 
upper GI-tract by q-PCR (Supplementary Figure S2), detailed inspection of specimens 
involved did identify single Hoxa13-positive cells in the stomach of Hoxa13-GFP mice 
Figure 5. HOXA13 expression in upper GI tract. (A) Representative example of anti-GFP IHC of a 
Hoxa13-GFP heterozygous mouse with GEJ (n=3). Hoxa13 is expressed in single cells of stomach starting 
from GEJ (5-6) and absent in the esophagus and stroma (1-4). 
A







Figure 5. Continued. (B) HOXA13 expression as measured by RNA ISH in a representative example of an 
adult human GEJ with magnification panel of: A – esophagus (blue), B – GEJ area, C – proximal stomach 
(pink). Orange circles indicate the positive signal in the overview image. 
B
by immunohistochemistry. Such signal was present at the basolateral side along the 
stomach starting from the GEJ, but not seen in the squamous cells along the esophagus, 
nor the stroma (Figure 5A and Supplementary Figure S7). This is of particular interest 
as the GEJ has been suggested as a place of origin of BE (41). A littermate negative 
Chapter 2
54
for Hoxa13-GFP showed no positivity (Supplementary Figure S6D, Supplementary 
Figure S7D). 
Subsequently, we employed ISH for HOXA13 on surgical samples from the human GEJ 
of three adult patients to analyze the presence of HOXA13-expressing cells in the human 
upper GI tract. In all three specimens, the GE junction area contained a clear positive 
signal for HOXA13 mRNA, some signal was seen in cells of the proximal stomach, 
while signal was even lower in the squamous epithelium and stroma (Figure 5B and 
Supplementary Figure S8 A, B). We also studied HOXA13 expression in the GEJ of 
three spontaneously aborted human fetuses of 17-20 weeks of age, a gestation period 
characterized by transition of the esophageal epithelium from columnar to a squamous 
phenotype. We observed high and specific HOXA13 expression at the gastric cardia, 
while more distal stomach and epithelium of esophagus were less positive (Figure 5C, 
Supplementary Figure S8 C, D). These data imply that HOXA13-positive cells are 
present in the human embryonic esophagus during the epithelial transition period, 
reduced in adult squamous esophagus, and increase again in BE. Thus, strikingly, the 
Figure 5. Continued. (C) Overview of a representative example of a 17-week old fetus GEJ: A) Gastric 
epithelium of the proximal stomach, B) GEJ area, C) Stratified esophageal epithelium of the distal esophagus.
C







epithelium of both the human and mouse adult upper GI tract, in particular the GEJ, is 
characterized by the presence of a subpopulation of HOXA13/Hoxa13-positive cells in 
an otherwise HOXA13-negative surrounding.
HOXA13 affects differentiation potential and posteriorizes 
Having established that individual HOXA13-positive cells reside in the physiological upper 
GI tract and are enhanced in BE tissue, we next set out to investigate the potential role of 
this population of cells in the etiology of BE. To this end, we further analyzed the single 
cell RNA-seq (44) data set mentioned above. In this study, the GEJ was not sampled for 
analysis. However, the 4% of cells of the normal esophagus that express HOXA13 exhibit 
transcriptional overlap with cells derived from BE tissue as seen from the t-Distributed 
Stochastic Neighbour Embedding (t-SNE) plot (Figure 6A). Gene expression analysis 
indicates that these cells are derived from esophageal submucosal glands (ESMG) 
(Figure 6B and Supplementary File S1) (44, 45). Specifically, and in contrast to the 
HOXA13-negative cell population, >70% of the HOXA13-positive cells from the normal 
squamous mucosa are positive for submucosal markers LEFTY1 and OLFM4, designated 
ESMG markers, which have also been described as markers of BE progenitor cells (44). 
Additionally, HOXA13-positive cells express mucosal markers TFF3, Lyz and SOX9, as well 
as columnar and BE markers TFF1, KRT7, VIL1, MUC5B, MUC3A, MUC13, MUC1, 
CEACAM5, while being negative for keratinization marker IVL and basal epithelial cell 
marker p63 (Figure 6B and Supplementary File S1 for the list of genes enriched in 
HOXA13-positive cells). In BE, the percentage of cells positive for these columnar and 
ductal markers increase also in the HOXA13-negative population, suggesting either that 
upon differentiation some of these cells might lose HOXA13 expression, or that there 
is more than one population giving rise to BE tissue. This would be in line with mouse 
data, as the murine esophagus lacks ESMGs and Hoxa13-positive cells. (Of note, we were 
unable to assess HOXA13 presence in human submucosal glands of the esophagus, as no 
ESMGs were present in our sections as determined by expert pathologist). 
The cell of origin with respect to formation of the BE segment should be able to generate 
a variety of differentiated cell types that exhibit colonic, gastric, pancreatic acinar or 
other phenotypes (46, 47). In chick embryos, HOXA13 regulates regionalization after 
1.5 days of development, showing the involvement of HOXA13 in early differentiation, 
consistent with an effect of this gene on cellular phenotype in such pluripotent progenitor 
cells (48). In an effort to experimentally test the influence of HOXA13 on cell fate, we 
generated HOXA13-inducible pluripotent mouse embryonic stem cells (mESCs). These 
pluripotent mESCs can be efficiently differentiated to multipotent definitive endoderm, 
as determined by membrane expression of CXCR4 and E-cadherin (Figure 6C). This 
was further confirmed by RNAseq, showing a strong upregulation of definitive endoderm 
markers such as Sox17 and Foxa1 in these differentiated cells, while pluripotency 
markers such as Nanog are downregulated (see Supplementary Table S1). Using 
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Figure 6. (A) HOXA13+ cells of normal esophagus are clustering together with BE cells in T-SNE plot based 
on single cell RNA expression profi ling (44). (B) Analysis of single cell RNA-seq data revealed that HOXA13+ 
cells express submucosal glands markers, BE markers and have decreased expression of squamous markers 
(p63, IVL) in healthy esophagus in contrast to HOXA13- population. Th is diff erence is not observed in BE. 
(C) HOXA13-overexpressing defi nitive endoderm is relatively resistant to terminal diff erentiation. Mouse ESC 
cells with and without forced HOXA13 expression were diff erentiated from pluripotent stem cells to defi nitive 
endoderm. Th e percentage of diff erentiated defi nitive endoderm cells, defi ned as CXCR4+/E-cadherin+ cells, 
was analyzed by FACS analysis (upper panels). Lower panels (representative light microscopy images) show 
morphological diff erences in cultures of HOXA13 overexpressing and wildtype mESCs after the diff erentiation 
protocol. Diff erentiation to defi nitive endoderm induces a fl attening of cell layers, with larger and irregular 
shaped cells. (Di) Quantifi cation of FACS analysis results indicates that the percentage of CXCR4+/E-
cadherin+ cells in cell cultures under diff erentiation conditions is decreased in HOXA13-overexpressing cell 
cultures under diff erentiation conditions. Mean±SEM, ***p<0.001 (Dii). (E) Model of cellular identity in BE 
development. Th e X-axis represents time (hypothetical units) following exposure to GERD-inducing agents. 
Y-axis shows diff erentiation during embryology and pathology. Z-axis indicates the positional identity of GI-
tract tissues. Several theories exist regarding the cell of origin of BE: they may be fully diff erentiated esophageal 
or stomach cells, or less diff erentiated cells within these organs (depicted by the 4 cells on the Y-Z plane). 
Irrespective of its location or diff erentiation state, this cell or origin might lose its correct positional identity 
or maintain its aberrant positional identity and resembles a defi nitive endoderm like cell. Th is is visualized by 
the blue rectangle harboring the cell with the thicker blue contour. In toto, for the model of cellular identity in 
BE, these data suggest that HOXA13 expressing clones in the GEJ, depicted in orange, may outcompete clones 
with another positional identity, providing an explanation for the distal phenotype observed in BE.







ingenuity pathway analysis (IPA) to further analyze differently expressed genes, a positive 
association was found with “differentiation of embryonic cells” (z=1.82, p=6.38·10-15). 
Intriguingly, when HOXA13 expression was induced, cells differentiated less effectively 
towards definitive endoderm as determined by CXCR4+/E-cadherin+ expression and 
morphological assessment (Figure 6C and Di). Consistent with a reduced unilinear 
differentiation, clones expressing HOXA13 showed greater expansion (Figure 6Dii).
We next contrasted the transcriptome of non-differentiated, pluripotent HOXA13-
overexpressing and control cultures to identify potential molecular mediators of the 
HOXA13 effects observed. Results of IPA analysis of differential gene expression are broadly 
consistent with HOXA13 conferring a pluripotent phenotype. Specifically, forced HOXA13 
expression results in upregulation of the “role of Nanog in mammalian embryonic cell 
pluripotency” category (z=1.34, p=2.32·10-3), an effect that involves Sox2, Nanog, Tbx3, 
Hesx-1, and Dppa-1 amongst others (49, 50) (See Table 1 for more details/results, fold 
changes, and q values with regard to this experiment). HOXA13 expression also appears 
to downregulate Wnt signaling, possibly through BMP signaling (51). Wnt signaling is 
known to promote mesoendodermal differentiation (52), these results are consistent with 
HOXA13-mediated downregulation of Wnt signaling during axial elongation (53). Thus, 
the transcriptional profile provoked by HOXA13 is consistent with maintaining a relatively 
pluripotent phenotype which in turn may increase compartment expansion.
HOXA13 expression does not block endodermal differentiation of mESC cells completely, 
suggesting that a role for HOXA13 in this compartment is still relevant. Definitive 
endoderm is a feature of the entire GI tract epithelium, and does not distinguish upper and 
lower GI epithelium per se. To investigate the role of HOXA13 in this cell compartment 
and test our prediction that HOXA13 expression would predispose endoderm to acquire 
distal phenotypes, we sorted CXCR4+/E-cadherin+ cells of HOXA13-positive and 
negative cultures and contrasted their mRNA expression. HOXA13 upregulates gene 
expression associated with determination of morphology in definitive endoderm cells. 
In IPA analysis, “actin cytoskeleton signaling” was most activated (z=3.00, p=3.74·10-2). 
“RhoA signaling”, which stimulates actin polymerization, (z=2.12, p=1.12·10-2) was also 
stimulated. HOXA13 supports distal epithelial functions with upregulation of microvillus-
associated genes, Ezr and Vill, keratins, Krt19 and Krt20, tetraspan network genes, Igsf8, and 
exocrine function associated genes such as Gcnt3, normally expressed in the distal GI-tract 
epithelium (33). In addition, more transcripts of “Cell proliferation of carcinoma cell line” 
(z=1.13, p=1.5·10-6) and “Neoplasia of cancer cells” (z=1.13, p=2.22·10-4) categories, such 
as Fgfr2 and Nek2, were detected. Thus, forced HOXA13 expression during endodermal 
differentiation supports caudal epithelial functions and proliferative potential (see Table 1 
for fold changes and q values; see Supplementary Table S2 for more relevant molecules). 
Together, these data are in apparent agreement with HOXA13-expressing cells displaying 
a progenitor phenotype and having a competitive advantage, while simultaneously 
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driving the acquisition of a more distal columnar phenotype once committed to 
differentiation (see Figure 6E).
HOXA13 and the chromosome 1 epidermal differentiation complex 
Further support for a role of HOXA13 in the loss of the squamous phenotype and the 
appearance of caudal columnar phenotypes in the esophagus comes from experiments in 
Table 1. Fold changes and q values for the mRNAs mentioned in the results section of the main text 
pertaining to cell culture models analyzed by RNA-Seq
Gene name Fold change 
q value
(multiple testing 




Forced HOXA13 in mESC confers a relative 
competitive advantage in multipotent cell cultures 
through upregulation of Nanog signaling and 
downregulation of Wnt signaling
Forced HOXA13 expression supports caudal 
epithelial functions and appears to promote 
proliferation in DE
Sox2 1.43 0.01 Sox17 12.55 0.00
Nanog 1.47 0.00 Lgr5 5.39 0.00
Tbx3 3.53 0.00 Nanog 0.20 0.02
Hesx-1 20.56 0.00 Ezr 2.20 0.00
Dppa-1 64.95 0.00 Vill 2.58 0.048
Igf2 3.61 0.00 Krt19 2.34 0.00
Wnt3 0.43 0.00 Krt20 2.84 0.01
Wnt4 0.36 0.00 Igsf8 4.67 0.00
Wnt6 0.36 0.00 Gcnt3 3.51 0.00
Wnt8a 0.48 0.01 Fgfr2 2.81 0.00
Sp8 0.12 0.00 Nek2 2.35 0.01
Lef1 0.34 0.00 HOXA13 downregulates the chromosome 
1 epidermal differentiation complex, is pro-




Fgf8 0.10 0.00 ANXA9 0.48 0.04
Cdx1 2.47 0.00 EVPL 0.61 0.03
Grhl3 5.00 0.00 SCEL 0.52 0.01













Figure 7. HOXA13 counteracts squamous identity and increases growth of esophageal cells. (A) Two models 
were constructed to investigate the function of HOXA13 at the GEJ. One model used EPC2-hTERT, a 
primary immortalized human squamous esophageal cell line, characterized by low HOXA13 expression, 
in which HOXA13 was transduced. Th e second model employed BAR-T, a primary immortalized human 
BE cell line, characterized by high HOXA13 expression, in which HOXA13 was knocked out. (B) H&E 
staining of the squamous esophagus of a patient without BE indicating the expected location of some of 
the products of the Ch1q21.3 epidermal diff erentiation complex along with other genes from the cornifi ed 
envelope of the epidermis. 
which we investigated the eff ect of HOXA13 directly on esophageal cell models. To this end, 
we used CRISPR-Cas9 technology to delete HOXA13 from BAR-T, a primary monoclonal 
immortalized cell line derived from metaplastic tissue of a BE patient, with cells expressing 
both columnar and squamous markers (22). Th ree separate HOXA13 knock-out clones 
were selected to circumvent potential off  target eff ects. Reversely, we provoked lentivirus-
mediated HOXA13 expression in EPC2-hTERT, an immortalized squamous esophageal 
cell line. For these latter experiments we used a mixed cell population of lentivirally 
transduced cells as to avoid clonal artifacts infl uencing results. Transcriptomes in these two 
models (Figure 7A) were contrasted to their respective control lines. Th ere was substantial 
overlap in the gene sets signifi cantly aff ected by losing HOXA13 in BAR-T compared with 
those signifi cantly aff ected by gaining HOXA13 in EPC2-hTERT, taking into account the 
direction of regulation (X2 test: p=4.74·10-34) (see Supplementary Table S3). Investigation 
of this overlap across the two technically independently generated datasets limits the 
incidence of chance fi ndings or single model system bias. Overlapping genes positively 
aff ected by HOXA13 expression in esophageal cells are IL7r, FAM196B, ADAMTS6, 
NRG1, LTBP1, JAG1, ELL2, SMAD7, C12ORF75, AXL, TIPARP, IKBIP, DUSP7, and 
GOLIM4. Downregulated by HOXA13 expression are SERPINB13, MYO5C, KLK7, 
ANXA9, TMPRSS4, TTC9, MATN2, TNFAIP2, RAB27B, HCAR2, C6ORF132, EXPH5, 
MAP3K5, and FUCA1. IPA analysis of the results predicts an increase in “(malignant) 
cell transformation” (z=2.00, p=5.81·10-3) and a decrease in “infl ammation of an organ” 
(z=-2.59, p=8.29·10-3; gene function is described in Supplementary Table S3) in cells 
expressing HOXA13. Intriguingly, HOXA13 downregulates the epidermal diff erentiation 
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complex (EDC); Figure 7B and C). Th e EDC, located on chromosome 1q21.3, contains 
clustered multigene families of genes associated with cornifi ed envelope formation in 
stratifi ed squamous epithelia, such as the S100 and the small proline-rich region (SPRR) 
genes (54). Among the overlapping downregulated genes in both cell models, ANXA9 is 
also associated with diff erentiating keratinocytes (55), and EVPL, SCEL, and KLK7 are 
cornifi ed envelope genes (56-58). EMP1 and SERPINB13 downregulation is associated 
with increased disease severity in gastric cancer (EMP1) and head and neck squamous 
cell carcinoma (SCC) (SERPINB13) (59, 60). See Table 1 for fold changes and q values 
and Supplementary Table S3 for more diff erentially expressed molecules related to 
Figure 7. Continued. (C) HOXA13 leads to a downregulation of genes in the Ch1q21.3 epidermal 
diff erentiation complex in both model systems. A cubic spline fi t of HOXA13 mRNA regulation is shown, 
with the BAR-T control transduced cell line presented compared to its HOXA13 knock-out counterpart, and 
HOXA13 overexpressing EPC2-hTERT cells presented compared to their parental line. (D) HOXA13 knock-
out in a BE cell line reduces the growth of the cell pool, as measured by MTT assay. Mean±SEM, *p<0.05; 
***p<0.001. (E) HOXA13 overexpression in a EPC2-hTERT cell line increases its growth in 3D culture (area 
of spheroids, Mean±SEM, *p<0.05). (F) EPC2-hTERT cells with HOXA13 overexpression are less sensitive to 
bile/acid exposure. MTT data presented as % of corresponding vehicle-treated controls. Mean±SEM, *p<0.05.







morphology. The downregulation of a gene region known to be essential for maintaining 
a squamous phenotype provides mechanistic support to the notion that altered HOXA13 
expression is cardinal for provoking the BE phenotype. 
These experiments also provide mechanistic support for the notion that HOXA13 
expression may offer an explanation as to why BE is prone to progression to EAC. 
HOXA13 mediates down-regulation of the EDC and many EDC and cornified 
envelope genes are progressively down-regulated in the BE to EAC cascade (56, 61). In 
BE, EAC, and esophageal SCC, loss of heterozygosity (LOH) of the EDC is common 
(62-64). Low EDC gene expression predicts chemotherapy non-response and LOH of 
the EDC is associated with reduced survival in curatively treated EAC patients (63, 65). 
In our experimental models, we observed HOXA13-mediated upregulation of genes 
associated with Notch signaling, specifically DLL1, FURIN, and JAG1. Notch signaling 
is associated with malignant transformation (66, 67). In IPA analysis “Non-melanoma 
solid tumor” (z=2.03, p=9.28·10-8) and “invasion of cells” (z=2.08, p=2.47·10-3) were 
shown to be activated by HOXA13, whereas HOXA13 expression negatively influenced 
the “Apoptosis” (z=-1.52, p=2.23·10-3) and “killing of cells” (z=-2.03, p=2.03·10-3) 
categories. Many individual genes showed differential regulation in a pro-oncogenic 
direction (see Supplementary Table S3).
In conclusion, using HOXA13 knock-out and overexpression in a Barrett’s and a 
squamous cell line, we show that HOXA13 downregulates the epithelial differentiation 
complex and other cornified envelope genes which normally function to maintain 
squamous epithelial morphology and act as tumor suppressor genes. Additionally, 
Notch signaling is overexpressed and many individual genes show differential regulation 
in a pro-oncogenic direction.
HOXA13 supports columnar phenotype in vitro and in vivo and provides prolife-
rative advantage in the presence of  bile/acid
Having established the transcriptional effect of HOXA13 on BAR-T and EPC2-hTERT 
cells, we next investigated the functional consequences of HOXA13 in these cells. As 
was seen for mESCs, HOXA13 expression significantly enhances the growth-rate of 
esophageal cells. For BAR-T cells, a proliferative advantage of HOXA13 expression 
was seen in 2D cultures (Figure 7D), while for EPC2-hTERT the positive effect of 
HOXA13 expression on cell growth was more noticeable under 3D culture conditions 
(Figure 7E). Moreover, HOXA13 expression decreases the sensitivity of keratinocytes 
to bile/acid exposure (Figure 7F), consistent with the notion that HOXA13 confers 
cellular protection under GERD-like conditions. 
To gain further insight into the role of HOXA13 in cell morphology and organization, 
we made use of the fact that EPC2-hTERT cells can be differentiated in 3D spheroid 
cultures, and become organized in layers with a more flattened cytological aspect in the 
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middle of spheroids and high expression of keratinization markers such as involucrin, 
similar to esophageal stratifi ed epithelium (see example in Figure 8Ai for diff erentiated 
morphology) (36). Upon overexpression of HOXA13, EPC2-hTERT spheroids increase 
in size while maintaining a less diff erentiated phenotype (undiff erentiated morphology, 
Figure 8A). Quantifi cation of these morphological states indicates that in control 
cultures, 80% of spheroids attain a stratifi ed epithelial phenotype, while overexpression 
of HOXA13 reduces this number to 28.6% (p<0.05, Figure 8Aii). Th is was further 
confi rmed by staining for involucrin as a marker of keratinization, showing a decreased 
expression in spheroids derived from HOXA13-overexpressing EPC-hTERT cells. Th us, 
in primary immortalized esophageal cells HOXA13 overexpression reduces keratinization 
(Figure 8Ai and Aiii).
We further investigated the morphological role of HOXA13 in the BE-derived BAR-T 
cell line. In 2D cultures, an altered spatial distribution in growth pattern was observed, 
Figure 8. HOXA13 supports intestinal-type columnar epithelial diff erentiation. (A) HOXA13 overexpression 
impairs squamous diff erentiation of EPC2-hTERT spheroids as seen from the representative pictures (Ai) 
and quantitative assessment of morphologies based on H&E (Aii) or anti-involucrin (IVL) IHC (Aiii). 
Median with interquartile range, *p< 0.05. (B) HOXA13 KO aff ects spatial distribution of BAR-T cells. 
Line at mean, ***p<0.001. (C) Th e length of columnar and mixed BAR-T epithelium decreases upon 
HOXA13 KO in the rat trachea in vivo tissue reconstitution model. Mean±SEM, *p<0.05. 







with cells growing more closely together in the absence of HOXA13 suggesting eff ect on 
tissue morphology (Figure 8B). Th e BAR-T cell model also allows testing the eff ect of 
HOXA13 on columnar versus squamous diff erentiation in in vitro and in vivo settings. A 
3D in vivo tissue reconstitution model was employed in which BAR-T cells were grafted 
in the lumina of devitalized and denuded rat tracheas and implanted in NOD SCID 
mice. Under these conditions, parental non-transfected BAR-T cells produce both 
intestinal-type columnar epithelium and stratifi ed squamous epithelium from the same 
clone. Hence this cell line has the potential to produce two types of morphologically 
distinct epithelia (22, 68) (Supplementary Figure S9 and Figure 8D). Th us the 
epithelium in the model fi nds itself on a tipping point between both morphologies. Th is 
characteristic makes the in vivo tissue reconstitution model ideally suited for studying the 
infl uence of modulators of morphology, i.e. to show if the modulator favors intestinal-
type columnar epithelium or stratifi ed squamous epithelium. Studying the eff ect of 
Figure 8. Continued. (D) Representative examples of H&E (Di), PAS staining (Dii), anti-IVL IHC (Diii) of 
BAR-T epithelium from the rat trachea in vivo tissue reconstitution model. H&E staining shows more layers of 
cells in HOXA13+ wild type cells. PAS stains polysaccaride molecules, and positivity is indicative of goblet-like 
cells. Th e arrows point to PAS positivity, which is present in the right panel but not in the left panel, where the 
BAR-T HOXA13- cells are shown. IVL staining is strong in morphologically squamous cells in the left hand 
panel and weaker in the HOXA13+ epithelium. (E) HOXA13- and HOXA13+ representative pictures of H&E 
staining (Ei), PAS staining (Eii) and IVL IHC (Eiii) of the BAR-T organotypic cell culture system indicate 
that HOXA13 KO reprograms the columnar epithelium phenotype towards squamous keratinized epithelium. 
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HOXA13 knock-out, two important observations were made. Firstly, HOXA13 knock-
out decreases the length of columnar-like epithelium which contains PAS positive cells 
and is negative for involucrin (Figure 8C, D, E). Thus, loss of HOXA13 counteracts the 
proliferation of the intestinal-type columnar epithelium while the stratified squamous 
epithelial proliferation remains present. Secondly, HOXA13 knock-out impairs epithelial 
proliferation in general, as inferred from the thickness of the epithelial layer (Figure 
8Di; Supplementary Figure S9B). In vitro 2D organotypic ALI cultures of these cell 
lines confirm the in vivo findings, with HOXA13 knockout reprogramming the BAR-T 
epithelial cells towards a squamous keratinized differentiated epithelium (Figure 8E). 
In conclusion, HOXA13 supports intestinal-type columnar epithelial differentiation and 
proliferation of the Barrett’s epithelium confirming the notion that HOXA13 expression 
can mediate both a competitive advantage as well as a predisposition to the formation 
of columnar phenotypes. 
Discussion
In this study, we extensively characterized HOX gene expression and localization in mice 
and men, demonstrating a collinearity of these genes along the gastrointestinal tract. 
Following in depth analysis of one of these HOX genes, HOXA13, we observed single 
HOXA13-positive cells in the upper GI tract, which present rare exceptions to the HOX 
gene collinearity theory and are not reported before to our best knowledge. Specifically, 
in the normal physiology of the esophagus and proximal stomach, non-squamous 
structures such as the epithelium at the GEJ, glandular cells of ESMGs and glands 
of stomach contain single cells expressing HOXA13. The fact that these cells have not 
been described before may be a reflection of the fact that homogenization of tissues for 
qPCR masks this fraction, and that single cell analysis of the GI tract for this gene has 
not been performed before. We observe that GI pathology with distal phenotypes like 
intestinal metaplasia of the esophagus and stomach are characterized by an expansion 
of HOXA13-positive cells, while conversely, a relatively low expression of HOXA13 is 
found in the phenotypically rostral Paneth cell metaplasia and pyloric metaplasia of the 
colon, compared to the surrounding physiological tissue.
It is clear that in normal physiology, HOXA13 contributes to the distal phenotype of the 
caudal GI tract, begging the question as to the role and origin of the HOXA13-expressing 
compartment now observed in the upper GI tract. We demonstrate that esophageal 
HOXA13-positive cells express columnar and BE markers and show gene expression 
patterns overlapping with BE-derived cells. Functionally, HOXA13 provides cells with 
several properties required for development of a BE segment. HOXA13 maintains cells in a 
stem-like progenitor state, while conferring a proliferative advantage, and resistance to bile 
and acid exposure. Furthermore, in cells that are lineage committed, HOXA13 supports 







a phenotypically columnar phenotype, most likely partly driven by downregulation of 
the chromosome 1 epidermal differentiation complex. Thus, our data are consistent with 
the hypothesis that BE arises as a consequence of the expansion of resident HOXA13-
positive cells under abrasive environments such as GERD. Several potential theories have 
been proposed as to the origin of BE: transdifferentiation of basal cells in the squamous 
epithelium, extension of a special population of cells from the gastroesophageal junction, 
repopulation of the esophagus after injury with cells derived from progenitors ESMGs 
or ducts, resident embryonic stem cells or circulating bone marrow cells (69). These 
potential sources of esophageal columnar epithelium are not mutually exclusive, and BE 
may have more than one precursor cell or location. Our study supports the previously 
proposed hypothesis that BE may originate from ESMGs and the GEJ as HOXA13 is 
expressed in OLMF4+, LEFTY1+ cells of ESMGs, recently suggested as a cell of BE origin 
(44). The fact that in addition to the GEJ, rare HOXA13+ cells are found in the human 
esophagus and stomach, is consistent with the observation that after esophagogastrostomy 
BE can reoccur in patients, indicating that the involvement of the GEJ is not an absolute 
prerequisite for the development of BE (70). Furthermore, our data show that HOXA13 
is already present at stem cell level, supportive of the notion that BE may arise from a 
cell with stem-cell like characteristics. While HOXA13 expression overlaps greatly with 
KRT7, a columnar cytokeratin seen in Barrett’s, we did not observe direct transcriptional 
overlap with the previously described KRT7+KR14+TP63+ cell of BE origin. However, 
KRT7+KR14+TP63+ cells gave rise to BE-like epithelium only upon ectopic expression 
of CDX2 (71). Lineage-tracing studies are needed to further confirm whether one or 
more types of cells of origin might exist for BE. While we focused on HOXA13 here, it is 
conceivable that other HOX paralogues are involved in BE pathophysiology, in particular 
caudal genes such as HOXA10, 11, B13, and C10 are interesting candidates for further 
investigation, in particular as disruption of collinearity was reported for cluster B in BE 
(9) and in duodenum of murine embryos (12). 
BE is considered as the precursor lesion for EAC, a dangerous form of cancer of which the 
incidence has substantially increased in recent decades. Increased insight into the patho-
genesis of BE may aid development of novel prevention and treatment strategies for EAC. 
HOXA13 is involved in ESCC (72) and other types of cancer (73-76). Here we show that 
expression of HOXA13 also increases in EAC and colorectal cancer, provides proliferative 
advantage to the cells and activates cancer-related genes transcription like Notch signaling. 
Hence, we speculate that HOXA13 may play a role in BE progression towards EAC. 
In toto, the present study identifies a previously unrecognized importance of regional 
patterning by HOX genes in the gut epithelium. In Barrett’s esophagus, gastric IM, 
and heterotopia of the upper GI-tract, a colon-like HOX gene expression is present, 
especially characterized by HOXA13 upregulation. Strikingly, single cells expressing the 
generally thought to be distally-restricted HOXA13 gene are present in the physiological 
upper GI tract, in particular the GEJ, where it supports a columnar phenotype and 
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may confer a relative competitive advantage. Thus, HOXA13 mediates BE phenotype 
and proliferative potential and hence appears a rational target for strategies aimed at 
counteracting EAC development.
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Supplementary Figure S1. Locations of forceps biopsies taken along the human GI-tract and sections of 
murine GI-tract analyzed. (A) Location of the forceps biopsies taken along the GI-tract are indicated by 
number in the schematic illustration of the GI-tract: 1) esophagus, 2) stomach, 3) duodenum, 4) jejunum, 
5) proximal ileum, 6) distal ileum, 7) ascending colon, 8) descending colon and 9) sigmoid/rectum. Lesions 
studied: a) gastric inlet patch; b) CLE, BE, EAC; c) gastric IM; d) Meckel’s diverticulum; e) pyloric and 
Paneth cell metaplasia (from the colon). (B) Sections of mouse GI-tract used: 1) esophagus, 2) stomach, 
3) duodenum, 4) jejunum, 5) proximal ileum, 6) distal ileum, 7) cecum and proximal colon, 8) proximal 
colon and distal colon and 9) distal colon.
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Supplementary Figure S2. HOX cluster gene expression along the adult human and mouse gut. (A) 
Overview of HOX cluster gene expression in the diff erent epithelial regions along the human and mouse 
adult GI tract. Th e Y-axis represents the fold changes of mRNA expression relative to the average mRNA 
expression of all HOX genes of a given cluster. (B - E) Individual HOX gene expression of the HOXA, B, 
C, and D clusters is depicted. Th e Y-axis represents the fold changes of mRNA expression relative to the 
average mRNA expression of the depicted HOX gene. Individual mice are not shown. Error bars represent 
the standard error of the mean (SEM). Human data, n=3. Mouse data, n=4.
A











Supplementary Figure S2. Continued.











Supplementary Figure S2. Continued.







Supplementary Figure S3. HOX 
coding is established at the level of 
the stem cell. Public data of Wang et 
al. contains the mRNA expression of 
human stem cells isolated from the 
GI-tract and either cultured as stem 
cells or diff erentiated in an air-liquid 
interface (ALI). Right column: HOXB, 
C, and D cluster gene expression in 
the large (n=3 in technical duplicate) 
compared to the small intestine 
(n=3 in technical duplicate). Left 
panels: HOXB, C, and D cluster gene 
expression in Barret’s esophagus (BE, 
n=12) vs squamous esophagus (n=2) 
in technical duplicates are depicted 
for stem cell cultures and n=1 each 
for ALI diff erentiated samples in 
technical duplicates. Normalization 
was performed by setting mRNA 
expression to 1 for the small intestine 
or squamous esophagus. HOX gene 
expression in stem cell and ALI 
cultures are similar, which is not 
seen in the dataset in general. HOXB 
cluster genes have a higher expression 
in the large versus the small intestine 
(left column). No clear regulation 
of the HOXC or D clusters is seen, 
with exception of an upregulation 
of HOXC10 in the ascending colon. 
HOXB cluster genes are upregulated 
in BE stem cells vs squamous 
esophagus, including mid cluster and 
5’ HOXB genes. HOXC10 is the most 
pronounced HOXC gene upregulated 
in BE stem cells. *p<0.05; **p<0.01; 
***p<0.001; NA: not available.
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Supplementary Figure S4. HOX cluster gene expression in BE, esophageal adenocarcinoma and gastric 
IM, and colon. Comparison of the mRNA expression levels of the squamous esophagus from GERD 
patients (n=13), BE (n=13), EAC (n=9), IM of the stomach (n=12), and material from the colon (n=3). 
Expression in BE was compared to expression in the squamous esophagus of matched samples from the 
same patients (SQ (GERD)) by two sided Student’s t-tests. *p<0.05; **p<0.01; ***p<0.001. Y-axis values 
represent the fold change in mRNA expression in relation to the average mRNA expression of all HOX 
genes in all samples. Error bars represent the SEM.







Supplementary Figure S5. Gene expression of lncRNA HOTTIP and lncRNA HOTAIR, in the normal 
squamous esophagus and BE tissue from BE patients. (A) HOTTIP expression, normalized to mean 
expression in the squamous esophagus, is overexpressed in BE as tested with a Wilcoxon signed rank test. 
Matched squamous esophageal and BE were taken from the same patient (n=13). (B, C) Correlations 
between expression levels of HOTTIP and HOTAIR and HOXA13 in squamous and BE tissues were tested 
with a non-parametric Spearman test. HOTTIP expression does not correlate with HOXA13 in normal 
squamous esophagus (B), but does correlate to HOXA13 in BE tissue (C). (D) HOTAIR is overexpressed 
in BE tissue (Wilcoxon signed rank test) and does not correlate with HOXA13 expression (E, F). *p<0.05; 
**p<0.01; ***p<0.001. Error bars represent the SEM.
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Supplementary Figure S6. Expression of Hoxa13 in murine GI tract. Anti-GFP IHC of Hoxa13-GFP 
mouse model was performed on swiss roles of bowels isolated from three Hoxa13+/- mice (A-C) and one 
Hoxa13-/- negative control mouse (D). Overall presentation of swill role and close ups of proximal (1) and 
distal (2-4) colon. (E) Th e distal Hoxa13 expression border is the anal SCJ (confocal images).







Supplementary Figure S6. Continued.
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Supplementary Figure S6. Continued.







Supplementary Figure S7. Expression of Hoxa13 in murine upper GI tract. Anti-GFP IHC of Hoxa13-
GFP mouse model was performed on upper gastrointestinal tract isolated from three Hoxa13+/- mice (A-C) 
and one Hoxa13-/- negative control mouse (D). Magnifi cation of squamous esophagus and stomach 
indicated in the overview image are presented on the right.
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Supplementary Figure S8. (A, B) HOXA13 expression as measured by RNA ISH in a representative 
example of an adult human GEJ with magnification panel of: A – esophagus, B – GEJ area, C – proximal 
stomach. (C, D) HOXA13 expression as measured by RNA ISH in a representative example of a fetus 
human GEJ with magnification panel of: A – esophagus, B – GEJ area, C – proximal stomach.
A












Supplementary Figure S8. Continued.
C











Supplementary Figure S9. Proof of the human origin of epithelium in the rat trachea in vivo tissue 
reconstitution model. (A) Staining of the in vivo tissue reconstitution model with intestinal/glandular 
and squamous markers shows that parental BAR-T cells form intestinal-type columnar epithelium (left), 
squamous epithelium (middle), and multi layered epithelium with mixed phenotype (right) from the same 
clone. Human origin of the epithelium was confi rmed by staining for human mitochondria. (B1) HOXA13- 
and (B2) HOXA13+ representative examples of the BAR-T epithelium stained for human mitochondria.







Supplementary Figure S10. Summary fi gure.
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Supplementary Table S1. Differentially regulated genes in definitive endoderm versus non-differentiated 
KH2 mESCs. Pluripotent mESC gene expression was compared to CXCR4+/E-cadherin+ FACS selected 
definitive endoderm cell gene expression. Both samples did not express HOXA13. Common definitive 
endoderm or pluripotency markers are included.
Fold change and q value of CXCR4+/E-
cadherin+ vs non-differentiated mESCs cells Reference
Definitive endoderm markers
Sox17 12.55 0.00 [2-5]
Foxa1 4.30 0.00 [3, 5]
Gata4 6.86 0.00 [2]
Lgr5 5.39 0.00 [6]
Pax3 25.91 0.00 [3]
Bmp2 16.32 0.00 [4]
Tacstd2 17.55 0.00 [3]
Bmp4 4.73 0.00 [4]
Pluripotency markers
Nanog 0.20 0.02 [4]
Tcl1 0.01 0.00 [7]
Dppa3 0.02 0.00 [8]







Supplementary Table S2. HOXA13 induced differentially regulated genes in mouse definitive endoderm 
cells. Molecules associated with epithelial identity, the cytoskeleton (microvilli, keratins, and the tetraspan 
network), exocrine function, oncogenic molecules, and specific signaling pathways were included. All fold 
change and q values depicted pertain to the BAR-T dataset. Information in the “known function” and 
“Detailed description” columns was obtained through non-systematic review and should not be considered 
as an exhaustive overview of the literature. In the first column, molecules of which the direction of regulation 
by HOXA13 is in line with their relative expression in the distal compared to the proximal GI-tract are 









and q value of 
HOXA13 +/- 
CXCR4+/E-
cadherin+ DE Detailed description 
Epithelial identity: EMT was downregulated (p value 6.69E-6, z-score -3.184), i.e. the HOXA13 
overexpressing definitive endoderm cells have a more epithelial identity. 
Cdh1 1.99 0.10 E (epithelial)-cadherin, links the actin cytoskeleton to cell-cell 
adhesions, inactivation was found to be associated with EMT, leading to 
diffuse gastric cancer and lobular breast carcinomas [9].
Cdh2* 0.46 0.03 N (neuronal)-cadherin, was found to create cell-adhesion zippers [10]. 
Vim* 0.43 0.10 Vimentin, from the intermediate filaments type III gene family, was 
found to be a protein binding to actin associated with the actin core 
bundle of the brush border [11].
Bmp7† 3.49 0.00 Was found to decrease EMT in mouse kidney tubule cells [12].
Jag1 0.38 0.00 Jagged 1, is a ligand of the NOTCH pathway, this pathway was found 
to be associated with malignant transformation [13-15].
Mgat5* 4.31 0.00 Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase, was found to enhance EMT in mouse 
keratinocytes [16].
Prrx2* 0.40 0.03 Paired mesoderm homeobox protein 2, was found to promote EMT in 
breast cancer [17].
Scube3 0.31 0.00 Signal peptide, CUB domain and EGF like domain containing 3, was 
found to regulate EMT in lung cancer [18].
“Formation of epidermis” (p value 3.68E-12, z-score 0.908) was upregulated, in line with the more 
epithelial character of HOXA13+ cells.
Pkp3 21.18 0.00 Plakophillin was found to be a desmosomal component [19]. Was found 
to mediate desmosome assembly and adherens junction maturation [20].
Dsc2 2.29 0.01 Desmocollin 2, desmosome component [21].
Emp1† 1.97 0.00 Epithelial membrane protein 1, was found to be associated with 
oncogenesis [22].
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Evpl† 2.44 0.01 Envoplakin, cornified envelope gene, was found to be downregulated in 
ESCC [24].
An upregulation of “actin cytoskeleton signaling” (p value 3.74E-2, z-score 3.000) was the most 
pronounced z-score in the pathway analysis of IPA, and directly related to its morphological phenotype 
[25]. In line with this is the activation of “integrin signaling” (p value 1.34E-2, z-score 1.732).
Microvilli:
Clic5* 3.51 0.00 Chloride intracellular channel 5, was found to form a complex with 
EZR and PODXL (FC1.61, q=0.16). Was found to be associated with 
increased migration and invasion in a hepatocellular carcinoma (HCC) 
cell line together with CLIC5 [26].
Ezr* 2.20 0.00 Ezrin, cytovillin, or villin-2, a cytoplasmic membrane protein and protein-
tyrosine kinase substrate in microvilli. It was found to be an intermediate 
between actin cytoskeleton and plasma membrane. Was found to 
maintain cell surface structure important for adhesion and migration [27]. 
In ESCC it was found to be associated with reduced survival [28-30]. 
Pls3 2.55 0.00 Plastin 3, was found to be a microvillus component [31]. 
Overexpression increases length and density of microvilli. Abundant 
Pls3 is associated with cisplatin and UV radiation resistance [32, 33]. 
Vav3* 2.53 0.03 Vav guanine nucleotide exchange factor 3 is associated with actin 
cytoskeletal rearrangements. Vav3 was found to be overexpressed in BE 
and EAC [34].
Vill* 2.58 0.048 Villin like, was found to be associated with and modifies actin filaments 
in microvilli [35].
“RhoA signaling” was activated (p value 1.12E-2, z-score 2.12), although Rhoa itself was not 
differentially regulated. Villi in RhoA KO mice are noticeably shorter and intestinal epithelial 
architecture was disorganized compared to that of WT mice [36].
Atp8b1* 2.55 0.00 ATPase phospholipid transporting 8B1, was found to be expressed in 
differentiated enterocytes and where it was required for apical protein 
expression and microvillus formation [37, 38].
Eps8* 1.84 0.046 Epidermal growth factor receptor pathway substrate 8, was found to be 
required for intestinal cell apical morphology [39]. KO mice have a 25% 
reduction in intestinal microvilli length [40]. Eps8L1 (FC2.98, q=0.02).
Myo5b* 2.18 0.03 Myosin5B mutations cause microvillus inclusion disease, and disrupt 
epithelial cell polarity. It is essential for microvillus function [41].
Keratins:
Krt15† 2.50 0.054 Keratin 15, was found to be expressed in the esophagus and glandular 
prostate cells. Long-lived keratin 15+ esophageal progenitor cells were 
found to contribute to homeostasis and regeneration [42].
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KRT19* 2.34 0.00 Keratin 19, is a columnar keratin [14]. 
KRT20* 2.84 0.01 Keratin 20, is a more distal GI tract marker [43]. 
Krt81 4.01 0.00 Keratin 81, is a hair keratin. It was found to be expressed in normal 
and breast cancer cells and contributes to their invasiveness [44]. 
In PDAC patients receiving chemotherapy it was associated with a 
dismal prognosis [45]. It is associated with a malignant phenotype in 
hepatoblastoma patients [46]. 
Tetraspan network: by connecting several molecules, the tetraspan network may organize the 
positioning of cell surface proteins and play a role in signal transduction, cell adhesion, and motility 
[47].
Cd9 2.03 0.04 Motility related protein-1 clustering was found to be accompanied by 
the formation of microvilli that protrude from either side of adjacent 
cell surfaces, thus forming structures like micro-villi zippers [48]. 
Cd82† 4.12 0.00 CD82 was found to be associated with favorable outcomes in cancer 
patients [49].
Igsf8 4.67 0.00 Immunoglobulin superfamily, member 8 links the tetraspanin web 
to the actin cytoskeleton through their direct association with ezrin-
radixin-moesin proteins [50].
Exocrine function: molecules from the list “development of exocrine gland” (p value 8.50E-7, z-score 
0.914) in IPA:
Dkk1* 0.36 0.03 Dickkopf WNT signaling pathway inhibitor 1, was found to decrease 
differentiation of mucous secretory cells in the mouse small intestine 
[51].
Erbb3 2.89 0.00 Human epidermal growth factor receptor 3 was found to limit the 
number of Paneth cells [52]. Paneth cell metaplasia in the distal colon 
occurs exclusively in mucosa affected by inflammatory bowel disease, 
even in the inactive phase [53]. This is in line with our observation that 
Paneth cell metaplasia in the colon is characterized by a decrease in 
HOXA13 expression (see main text). As a decrease in Erbb3 signaling 
which subsequently does not limit the number of Paneth cells could 
lead to an increased Paneth cell number. Physiological Paneth cell 
distribution is inverse to HOXA13 expression, also in line with the 
observation in Paneth cell metaplasia. 
Fgfr2 2.81 0.00 Fibroblast growth factor receptor 2, inhibition of Fgfr2b in rat in organ 
culture decreases development of pancreas exocrine cells [54]. 
Gcnt3* 3.51 0.00 Glucosaminyl (N-acetyl) transferase 3, mucin type, was found heavily 
expressed in colon, small intestine, trachea, and stomach, where mucin 
is produced [55]. 
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Ncoa2 1.92 0.00 Steroid receptor coactivator 2 was found critical for progesterone-
dependent uterine function and mammary morphogenesis in the mouse 
[56]. 
Shh signaling:
Ptch1* 2.26 0.02 Patched 1, its levels correlate with Hedgehog pathway activity [57]. It 
was found increased in BE, and may contribute to its etiology [58].
Smo 0.62 0.04 Smoothened, frizzled class receptor, was found to decrease SMO 
expression correlates with less Hedgehog pathway activity. Hedgehog 
pathway activity serves to induce the proximal tractus, especially the 
esophagus [59]. 
Wnt signaling:
Dkk1 0.36 0.03 Dickkopf WNT signaling pathway inhibitor 1, see above.
Fzd7 2.10 0.03 Frizzled class receptor 7, deletion in mouse adult intestinal epithelium 
was found to lead to stem cell loss in vivo and organoid death in vitro 
[60]. 
Wnt2b 0.23 0.00 Wnt family member 2b.
Wnt3* 0.47 0.053 Wnt family member 3 was found to be necessary and sufficient to 
induce Paneth cell formation [61]. Wnt3 is produced specifically by 
Paneth cells [62]. 
Wnt5a* 0.37 0.03 Wnt family member 5a, overexpression from 10.5 dpc until 18.5 dpc 
was found to result in drastic shortening of the small intestine, colon, 
cecum and stomach [63]. It inhibits proliferation of intestinal epithelial 
stem cells [64]. It up-regulates the expression of the tumor suppressor 
15-PGDH and induces differentiation of colon cancer cells [65].
Wnt10a 3.21 0.00 Wnt family member 10A was found to promote an invasive and self-
renewing phenotype in ESCC [66].
Sox signaling:
Sox9* 2.55 0.00 SRY-box 9, was found to be correlated with ERBB3 in pancreatic 
ductal AC [67]. Sox9 induces Paneth cells which is not in line with the 
function of Erbb3 and Wnt3 [68]. SOX9 is essential in the development 
of embryonic CLE, but is switched off in post-natal life, and is re-
expressed again in BE [69-72]. Sox9 was found to drive columnar 
differentiation of SQ [73].
Sox11* 0.60 0.00 SRY-box 11, knock out was found to cause hypoplasia of the lung, 
stomach, and pancreas [74]. 
Sox13 3.03 0.00 SRY-box 13, expressed in pancreas and liver, an autoantigen in primary 
biliary cirrhosis, Sox13 was found to inhibit canonical Wnt signaling in 
T cells [75].
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Glypicans:
Gpc1 2.41 0.00 Glypican 1, can be a biomarker for relapse of stage III CRC and may be 
involved in EMT activation, invasion, and migration of CRC [76]. It 
was found to be a marker of pancreatic cancer and ex vivo it appears to 
have an oncogenic role [77]. GPC1 is an independent prognostic factor 
in ESCC [78].
Gpc2 0.51 0.049 Glypican 2, a neuroblastoma oncoprotein and candidate 
immunotherapeutic target [79]. 
Gpc3 0.23 0.00 Glypican 3, is a fetal gut marker [80].
Gpc6 0.24 0.00 Glypican 6, was found to be hypermethylated in cancer and mRNA is 
down-regulated [81].
Interleukin:
Il1rn 5.15 0.00 Interleukin 1 receptor antagonist, was found to be downregulated in BE 
and EAC [82] typical SQ marker, downregulated in ESCC [83].
Il5ra 3.06 0.00 Interleukin 5 receptor subunit α, heterozygous mutants were more 
frequent in atopic dermatitis of Koreans [84], which implicates il5ra in 
epithelial homeostasis.
Il22ra1 3.10 0.01 Interleukin 22 receptor subunit α 1, was found to mediate fucosylation 
promotes intestinal colonization resistance to E. faecalis [85]. It was 
found to have a higher expression in the colon compared to the cecum 
in line with the expression of HOXA13 in the colon with exception of 
the cecum [86].
Apoptosis/necrosis:
Casp8* 2.30 0.00 Caspase 8, high Caspase-8 was found to be a negative markers of OS 
[87]. 
Cxcl1* 3.15 0.00 CXC motif chemokine ligand 1, was found important for mucosal 
barrier [88].
Ripk3 2.19 0.04 Receptor interacting serine/threonine kinase 3, a substrate of caspase 
8 [89, 90]. The RIPK1-RIPK3 necrosome was found to promote 
pancreatic oncogenesis through upregulation of the chemokine CXCL1 
(See below) [91]. Loss of RIPK3 appears to promote tumors in the 
colon [92].
BE/metaplasia specific, oncogenic molecules:
Anxa1† 1.69 0.00 Annexin A1, was found to promote the proliferation of ESCC cells [93]. 
High expression is frequent in EAC and GEJ AC, correlates with more 
advanced pathologic T stage and the presence of distant metastasis, and 
is an independent prognostic factor for patient survival [94].
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Artn 2.21 0.04 Artemin, is hypoxia responsive and was found to promote oncogenicity 
and increased tumor initiating capacity in HCC [95].
Fgfr2 2.81 0.00 Fibroblast growth factor receptor 2, has been found to be highly 
expressed early in progression from BE to EAC [96].
Fgf13 2.37 0.02 Fibroblast growth factor 13, tumor suppression by TP53 was found to 
be involved in inhibiting FGF13 [97].
Sparc 0.41 0.00 Secreted protein acidic and cysteine rich, expression correlates with 
matrix metallopeptidase 2 (MMP2; FC=0.25, q=0.00) expression 
in esophageal tumors, and high SPARC expression was found to be 
correlated significantly with lymph node metastasis and poor patient 
prognosis [98].
Oncogenic molecules:
Atp2c2* 7.38 0.00 ATPase secretory pathway Ca2+ transporting 2, the Orai1-Atp2c2 
complex was found to be associated with constitutive store-independent 
Ca2+ signaling which promotes tumorigenesis [99].
Cd55 4.79 0.00 Decay accelerating factor, was found to prohibit formation of the 
membrane attack complex indirectly [100].
Ezr* 2.20 0.00 Ezrin, was found to be associated with reduced survival in ESCC [28-
30]. 
Nek2* 2.35 0.01 NIMA related kinase 2, was found to be overexpressed in a wide 
variety of human cancers implicating in various aspects of malignant 
transformation, including tumorigenesis, drug resistance and tumor 
progression. NEK2 inhibitors are being developed [101].
Nkd1* 0.22 0.00 Naked cuticle homolog 1, downregulation was found to promote HCC 
progression and promotes gastric cancer migration and invasion [102, 
103]. NKD1 expression is reduced in HCC and is associated with a poor 
prognosis [104].
Pim1* 2.61 0.00 Pim-1 proto-oncogene, serine/threonine kinase, was found to regulate 
glycolysis and promotes tumor progression in HCC [105]. Pim1 is a 
pro-survival kinases that is commonly amplified in cancer [106].
Slc2a1 2.01 0.01 Solute carrier family 2 member 1, was found to be a marker of HGD, 
EAC and gastric cancer [107, 108]. Slc2a1 expression in CRC is 
independently associated with poor prognosis [109].
Spink6 15.13 0.00 Serine peptidase inhibitor, Kazal type 6, in nasopharyngeal carcinoma 
was found to promote metastasis [110].







Supplementary Table S3. HOXA13-induced differentially regulated genes in the BAR-T dataset. Multiple 
testing corrected significantly differentially regulated genes in the same direction in both the BAR-T and 
EPC2-hTERT dataset (n=28); molecules which have been associated with morphological characteristics 
in literature; molecules, not described in the main text, which are associated in literature with oncogenic 
characteristics are described in more detail. All FC and q values shown pertain to the BAR-T dataset. 
Information in the “known function” and “Detailed description” columns was obtained through non-
systematic review and should not be considered as an exhaustive overview of the literature.
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All multiple testing corrected, significantly regulated genes, in the same direction in both the BAR-T 
and EPC2-hTERT datasets. 
IL7R 3.07 0.00 immunity Interleukin 7 receptor, blockade of the IL-7/IL-7R 
signaling pathway was found to render T cell-deficient 
mice more sensitive to chemically-induced intestinal 
epithelial cell damage and subsequent colitis [111].
FAM196B 2.32 0.02 cancer Family with sequence similarity 196 member B, was 
found to promote proliferation of gastric cancer cells 
through the AKT signaling pathway [112].
ADAMTS6 2.13 0.03 cancer ADAM metallopeptidase with thrombospondin type 
1 motif 6, is upregulated in breast cancer where it was 
found to suppress tumor progression via the ERK 
signaling pathway [113, 114].
NRG1 2.07 0.02 cancer Neuregulin 1, ligand of ERBB3, paracrine NRG1/
ERBB3 signaling was found to promote CRC cell 
progression, and high NRG1 expression is associated 
with poor prognosis in CRC [115].
LTBP1 1.94 0.02 cancer Latent transforming growth factor β binding protein 1, 
its expression increases with glioma progression [116]. 
JAG1 1.85 0.04 morphology Jagged 1, is a ligand of the NOTCH pathway, this 
pathway was found to be associated with malignant 
transformation [13-15].
ELL2 1.82 0.02 cancer Elongation factor for RNA polymerase 2, was found 
to be part of the super elongation complex and in 
combination with HOXA9 and 10 associated with 
leukemia. ELL2 regulates DNA non-homologous end 
joining repair in prostate cancer cells [117].
SMAD7 1.80 0.05 cancer/
immunity
SMAD family member 7, is a TGFβ type 1 receptor 
antagonist. It was found to block TGFβ1 and activing 
from binding to the receptor, which prevents access to 
SMAD2 [118].
C12orf75 1.78 0.03 cancer Chromosome 12 open reading frame 75, is 
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AXL 1.70 0.04 immune 
regulation, 
cancer
AXL receptor tyrosine kinase, was found to be a 
negative predictor of survival in EAC and ESCC [120]. 
AXL also contributes to a reduction in inflammation 
(Dransfield and Farnworth, 2016). 
TIPARP 1.57 0.00 cancer TCDD inducible poly(ADP-ribose) polymerase, was 
found to be overexpressed in meningioma and its locus 
was associated with ovarian cancer in a GWAS [121, 
122].
IKBIP 1.56 0.02 cancer Inhibitor of nuclear factor kappa-B kinase-interacting 
protein, was found to be a TP53 target gene with pro-
apoptotic function [123].
DUSP7 1.52 0.04 cancer Dual specificity phosphatase 7, was found to be 
overexpressed in myeloid leukemia and other 
malignancies [124].
GOLIM4 1.47 0.04 morphology Golgi integral membrane protein 4, was found to be 
essential for podocyte cytoskeleton [125]. It mediates 
endosome exit [126].
FUCA1 0.69 0.02 cancer α-L-fucosidase 1, loss-of-function mutations are found 
in several cancers, its expression is reduced in CRC, and 
low expression is associated with poorer prognosis in 
several cancers [127]. Has high expression in the distal 
vs the proximal GI-tract [128].
MAP3K5 0.63 0.04 immune 
regulation, 
cancer
Mitogen-activated protein kinase kinase kinase 5, also 
called apoptosis signal-regulating kinase 1. Knockdown 
of MAP3K5 blocked dextran sulfate sodium induced 
tight junction disruption and subsequent barrier 
dysfunction [129].
EXPH5 0.56 0.04 morphology Exophilin 5, mutations result in a skin fragility 
phenotype [130].
C6orf132 0.56 0.03 unknown Chromosome 6 open reading frame 132. 
HCAR2 0.50 0.05 cancer/
immunity
Hydroxycarboxylic acid receptor 2, is a G-protein-
coupled receptor for the bacterial fermentation 
product butyrate and was found to function as a tumor 
suppressor in colon [131, 132].
RAB27B 0.50 0.03 cancer RAB27B, member RAS oncogene family, decreased 
expression was found to correlate with metastasis and 
poor prognosis in CRC [133]. However, it prevented 
cancer invasion and proliferation in pancreatic ductal 
AC cells [134].
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TNFAIP2 0.49 0.03 cancer TNFα induced protein 2, downregulation was found to 
suppress proliferation and metastasis in ESCC through 
activation of the Wnt/β-catenin signaling pathway 
[135].
MATN2 0.49 0.04 cancer Matrilin 2, was identified as a tumor suppressor in 
HCC [136].
TTC9 0.48 0.02 cancer Tetratricopeptide repeat domain 9, up-regulation is 
coupled with progesterone-mediated growth inhibition 
and induction of focal adhesion [137].
TMPRSS4 0.48 0.02 cancer Transmembrane serine protease 4, overexpression 
appears a poor prognostic factor for solid tumors [138].
ANXA9 0.48 0.04 morphology Annexin A9, and periplakin (PPL; FC0.57, q=0.21, p 
0.01) co-localize in the epidermis, ANXA9 was found 
upregulated in differentiating keratinocytes [23].
KLK7 0.42 0.01 morphology Kallikrein related peptidase 7, also called stratum 
corneum chymotryptic enzyme is a proteinase generally 
present in the stratum corneum [139].
MYO5C 0.42 0.01 morphology Myosin VC, is involved in actin mediated membrane 
trafficking. Myo5c appears to mediate apical exocytosis 
of secretory vesicles [140, 141].
SERPINB13 0.38 0.00 cancer Serpin family B member 13, was found downregulated 
in many types of cancer, its expression in head and neck 
SCC associates with poor clinical outcome (de Koning 
et al., 2009; Shiiba et al., 2010).
Morphology associated genes from the BAR-T dataset.
MCAM 3.47 0.00 morphology Melanoma cell adhesion molecule, it mediates the 
extension of microvilli in mouse melanoma cell lines 
[142]. When subjects with fatal asthma are compared 
to controls it is located at the brush border of airway 
epithelium of the subjects [143]. 
SHROOM4 2.54 0.00 morphology Shroom family member 4, was found to be regulator 
of cyto-skeletal architecture [144]. In Xenopus, cells 
expressing Shroom family of protein members tend 
to be elongated, this is associated with microtubule 
bundles arranged along the apico-basal axis [145]. 
NIPAL4 2.05 0.00 morphology NIPA like domain containing 4, also called Ichthyin, is 
mutated in ichthyosis. In Nipal4 knock-out mice, the 
number of stratum corneum layers was from 10 to 20, 
indicative of hyperkeratosis [146]. 
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TMOD2 1.74 0.02 morphology Tropomodulin 2, is a neuronal-specific actin-
regulatory protein, was found to cap the pointed end 
of actin filaments preventing both elongation and 
depolymerization [147]. 
EXPH5 0.56 0.04 morphology Exophilin 5, see above.
FBLN1 0.52 0.02 morphology Fibulin-1, is a secreted extracellular matrix glycoprotein 
[148, 149].
MPP7 0.51 0.02 morphology Membrane palmitoylated protein 7, forms a complex 
with the polarity protein DLG1 and was found to 
facilitate epithelial cell polarity and tight junction 
formation [150]. It is overexpressed in metaplasia [151, 
152].
SPTBN2 0.47 0.02 morphology Spectrin β, non-erythrocytic 2, is a components of a 
cell's membrane-cytoskeleton [153].
MUC5AC 0.37 0.00 morphology Mucin 5AC, oligomeric mucus/gel-forming, is a gastric 
mucin [128].
ITGB7 0.34 0.00 morphology Integrin subunit β 7, affects multiple myeloma-cell 
adhesion and migration [154].
Cancer associated genes from the BAR-T dataset.
DLL1 2.57 0.00 pro-
oncogenic
Notch signaling was found to be associated with 
malignant transformation at the GEJ [14, 155]
MAF 2.39 0.00 pro-
oncogenic
MAF bZIP transcription factor, also called c-MAF, 
was found to be a mediator of bone metastasis in 
breast cancer [156]. Overexpressing c-Maf enhanced 
cholangiocarcinoma growth in mice [157]. 
FAM196B 2.32 0.02 pro-
oncogenic
Family with sequence similarity 196 member B, see 
above.
EPGN 2.23 0.03 pro-
oncogenic
Epithelial mitogen, was found to be an activator of 
Erbb1 and can act as a mitogen [158].
FBXO2 2.19 0.02 pro-
oncogenic
F-box protein 2, the overexpression of which was found 
to induce EMT in gastric cancer cells, and is associated 
with more lymph node metastasis and shorter overall 
survival [159].
ADAMTS6 2.13 0.03 pro-
oncogenic
ADAM metallopeptidase with thrombospondin type 1 
motif 6, see above.
BCL11B 2.12 0.01 pro-
oncogenic
B cell CLL/lymphoma 11B, its impairment was found 
to promote tumor development in mouse and human 
intestine [160]. On the other hand, it was identified as a 
potential oncogene in AML [161].
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NRG1 2.07 0.02 pro-
oncogenic
Neuregulin 1, see above.
NDRG1 2.05 0.00 anti-
oncogenic
N-myc downstream regulated 1, was found to be a 
potent, iron-regulated growth and metastasis suppressor 
that was found to be negatively correlated with cancer 
progression in a number of tumors [162].
TGFBI 2.03 0.02 pro-
oncogenic
Transforming growth factor β induced, was found to 
promote the growth of GI-tract tumors, specifically 
ESCC and gastric cancer [163].
IL1B 2.00 0.00 pro-
oncogenic
Interleukin 1 β, was found to be sufficient to induce 
esophagitis, BE, and EAC in a mouse model (Quante et 
al., 2012). MMP9 (FC2.06, p=0.001, q=0.051) could 
upregulate Il1β in the mouse (Fang et al., 2017).
LAMC2 1.94 0.00 pro-
oncogenic
Laminin subunit γ 2, in ESCC and CRC LAMC2 is 
upregulated and was found to be associated with worse 
survival [164, 165].
CD274 1.90 0.03 pro-
oncogenic
CD274 molecule, also called programmed cell death 
1 ligand 1, and programmed cell death 1 ligand 2 
(PDCD1LG2; FC=1.99, q=0.053, p=0.00) were both 
upregulated. 
GRB10 1.87 0.00 pro-
oncogenic
Growth factor receptor bound protein 10, is 
upregulated in CRC vs peritumor tissue [166]. 
Overexpression in CRC was found to be associated with 
decreased survival [167]. 
ELL2 1.82 0.02 pro-
oncogenic
Elongation factor for RNA polymerase II 2, see above.
SMAD7 1.80 0.05 unknown SMAD family member 7, see above
C12orf75 1.78 0.03 pro-
oncogenic
Chromosome 12 open reading frame 75, see above.
ITGA5 1.77 0.00 pro-
oncogenic
Integrin subunit α 5, overexpression of the ITGA5 
is correlated with an increased risk of perineural 
invasion in CRC [168]. ITGA5 was found to modulate 
apoptosis, adhesion, migration, and facilitates cancer 
cell invasion through enhanced contractile forces [169, 
170].
AXL 1.70 0.04 pro-
oncogenic
AXL receptor tyrosine kinase, see above.
DUSP7 1.52 0.04 pro-
oncogenic
Dual specificity phosphatase 7, see above.
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LPCAT1 1.50 0.02 pro-
oncogenic
Lysophosphatidylcholine acyltransferase 1, its expression 
was higher in CRC vs normal mucosa. A CRC cell 
line with overexpression, SW480, were found to 
significantly increase their growth rate [171]. 
FURIN 1.49 0.03 pro-
oncogenic
Notch signaling was found to be associated with 
malignant transformation at the GEJ [14, 155].
MAP3K5 0.63 0.04 unknown Mitogen-activated protein kinase kinase kinase 5, see 
above.
CTSD 0.53 0.03 unknown Cathepsin D, can either induce apoptosis in presence 
of cytotoxic factors, but in certain studies an inhibitory 
role in apoptosis was also reviewed [172].
APOBEC3B 0.50 0.02 anti-
oncogenic
Apolipoprotein B mRNA editing enzyme catalytic 
subunit 3B, was found to be an enzymatic source of 
mutations in various cancer types [173].
HCAR2 0.50 0.05 pro-
oncogenic
Hydroxycarboxylic acid receptor 2, see above.
RAB27B 0.50 0.03 anti-
oncogenic
RAB27B, member RAS oncogene family, see above.
PHLPP1 0.49 0.02 pro-
oncogenic
PH domain and leucine rich repeat protein phosphatase 
1, is an important regulator of Akt serine-threonine 
kinases and protein kinase C isoforms. It may act as 
a tumor suppressor in several types of cancer due to 
its ability to block growth factor-induced signaling in 
cancer cells [174, 175].
TNFAIP2 0.49 0.03 anti-
oncogenic
TNFα induced protein 2, see above.
TMPRSS4 0.48 0.02 anti-
oncogenic
Transmembrane serine protease 4, see above.
RTKN2 0.47 0.02 anti-
oncogenic
Rhotekin 2, was found to be increase proliferation and 
reduces apoptosis in pancreatic cancer, CRC, and HCC 
[176-178].
LTBP3 0.37 0.00 pro-
oncogenic
Latent-transforming growth factor β-binding protein 3, 
promotes early metastatic events [179, 180].
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AgeI HoxA13 F GGTGGTACCGGTGCCACCATGACAGCCTCCGTGCTCCT
XbaI HoxA13 R ACCACCTCTAGATTAACTAGTGGTTTTCAGTT
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Pre HOXA13 FW2 GCTTTGCATACGCCGTGG
Rat HoxA13 1 F GGGCTATGACAGCCTCCGT
Rat HoxA13 1 R ATGTTCTTGTTGAGCTCGTCGG
Rat HoxA13 2 F GTCGTCTCCCATCCTTCAGA
Rat HoxA13 2 R TATCCTCCTCCGTTTGTCCTT
Rat HoxA13 3 F CTGGAACGGCCAAATGTACT 
Rat HoxA13 3 R CCTCCGTTTGTCCTTGGTAA 
Rat Hmbs F TCCTGGCTTTACCATTGGAG
Rat Hmbs R TGAATTCCAGGTGAGGGAAC
Rat Hprt F AGGCCAGACTTTGTTGGATT
Rat Hprt R GCTTTTCCACTTTCGCTGAT
Rat Sdha F TCCTTCCCACTGTGCATTACAA
Rat Sdha R CGTACAGACCAGGCACAATCTG
Rat Mapk6 F TAAAGCCATTGACATGTGGG
Rat Mapk6 R TCGTGCACAACAGGGATAGA
Rat Rps18 F AAGTTTCAGCACATCCTGCGAGTA
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Supplementary Table S5. Mouse ESC culture medium and differentiation medium components
Details of used products to culture mESCs. 
Product Product details Manufacturer 
Dulbecco’s Modified Eagle 
Medium (DMEM) 
DMEM 4.5 g/L Glucose with 
L-Glutamine
82% Lonza
Foetal Bovine Serum (FBS) 15% Biowest (Nuaillé, France)
Penicillin/Streptomycin 10,000 Units/mL Penicillin, 
10,000 µg/mL Streptomycin
1% Thermo-Fisher Scientific 
MEM Non-Essential 
Amino Acids 
1% Thermo-Fisher Scientific 
Leukaemia Inhibitory 
Factor (LIF) 





55 mM in DPBS 0.1% Thermo-Fisher Scientific 
Sodium Pyruvate 100 mM 1% Thermo-Fisher Scientific
Details of the components used to differentiate the mESCs to definitive endoderm cells.
 Product Product details Manufacturer 
Activin A 50 ng/mL Thermo-Fisher Scientific
(Recombinant Human β-Fibroblast Growth 
Factor, 154 a.a.) 
50 ng/mL PeproTech EC Ltd. (London, UK)
CHIR 5 µM Cayman Chemical (Ann Arbor, USA)
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Supplementary Table S6. All antibodies used in this study
Details of antibodies.
Antibody Concentration Manufacturer Product # RRID
PE rat anti-mouse (clone 
2B11) CD184 (CXCR4) 
1:250 BD Pharmingen 551966 AB_394305
Alexa Fluor 488 rat anti-











monoclonal (clone OV-TL 
12/30) CK7




monoclonal (clone 415909) 
TFF3


































Rabbit polyclonal anti-GFP 1:100 Merck Millipore, 
Billerica, USA
#AB3080 AB_91337







Supplementary Macro and other data files


































Supplementary File S1. Contains mRNA expression determined by single cell RNA-
Seq. The expression is depicted as present or not present in HOXA13-positive and 
negative cell fractions in both the healthy esophagus and BE. This data file can be 
obtained through communication with the authors. 
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Abstract
HOXA13 overexpression has been detected in human ESCC tissue and high HOXA13 
protein expression is correlated with a shorter median survival time in ESCC patients. 
Although aberrant expression of HOXA13 in ESCC has thus been established, little 
is known regarding the functional consequences thereof. The present study aimed to 
examine to what extent aberrant HOXA13 might drive carcinogenesis in esophageal 
keratinocytes. To this end, we overexpressed HOXA13 in a non-transformed human 
esophageal cell line EPC2-hTERT, performed gene expression profiling to identify 
key processes and functions, and performed functional experiments. We found that 
HOXA13 expression confers oncogenic hallmarks to esophageal keratinocytes. It provides 
proliferation advantage to keratinocytes, reduces sensitivity to chemical agents, regulates 
MHC class I expression and differentiation status and promote cellular migration. Our 
data indicate a crucial role of HOXA13 at early stages of esophageal carcinogenesis.
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Esophageal cancer is the 8th most common cancer worldwide and the 6th cause of cancer 
related death (1-3). Moreover, the prevalence of esophageal cancer has been growing; it 
rose by 44% from 1990 and reached 455,800 new cases per year in 2012. Approximately 
85% of patients have a histological subtype called esophageal squamous cell carcinoma 
(ESCC), which is especially frequent in Eastern Asia, particularly in China (2, 4). 
Contributing to ESCC development are environmental factors (alcohol consumption 
and tobacco use, a diet low in fruits and vegetables, ingestion of very hot food and 
beverages, etc.), genetic factors (e.g. aldehyde dehydrogenase (ALDH2) deficiency) and 
predisposing diseases (achalasia, tylosis) (3, 5). ESCC arises from dysplastic precursor 
lesions: patches of squamous epithelial cells exhibiting nuclear atypia and abnormal 
maturation, but which do not invade through the basement membrane until disease 
progression to invasive carcinoma occurs (6). ESCC is usually diagnosed at an advanced 
stage and prognosis is poor, with only 15% to 25% of patients diagnosed with ESCC 
surviving for 5 years after diagnosis (7). 
While some studies have investigated the molecular pathways underlying ESCC 
development, disease etiology is still poorly understood. However, a possible role for HOX 
genes in ESCC development is now emerging. HOX genes are a highly conserved family 
of transcription factors which play a crucial role in the development of an embryo along 
the anterior-posterior axis (8, 9). In humans, 39 HOX genes are expressed with temporal 
and spatial collinearity (10, 11) which persists in adult tissues such as the skeleton and 
digestive system (12). For example, The HOX13 paralogues (HOXA13, HOXB13, and 
HOXD13) show high expression in the hindgut region and weak expression in the 
foregut including the esophagus (13). As carcinogenesis can be seen as an aberrant form 
of organogenesis, these transcription factors may also regulate carcinogenic pathways 
(14-19). Both tumor-promoting and tumor-suppressing properties have been ascribed 
to HOX genes (20). HOXA13 overexpression has been detected in human ESCC tissue 
(21), and in other types of cancer like gastric cancer, cervical cancer, ovarian cancer 
and prostate carcinoma (22-25). High HOXA13 protein expression is correlated with 
a shorter median survival time in ESCC patients (26) and poor clinicopathological 
characteristics of patients (27). The expression profile of HOXA13, ANXA2 and SOD2 
was suggested as predictive marker of the postoperative outcome of patients with ESCC 
(28). Expression of FGF2, the normal morphogen of HOXA13, also correlates with 
poor survival of patients with ESCC (29).
Although aberrant expression of HOXA13 in ESCC has thus been established, little 
is known regarding the functional consequences thereof. One study investigated the 
molecular targets of HOXA13 in a cancer cell model of ESCC by CHIP-DSL and 
identified 1938 gene promotors. The targeted genes mostly regulate cell proliferation, 
survival, and migration (30) and functional assays confirmed that knockdown of 
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HOXA13 decreased tumor growth in vivo and colony formation of ESCC cell lines 
in vitro (26). Similarly, elevated HOXA13 expression promoted the proliferation and 
metastasis of gastric cancer partly via activating Erk1/2 (31) while downregulation of 
HOXA13 sensitizes human ESCC to chemotherapy (32).
Although HOXA13 seems to play a prognostic role when esophageal cancer has already 
been established, it remains unknown if there is a causal relationship between HOXA13 
and ESCC and whether this factor can drive neoplastic transformation. Advancement 
of high-throughput genomic technologies has led to a better understanding of the 
molecular basis of ESCC development (33, 34). ESCC and even its precursor lesion are 
highly mutated and heterogeneous diseases, but early events of ESCC are not completely 
clear. The present study aimed to examine to what extent aberrant HOXA13 might 
drive oncogenic hallmarks in esophageal keratinocytes. To this end, we overexpressed 
HOXA13 in a non-transformed human esophageal cell line, performed gene expression 
profiling to identify key processes and functions, and employed functional experiments 
to study the role of HOXA13 in keratinocytes. 
Methods
Cell lines 
EPC2-hTERT cells (35) are normal hTERT immortalized human esophageal 
keratinocytes. Cells were routinely cultured in keratinocyte–serum-free medium (KSFM) 
without calcium chloride (CaCl2) (17005042, Gibco), supplemented with 50 μg/ml 
bovine pituitary extract (BPE) (129-5, Cell Aplications), 1 ng/ml human recombinant 
epidermal growth factor (EGF) (E9644-.2 Sigma) and Penicillin-Streptomycin (100u/
ml, Gibco). Cell line identity was confirmed with short tandem repeats (STR) analysis 
by DSMZ and cells were routinely checked for Mycoplasma infection (Eurofins, 
Ebersberg, Germany). 
Generation of  EPC2-hTERT HOXA13 overexpression model
Amplification of the human HOXA13 gene including its single intron 
was performed with Q5 polymerase using primers (AgeI HoxA13 F; 
GTGGTACCGGTGCCACCATGACAGCCTCCGTGCTCCT, and XbaI HoxA13 
R; ACCACCTCTAGATTAACTAGTGGTTTTCAGTT). The gene was cloned into 
pEN_TmiRc3 using AgeI and XbaI restriction sites, a gift from Iain Fraser (Addgene 
#25748, Cambridge, USA) (36). Subsequently, two plasmids with and without the 
HOXA13 insert were prepared. The HOXA13 insert was transferred into pSLIK-Venus, 
using a Gateway reaction (37). pSLIK-Venus was a gift from Iain Fraser (Addgene 
#25734) (36). Both plasmids were sequenced by LGC Genomics (Teddington, UK). 







Next, they were packaged into lentiviral particles following transfection in HEK293T 
cells with third generation packaging plasmids. The supernatant was collected and 
ultracentrifuged. EPC2-hTERT cells were transduced with the virus and YFP (pSLIK-
Venus) positive cells were sorted by Fluorescence-Activated Cell Sorting (FACS; BD 
FACSCantoTM II, BD Biosciences, San Jose, CA). These cells were grown and analyzed 
as a heterogeneous cell pool. Cells transduced with control vector are hereafter called 
‘control’, while cells transduced with the HOXA13-containing plasmid are denoted as 
HOXA13+ cells. While HOXA13 gene expression was supranormally induced by 1.25 
μg/ml doxycycline in the culture medium, ‘leakage’ of the vector caused HOXA13 
overexpression even in absence of doxycycline (Supplementary Figure S1A) (38, 39). 
Doxycyclin itself affected growth of EPC2-hTERT cells (Supplementary Figure S1B). 
For this reason, doxycycline was not added to functional assays with longer timepoints.
RNA isolation
RNA was isolated using the NucleoSpin RNA isolation kit (Macherey Nagel, Düren, 
Germany). RNA concentrations were measured using a Nanodrop spectrophotometer 
and samples were stored in RNA storage solution (Sodium Citrate pH 6.4), obtained 
from Ambion (Foster City, USA) and kept at -80°C. RNA integrity and quantity were 
determined by the Agilent 2100 Bioanalyzer.
RNA-Seq
The EPC2-hTERT samples were prepared with the TruSeq Stranded mRNA Library 
Prep Kit. Sequencing took place according to the Illumina TruSeq v3 protocol on an 
Illumina HiSeq2500 sequencer. 50 base-pairs reads were generated and mapped against 
reference genome hg19 with Tophat (version 2.0.10). Expression was quantified using 
HTseq-count (0.6.1). Data were processed using R. version 3.2.5, (40) module DeSeq2 
(41). Generated fold changes (FCs) and p values were analyzed using ingenuity pathway 
analysis (IPA) (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/
ingenuitypathway-analysis) (42). 
Only differentially expressed genes with a p value <0.05 in RNA-Seq were used as input 
data. In IPA analysis, p value (calculated using a Right-Tailed Fisher’s Exact Test) reflects 
the likelihood that the association or overlap between a set of significant molecules 
from the experiment and a given process/pathway/transcription neighborhood is due to 
random chance. The smaller the p value, the less likely that the association is random. 
The p value does not consider the directional effect of one molecule on another or 
the direction of change of molecules in the dataset. Z-scores, a statistical measure 
of correlation between relationship direction and gene expression were considered 
significant when > 2 or < -2. Z-score takes into account the directional effect of one 
molecule on another molecule or on a process and the direction of change of molecules 
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in the dataset. Canonical pathway analysis identified the pathways most significant to 
the data set, based the ratio of the number of proteins from the data set that map to a 
pathway divided by the total number of proteins assigned to this canonical pathway.
FACS
EPC2-hTERT cells were stained with 5 μl of Anti-human HLA-ABC (APC) antibody 
per 50 μl (Clone W6/32, eBioscience, #17-9983-41) in 2% mouse serum, for 15 
minutes at room temperature. Cells were analyzed on a FACSCanto II flow cytometer 
(BD Biosciences, San Jose, CA) and analyzed with FlowJo v10 (FLOWJO, LLC).
MTT assay
MTT assays were performed as previously described (43). Transduced EPC2-hTERT 
cells were seeded in a 96-wells plate, 1000 cells/well. After 24 h, 3, 5 and 7 days 10 μl of 
5 mg/mL MTT reagent (Sigma-Aldrich Chemie BV) was added to 100 μl of culturing 
medium. After 3h of incubation at 37°C, medium was replaced by dimethyl sulfoxide 
(DMSO; Sigma-Aldrich). OD was measured in a Model 680 XR microplate reader 
(Bio-Rad, USA). This experiment was repeated three times.
Cell adhesion test
EPC2-hTERT cells were in seeded in 96 well plate (20,000 cells per well). After 60 mins, 
90 mins, 2 h, 3 h, 4 h, 6 h unattached cells were removed from the wells and counted 
by hemocytometer with Trypan Blue (Sigma-Aldrich Chemie BV). This experiment was 
repeated four times.
3D culture EPC2-hTERT cells 
3D culturing of EPC2-hTERT cells was performed as previously described (44). 4000 
EPC2-hTERT cells were seeded in 50 μL drop of ice-cold 1:1 mixture of Matrigel 
basement membrane matrix (Corning BV) with culture medium in a 24 well plate 
for cell suspension, and incubated at 37°C for 30 minutes. After solidification, 500 
μL of medium was added supplemented with 0.6 mM CaCl2. Y27632 (10 μM) was 
included in medium only first 24 h after seeding. Medium was refreshed every 2-3 days. 
Pictures were made every three days. Morphological assessment was performed on day 
12. Differentiated spheroids were characterized by at least three layers of prolonged cells 
and a nuclei-free mass in the middle, undifferentiated spheroids had round nuclei and 
lacked the cell-free area in the center. The area of the spheroids was measured with FIJI 
(45) on photographs taken on day 2, 5 and 8 of culture.







Histology and immunohistochemistry of  3D culture
EPC2-hTERT spheroids were fixed in 4% formaldehyde for 7 mins on day 11, washed 
with PBS, put in 2% agarose, and embedded in paraffin. Then 4 μM slices were sectioned 
for H&E and immunohistochemistry staining. 
For IHC, slides were deparaffinized and rehydrated followed by sodium citrate antigen 
retrieval (microwaved for 15 min at 200 Watt). Then they were blocked with Goat 
serum diluted 1:10 in PBS and incubated overnight at 4°C with anti-IVL (mouse 
monoclonal anti-IVL I9018, 1:500; Sigma-Aldrich) or anti-CK19 (rabbit monoclonal 
anti-cytokeratin-19 EP72, 1:100, BSB 5382, ITK Diagnostic). After this, secondary 
antibodies (Dako EnVision+System-HRR labeled Polymer Anti Mouse, Dako) were 
applied for 30 mins at RT. Next, slides were counterstained with hematoxylin for 10s, 
dehydrated, and mounted with Pertex. Stained objects were captured and imaged with 
Axiovert 40 CFL Zeiss microscope (20x objective), Leica DFC400 digital camera and 
Leica Application Suite software (Leica Microsystems). Quantification was based on the 
percentage of positive cells and intensity of the staining (scores ranged from 0, 2 to 9). 
2D migration assays 
2D migration assays were performed as previously described (46). Sterile coverslips 
placed in an Attofluor incubation chamber were coated with gelatin (1 mg/ml) and 
incubated for 1 h at 37°C, prior to cell seeding. A removable circular sterile migration 
barrier was inserted into the chamber, which prevents cell growth in the center of the 
coverslip. 2.5×105 EPC2 HOXA13 overexpression and control cells were seeded around 
this barrier and the rings were incubated at 37°C for 24 h. A confluent monolayer 
grew in the periphery and a cell-free area was present in the center of the coverslip. 
After removing the migration barrier, time-lapse imaging was conducted at 37°C under 
humidified 5% CO2 airflow for 24 h on an Axiovert 100M inverted microscope, equipped 
with an AxioCam MRC digital camera, using a 10X/0.30 Plan-Neofluar objective (Carl 
Zeiss B.V., Sliedrecht, Netherlands). ‘Total migration’ is the net track movement of cells 
in 24 h, ‘effective migration’ is the directional movement of cells to the cell-free center 
of the coverslip. Migration efficiency was determined as the percentage of directional 
movement over the total track distance. Velocity was defined as distance per hour. For 
each cell line, at least three independent migration assays were performed, data of one 
representative experiment are depicted. 
3D-migration using cell dispersion assay 
The procedure was performed as described before (47). Cytodex-3 microcarrier beads 
(Sigma–Aldrich) were mixed with 5×105 EPC2-hTERT HOXA13 overexpression 
and control cell suspensions, which constitutes a density of 40 cells per bead. These 
suspensions were incubated at 37°C for 6 h with gentle mixing. The bead suspension 
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was transferred to a 25 cm2 tissue culture flask and incubated for 48 h to ensure complete 
coating of beads and to remove unattached cells. Coated beads were embedded in 1.6 
mg/ml collagen gel (collagen: modified Eagle’s medium: 7.5% w/v NaHCO3 in the 
ratio 11:8:1) in a 24-well plate such that each well had approximately 150 beads. Plates 
were incubated at 37°C for 2 h for the beads to settle in the gel and the polymerized gels 
were covered with 500 μl DMEM, 10% FBS, 1% p/s. Cell dispersion was measured as 
the maximum migrated distance from the surface of the bead into the collagen gel. All 
measurements were performed using AxioVision 4.5 software and assays were performed 
twice with ten beads per group. Two-way analysis of variance was performed to calculate 
p values.
Phosphoprotein profiling 
EPC2 control and HOXA13 transduced cells were seeded in a 6 well plate. When 
they reached 80-90% of confluency, total proteins were extracted in 300 μl Laemmli 
Buffer (SDS 4%, glycerol 20%, Tris-Cl (pH 6.8) 120 mM, bromophenol blue 0.02% 
(w/v) and DTT 0.1 M) and the protein concentrations were measured using RC DC 
Protein Assay (Bio Rad). Western blotting was performed as described before (47, 48). 
Briefly, proteins were resolved by SDS-PAGE and blotted onto Immobilon FL PVDF 
membranes (Millipore, Bedford, MA, USA). Membranes were blocked in Odyssey 
Blocking Buffer (Thermo Fisher Scientific) and incubated overnight at 4°C with primary 
antibody (See Supplementary Table S1 for details), followed by the appropriate Alexa-
linked secondary antibodies, at 1:5000 dilution, in Odyssey Blocking Buffer for 1 h. 
The fluorescent bands were detected using fluorescent Odyssey Imaging System and 
densitometric analysis was performed with Image Studio Lite Ver.5.2 (49). All blots were 
reprobed for Actin to control for equal loading and normalized results are represented 
as ratios of protein of interest over Actin levels per lane. Three independent experiments 
were performed, run together on one blot, and heat maps of the phospho-protein profile 
in the 6 samples were constructed with CIMminer (Genomics and Bioinformatics 
Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National 
Cancer Institute) (50). For some samples, more than one western blot was run for 
particular phospho-proteins – in this case the mean for that particular sample was used 
for heatmap preparation. 
Drug sensitivity assay 
10,000 EPC2 cells per well were seeded in 96 well plate. Next day, 10 μl of chemical 
compounds were added to 90 μl of cell culture medium and added to cells (see 
Supplementary Table S2 for the information on compounds and range of its serial 
dilution). The final concentration of solvents (DMSO, Ethanol or dH2O) was 1%. 
Appropriate controls for solvents were made. After incubation for 72 h, MTT test was 
performed as described above. Each concentration was tested in quadruplicates, and 







experiments were performed at least three times for each drug (Supplementary Table 
S2).
Statistics 
A two-way analysis of variance (ANOVA) was used to test for significant differences 
at each time point in the MTT assay, measurement of area of spheroids, and for 3D 
migration assay (Graphpad Prism 5; GraphPad Software Inc., USA). For the comparison 
of the level of MHC class I, IHC score, Western Blot data, and for the 2D migration 
assay a t-test or Mann-Whitney test was used based on the result of normality test 
(either a Komogorov-Smirnov test, the D’Agostino, Pearson omnibus normality test 
or the Shapiro-Wilk normality test). P values <0.05 were considered to be statistically 
significant. Statistical analyses of proportions were performed with “N-1” Chi-squared 
test using MedCalc for Windows, version 18.11.3 (MedCalc Software, Ostend, Belgium) 
https://www.medcalc.org/calc/comparison_of_proportions.php.
Results 
HOXA13 alters keratinocyte gene expression profiles 
In order to investigate the tumor-initiating role of HOXA13 in ESCC, we overexpressed 
this transcription factor in the primary immortalized esophageal squamous epithelial 
cell line EPC2-hTERT, which has low endogenous levels of HOXA13, and determined 
the ensuing molecular consequences by RNAseq profiling. A log2FC of 5.24 confirmed 
successful overexpression of HOXA13 (p<3.14 E-215). This affected 2995 genes: 1745 
(58.3%) were downregulated and 1250 upregulated (p<0.05) (log2 fold change (FC) 
ranging from -5.28 to 4.97). The top 20 of HOXA13-induced differentially expressed 
genes and functions of their products are reported in Table 1. Upregulation of ANPEP, 
MAGEA11, LCP1, CSAG1, CSAG1, ZNF486, MAGEA12, GPC4, CYP24A1, LRRC38 
was observed, while UBR1, PSMB8, UBR1, PSMB8, EPSTI1, SAMD9L, APOL6, 
TLR3, GBP1, SLC12A7, HS6ST2, SFRP1 are down-regulated. Subsequently, in silico 
functional enrichment analysis was performed for all differentially expressed genes. 
Canonical pathway analysis indicates that HOXA13 influenced both metabolic and 
signaling pathways. The top canonical pathways affected include Antigen Presentation 
Pathway, Molecular Mechanisms Of Cancer, Epithelial Adherent Junction Signaling 
and 14-3-3 protein-Mediated Signaling. An extended list of pathways based on Z-scores 
> 2 and < -2 is shown in Figure 1A and B. A clear indication of altered cytoskeletal 
rearrangement was seen, as evidenced by the signaling by Rho family GTPases, Rac 
GTPase signaling and its downstream PAK signaling. IPA prediction indicates that 
altered transcriptome upon HOXA13 expression would affect the following molecular 
and cellular categorical functions: Cell Death And Survival, Cellular Movement, 
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Cellular Assembly And Organization, Cellular Function And Maintenance, Cellular 
Development. On organismal level HOXA13 overexpression affects Physiological System 
Development, Organismal Survival, Organismal Development, and Cardiovascular 
Development and Function. 
Functional analysis identified the toxic functions and diseases that were most significant to 
the data set. The top three Disease and Disorders categories identified were Cancer (p value 
Table 1. Top HOXA13-induced differentially expressed genes
Gene log2FoldChange p value Protein function, biological processes 
HOXA13 5.46 3.14E-215  
ANPEP 4.97 2.35E-255 membrane alanyl aminopeptidase
MAGEA11 2.55 3.91E-39 part of the androgen receptor signaling pathway, 
linked to cancer development
LCP1 2.38 3.37E-60 actin binding, actin filament network formation, cell 
migration
CSAG1 2.13 1.11E-26 unknown, tumor antigen
ZNF486 2.11 6.81E-37 DNA binding, regulation of transcription
MAGEA12 2.10 1.40E-26 protein binding, tumor antigen
GPC4 1.94 6.34E-22 transmembrane receptor, cell proliferation and 
differentiation
CYP24A1 1.82 3.75E-20 mitochondrial monooxygenase
LRRC38 1.81 6.58E-26 potassium channel regulator, ion transport
UBR1 -3.06 3.14E-293 ubiquitin-protein ligase activity, protein catabolic 
process
PSMB8 -3.11 3.00E-138 antigen presentation, interferon signaling, protein 
ubiquitination
EPSTI1 -3.15 2.04E-59 unknown
SAMD9L -3.72 1.21E-123 protein binding, proliferation, cell division, 
differentiation
APOL6 -3.86 4.44E-161 lipid binding, lipid transport; lipoprotein metabolic 
process
TLR3 -3.94 2.06E-110 transmembrane receptor, pathogen recognition and 
activation of innate immunity
GBP1 -4.16 5.79E-135 guanylate binding, cell response to interferon
SLC12A7 -4.60 1.95E-150 electroneutral potassium-chloride cotransporter, cell 
volume homeostasis
HS6ST2 -4.64 1.03E-150 heparan sulfate 6-O-sulfotransferase, 
glycosaminoglycan biosynthesis
SFRP1 -5.28 2.40E-263 cysteine endopeptidase, soluble modulators of Wnt 
signaling







Figure 1. In silico functional enrichment analysis: signaling (A) and metabolic (B) canonical pathways 
regulated by HOXA13. Z-score > 2 or < -2. (C) Organismal injury and abnormalities caused by HOXA13 
overexpression. Downregulated processes by HOXA13 are shown in blue, upregulated processes in orange. 
General cancerous processes are decreased (‘cancer‘), while “upper GI tract tumor”, “upper GI tract cancer”, 




= 7.98E-08 – 1.22E-83, #Molecules = 2739), Organismal Injury And Abnormalities (p 
value = 8.08E-08 – 1.22E-83, #Molecules = 2768) and Gastrointestinal Disease (p value = 
8.08E-08 – 7.69E-08 – 9.19E-68, #Molecules = 2533). Z-score for cancerous processes in 
general was negative (Z-score = -2.507) indicating inhibition of such processes, however, 
for such categories as Upper Gastrointestinal Tract Tumor, Upper Gastrointestinal Tract 
Cancer and Squamous-cell Carcinoma, Z-scores were positive (Z-score = 2.451, Z-score 
= 2.236, Z-score = and 2.157 respectively) indicating activation of these processes (Table 
2, Figure 2).Upstream regulator analysis for the 2995 genes involved in the preceding 
processes was used to identify the potential upstream transcriptional regulators that 
can explain the observed gene expression changes our dataset (42). TP53 (log2FC = 
0.032, activation Z-score = -1.723, p=295E-35), TGFB1 (log2FC = 0.156, activation 
Z-score = 1.456, p=5.88E-33), TNF-α (log2FC = 0.155, activation Z-score = -2.773, 
p=3.78E-32), IFNL1 (activation Z-score = -6.991, p=1.93E-30) and OSM (activation 
Z-score = -2.167) were indicated as the most significant regulators, of which TP53 (51), 
TGFB1 (52) and TNF-α (53) have previously been implicated in ESCC pathogenesis. 
In total, these results suggest a specificity of HOXA13 for gastrointestinal tumorigenesis 
and squamous cells carcinomas in particular. 
Table 2. IPA predicted toxic functions and diseases caused by HOXA13 overexpression
Categories p value Predicted activation state
Activation 
Z-score #Molecules
Cancer 1.80E-76 Decreased -2.5 2690
Necrosis of tumor 1.83E-08 Decreased -2.4 135
Cell death of tumor cells 4.35E-08 Decreased -2.4 131
Necrosis of tumor 1.83E-08 Decreased -2.4 135
Upper gastrointestinal tract tumor 2.20E-18 Increased 2.5 754
Upper gastrointestinal tract cancer 4.12E-17 Increased 2.2 599
Squamous-cell carcinoma 2.95E-14 Increased 2.2 805
Gastroesophageal cancer 6.94E-13 Increased 2.0 483
HOXA13 influences oncogenic cellular phosphoprofile
Next, we investigated to what extent HOXA13-induced transcriptomic changes 
are translated to altered signal transduction patterns. To this end, we performed 
phosphoprotein profiling to quantify the expression and activation status of several 
important signal transduction pathways and targeted some of these pathways with 
molecular inhibitors. A distinctly altered phosphoprofile was seen upon HOXA13 
overexpression, as evidenced by the clustering of control and overexpressing samples 
(Figure 2A, Supplementary Figure S2 for individual western blot examples and 







Figure 2. Phosphorylation events are modulated by HOXA13. (A) HOXA13 influences cellular phosphoprofile 
as determined by western blot analysis. Heat map of the phospho-protein profile is shown. Increased 
phosphorylation is depicted in red, conversely decreased phosphorylation is depicted in blue. Magnitude of 
the phosphorylation differences is indicated by the scale bar in the top left corner. Statistical significance in 
phosphorylation status of individual proteins as calculated in Figure S2 is indicated on the right side of the 
figure with an asterisk *p<0.05. (B) HOXA13 overexpression causes different sensitivity of keratinocytes to 
protein activity inhibitors (Ship, MEK, FAK and PAK). Representative figures are shown. *p<0.05.
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quantification). HOXA13 overexpressing cells showed inactivation of the tumor 
suppressor lipid phosphatase PTEN as evidenced by increased inhibitory phosphorylation 
at Ser380. PTEN is known to inactivate the Akt survival pathway, which was consistent 
with a non-significant increase in Akt phosphorylation at Ser473, although surprisingly, 
phosphorylation at Thr308 was decreased. However, HOXA13 overexpressing cells were 
significantly less sensitive to inhibition of Akt by treatment of cells with a SHIP2 lipid 
phosphatase inhibitor (54) (Figure 2B-i), suggesting overall enhanced Akt activity levels 
in these cells. 
Significant activation of mitogen-activated growth signaling was also observed through 
enhanced activation of ERK1/2 (as evidenced by phosphorylation at Thr202/Tyr204) 
and its target substrate MEK1 (at Thr292). As MEK1 phosphorylation at Thr292 itself 
inhibits functionality of this protein, we also investigated cell growth in the presence of a 
MEK1/2 inhibitor (Figure 2B-ii). Overexpression of HOXA13 did not make cells more 
sensitive to targeting of MEK1, suggesting that activation of ERK1/2 upon HOXA13 
overexpression exerts its effects via other targets. Indeed, a significant upregulation of 
the ERK2 substrate 4e-BP1 (Thr70) in HOXA13 overexpressing cells was seen, which is 
known to enhance mRNA translation. 
In light of the effects seen on cytoskeletal regulation on mRNA level in our sequencing 
efforts, we also investigated several phospho-proteins involved in actin modulation 
and adhesion. In particular adhesive properties appeared to be affected by HOXA13 
overexpression, as evidenced by significantly enhanced phosphorylation of Integrin-β3 
(Tyr 785) and focal adhesion kinase (FAK, Tyr391). While inhibition of FAK affected 
control cells more than HOXA13-overexpressing cells at low concentrations, higher 
concentrations indicated enhanced sensitivity upon HOXA13 overexpression, suggesting 
that the effect of FAK activity present in the cell may be dichotomous (Figure 2B-iii). 
HOXA13-overexpressing EPC2-hTERT cells were more resistant to inhibition of PAK, 
a target of the cytoskeletal GTPases Rac and CDC42 (Figure 2B-iv). While we did not 
observe a clear difference in phosphorylation of PAK1, PAK2 phosphorylation could 
not be visualized. Taken together, these data suggest that oncogenic signaling is activated 
upon HOXA13 overexpression, with, in particular, ERK-induced translational control 
and cytoskeletal signaling playing important roles.
HOXA13 downregulates MHC class I in keratinocytes 
Having demonstrated that HOXA13 overexpression induces numerous molecular 
changes associated with tumorigenesis, we next investigated to what extent these 
changes translate to cellular consequences. Functional enrichment analysis predicted 
that the antigen presentation pathway is affected (Figure 3A), with HOXA13 regulating 
expression of genes associated with the major histocompatibility complex (MHC) class 
I: HLA-A (FC=0.22), HLA-B (FC=0.21), HLA-C (FC=0.57), B2M (FC=0.55) and 







TAP1 (FC=0.63) (Figure 3B). To validate this on protein level, EPC2-hTERT cells were 
stained with antibodies against MHC class I and analyzed by FACS. Confirming RNA 
sequencing data, HOXA13 overexpression decreases MHC class I protein expression 
on EPC2-hTERT cells (FC=0.17, p=0.0286) (Figure 3C). This suggests activation of 
immune escape mechanisms upon HOXA13 expression in esophageal keratinocytes. 
Figure 3. HOXA13 downregulates MHC class I and affects the antigen presentation pathway. (A) 
Illustration of the antigen presentation pathway. Molecules with a decreased expression upon HOXA13 
overexpression are indicated in green. IPA analysis based on RNAseq data. (B) RNA expression data of 
genes associated with MHC class I as determined by RNAseq. (C) HOXA13 decreases expression protein 
expression of MHC class I. Quantification of FACS data is shown in upper panel (p<0.05), representative 
example is shown in lower panel.
HOXA13 overexpression provides a proliferative advantage to esophageal ke-
ratinocytes and decreases paclitaxel-induced cell death 
Next, we investigated cellular proliferation potential of EPC2-hTERT cells, as a 
hallmark of tumorigenesis. As shown in Figure 4A, induction of HOXA13 in esophageal 
keratinocytes does not affect 2D growth as determined by MTT assay. However, in 
line with RNA analysis predicted decrease in cell death upon HOXA13 overexpression 
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Figure 4. HOXA13 confers resistance to drug-induced cell death. HOXA13 overexpression does not affect 
2D growth of esophageal cells (MTT data) (A) but makes them more resistant to paclitaxel-induced death 
(B). MTT was performed after 3 days of paclitaxel treatment (0.002–0.19μM). Data are presented as % of 
vehicle-treated corresponding control. Mean±SEM, *p<0.05.
Figure 5. HOXA13 promotes growth of EPC2-hTERT spheroids. (A) Representative illustrations of EPC 
spheroids after 2-8 days in 3D culture. (B) Area of spheroids measured on day 2, 5 and 8, Mean±SEM, 
*p<0.05.
(Table 2), we observed a decreased sensitivity of HOXA13 overexpressing keratinocytes 
to paclitaxel, a chemotherapeutic agent targeting the cytoskeleton and used for ESCC 
treatment (Figure 4B).







To gain further insight into the role of HOXA13 in cell growth, we cultured EPC2-
hTERT spheroids in 3D cultures, allowing assessment of growth of individual colonies 
in a more physiological setting. We found that spheroids derived from EPC2-hTERT 
cells with HOXA13 overexpression are 1.5 times bigger in size upon 8 days of culture 
(p<0.05) (Figure 5A,B), indicating a proliferative advantage of cells upon overexpression 
of HOXA13. 
HOXA13 overexpression changes the morphology and differentiation status of  
EPC- derived spheroids
EPC2 spheroids are characterized by a proliferation-differentiation gradient with Ki-67 
staining seen in the basaloid cell layer and more differentiated cells toward the center 
of these structures (44). As shown in Figure 6A, upon one week of culturing, EPC2-
hTERT spheroids become organized in layers with a more flattened cytological aspect 
Figure 6. HOXA13 overexpression influences spheroid morphology and differentiation status. (A) 
Representative pictures of H&E, anti-involucrin (IVL) and anti-cytokeratin-19 (CK19) staining of EPC2-
hTERT spheroids. (B) Spheroids with a more differentiated aspect are more frequently observed for control 
EPC2-hTERT spheroids compared to HOXA13-overexpressing EPC2-hTERT spheroids (*p<0.05). (C) 
EPC2-hTERT spheroids with HOXA13 overexpression express less involucrin (IVL) and D) cytokeratin 19 
(CK19) (Median with range,*p<0.05).
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in the middle of spheroids, reminiscent of differentiated stratified epithelium. Upon 
overexpression of HOXA13, not only do spheroids become bigger (notice the increased 
number of nuclei, consistent with a proliferative advantage), they also are kept in a 
less differentiated state. Quantification of morphology indicates that 50% of spheroids 
obtain a differentiated morphology in control cells vs 22% upon forced HOXA13 
expression (p<0.05, Figure 6A, lower panel). We also investigated the expression of 
involucrin and cytokeratin 19 as a markers of differentiation and keratinization. Intensity 
of both stainings was significantly lower in HOXA13 overexpressing EPC2-hTERT 
spheroids (IVL: median IHC score for control = 3, N=28, for HOXA13+ cells = 2, 
N=43, p<0.05, CK19: IHC score for control = 5, N=22, for HOXA13+ cells = 0, N=22, 
p<0.05) (Figure 6B). Thus, these results indicate that HOXA13 overexpression prevents 
the differentiation of keratinocytes, which is consistent with the effect of HOXA13 seen 
on cellular assembly and organization as well as on cellular development in IPA analyses.
Figure 7. HOXA13 does not influence adhesion of EPC2-hTERT cells, but affects cellular migration. (A) 
Adhesive properties of keratinocytes per se are not affected by HOXA13 overexpression. (B-G) HOXA13 
promotes cellular migration in 2D migration assay as determined by: (D) total migration (E) efficiency, 
(F) effective migration and (G) velocity of migration. Mean±SEM, **p<0.01. Representative pictures 
of Individual cell tracking show cell migration in 24 h time-lapse microscopy of control cells (B) and 
HOXA13-overexpressing cells (C).







HOXA13 promotes cellular migration
IPA analysis, as well as phosphoprotein profiling, indicated a direct effect of HOXA13 on 
cytoskeletal rearrangement and cellular adhesion. Therefore, we first tested the adhesive 
strength of EPC2 cells upon replating, but no difference in time to adhesion was seen 
between wild type and overexpressing cells (Figure 7A). More advanced adhesive 
properties are also required for migration and invasion of cells. Therefore, we investigated 
a migratory ability of these cells using 2D ring-barrier assays to track individual cell 
movement. Indeed, HOXA13 significantly increases total migration, effective migration 
and velocity of EPC2 cells in 2D migration assay (Figure 7) (p<0.01). Furthermore, 
a pronounced increase in migratory distance of keratinocytes was seen in 3D cultures 
upon HOXA13 overexpression, indicating that HOXA13 enhances invasive potential of 
esophageal keratinocytes (p=0.0038) (Figure 8).
Figure 8. HOXA13 promotes cellular migration in 3D migration assay. (A) Migratory distances of 
cell invading collagen matrix were measured for HOXA13-overexpressing cells and control cells over 7 
days, Mean±SEM, **p<0.01. (B) Representative photographs of cells migrating in collagen matrix from 
microcarrier beads in 7 days.
Discussion
A better understanding of the molecular mechanisms behind ESCC development might 
reveal new targets for its treatment and early diagnosis. Homeobox genes were shown to 
be responsible not only for proper embryonic development and differentiation of stem 
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cells but they are also associated with cancer development (55). One of these genes, 
transcriptional factor HOXA13, has previously been investigated in human ESCC 
tissue and in cancerous cell lines (26, 56). However, its role was not reported for early 
stages of ESCC or for squamous dysplasia. In this study, we overexpressed HOXA13 
in primary immortalized esophageal keratinocytes and compared them to wild type 
keratinocytes in terms of hallmarks of cancer to investigate HOXA13 as a driver of 
esophageal carcinogenesis. Initiation of cancer implies the cellular acquisition of several 
oncogenic characteristics, including selective growth and proliferative advantage, 
altered stress response favoring overall survival, vascularization, invasion and metastasis, 
metabolic rewiring, an abetting microenvironment, and immune modulation (57, 58). 
Furthermore, cancerous cells are characterized by some level of dedifferentiation and 
heterogeneity (59). 
First of all, we found that HOXA13 downregulates MHC class I in keratinocytes and 
affects an antigen presentation pathway. Downregulation of MHC class I and escape 
from immune response is associated with the clinical course of ESCC (60). Our results 
indicate that HOXA13 expression may drive the immune escape of neoantigen-bearing 
transformed keratinocytes. 
Second, we observe that overexpression of HOXA13 provides a proliferative advantage 
to keratinocytes and decreases their sensitivity to paclitaxel-induced cell death. Upon 
overexpression of HOXA13, cells showed increased resistance to paclitaxel treatment 
and formed bigger spheroids in 3D culture. These data are in line with clinical data 
previously obtained (32) showing that downregulation of HOXA13 sensitizes human 
ESCC to chemotherapy and with experiments done on cancerous cell lines showing 
that HOTTIP/HOXA13 enhances ESCC cell proliferation in vitro and in vivo (56). 
However, while these earlier publications suggest that HOXA13 plays a role in the 
maintenance of tumor cell characteristics, our data suggest that overexpression of this 
gene can drive tumorigenesis. Nevertheless, thus far, no activating HOXA13 mutations 
have been reported for ESCC, suggesting alternative mechanisms for its over-expression 
in this tumor type. IPA analysis of our dataset revealed TGF-β1 and TP53 as the 
most significant regulators of signaling pathways affected by HOXA13 overexpression. 
Mutation of TP53 is an early and most common event in esophageal carcinogenesis and 
is typical also for squamous dysplasia and other types of esophageal cancer (34). TGF-β1 
also plays an important role in pathogenesis of ESCC (61) as it regulates epithelial-
to-mesenchymal transition (EMT) of ESCC. As HOXA13 was reported to induce the 
EMT cascade (56), it is conceivable that in vivo, TGF-β1 drives this effect. 
Losing epithelial traits (dedifferentiation) is an important step during tumorigenesis 
which at early stages is required for local migration/invasion and at later stages contributes 
to macroscopic metastases (62). Moreover, differentiation status of ESCC is associated 
with clinical outcome (63, 64). The prognosis of patients with keratinizing ESCC has 







been reported to be significantly better than that of patients with non-keratinizing 
tumors (63). In the present study, RNA expression data, morphology data on EPC2 
spheroids and anti-IVL staining all indicate that HOXA13 limits the differentiation of 
keratinocytes. Concomitantly, we observed that HOXA13 promotes cellular migration, 
which is in line with data from cancerous cell lines (56). Our study further suggests that 
Integrin-β3, FAK, PAK, GTPases Rac, and CDC42 are likely candidates to be involved 
and mediate this effect.
We acknowledge several limitations to our study. Tumors are heterogeneous, and 
HOXA13 may not play a similar role in all patients developing ESCC. Here, we 
employed a heterogeneous pool of EPC2-hTERT cells, but while cell lines are by nature 
heterogeneous, this does not fully reflect the heterogeneity of patients. Future studies are 
needed to confirm HOXA13 overexpression in esophageal premalignant lesions. Second, 
while our studies implicate a role for HOXA13 in driving oncogenic hallmarks, and 
previous publications have clearly shown the overexpression of HOXA13 in malignant 
tissues, the driving mechanisms for this overexpression remain to be elucidated.
In toto, we show here that HOXA13 expression confers oncogenic hallmarks to esophageal 
keratinocytes. It provides proliferation advantage to keratinocytes, reduces sensitivity 
to chemical agents, regulates MHC class I expression and differentiation status and 
promote cellular migration. Our data indicate a crucial role of HOXA13 at early stages 
of esophageal carcinogenesis.
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Supplementary Figure S1. (A) HOXA13 is overexpressed in EPC2-hTERT HOXA13-transduced cells 
even without doxycycline (dox) treatment in contrast to control EPC2-hTERT cells (empty vector 
transduced). qPCR data are calculated relatively to corresponding control with or without dox treatment. 




Supplementary Figure S2. HOXA13 influences cellular phosphoprofile as determined by western blot 
analysis. Three independent experiments were performed to obtain lysates of HOXA13+ and control cells. 
These lysates were subsequently blotted a minimum of 1 time, results in an N of at least 3 for control 
and HOXA13+ cells. (A) Representative examples of control and HOXA13+ cell lysates are shown for the 
presence of indicated phopho-proteins. (B) Quantification of western blots.







Supplementary Figure S2. Continued.
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Supplementary Table S1. List of primary antibodies used for phosphoprotein profiling (65)




1 pErk (Thr202/Tyr204) CST 4696 mouse 1:1000 +
2 pS6 (Ser235/336) CST 4856 rabbit 1:1000 +
3 pS6 (Ser240/244) CST 5364 rabbit 1:1000 +
4 pAkt (Thr308) Signal way 11055-2 rabbit 1:1000 +
5 pAkt (Ser473) CST 4060S rabbit 1:1000 +
6 p-4e-BP1 (Thr70) CST 9455 rabbit 1:1000 -
7 pp38 (Thr180/Tyr182) CST 4511 rabbit 1:1000 +
8 pFAK (Tyr391) Invitrogen 44-625G rabbit 1:1000 +
9 pFAK (Tyr861) ITK 21076-1 rabbit 1:1000 +
10 pcofilin (Ser3) Signal Way 11139 rabbit 1:1000 -
11 pRhoK2 (Ser1379) Signal Way 13005 rabbit 1:1000 -
12 pSrc (Tyr416) CST 2113 rabbit 1:1000 +
13 p-integrin beta 3 (Tyr785) Signal way 11060-1 rabbit 1:1000 -
14 pPAK2 (Ser192/197) CST 2605 rabbit 1:1000
15 pMEK1 (Thr292) Merck 07-348 rabbit 1:1000 -
16 pPTEN (Ser380) CST 9551 rabbit 1:1000 -
17 β-actin SCBT - 
Santa Cruz 
Biotechnology
477778 mouse 1:1000 N/A
Supplementary Table S2. List of chemicals for drug sensitivity test
Compound Target Manufacturer Solvent Concentration range
1 Paclitaxel Tubulin Sigma-Aldrich, 7191-1MG DMSO 0.002-0.2 uM
2 FAK inhibitor 14 FAK Sigma-Aldrich, SML0837-10MG H2O 0.05-33 uM
3 FRAX1036 PAK-1 Selleckchem, S7989 Etanol 0.02-50 uM
4 U0126-EtOH MEK1/2 MedChemExpress, HY-12031 DMSO 0.05-33 uM
5 2PIQ SHIP2 Synthesized (66) DMSO 2.3-11 uM
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Abstract
The transformation of normal colonic epithelium to colorectal cancer (CRC) involves a 
relatively ordered progression, and understanding the molecular alterations involved may 
aid rational design of strategies aimed at preventing or counteracting disease. HOXA9 is 
an oncogene in leukemia and has been implicated in CRC pathology, although its role in 
disease etiology remains obscure at best. We observe that HOXA9 expression is increased 
in colonic adenomas compared to location-matched healthy colon epithelium. Its forced 
expression results in dramatic genetic and signaling changes, with increased expression 
of growth factors IGF1 and FLT3, super-activity of the AKT survival pathway and a 
concomitant increase in compartment size. Furthermore, a reduced mRNA expression 
of the epithelial to mesenchymal transition marker N-cadherin as well as reduced activity 
of the actin cytoskeletal mediator PAK was seen, which is in apparent agreement with 
an observed reduced migratory response in HOXA9 overexpressing cells. Thus HOXA9 
appears closely linked with adenoma growth while impairing migration and metastasis 
and hence is both a marker and driver of premalignant polyp growth.
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Colorectal cancer (CRC) is the second most common cancer in men and the third in 
women (1). Its incidence has slightly risen in The Netherlands over the past decades while 
prognosis improved (2). In Europe, high CRC prevalence has resulted in the initiation of 
many national CRC screening programs (3). These programs are continuously evaluated 
and improved (4, 5). In Europe, incidence rates are declining, probably due to changes in 
life style and more intensive screening. However, CRC is still the second leading cause of 
cancer death in Europe (6). Obviously, better understanding of the molecular pathways 
that mediate progression from normal colonic epithelium to invasive carcinoma would 
aid efforts aimed at improving prevention and treatment of CRC.
Better definition of molecular markers that relate to the natural history of early CRC 
would prove exceedingly useful. About thirty years ago Vogelstein et al. described the 
importance of premalignant lesions and their role in the adenoma-carcinoma sequence 
(7). The prevalence of these premalignant lesions is considered to be 25 percent at the 
age of 50 years and increases up to 50 percent at the age of 70 (8-11). It is fair to say that 
the mechanisms that drive growth of premalignant lesions remain poorly understood. 
Also stratifying early lesions into those that are truly benign to those that are at risk to 
undergo micrometastasis is not yet possible. Identifying the molecular determinants 
involved defines a major question in contemporary preclinical cancer research. 
Molecular pathways that underlie carcinogenesis are often aberrations of normal cellular 
physiology. Carcinogenesis can be seen as an aberrant form of organogenesis (12-14). 
Homeobox genes, which include the HOX gene clusters, regulate important pathways 
with relation to both embryogenesis and carcinogenesis (15). The evolutionary well-
conserved mammalian HOX genes encode for transcription factors regulating the 
formation of tissues, structures and organs along the longitudinal body axis during 
embryology (15-17). Thus far, 39 HOX genes have been identified in humans, which 
are organized in four clusters (A to D) on separate chromosomes (7, 17, 12, and 2 
respectively). During embryogenesis the different HOX clusters are expressed with 
temporal and spatial collinearity (18). The nested pattern of HOX genes along the 
length of the human body’s axis is most clearly observed in segmented structures like 
the vertebrae, branchial arches and limbs (19-21). However, position specific expression 
of HOX genes is also present in discreet organs, including the human gut (22, 23). 
However, the specific functionality of expression of single HOX genes in gastrointestinal 
pathophysiology remains to be established.
As HOX genes are important regulators of tissue growth and differentiation, it is 
conceivable that they also play a role in malignant transformation. This has led to 
an increasing interest in HOX expression patterns in different forms of cancer (24-
30). Interestingly, when screening for the expression of HOX family members in 
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gastrointestinal pathophysiology we observed markedly high expression of HOXA9 
in esophageal adenomas as compared normal esophagus (unpublished data). HOXA9 
overexpression as a result of the NUP98-HOXA9 translocation-derived fusion gene 
is seen in patients with the premalignant Myelodysplastic Syndrome as well as overt 
myeloid leukemia (31). In MDS, in particular patients with refractory anemia with excess 
of blasts in transformation (REAB-t) show HOXA9 fusion genes (32). In line with the 
fact that the NUP98/HOXA9 fusion transcript has been shown to induce hematopoietic 
hyperproliferation (33) this suggests that it drives the transformation process of MDL 
to AML. HOXA9 overexpression was also shown to be the strongest factor associated 
with poor prognosis in AML (34). In addition to hematopoietic malignancies, HOXA9 
has a pro-oncogenic effect in epithelial ovarian cancer, osteosarcoma, breast, and 
oral squamous cell cancer (35-37). Moreover, an upregulation of HOXA9 has been 
described in CRC (38-41). However, it is as yet unclear whether this upregulation 
of HOXA9 is already present in premalignant colonic tissues. Furthermore, to what 
extent aberrant HOXA9 expression may drive oncogenic hallmarks is unknown. The 
above-mentioned considerations prompted us to compare HOXA9 expression between 
adenoma tissue and location matched healthy colon epithelium and to investigate the 
role of HOXA9 in oncological transformation of colonic epithelial cells. We observe that 
HOXA9 is overexpressed in colonic adenomas and drives compartment expansion but 
concomitantly counteracts metastasis. Thus, HOXA9 expression emerges as a molecular 
determinant for pre-micrometastatic colonic adenomas and may be a marker for benign 
polyp growth in the colon. 
Materials and methods
Sample collection and preparation
Participants were recruited at the Havenziekenhuis (Rotterdam, The Netherlands) in the 
context of the nationwide screening for CRC. Asymptomatic patients, aged between 55 
and 75 years, with a positive immunologic fecal occult blood test (iFOBT) were referred 
to this hospital for colonoscopy. If during colonoscopy a premalignant lesion was found, 
biopsies were taken; one from the center of the premalignant lesion and another from 
healthy mucosa located in the vicinity of the lesion. Biopsies were immediately stored in 
RNAlaterTM (Qiagen, Germany) at 4°C and stored at -80°C within 24 h until RNA was 
extracted. After the biopsy was taken the remainder of the colonic polyp was resected 
and examined by a pathologist. Only biopsies from lesions classified as tubular adenoma 
with low grade dysplasia were included for further examination. Thus, only early stages 
in the adenoma-carcinoma sequence were studied (7). The biopsies were collected as part 
of the ‘biobank for premalignant colonic lesions’ and material collection was approved 
by the medical ethical committee of both the Erasmus Medical Center (Rotterdam, The 







Netherlands; MEC-2015-199) and the Havenziekenhuis. Written informed consent 
was obtained from all participants.
Transduction
A GeneArt bacterial plasmid (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) containing the HOXA9 gene and a kanamycin resistance gene were used for 
the construction of the lentiviral vector. Firstly, the HOXA9 gene was cloned into the 
pEN_TmiRc3 plasmid, which was a kind gift from Iain Fraser (California Institute of 
Technology, California, USA). Subsequently, the HOXA9 insert was transferred into a 
pSLIK-Hygro plasmid, also received from Iain Fraser (plasmid #25737; Addgene, USA), 
using a Gateway reaction. The same procedure was followed to create a control plasmid, 
lacking the HOXA9 insert. All created plasmids were sequenced by LGC Genomics 
(LGC Genomics GmbH; Germany) and were confirmed to be sequence correct. The 
pSLIK-Hygro plasmid was transiently transfected in HEK293T cells together with three 
packaging plasmids (VSV-G, MD, and REV). After two days the medium was harvested 
and viral particles were collected by ultracentrifugation. Caco-2 cells were transduced 
with the concentrated virus, after one day the transduced cells were selected by adding 
hygromycin B (Thermo Fisher Scientific, The Netherlands) (400 µg/mL) for a period of 
one week. Expression of HOXA9 was confirmed after stimulation doxycycline hyclate by 
qRT-PCR (see Supplementary Figure S1).
Cell culture
The monthly short tandem repeat identity-verified (verification commercially performed 
by the molecular pathology department of the Erasmus MC) and American Type Culture 
Collection (ATCC, Manassas, VA)-obtained mycoplasma-free (monthly commercially 
checked by GATC Biotech, Konstanz, Germany) human human CRC cell line Caco-2 
was cultured at 37°C in a 5% CO2 incubator using Dulbecco’s modified Eagle’s medium 
(DMEM; Lonza, Basel, Switzerland) containing 10% fetal calf serum (FCS; Sigma-
Aldrich) and 1% Penicillin/Streptomycin (antibiotics) (P/S; Gibco, USA). The cells 
were routinely confirmed to be mycoplasma free using the LookOut Mycoplasma PCR 
Detection Kit (Sigma-Aldrich). Before performing experiments, HOXA9 expression 
in transduced Caco-2 cells was induced by culturing in the presence of 0.5 ng/mL 
doxycycline hyclate (Sigma-Aldrich) and 200 µg/mL hygromycin B for up to three days. 
RNA isolation, cDNA synthesis and PCR Array/qRT-PCR
Total RNA was extracted with the NucleoSpin® RNA kit (Machery-Nagel, Germany). 
For cDNA preparation the reverse transcription system from TAKARA (TAKARA 
BIO INC) was used according to the manufactures manual. A cDNA concentration 
of 10 ng/µl for patient material and 30 ng/µl for Caco-2 cells was used for qPCR. The 
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commercially available RT2 ProfilerTM PCR Array (PAHS-033ZC-2; Qiagen, Germany) 
was used. This array focuses on genes important in human cancer (See Figure 2B). 
Gene expression in HOXA9 overexpressing cells were expressed as compared to control 
cells by ΔΔCT method, using ACTB, B2M, GAPDH, HPRT1, and RPLPO represented 
on the plate as housekeeping controls. In addition, potential interesting candidates as 
derived from the array as well as HOXA9 targets identified in literature but not present 
in the array were tested separately (for primers and conditions, see Table S1) in three 
independent experiments. Quantitative PCR was performed with SYBR Green (Applied 
Biosystems, USA) in an IQ5 PCR machine (Bio-Rad, Hercules, California, USA). To 
establish a loading control, TPT1, UBC, and GAPDH were used as reference genes (42). 
The ΔΔCT method was used to calculate expression values. 
(Phospho)protein profiling
Caco-2 control and HOXA9 transduced cell lines were seeded in a Petri dish (60 cm) at 
500,000 cells/dish and treated with 0.5 ng/mL doxycycline hyclate. After 72 h, proteins 
were extracted in 500 µl Laemmli Buffer (SDS 4%, glycerol 20%, Tris-Cl (pH 6.8) 120 
mM, bromophenol blue 0.02% (w/v) and DTT 0.1 M) and the protein concentrations 
were determined using a commercial kit (RC DC Protein Assay – Bio Rad). Western 
blotting was performed as described (43, 44). In short, 40 µg protein was resolved by 
SDS-PAGE and blotted onto Immobilon FL PVDF membranes (Millipore, Bedford, 
MA, USA). Membranes were blocked in Odyssey Blocking Buffer (PBS) and incubated 
overnight at 4°C with appropriate primary antibody (See Table S2 for details), followed 
by the appropriate Alexa-linked secondary antibodies, at 1:5000 dilution, in Odyssey 
Blocking Buffer for 1 h. The fluorescent bands were detected using fluorescent Odyssey 
Imaging System and densitometric analysis was performed with ImageJ (45). All 
blots were reprobed for Actin to control for equal loading and normalized results are 
represented as ratios of protein of interest over Actin levels per lane. Three independent 
experiments were performed, run together on one blot, and heat maps of the phospho-
protein profile (46) in the 6 samples were constructed with CIMminer (Genomics and 
Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer 
Research, National Cancer Institute) (47).
Cell count and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
For these experiments 4·105 cells of the HOXA9 transduced and control transduced cell 
lines were seeded and cultured for six days in separate T75 Cellstar culture flasks. After six 
days of culturing the number of cells in both flasks was measured using a CellometerTM 
Auto T4 cell counter (Nexcelom Bioscience LLC, USA). After six days of stimulation, 
the total number of HOXA9 overexpressing cells in the T75 flask was calculated relative 
to the number of cells in the control cell line. This experiment was repeated four times. 
MTT assays were performed as previously described (48). Transduced Caco-2 cells were 







seeded in a 96-wells plate, each well containing 1000 cells. After 24, 48, 72 and 96 h cell 
metabolic activity and viable cells were detected by firstly adding 10 µl 5 mg/µl MTT 
to 100 µl DMEM, followed by three h incubation at 37°C and replacing the DMEM 
by dimethyl sulfoxide (DMSO; Sigma-Aldrich). Intensity of color was measured in a 
Model 680 XR microplate reader (Bio-Rad, USA). This experiment was repeated eight 
times.
3D spheroid-based cell expansion assay
Cytodex-3 microcarrier beads (Sigma–Aldrich) were mixed with 5×105 Caco-2 HOXA9 
overexpression and control cell suspensions, at a density of 40 cells per bead and 
incubated at 37°C for 6 h with gentle mixing. The suspension was transferred to 25 cm2 
flasks and incubated for 48 h. Coated beads were embedded in 1.6 mg/ml collagen gel 
(collagen: modified Eagle’s medium: 7.5% w/v NaHCO3 in the ratio 11:8:1), put in 
plates, incubated at 37°C for 2 h to polymerize and covered with 500 µl DMEM, 10% 
FBS, 1% P/S, 5 ng/ml doxycycline. Spheroid growth was measured by quantifying the 
cell layer extending from the surface of the bead. Ten coated beads were photographed 
every 24 h with a 10× objective. All measurements were performed using AxioVision 
4.5 software and assays were performed three times independently. Data was statistically 
analyzed by two-way ANOVA. 
Migration assay
Migration assays were performed as described (49). Briefly, a barrier is inserted in a 
culture chamber, this prevents cells from entering a defined area occupied by the barrier. 
Cells were seeded around this barrier to form a monolayer, the barrier is removed, and 
migration into the defined cell-free area is measured. 
cBioportal query
We performed a query on the 15th of April 2018 on http://www.cbioportal.org (50, 
51). We selected all 8 studies from the category “bowel” including a total of 3473 cases. 
This included four published studies (52-55), and “colorectal adenocarcinoma (TGCA, 
Provisional)”, “Colorectal adenocarcinoma (TCGA, PanCancer Atlas)”, “Rectum 
adenocarcinoma (TGCA, PanCancer Atlas)”, and “Targeted sequencing of 1134 samples 
from metastatic colorectal cancer samples (MSK, Cancer Cell 2018)”. 
Statistics
Relative expression of potential target genes was calculated comparing the transduced 
cell line overexpressing HOXA9 to the control cell line. The one-sample t-test was used 
to test for statistical significance. The Komogorov-Smirnov test, the D’Agostino and 
Pearson omnibus normality test and the Shapiro-Wilk normality test were used for each 
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target gene to see if the results came from a Gaussian distribution. If this assumption was 
violated the relative expression of the target gene was displayed using the median and the 
interquartile range. In those cases the Wilcoxon Signed-Rank Test was used to test for 
difference in expression. The Student’s t-test was used to test for statistical significance 
in phospho-protein profile. To test for significance of the observed difference in cell 
number after six days of stimulation the paired t-test was used (Graphpad Prism 5; 
GraphPad Software Inc., USA). A two-way analysis of variance (ANOVA) was used to 
test for significant difference at each time point in the MTT assay. P values <0.05 were 
considered to be statistically significant. Given that the biological significance of a given 
fold-change is likely to depend on the gene and on the experimental context no fixed 
fold change cut-off was employed in this study. 
Results
HOXA9 is overexpressed in colonic adenomas
HOX genes have been linked to cancer development and especially HOXA9 is interesting 
in this respect as it functions as an oncogene in various hematological malignancies (56). 
It has been reported that HOXA9 contributes to self-renewal and overpopulation of 
cancer stem cells in CRC (57). Thus, we decided to investigate whether HOXA9 mRNA 
expression is deregulated in colonic premalignant tissue. To this end we collected 27 
biopsies from colonic adenomas and location-matched healthy tissue and determined 
HOXA9 expression by qPCR. A direct comparison between the paired adenoma and 
healthy tissues demonstrates significantly increased HOXA9 mRNA expression levels in 
the adenoma samples (fold change (FC) 1.95; p<1.0∙10-4; Figure 1). 
Figure 1. mRNA expression of HOXA9 in colonic adenoma tissue and matched healthy control tissue. 
Paired tissue samples were taken and analyzed for HOXA9 expression by RT-qPCR. In the left panel (A) 
mean expression levels with standard error of the mean (SEM) are depicted. In the right panel (B) the pairs 
are linked and the result of a paired sample t-test is shown (p<0.0001).







Of note, five patients did not adhere to this trend of upregulated HOXA9 in their 
adenomatous tissue, however, no differences in clinical parameters (age, gender, ethnicity 
or type of polyp) could be detected and no follow-up data was available to assess long 
term consequences of differences in HOXA9 between patient groups. We concluded that 
pre-malignant colonic polyps are characterized by an abundance of HOXA9 expression 
as compared to healthy colonic tissue.
HOXA9 overexpression substantially alters the oncogenic mRNA profile
Having shown that HOXA9 upregulation is an early event during colonic carcinogenesis, 
we next investigated the molecular consequences of this upregulation by overexpressing 
HOXA9 in the CRC model cell lines. Transduction of such cells with an inducible 
HOXA9 lentiviral vector results in a ≈ 30-70 fold increase in HOXA9 mRNA expression 
upon doxycycline induction, when compared to cells transduced with a control plasmid 
(Supplementary Figure S1). Next, the effect of HOXA9 overexpression on potential target 
genes was examined. To identify potentially interesting HOXA9 targets, we employed 
the Cancer Pathway Finder RT2 Profiler PCR Array (Figure 2A). Intriguingly, analysis 
of the differentially expressed genes showed that the most drastically downregulated gene 
was CCL2, which encodes for the chemokine MCP-1, and is a well-known mediator 
of tumor metastasis. Indeed, high levels of CCL2 are associated with poor outcome in 
CRC patients due to high incidence of metastasis (58, 59). Thus, this result implies that 
HOXA9 expression might be specific to pre-metastatic lesions.
Other downregulated genes included the metabolism genes ACLY and ACSL4 and the 
apoptosis genes CASP2 and CASP7. Among the most prominently upregulated genes 
were the cell cycle genes CCND2, CCND3, SKP2 and MKI67 and the growth factor 
FGF2, suggesting that HOXA9 overexpression provokes a proliferative phenotype. 
Another highly upregulated gene is the insulin growth factor binding protein 7 (IGFBP7). 
This gene is part of the category of IGF1 signaling modulating genes, and while often 
considered tumor suppressive, has also been shown to be upregulated in some cancers, 
and may have growth stimulatory effects in CRC (60-62). HOXA9 overexpression led 
to overexpression of the HMG-box gene SOX10. This gene is best known for its role in 
neural crest differentiation during embryogenesis, but its ectopic expression in tumors 
has also been shown to confer tumor aggressiveness in some tumor types (63-66), 
although a tumor suppressive role has also been reported (67). In conjunction, these 
results are best interpreted as indicating that HOXA9 expression may stimulate adenoma 
growth and is responsible for compartment expansion but concomitantly would be 
associated with non-metaplastic behavior. 
Taken together, this exploratory analysis suggests a decreased migratory phenotype, 
with reduced apoptosis, and increased proliferation markers. Next, we expanded on 
these findings by designing qPCR primers for a range of target genes not included 
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Figure 2. Effect of HOXA9 overexpression on target genes. (A) The RT2 ProfilerTM PCR Array was 
used to detect differential expression profiles between HOXA9 overexpressing cells and control cells. 
Depicted are the mRNA levels quantified in a single experiment. mRNAs in red are downregulated 
upon HOXA9 overexpression compared to a control transduced Caco-2 cell line, conversely, mRNAs 
in green are upregulated. See scale bar in the right upper corner for the magnitude of the fold changes. 
(B) The overexpression of HOXA9 is depicted in this panel. RT-qPCR was performed on 25 mRNA targets 
identified to be modulated by HOXA9 in literature (Table S2). Of these, 6 were not detectable by qPCR, 
the expression of the remainder of mRNAs (19) are shown as a fold chance compared to control cells. 
Expression data of mRNAs that did not meet the assumption of Gaussian distribution, according to both 
the Komogorov-Smirnov test, the D’Agostino and Pearson omnibus normality test, and the Shapiro-Wilk 
normality test were indicated with an * next to their name on the X-axis. Expression data of mRNAs that 
did not meet assumption of Gaussian distribution are presented as medians ±IQR. *p<0.05, **p<0.01, 
***p<0.001. For the genes that did meet the assumption of Gaussian distribution, results presented as 
means ± SEM.







in the array, but with specific connection to HOXA9 as identified in literature search 
including all tissues and model systems (see Supplementary Table S1; (68-72). In 
addition, we also verified the main interesting finding of the Cancer Pathway Finder 
array, CCL2 expression using alternative primers. The statistically significantly regulated 
genes with the highest upregulation were FLT3 (mean FC=3.8), IGF1 (mean FC=2.8), 
PTGS2 (mean FC=2.4) and WNT5a (mean FC=1.8). FLT3, IGF1 and WNT5a are all 
associated with compartment expansion (Figure 2B). FLT3 is a tyrosine kinase receptor, 
IGF is a growth factor which stimulates phosphorylation dependent kinase cascades via 
the IGF-receptor, and WNT5a activates intracellular signaling through ligation to the 
Ror2/Frizzled receptors. Overexpression of PTGS2 (better known as COX2) has been 
associated with adenomatous changes and its inhibition is well-established to counteract 
colorectal polyp formation (73, 74). The genes with the highest relative downregulation 
were CYBB (mean FC=0.2), encoding for the NADPH oxidase complex protein NOX2, 
and CCL2 (mean FC=0.2). Interestingly, a switch in expression from NOX1 to NOX2 
induced a migratory invasive phenotype in colorectal cancer cells (75), which, together 
with the decreased CCL2 expression, suggests that HOXA9 overexpression decreases 
CRC migratory behavior. Genes associated with epithelial to mesenchymal transition 
(EMT) (BMP1, BMPR2, KRT19, VIM and ZEB) measured in this study showed little 
to no difference in expression as a result of HOXA9 overexpression. Overall, a picture 
emerges that HOXA9 is associated with polyp formation but also counteracts malignant 
progression.
Changes in cellular phosphoprofile support a role for HOXA9 in polyp growth but 
not malignant expansion
As HOXA9 overexpression modulates genetic transcription patterns towards an early 
proliferative phenotypes, we next sought to determine to what extent HOXA9 induced 
changes are translated to altered signal transduction patterns. We performed extensive 
(phospho) protein profiling to quantify the expression and activation status of several 
important signal transduction molecules (Supplementary Table S2). Analysis of 
constitutive expression of signaling molecules did not reveal significantly discriminative 
patterns between HOXA9 overexpressing and mock transduced cell pools (Supplementary 
Figure S2A, B). However, a distinct phosphoprofile upon HOXA9 overexpression was 
seen, as evidenced by the clustering of control and overexpression samples (Figure 3).
The most discriminate findings were a clustering of downregulated p-S6 (FC=0.50, 
p<1.0·10-4) and p-PDK1 (FC=0.45, p=5.9·10-3) upon HOXA9 overexpression (see 
Figure 4 for individual analyses). Canonical signaling dictates that activity of PDK1 
results in phosphorylation of the Thr308 residue of AKT, a survival protein, while 
phosphorylation of this protein on its Ser473 residue is dependent on the mammalian 
target of rapamycin (mTOR) when in association with Rictor in the so called mTORC2 
complex (Figure 5A). Fully activated AKT in turn is known to activate the mTOR/Raptor 
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Figure 3. HOXA9 influences cellular phosphoprofile. Heat maps of the phospho-protein profile constructed 
with CIMminer. Increased phosphorylation is depicted in red, conversely decreased phosphorylation is 
depicted in blue. See scale bar in the top left corner for magnitude of the phosphorylation. Euclidian 
distance between the samples is depicted on top. For the phosphorylation status of the various signaling 
proteins Euclidian distance is depicted to the left. Statistical significance was indicated on the right side 
of the figure with an asterisks *p<0.05, **p<0.01, ***p<0.001. Orange boxes and arrows are placed over 
molecules or molecule pairs to clarify the direction of regulation visually.
complex (mTORC1), which results in phosphorylation both the ribosomal S6 kinase 
and the translation factor 4E-BP regulating cell size and protein synthesis, respectively 
(76). However, our results indicate an uncoupling with canonical mTOR signaling 
in cells overexpressing HOXA9: 1) the decreased PDK activity was not accompanied 
by reduced AKT-thr308 phosphorylation, but corresponded closely to decreased S6 
phosphorylation. 2) While there was a trend towards lower mTOR phosphorylation, 
this was not significant, suggesting that the phosphorylation of S6 upon HOXA9 is not 
a direct effect of reduced mTOR signaling. 3) 4E-BP phosphorylation was significantly 
increased (FC=1.21, p=2.0·10-3), rather than decreased in HOXA9 overexpressing cells. 
Uncoupling between mTOR and its downstream targets is not unprecedented, as a 
direct activation of S6 via PDK1 has also been described (77, 78), and 4E-BP1 signaling 
can be independent of mTOR activity in CRC (79). However, this begs the question as 
to what activates 4E-BP, if not mTOR. Based on our dataset, it is tempting to speculate 
that AKT activity (FC=1.6, p=2.12∙E-2) may bypass mTOR in the phosphorylation 
of 4E-BP (Figure 5B). Adding a further layer of complexity, it was previously shown 







that knockdown of Rictor promotes AKT phosphorylation, and it is conceivable that 
HOXA9 modulates part of the mTORC2 complex rather than mTOR per se (80). 
Another interesting feature revealed by the phosphoprofiling was a significantly 
downregulation of PAK activity (FC=0.75, p=2.1·10-2), a protein involved in cytoskeletal 
rearrangement and migration. The direct upstream activator of PAK is the GTPase RAC1 
(81). While we did not observe any significant changes in activity of RAC1 as measured 
by its phosphorylation, there was a trend towards reduced RAC1 phosphorylation levels 
in HOXA9-overexpressing cells. It should be noted that the role of phosphorylation for 
Figure 4. HOXA9 induces differential protein expression. (A) Western blots of the five proteins for which 
the phosphorylation status was significantly altered by HOXA9, their names are depicted on the right, 
and the size of the band is indicated on the left. The HOXA9 status of the samples is depicted on top. 
(B) The results of densitometric analysis of the fluorescence bands are depicted expressed in normalized 
densitometry values (AU, arbitrary units). Blots were reprobed for actin for loading control. Additionally, 
their corresponding p values are depicted above the panels.
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RAC1 activity has been questioned, and its activity is best measured by demonstrating 
it’s GTP-loading. However, we have also previously shown that PAK activity can be 
mediated through AMPK-tubero sclerosis complex (TSC), independent of mTOR 
and RAC1 (82). In toto support these observations the notion that HOXA9 expression 
supports benign but not malignant compartment expansion.
Figure 5. HOXA9 influences mitogenesis, protein translation, and actin modulation. (A) Canonical 
signaling pathways of phosphoproteins. (B) Altered signaling upon HOXA9 overexpression. Red arrows 
indicate statistically significant directional regulation, pink arrows depict a trend in regulation.
HOXA9 overexpression stimulates adenoma growth
Taken together our mRNA and protein analyses of forced HOXA9 expression indicates 
that this gene provokes increased growth-factor (IGF1, FLT3, WNT5a) action, enhances 
survival (pAKT) signaling and protein synthesis (phosphorylation of p-4E-BP1 which 
relieves its suppressive action on the translation-initiation factor eIF4E, resulting in 
increased translational activity (83). We next sought to validate whether these molecular 
consequences of HOXA9 overexpression translate into cellular phenotypic changes. 
Therefore, we compared the cell pool growth of both the HOXA9 overexpressing and 
control cell lines. Starting with equal cell numbers, 70% more cells were seen after 6 
days of culture in cell cultures of HOXA9 overexpressing cells as compared to controls 
(p<4.0·10-3; Figure 6A), suggesting that HOXA9 confers a growth advantage to cells. 
To confirm this, the cell pool size was measured daily for four consecutive days. Figure 
6B shows that HOXA9 overexpressing cells have a significantly increased growth rate 
compared to control cell cultures (day two, p<0.05, day three, p<1.0·10-3, and day four, 
p<1.0·10-3; Figure 6B). We further confirmed these data by culturing cells in a 3D 
spheroid-based model, which again indicated that HOXA9 overexpressing cells grow 







faster in 3D as compared to control cells. (p=0.0272; Figure 6C1 for quantified results 
and C2 for illustrations of cells on the beads). Hence increased HOXA9 expression may 
be directly related to the compartment size expansion that characterizes the adenomatous 
epithelium.
HOXA9 overexpression inhibits cellular migration suggesting that its expression is 
specific for the adenoma stage in CRC progression
The reduced expression of chemokines (CCL2) and cytoskeletal modulators (pPAK) 
suggests that motility of cells might be affected upon overexpression of HOXA9 (84, 85). 
Figure 6. HOXA9 overexpression results in increased growth of the cell pool. (A) Cell count after six days 
stimulation with doxycycline. Amount of control cells after six days is the reference value. (B) MTT assay 
measuring viable cells in HOXA9 and control transduced Caco-2 cells. Results are represented as mean ± 
SEM of three independent experiments. *p<0.05, ***p<0.001 compared with control by Student’s t-test. 
(C1) 3D-migration assay, quantified results of one representative experiment (out of three) with data of ten 
coated beads. (C2) Photographs of control and HOXA9 overexpressing cells on beads in gelatin at days 1, 
2, 3, 4, and 7. “d”=day. Data was statistically analyzed by two-way ANOVA.
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Therefore, we investigated migratory ability of these cells using 2D ring-barrier assays 
which, unlike conventional scratch assays, are not influenced by proliferative capacity of 
cell cultures but use time-lapse microscopy to track individual cell movement. Results 
show that HOXA9 overexpression leads to a significant reduction in individual cell 
migration, compromising the total and effective migration after three days, as well as in 
the efficiency and speed of cellular migration (Figure 7). 
Tubular adenoma is the precursor to full blown CRC but is considered to have no 
metastatic potential. The present study shows that HOXA9 is highly expressed in 
colonic tubular adenomas and this expression can drive compartment expansion in a 
preclinical model. However, forced expression of HOXA9 also counteracts CCL2 and 
metastasis. In conjunction, these findings suggest that HOXA9 is a defining molecular 
marker of specifically the tubular adenoma stage in CRC development. This would 
fit a recent report that showed that in full blown CRC, tumors are characterized by 
increased HOXA9 expression but that such expression does not correlate with clinical 
outcome (41). Here we show that this increase is particularly manifest at the adenoma 
stage, but our mechanistic studies also reveal that for successful metastasis, HOXA9 
expression is inhibitory. Thus, increased HOXA9 expression has a specific pro-oncogenic 
functionality only at early stage of the CRC process and can be considered a marker of 
these early stages.
Figure 7. HOXA9 overexpression inhibits cellular migration. Individual cells were tracked in time laps 
microscopy of cellular migration for control cells (A) and HOXA9 overexpressing cells (B). A minimum of 
10 cells were traced for each condition per experiment, and total migration (C), effective migration (D), 
efficiency (E) and velocity (F) of migration were calculated. Results are represented as mean ± standard error 
of the mean (SEM) of three independent experiments.








CRC remains a major health problem. Better definition of molecular markers that 
relate to the natural history of early CRC would prove exceedingly useful. In this 
study we compared HOXA9 expression between adenoma tissue and location matched 
healthy colon epithelium and we subsequently decided to investigate the role of 
HOXA9 in oncological transformation of colonic epithelial cells. We observe that 
HOXA9 is overexpressed in colonic adenomas and drives compartment expansion but 
concomitantly counteracts metastasis. Thus, HOXA9 expression emerges as a molecular 
determinant for pre-micrometastatic colonic adenomas and may support benign polyp 
growth in the colon. 
Potential mechanisms mediating increased HOXA9 expression in adenoma
Based on the data from the publically available cBioPortal (Supplementary Figure S3), 
gene amplification appears not to be involved in the increase of HOXA9 levels in CRC 
(50) (not shown). Given that gene amplifications are rare in colonic adenomas this 
is in line with our findings. Also chromosomal translocation, which can drive altered 
HOXA9 expression in hematological malignancies, does not appear an important factor 
in this respect (not shown). Furthermore, HOXA9 was not found to be differentially 
methylated in CRC (86). Bhatlekar et al. found that HOXA4 and HOXA9 are up-
regulated in CRC stem cells (57). Their data indicates that HOXA9 aids self-renewal 
and overpopulation of stem cells in CRC. Multiple reports have described HOXA9 as 
a pro-oncogenic factor in other solid tumors (87). Hence, increased HOXA9 expression 
may well be driven by selection of clones that have a competitive advantage because of 
relatively high HOXA9 expression and the resulting outcompeting of cells not having 
such high expression. In line with this train of thought is that β-catenin signaling, 
activated upon WNT5A ligation to its receptor, is required for HoxA9-mediated 
transformation in the hematopoietic system (88). Additionally, colonic adenomas are 
almost universally characterized by high levels of β-catenin signaling (89). However 
further experimentation is obviously necessary to substantiate this notion.
Conclusion
In conclusion, HOXA9 is overexpressed in colonic adenomas. It inhibits cellular 
migration which appears to be mediated by effects on PAK activity. Strikingly, the pro-
oncogenic phenotype of HOXA9 alteration in hematologic malignancies was also found 
in this study as HOXA9 stimulates cell growth. This phenotype appears to be mediated 
through increased IGF1, FLT3, PTGS2 and p-AKT and p-4E-BP1. This is the first 
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Supplementary Figure S1. Forced HOXA9 overexpression in Caco-2 cells. HOXA9 mRNA expression 
in Caco-2 cell lines after stimulation with decreasing concentrations of doxycycline. Con: control cells, 
untreated with doxycycline. D: day. Maximal HOXA9 expression was observed after two days of doxycycline 
treatment, in order for HOXA9 to mediate its full effects, all functional experiments were performed after 
3 days of doxycycline treatment.







Supplementary Figure S2. Heat maps of the protein profile constructed with CIMminer. Increased protein 
levels or phosphorylation of proteins is depicted in red, conversely decreased phosphorylation is depicted in 
blue. See scale bar in the top left corner for magnitude of the phosphorylation. Euclidian distance between 
the samples is depicted on top. For the phosphorylation status of the various signaling proteins Euclidian 
distance is depicted to the left. (A) Total protein levels. (B) All total and phosphoprotein levels.
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Supplementary Figure S3. Visual representation of the cBioportal analysis of potential HOXA9 mutations, 
amplifications, and chromosomal translocations. (A) All cases visualized with their study of origin, indicated 
in the legend. (B) The magnification shows the individual cases with alterations, indicated in the legend.
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Vitamin D receptor polymorphisms 
are associated with reduced esophageal 
vitamin D receptor expression 
and reduced esophageal 
adenocarcinoma risk
Abstract
Epidemiological studies indicate that vitamin D exerts a protective effect on the 
development of various solid cancers. However, concerns have been raised regarding 
the potential deleterious role of high vitamin D levels in the development of esophageal 
adenocarcinoma (EAC). This study investigated genetic variation in the vitamin D 
receptor (VDR) in relation to its expression and risk of Barrett esophagus (BE) and EAC. 
VDR gene regulation was investigated by immunohistochemistry, reverse transcriptase–
polymerase chain reaction (RT-PCR) and gel shift assays. Fifteen haplotype tagging single-
nucleotide polymorphisms (SNPs) of the VDR gene were analyzed in 858 patients with 
reflux esophagitis (RE), BE or EAC and 202 healthy controls. VDR mRNA expression 
was higher in BE compared with squamous epithelium. VDR protein was located in 
the nucleus in BE. An rs1989969T/rs2238135G haplotype was identified in the 5′ 
regulatory region of the VDR gene. It was associated with an approximately two-fold 
reduced risk of RE, BE and EAC. Analysis of a replication cohort was done for BE that 
confirmed this. The rs1989969T allele causes a GATA-1 transcription factor binding 
site to appear. The signaling of GATA-1, which is regarded as a negative transcriptional 
regulator, could explain the findings for rs1989969. The rs2238135G allele was associated 
with a significantly reduced VDR expression in BE; for the rs1989969T allele, a trend 
in reduced VDR expression was observed. We identified a VDR haplotype associated 
with reduced esophageal VDR expression and a reduced incidence of RE, BE and EAC. 












The incidence of esophageal adenocarcinoma (EAC) in Western Europe and North 
America has shown an upward trend for many decades. Despite advances made with 
respect to its treatment, EAC remains to have a poor prognosis. EAC often arises within 
Barrett esophagus (BE) (1, 2), a metaplastic condition of the distal esophagus, in which 
through longstanding gastroesophageal reflux esophagitis (RE), the normal squamous 
epithelium is replaced by columnar epithelium. In Western countries, the prevalence 
of BE has increased dramatically since the 1970s (3), which explains the increasing 
incidence of EAC. BE is likely caused by a combination of genetic and environmental 
factors (4), but few studies have examined the exact association with dietary components.
Vitamins and antioxidants are believed to be key dietary components, some of which 
pose anticarcinogenic action (5). Vitamin D is a micronutrient and is the precursor 
to the steroid hormone calcitriol. It is obtained from dietary sources, but can also be 
produced endogenously under the influence of solar ultraviolet-B radiation (6). Its main 
action lies in normal development and mineralization of a healthy skeleton. Despite 
this, the vitamin D receptor (VDR) is expressed in a variety of tissues that are not 
involved in calcium or phosphate metabolism. Considerable evidence exists in scientific 
literature, citing an inverse epidemiological relationship between vitamin D and the 
incidence of several cancers (5, 7). 
The protective properties of vitamin D have been most extensively studied for colorectal 
cancer. Several meta-analyses reported consistent protective effects of high vitamin D 
status for colorectal neoplasia (8-11). This could be explained by the finding that the 
VDR controls nuclear β-catenin levels in colon cancer cells and can thus attenuate the 
effect of mutations that activate the Wnt/β-catenin pathway (12). Additionally, Hummel 
et al. (13) showed that increasing dietary vitamin D intake prevents chemically induced 
preneoplastic lesions in mice colon. However, a large-scale randomized controlled trial, 
the Women’s Health Initiative, found that calcium and vitamin D supplementation had 
no effect on the incidence of colorectal cancer compared with the placebo arm after a 
7-year follow-up; this follow-up period is possibly insufficient for detecting the effect 
(14). A recent overview of the influence of vitamin D on cause-specific death shows 
an inverse association with cardiovascular, oncological and other causes of death (15). 
However, there have been notable exceptions to this protective character, as reported 
for serum 25-hydroxy vitamin D levels, exposure to vitamin D or increased exposure 
to sunlight and upper gastrointestinal cancer (16-19). In addition, a significant direct 
association was observed between the highest tertile versus the lowest tertile of vitamin 
D intake and EAC, even after adjustment for confounders (20). Similar observations 
have been made for pancreatic cancer risks (21). The research of Trowbridge et al. 
(22), although preliminary, suggests that EACs, which do not respond to neoadjuvant 
therapy, have greater expression of VDR than tumors that do respond completely. 
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A recent review from this group states that no association can be identified with the 
current epidemiologic data, but that sun exposure is consistently reported to be inversely 
associated with EAC (23).
Factors that govern the outcome of vitamin D–mediated chemoprevention may lie in 
differential expression and/or activity of enzymes responsible for local activation and 
degradation of vitamin D, or variations in the expression or signaling of the VDR itself. 
The VDR gene encompasses about 64 kb, consisting of a 5′ region containing noncoding 
exon 1a to 1f, the coding exons 2–9 and a 3′ UTR (Supplementary Figure S1A) (24-
27) It is known that VDR protein is expressed in BE and normal stomach mucosa (28). 
Additionally, it is present in the normal colon, where it is more abundantly expressed in 
premalignant and cancerous lesions (29). 
At present, little is known about the role of the VDR gene and its single-nucleotide 
polymorphisms (SNPs) in BE and EAC. Therefore, the aims of this study were to, 
first, analyze VDR RNA and protein levels in BE. Second, this study aims to analyze 
15 haplotype tagging SNPs (htSNPs) with respect to the risk of RE, BE and EAC 
development. HtSNPs are representative SNPs in a region of the genome with high 
linkage disequilibrium; each htSNP represents a group of SNPs (that is, a haplotype). The 
15 htSNPs chosen are sufficient to cover the common genetic diversity across the VDR 
gene (24). Thirdly, our study aims to analyze htSNPs that have a different frequency in 
patients versus controls for VDR expression level. Here, we report two SNPs: 1453C>T 
(rs1989969) and 1633G>C (rs2238135). The presence of the rs1989969 T/rs2238135 
G haplotype was associated with a reduced risk for BE; this finding was confirmed with 
a replication cohort. The same was found for RE and EAC in a single cohort for each 
condition. The rs1989969 T allele was found to create a GATA-1 binding site and is 
associated with a two-fold (p=0.11) decrease in VDR expression in BE. The G allele of 
rs2238135 is associated with a 2.5-fold (p=0.01) decrease in VDR expression in BE as 
well. Potential implications for vitamin D–based chemoprevention will be discussed.
Materials and methods
Human patients and healthy controls
The association between VDR alleles and esophageal disease was analyzed in a group 
of 708 patients with RE, BE or EAC who visited the endoscopy unit of the Erasmus 
Medical Center Rotterdam or the IJsselland Hospital in Capelle aan den IJssel between 
November 2002 and February 2005 (30). Additionally, subjects visiting a general 
practitioner during this period for symptoms unrelated to and without any previous 
symptoms of gastroesophageal reflux disease (GERD) were asked to participate and 
served as healthy controls (n=202). Patient characteristics are given in Table 1. We 







attempted to contact all patients and subjects included in the study to collect data 
regarding their genetic background. In roughly half of the cases, information on ethnic 
background was obtained. Less than 1% of successfully contacted study participants were 
of non-Caucasian descent. Subjects included in the RE population had endoscopically 
confirmed RE (n=307), which was graded according to the Los Angeles (LA) classification 
(31). Patients were diagnosed endoscopically with BE (n=260) if they had a columnar-
lined segment in the esophagus of >2 cm in length with histological signs of specialized 
intestinal metaplasia. The length of the columnar-lined segment was determined 
endoscopically by measuring the distance between the squamocolumnar junction (the 
location at which the light-pink mucosa of the squamous-lined esophagus joined the 
red mucosa of the columnar-lined epithelium) and the gastroesophageal junction. 
Endoscopic diagnosis of EAC (n=141) was confirmed by pathologic assessment of the 
histology of biopsies. An independent BE replication cohort (n=150) was collected from 
the Academic Medical Center, located in Amsterdam. BE was identified endoscopically 
by an expert gastroscopist. Random biopsy specimens were taken from each quadrant of 
the BE at every 2 cm according to standard protocol. The biopsy specimens used in this 
study were taken from the middle of the BE segment. The random biopsies therefore 
surround the study biopsies. All random biopsy specimens were analyzed by an expert 
gastrointestinal pathologist, and the study biopsy specimens were used only when they 
contained Barrett epithelium. Squamous epithelial biopsies were taken 5 cm above the 
squamous Barrett junction. This study was approved by the institutional ethics review 
committees, and all patients gave informed consent before participating in the study.
Genotyping
Genomic DNA was extracted from 5 mL whole blood by a wizard genomic DNA 
purification kit (Promega, Madison, WI, USA). Fifteen htSNPs across the VDR gene 
were genotyped with the use of the high-throughput TaqMan allelic discrimination 
assays. A random 5% of samples were independently repeated to confirm genotyping 
results.
Table 1. Patient characteristics
HC RE BE Repl BE EAC
Number of subjects 202 307 260 150 141
Mean age, y (range) 57 (18-90) 55 (19-88) 61 (33-95) 59 (30-87) 63 (38-87)
Male, % 57 56 69 89 82




Real-time PCR mRNA quantification from human esophagus samples
Total RNA was extracted from tissue biopsies by using TriReagent (Sigma-Aldrich, 
St. Louis, MO, USA) and purified by using an RNeasy micro column kit (Qiagen, 
Hilden, CA, USA). One-fortieth of a 1 μg cDNA synthesis reaction (iScript cDNA 
Synthesis Kit; Bio-Rad, Hercules, CA, USA) was used in a 25 μl quantitative reverse 
transcriptase–polymerase chain reaction (RT-PCR) using SYBR GreenER (Invitrogen 
(Thermo Fisher Scientific Inc., Waltham, MA, USA)). The following primers were 
used for VDR gene amplification: 5′-CCGCATCACCAAGGACAAC-3′ and 
5′-GCTCCCTCCACCATCATTCAC-3′. Duplicate samples were run in independent 
PCR runs, and the average level of VDR gene expression was normalized to RNA 
polymerase II and GAPDH gene expression by using the Pfaffl method (32). 
Immunohistochemical staining
From the formalin-fixed, paraffin-embedded tissue, 5-μm tissue sections were sliced 
and mounted on adhesive slides (Starfrost, Berlin, Germany). After deparaffinization 
in xylene and dehydration in alcohol, endogenous peroxidase was inactivated by 
incubation with 0.5% hydrogen peroxidase in methanol for 15 min. Antigen retrieval 
was performed by boiling the sections for 10 min in 10 mmol/L citric acid monohydrate 
buffer (pH 6.0). Sections were blocked with 5% bovine serum albumin. Anti-VDR 
monoclonal antibody (1:200; clone 9A7, Affinity Bioreagents, Golden, CO, USA) was 
incubated for 1 h at room temperature, followed by polyclonal biotin–labeled goat anti-
rat (1:500; Dako, Denmark). After 45 min of incubation with streptavidin–horseradish 
peroxidase (HRP) (1:300; Dako, Glostrup, Denmark), VDR was visualized by using 
3-amino-9-ethylcarbazole as a substrate and hematoxylin counterstaining. Sections were 
evaluated by using light microscopy (Axioskop 20; Zeiss, Oberkochen, Germany), and 
pictures were taken and analyzed by using Nikon software (NisElements 2008; Tokyo, 
Japan).
Electrophoretic mobility shift assay
Oligonucleotides used in electrophoretic mobility shift assay (EMSA) and 
supershift assays were 5′-CCAGGGTGGTTGTCTACCTGGATGTCACCT 
CTGACCTCTG-3′ (wild-type, representing the rs1989969 C allele) and 5′-CCAGG 
GTGGTTGTCTATCTGGATGTCACCTCTGACCTCTG-3′ (mutant represents 
the rs1989969 T allele; underlined section represents the GATA binding site, and the 
bold nucleotide represents the position of the rs1989969 SNP). Probes were 5′-end 
labeled with (γ-32P)ATP. Nuclear extracts were prepared from murine erythroleukemia 
(MEL) cells according to the methods used by Wall and coworkers (33). For EMSA 
experiments, 2.5 μg nuclear extract prepared from MEL cells was incubated for 30 
min at 37°C with 1-ng 32P-labeled or 25 ng unlabeled VDR oligonucleotide probe in 
a binding buffer consisting of 50 mmol/l Tris, pH 8.0, 250 mmol/l NaCl, 5 mmol/l 







dithiothreitol, 5 mmol/l ethylenediaminetetraacetic acid and 10% Ficoll in a total 
volume of 10 μl. In competition assays, 25-fold molar excess of unlabeled competitor 
was included in the binding reaction. For supershift assays, 2 μg GATA-1 (N6)X mouse 
monoclonal antibody (sc-265 X; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
was added to reaction mixtures 30 min before addition of the nuclear extract. The 
protein-DNA complexes were separated from free probes by electrophoresis through a 
4% nondenaturing polyacrylamide gel and visualized on a orthochromatic film (Super 
HR-U30; Fuji Film, Tokyo, Japan) and developed by using a Fuji medical film processor 
(Model FPM 100A).
Statistical analyses
Genotype distribution was tested for Hardy-Weinberg equilibrium. The study was 
powered (80%) to allow detection of a 10% difference in genotype distribution of the 
VDR SNPs or haplotypes between the groups by performing Pearson χ2 analysis. Odds 
ratio (OR) and 95% confidence interval (CI) were calculated by risk estimate analysis. 
Logistic regression analysis was applied to establish allele dose effects. Statistical analyses 
were conducted by using SPSS v11.0 (SPSS (IBM, Armonk, NY, USA)), and two-tailed 
significance was p<0.05. We did not adjust for multiple testing. However, a replication 
cohort was included for BE. One-tailed t-tests were performed to test the hypothesis 
that GG versus CC and TT versus CC genotypes were associated with lower VDR 
levels.
In silico sequence analysis
The human genomic DNA sequence of the intronic region near the noncoding exon 1c 
~1.5 kb upstream of the translation start site was downloaded from the National Center 
for Biotechnology Information database (http://www.ncbi.nlm.nih.gov). The reference 
sequence used was NC_018923.2. Transcription factor binding sites were predicted by 
PROMO (version 3.0.2), which is a virtual laboratory for the identification of putative 
transcription factor binding sites. PROMO uses the 8.3 version of TRANSFAC (34, 
35). The dissimilarity threshold was set at 5%.
Results
BE epithelium has a high expression of  VDR compared with squamous epithelium
We investigated VDR expression in normal squamous epithelium compared with BE 
tissue in individual BE patients. In the majority of patients (20 of 25, 80%), presence of 
BE correlated with a two-fold increase in VDR mRNA expression (Figure 1A; p=0.002). 
This result was associated with higher levels of VDR protein in the BE segment, especially 
in the epithelial compartment, as evident from immunohistochemical staining of 
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squamous and BE biopsies from the same patient (Figure 1B). As shown in Figure 1C, 
in most BE tissue, the VDR protein had a nuclear localization, suggesting activation of 
the receptor. Thus, VDR mRNA expression is upregulated and VDR protein is activated 
in BE compared with squamous epithelium.
The rs1989969 T/rs2238135 G haplotype is associated with reduced risk for 
neoplasm-associated esophageal disease
Genomic DNA was obtained from a group of 708 patients with RE, BE or EAC and 
compared with a group of 202 healthy controls without any symptoms of esophageal 
disease. Patient characteristics are given in Table 1. As shown in Table 2, rs1989969 
and rs2238135, the two htSNPs in the exon 1c region, were found to be differently 
distributed in healthy controls versus patients with RE, BE and EAC in this study. 
Thirteen other VDR htSNPs were found to not be significantly associated with the 
presence of esophageal disease (data not shown). As shown in Table 3, allele dose 
Figure 1. Esophageal expression of VDR in BE patients. (A) Relative mRNA levels of VDR in paired 
squamous and columnar epithelium samples of BE patients. In 20 of 25 patients, VDR mRNA was highest 
in columnar epithelium samples. Immunohistochemical staining of VDR in squamous (B) and paired 
columnar epithelium (C) clearly shows a number of VDR-positive nuclei in BE and its mere presence in 
the cytoplasm of epithelial cells. Arrows indicate some positively stained nuclei.







analysis revealed that individuals carrying the rs1989969 T/rs2238135 G haplotype 
were two-fold less susceptible to RE (OR 0.48, 95% CI 0.28–0.81), BE (OR 0.46, 
95% CI 0.26–0.80) and EAC (OR 0.50, 95% CI 0.27–0.96). A BE replication cohort 
closely mimicked the observations for the rs1989969 T/rs2238135 G haplotype (OR 
0.44, 95% CI 0.23–0.85).





























































HC, healthy controls; RE, reflux esophagitis; BE, Barrett’s esophagus; Repl BE, BE replication cohort; 
EAC, esophageal adenocarcinoma. AValues in italic are significant at 95% CI.





Odds Ratio (95% CI)A





0 GT copies 345 1 1 1 1
1 GT copies 507 0.76 (0.50-1.15) 0.84 (0.54-1.30) 0.88 (0.54-1.43) 0.74 (0.45-1.22)
2 GT copies 169 0.48 (0.28-0.81) 0.46 (0.26-0.80) 0.44 (0.23-0.85) 0.50 (0.27-0.96)
0 GC copies 442 1 1 1 1
1 GC copies 444 1.37 (0.93-2.02) 1.53 (1.02-2.30) 1.64 (1.03-2.61) 1.08 (0.67-1.74)
2 GC copies 125 1.05 (0.57-1.93) 1.84 (1.02-3.32) 0.95 (0.44-2.05) 1.40 (0.71-2.77)
0 CC copies 590 1 1 1 1
1 CC copies 376 1.65 (1.12-2.44) 1.12 (0.74-1.68) 1.98 (1.25-3.12) 1.56 (0.98-2.48)
2 CC copies 57 1.24 (0.68-3.16) 0.96 (0.41-2.21) 0.80 (0.27-2.40) 1.22 (0.47-3.16)
The CT haplotype contained too few alleles for a meaningful comparison. HC, healthy controls; RE, reflux 
esophagitis; BE, Barrett’s esophagus; BE Repl, BE replication cohort; EAC, esophageal adenocarcinoma. AThe 
CT haplotype contained too few alleles for a meaningful comparison. BValues in italic are significant at 95% CI.
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Identifi cation of  an rs1989969-dependent GATA-1 binding site in the VDR intronic 
region near the noncoding exon 1c
With the fi nding established that carriers of the T allele of rs1989969 and the G allele 
of rs2238135 are two-fold less susceptible to neoplasm-associated disease, we further 
analyzed these SNPs. Th e availability of a multispecies genomic sequence allowed us to 
examine the sequence conservation across the transcriptional unit and indicated various 
highly pan-vertebrate conserved regions, especially around the location of rs1989969 and 
rs2238135, near the non-coding exon 1c ~1.5 kb upstream of the translation start site 
(Figure 2). Th e strong evolutionary conservation in this region might well be consistent 
with a role in transcriptional regulation. Interestingly, rs1989969 was found to convert 
the transcriptionally inert majority allele into a canonical GATA-1 binding site (that is, 
T/A GATA A/G (36) (Figure 3, Supplementary Figure S1). rs1989969 could thus be 
expected to alter VDR expression in cell types expressing GATA-1 transcription factor. 
GATA1 expression has been shown in the human stomach and duodenum but not in 
the small intestine, appendix and colon (37). GATA1/2/3 ortholog expression has been 
reported in the esophagus of the polychaete annelid, Capitella (38). Additionally, GATA4 
and 6 mRNA was found to be expressed highly in the proximal gastrointestinal tract 
(39, 40). Th e various GATA transcription factors have closely related and sometimes 
overlapping binding sites, therefore GATA-4 and 6 could have a similar function to 
GATA-1 (36).
Figure 2. Comparative sequence analysis of multi-species alignment of the VDR exon 1c noncoding 
regulatory region. Th is region lies near the noncoding exon 1c ~1.5 kb upstream of the translation start site. 
Th e regions containing the rs2238135 and rs1989969 SNPs (in boxes) are highly conserved in the human 
genome and six other mammalian species. Th e SNPs rs2238135 and rs1989969 are indicated by an “S” 
and a “Y.” Th e “S” represents a G or a C, and the “Y” represents a C or a T according to the International 
Union of Pure and Applied Chemistry (IUPAC) nucleotide base code.







Figure 3. The VDR rs1989969 T allele causes a functional GATA-1 binding motif to appear. (A) A 
rs1989969-dependent GATA-1 binding site is predicted. (B) Gel shift assay using radioactively-labeled 
oligonucleotides from the rs1989969 region and nuclear extract of MEL cells. The arrow indicates the 
motility of the oligo–GATA-1 complex. Lane 1, Mut oligo without nuclear extract; lane 2, Mut oligo with 
nuclear extract; lane 3, with 100× excess of unlabeled Mut oligo (self-competitor); lane 4, with 100× excess 
of unlabeled WT oligo (non–self-competitor); lane 5, with complete non–self-competitor; lane 6, with 
100× excess unlabeled known GATA-1 oligo; lane 7, 1 μg anti–GATA-1 monoclonal antibody. The signal 
found on the Mut oligo (lane 2) was almost completely eliminated by a 100-fold excess of unlabeled self-
competitor and a known GATA-1 oligonucleotide (lanes 3 and 6) but not with WT and complete non–self-
oligonucleotides (lanes 4 and 5). Labeled WT oligo did not result in GATA-1 binding (data not shown).
Chapter 5
196
In EMSA, the binding of the GATA-1 transcription factor was tested by using 
oligonucleotides bearing the C and T allele of rs1989969, together with nuclear extracts 
and antibodies against GATA-1 (Figure 3A). Supershift experiments indicated that 
GATA-1 transcription factor binds to the oligonucleotide with the rs1989969 T allele, 
whereas the oligonucleotide bearing the common rs1989969 C allele does not show 
detectable binding (Figure 3B). Th us, the rs1989969 SNP results in a diff erential 
binding of GATA-1 to the VDR gene.
The rs1989969 and rs2238135 SNPs infl uence esophageal VDR expression
To study the functional consequences of the rs1989969 and rs2238135 SNPs on VDR 
expression, esophageal biopsies were taken from BE of patients, and VDR expression 
levels were determined by using quantitative RT-PCR. Th e expression of VDR in 
the esophagus was on average 2.5-fold lower in BE patients carrying two copies of 
the rs2238135 G allele versus subjects carrying two copies of the rs2238135 C allele 
(p=0.01). VDR expression was two-fold lower in BE patients carrying two copies of 
the rs1989969 T allele versus subjects carrying two copies of the rs1989969 C allele. 
However, this association did not reach statistical signifi cance (p=0.11; Figure 4). Th us, 
the rs2238135 C allele results in 2.5-fold higher esophageal VDR expression. Th e C 
allele of rs1989969, in which the GATA-1 binding site is absent, shows a trend in higher 
esophageal VDR expression.
Figure 4. Presence of the rs1989969 T or rs2238135 G allele decreases esophageal VDR expression. BE 
biopsies were analyzed for VDR mRNA levels by quantitative RT-PCR. In the fi rst panel, the esophageal 
expression of VDR was on average 2.5-fold lower in BE patients carrying two copies of the rs2238135 G 
allele versus subjects carrying two copies of the rs2238135 C allele (p=0.01, one-tailed). In the second panel, 
VDR expression was two-fold lower in BE patients carrying two copies of the T allele of rs1989969 versus 
subjects carrying two copies of the C allele of rs1989969. However, this association did not reach statistical 
signifi cance (p=0.11, one-tailed).








The incidence of EAC rises to date despite surveillance strategies. In many cases, the 
development of EAC is related to BE. This premalignant stage provides the opportunity 
to prevent the development of BE-related adenocarcinoma by stratifying BE patients at 
risk for neoplastic progression. Additionally, it provides the opportunity to identify BE 
patients who are likely to respond negatively to vitamin D supplementation. Vitamin D 
supplementation is likely to convey a level of chemopreventive properties against oncogenic 
transformation in other tissues. Identifying genetic, tissue-specific markers that distinguish 
individuals on their responsiveness to vitamin D would represent a rationale for detecting 
groups of patients that could benefit most from vitamin D–based chemoprevention. 
Obtaining DNA from blood would provide an easy and cheap way to identify patients 
that have the highest benefit. Therefore, the aim of this study was to investigate the role 
of VDR in BE; study the consequences of SNPs in the VDR gene on the development of 
RE, BE and EAC; and elucidate the mechanisms by which these SNPs exert their effect.
We found that BE epithelium has a two-fold higher expression of VDR mRNA compared 
with squamous epithelium. This result was concomitant with a higher expression of 
VDR protein detected by immunohistochemistry. In addition, VDR protein was found 
to predominantly have a nuclear localization, suggesting activation of the receptor. 
Subsequently, 15 htSNPs of the VDR gene were analyzed with respect to the risk of RE, 
BE and EAC development. The T allele of rs1989969 was associated with a reduced risk 
for BE. The same was found for RE in a single cohort. A similar trend was observed for 
EAC, also in a single cohort. The G allele of rs2238135 was associated with a reduced 
risk for RE in a single cohort. A similar trend was observed for BE and EAC. The 
presence of the rs1989969 T/rs2238135 G haplotype was associated with a reduced risk 
for BE; this finding was confirmed with a replication cohort. The same was found for 
RE and EAC in a single cohort. The two SNPs were further analyzed to elucidate the 
mechanisms by which they exert their effect. The rs1989969 minor T allele resulted in 
a GATA-1 binding site in the VDR intronic region near the noncoding exon 1c. This 
result was identified in silico and was verified by EMSA. Here, oligos containing the 
T allele of rs1989969 displayed strong GATA-1 transcription factor binding, whereas 
oligos derived from the major C allele were not capable of doing so. Furthermore, the 
VDR mRNA level in BE tissue of rs2238135 G allele carriers was found to be lower 
than the mRNA level in rs2238135 C allele carriers. A trend in the same direction was 
found for the rs1989969 T versus C allele. This finding resulted in possible vitamin D 
sensitivity in this organ. This result provides a mechanism that could explain why the 
rs1989969 T/rs2238135 G haplotype is associated with a reduced risk for neoplasm-
associated esophageal disease.
A role of vitamin D in the etiology of BE is expected from the well-known mutual 
positive interaction between VDR signaling and signaling of bone morphogenetic 
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proteins. Bone morphogenetic protein-4 expressed in RE induces a columnar phenotype 
in esophageal squamous cells and is thus possibly important for the precancerous process 
(41). The present study further supports this concept by establishing the upregulation of 
VDR signaling during the metaplastic process. GATA factors are well established, mostly 
negative transcriptional regulators. Accordingly, the rs1989969 T allele, which results 
in a GATA-1 binding site, reduces expression of the VDR. It was previously shown that 
IL-4 induces GATA1 expression, which, subsequently, represses VDR expression and 
enables monocyte-derived dendritic cell differentiation within inflammatory sites (42). 
This could take place in BE during inflammation, providing additional support for the 
here-presented findings.
The rs1989969 T/rs2238135 G haplotype was associated with a reduced incidence of 
RE at a level on par with the reduced incidence in BE and EAC observed in this study. 
This finding would support the notion that this haplotype exerts its effect on the risk of 
BE and EAC by reducing the rate of RE instead of reducing the rate of progression from 
RE to BE and EAC. Both SNPs reported here are haplotype tagging; the association 
found between the T allele of rs1989969 and a lower incidence of neoplasm-associated 
esophageal disease and VDR expression levels can in part be due to other genetic variation 
with which the rs1989969 T allele is associated. The same holds true for rs2238135. Its 
action could, in part, even be due to an association with rs1989969 by the linkage 
disequilibrium that exists between the two SNPs. Further research can improve our 
understanding of the relative importance of individual genetic variations with which the 
SNPs we report on are associated.
Chang et al. (43) found that rs2238139 (277+2550C>T) and rs2107301 (277+3260C>T) 
TT homozygotes had a significantly reduced risk of EAC compared with CC homozygotes. 
Unfortunately, however, we did not analyze the same SNPs and therefore extrapolation 
is not straightforward. Chang et al. also analyzed SNP rs2238135 for an association 
with EAC and reported negative results. Our study also reported negative findings for 
this particular association, but we did observe an association between the G allele of 
rs2238135 and both RE and reduced VDR expression in this study. An association 
was also observed in the BE replication cohort but not in the original cohort. The lack 
of association between rs2238135 and EAC might therefore be a consequence of our 
study being underpowered for this particular question. Unfortunately, the same reason 
has probably also prohibited us from being able to draw strong conclusions with regard 
to the relation between the rs1989969 T allele and reduced VDR mRNA expression in 
BE. Whereas genetic association studies require replication cohorts, this study did not 
include replication cohorts for both RE and EAC. Because a BE replication cohort was 
included and RE, BE and EAC are related conditions, extrapolation of our conclusions 
with respect to BE to RE and EAC is plausible. However, confirmation of our findings 
by others, especially with respect to RE and EAC, is necessary. Whereas the ethnic 







composition determined from roughly half of the subjects suggests no substantial ethnic 
admixture of our study group, this notion is uncertain.
Currently, a path between VDR SNPs, probably via influence of VDR expression, and 
the cancerous process has been established. This association is implied from theoretical 
(positive interaction with BMP signaling), epidemiological observations (dietary vitamin 
D intake and UV-B exposure are associated with increased risk for esophageal cancer) as 
well as the observations made in the present study. GATA transcription factor expression 
appears to be lower in the distal tract, which has been shown for GATA-1 (37), GATA4 
and 6 (39). In addition, the vitamin D-based chemopreventive effects in the colon 
might be transferred through mechanisms other than those involving these VDR SNPs. 
Therefore, we propose that individuals carrying more rs1989969 T and rs2238135 G 
alleles will benefit more from vitamin D–based chemopreventive strategies because 
they are less likely to be confronted with the negative consequences of these strategies, 
being malignant esophageal disease. Confirmation of this notion obviously requires 
reevaluation of previous trials involving dietary vitamin D supplementation, assessing 
the number of rs1989969 T and rs2238135 G alleles in the participants. If confirmed, 
the rs1989969 and rs2238135 SNPs would represent the first polymorphisms that 
stratify individuals for the use of a particular chemopreventive strategy.
Conclusion
This study serves as a proof of principle that SNPs in the VDR gene can modify the risk 
of RE, BE and EAC, probably through modification of VDR expression. To investigate 
how serious the impact of vitamin D truly is, additional research is needed into the 
mechanisms by which vitamin D affects the risk of developing RE, BE and its sequelae 
EAC. The rs1989969-dependent GATA-1 binding site in the VDR intronic region near 
the noncoding exon 1c, identified in silico and tested in EMSAs, provides a starting 
point for this. At the same time, evidence from epidemiological studies mimicking 
the true longlife effects of vitamin D are required to endorse the idea of personalized 
recommendations for vitamin D supplementation.
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Supplementary Figure S1. Genomic structure of the 12q13.1 locus and potential transcription factor 
binding sites in the exon 1c region of the VDR gene. (A) Genomic structure of the 12q13.1 locus. Th e 
VDR gene encompasses about 64,493bp consisting of a 5’ region containing non coding exon 1a to 1f, 
the coding exons 2 to 9, and a 3’ UTR (24-27). (B) Th e intronic region near the non-coding exon 1c 
approximately 1,5 kb upstream of the translation start site contains a number of potential transcription 
factor binding sites, including for GATA-1, AP-1, SRY and NFkappaB. Analysis of this region indicated 
that the rs1989969 T allele causes a GATA-1 binding site to appear. Transcription factor binding sites are 
indicated by underlining of the sequence and their respective name. Bold bases represent the two htSNPs 
investigated in this study, rs1989969 and rs2238135. S = G or C, Y = C or T, R = A or G according to Th e 
International Union of Pure and Applied Chemistry (IUPAC) nucleotide base code.
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Use of  immunohistochemical 
biomarkers as independent predictor 
of  neoplastic progression in 
Barrett’s oesophagus surveillance: 
a systematic review and meta-analysis
Abstract
The low incidence of oesophageal adenocarcinoma (EAC) in Barrett’s oesophagus 
(BE) patients reinforces the need for risk stratification tools to make BE surveillance 
more effective. Therefore, we have undertaken a systematic review and meta-analysis 
of published studies on immunohistochemical (IHC) biomarkers in BE to determine 
the value of IHC biomarkers as neoplastic predictors in BE surveillance. We searched 
MEDLINE, EMBASE, Web of Science, CENTRAL, Pubmed publisher, and Google 
scholar. All studies on IHC biomarkers in BE surveillance were included. ORs were 
extracted and meta-analyses performed with a random effects model. 16 different IHC 
biomarkers were studied in 36 studies. These studies included 425 cases and 1835 
controls. A meta- analysis was performed for p53, aspergillus oryzae lectin (AOL), 
Cyclin A, Cyclin D and alpha-methylacyl-CoA racemase. Aberrant p53 expression 
was significantly associated with an increased risk of neoplastic progression with an 
OR of 3.18 (95% CI 1.68 to 6.03). This association was confirmed for both non-
dysplastic BE and BE with low-grade dysplasia (LGD). Another promising biomarker 
to predict neoplastic progression was AOL, with an OR of 3.04 (95% CI 2.05 to 
4.49). In conclusion, the use of p53 IHC staining may improve risk stratification in BE 
surveillance. Aberrant p53 expression in BE patients appeared to be associated with a 













Development of oesophageal adenocarcinoma (EAC) is related to Barrett’s oesophagus 
(BE), a premalignant condition of the distal oesophagus. In BE, the pre-existent 
squamous epithelium is replaced by columnar epithelium which develops under the 
influence of chronic acid and bile reflux and frequently contains goblet cells (1-3). The 
progression from BE to EAC is a gradual process, in which intestinal metaplasia (IM) 
evolves to low-grade dysplasia (LGD), high-grade dysplasia (HGD) and eventually EAC 
(4). Therefore, current guidelines recommend endoscopic surveillance in BE patients 
to detect HGD or EAC at an early stage, with the aim to improve survival rates (5, 6). 
Several studies have shown that patients diagnosed with EAC during BE surveillance 
have earlier staged tumors and probably better survival compared to those diagnosed 
after the onset of symptoms (7-10). 
The estimated incidence of EAC in patients with BE was reported to be between 0.5 and 
1% per year (11-14). However, more recent population-based studies and two meta-
analyses have set this risk around 0.12% to 0.38% per year (15-18). This relatively 
low annual risk reinforces the need for risk stratification tools to make BE surveillance 
more effective. BE length, male gender, smoking, and LGD are known risk factors for 
progression to HGD and EAC (13, 15, 18-20). Two large population studies confirmed 
that patients with LGD have an approximately five times higher risk of progression 
compared to patients with non-dysplastic BE (15, 18). Thus, more intensive surveillance 
is recommended in BE patients with LGD (5, 6). However, the histological diagnosis of 
LGD is subject to a considerable inter- and intra-observer variation, because of sample 
error and overlap with features of non-neoplastic regenerative changes (21-24). 
Because none of the current clinical and histologic criteria are able to accurately predict 
which patients are likely to progress to HGD or EAC, there is an increasing interest 
in (molecular) biomarkers. Many immunohistochemical (IHC) biomarkers have been 
studied in BE progression, mainly because they can be applied to standard histological 
samples. In clinical practice, IHC biomarkers are relatively easily applicable compared 
to other techniques. Currently, the addition of p53 IHC to the histological assessment 
is recommended in the guideline of the British Society of Gastroenterology as it may 
improve the diagnostic reproducibility of a histological diagnosis of LGD (5).The use of 
IHC biomarkers as independent predictor of neoplastic progression is not yet performed 
in routine clinical care, neither for p53, nor for other IHC biomarkers. Therefore, this 
study aims to provide a systematic review and meta-analyses of all retrospective case 
control or cohort studies and prospective cohort studies investigating IHC biomarkers 




This review was conducted according to the PRISMA and MOOSE guidelines (S1 
MOOSE checklist, S1 PRISMA checklist) (25, 26). 
Definitions
BE was defined as columnar lined oesophagus (CLE). Neoplastic progression was 
defined as the development of HGD or EAC during follow up. Patients with neoplastic 
progression were classified as cases and patients without neoplastic progression as 
controls. 
Data sources and searches 
Records were identified by searching the following electronic databases: 1. EMBASE, 
2. MEDLINE, 3. Web of Science, 4. CENTRAL, 5. PubMed Publisher, 6. Google 
scholar until 09-12-2016 (S1 Search). The search strategy was constructed by applying 
a sensitivity maximizing approach. A combination of MESH subject headings and text 
words were used related to IHC markers for progression in patients with BE. The search 
was confined to English language publications. Conference abstracts indexed in Embase 
from the years 2014 - 2016 were included in order to be able to include new and 
unpublished papers. 
Study selection
Search results were combined and duplicates removed. Every article was screened on title 
and abstract level for relevance by a single author (SvO or VJ). Articles were reviewed 
full text by the same two independent authors and included if they met the following 
criteria: (1) association between IHC biomarker expression on formalin fixed paraffin 
embedded material and risk of neoplastic progression was assessed; (2) a cohort or case-
control study design; (3) patients with known or newly diagnosed BE with or without 
LGD at baseline; (4) patients defined as cases had to have progressed to either HGD 
or EAC during follow-up; (5) mean follow-up of at least one year from the time of 
initial BE diagnosis; (6) the possibility to extract an OR. Studies were excluded if: (1) 
BE cohorts included patients with HGD at baseline; (2) endoscopic therapies affecting 
neoplastic progression were performed during follow-up (Figure 1). Some manuscripts 
studied different biomarkers within the same population, these were considered as 
individual studies on the level of the individual biomarker. 
Data extraction 
For each included study two independent authors extracted data according to a 
standardized data extraction form and assessed the quality of the eligible studies (S1 








Standardized data extraction form). In case of disagreement consensus was reached by 
consulting a third author (MS). Odds ratio’s (OR)s and 95% confidence intervals (CI)s 
of individual IHC biomarkers were extracted or estimated from the data. If ORs could 
not be extracted directly from the text or the tables, ORs were calculated indirectly 
by using the numbers of cases and controls with an aberrant versus a normal IHC 
biomarker expression from text, tables, or figures. 
Quality assessment 
The quality aspects defined were: a difference at baseline between cases and controls of 
at least 10% (concerning baseline histology, age, sex, length of BE segment, and follow-
Figure 1. Flow chart of the study.
Fig 1. Flow chart of the study.
https://doi.org/10.1371/journal.pone.0186305.g001
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up time), adjustments in the form of regression for differences of known predictors of 
progression (such as baseline histology, age, sex, and length of BE segment), exclusion 
of prevalent cases, control stainings, number of pathologists, pathologist agreement 
and pathologist blinding. These aspects were assessed and reported on but not used as 
exclusion criteria.
Data synthesis and analyses
Meta-analysis were performed if at least two studies were available (27). If multiple 
studies in a single analysis included the same patients, the oldest study was excluded. 
An inverse variance random-effect model was used. If data on multiple definitions of 
aberrant staining were available, definitions were chosen to resemble those from other 
included studies for that IHC biomarker. If only one study was available, definitions 
of the authors of that study were used. Pooled estimates of effect, in the form of ORs, 
were calculated and investigated for statistical heterogeneity by visual inspection and the 
I-squared test (I2)=((Q-df )/Q)*100%, where Q was the chi squared statistic and df was 
its degree of freedom. Where possible, ORs adjusted for most factors were used in the 
analysis and unadjusted and adjusted ORs were pooled if necessary. Small study effects 
such as publication bias were assessed using a funnel plot. 
Sensitivity and subgroup analyses
Sensitivity analyses were performed in case of a large standard error (if small study effects 
were likely present as observed in the funnel plot), if no adjustments were made for 
known predictors of progression (such as sex, age, histology, i.e. non-dysplastic or LGD, 
and BE-length), and if only an abstract was available. We excluded individual studies 
from the most reliable analysis to evaluate the impact of single studies on pooled risk 
estimates and heterogeneity. Additional analyses were performed to assess if an IHC 
biomarker can be used as a predictor of neoplastic progression, independent of the 
presence of dysplasia. Therefore, all studies were summarized which included only non-
dysplastic BE patients, only BE with LGD patients, or in which adjustments were made 
for histology type. Additionally, two subgroup analyses were performed including either 
non-dysplastic or LGD BE patients.
Stringency of  the definition for aberrant staining used and its interpretation
The stringency level of the definition for aberrant staining and its interpretation 
could lead to variation in the predictive ability of the IHC biomarker investigated. To 
investigate whether this effect might be present, the proportion of controls deemed 
positive was plotted against the OR of each study. 










2081 records were retrieved, after removal of duplicates. After excluding 2050 records 
based on title and abstract, a total of 27 full text articles and four abstracts were assessed 
in detail (Figure 1). Of these, 19 full text articles and two abstracts were included in this 
review (28-49). These articles contained a total of 36 studies. 
Characteristics
A total of 36 studies were included, containing 2260 patients of which 425 cases, 
selected from a populations of more than 7000 BE patients. The proportion of male 
patients ranged from 66% to 100%. Mean duration of follow-up varied from 11.3 
months to 120 months. Most studies were retrospective case-control studies (n=33), 
and three prospective cohort studies. One study defined BE as CLE without IM, other 
studies defined BE as CLE with IM (n=23), or gave no definition (n=12). Endpoint was 
EAC in six studies and either HGD or EAC in 30 studies (Table 1).
Dilutions and definitions for aberrant staining used
For p53, the antibody DO-7 (Dako, Glostrup, Denmark) was frequently used with a 
dilution ranging from 1:20 to 1:1000. The definition for aberrant IHC staining was 
heterogeneous. Very intense staining was considered aberrant by all studies (being 
independent of the concentration used). However, intensity of staining was not a 
prerequisite for considering a staining pattern aberrant in seven studies (29-33, 37, 47). 
Three more recent studies also considered a total absence of staining as aberrant (35, 
36, 39). For aspergillus oryzae lectin (AOL), one study calculated the OR for aberrant 
AOL IHC staining in 2 or 3 epithelial compartments versus 0 or 1 compartment (34). 
Another study reported multiple ORs for aberrant AOL in 1, 2, or 3 versus 0 epithelial 
compartments (39). The OR of aberrant AOL IHC staining in 2 or 3 versus 0 or 1 
compartments was extracted from this second study and analyzed together with the data 
from the first study for the meta-analysis. 
Quality of  studies 
In 14 of the 36 studies there was at least a 10% difference in baseline histology between 
cases and controls. In these studies, around 32% of the cases had IND or LGD at 
baseline, versus 9% in the controls. In five studies an age difference at baseline of at least 
5 years was found between cases and controls, in four of these studies the case group 
was older. In six studies at least 10% more males were included in the case groups, 
96% males on average in the cases, versus 73% in controls. Information on length 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































longer BE segment was present; on average 5.9 cm versus 4.8 cm in the controls. In 
17 studies the total follow-up time differed by at least 10% between case and control 
groups. On average, follow up time was 51 months versus 59 months for cases versus 
controls, respectively. Seven studies excluded possible prevalent cases (29, 32, 34, 47, 
49). Fourteen studies adjusted for known predictors of progression (Supplementary 
Table S1). 16 studies did not describe technical validation of the staining. IHC staining 
was scored by one observer in 15 studies, by two observers in 13 studies, and by three 
observers in three studies. Kappa values were mentioned in only eight studies. Whether 
slides were assessed in a blinded manner was not mentioned in six studies, all other 
studies reported the use of blinding (Supplementary Table S1).
Meta-analyses
These were possible for p53, AOL, Cyclin A, Cyclin D, and alpha-methylacyl-CoA 
racemase (AMACR), which were studied 13, 2, 4, 3, and 2 times respectively. Of the 13 
studies, two included patients from the same population, which resulted in exclusion 
of the older study in analyses for which both would have been eligible (32, 34). The 
most frequent reasons for excluding articles were the absence of follow-up data and 
LGD being defined as neoplastic progression and end-point of the study (Figure 1). 
Biomarkers studied only once were MCM2, CD1a, β-catenin, COX2, Ki67, HER2, 
Sialyl Lewis, Wheat germ, Lewis, and SOX2. The same group published two studies on 
hERG1, both including patients from the same population (46, 48). Therefore, both 
studies were individually included without summary in a meta-analysis. 
p53 
A total of 12 studies were included in the meta-analysis. These contained 1905 patients, of 
which 342 cases. One study gave multiple ORs for various expression levels of p53 (34). 
For this study, only the OR for intense overexpression of p53 staining was considered 
positive. Individual patient data of one study were converted in order to extract an 
adjusted OR (35). The overall OR for neoplastic progression was 7.04 (95% CI 3.68 
to 13.46) for patients with aberrant p53 expression (Table 2 and Figure 2). Aberrant 
p53 expression, detected in both non-dysplastic BE and LGD patients, was significantly 
associated with the development of HGD or EAC. Significant heterogeneity (I2=56%, 
p<0.010) was observed between the included studies, which can be considered a moderate 
amount of heterogeneity (50). The 12 studies were plotted in a funnel plot which shows 
that small study effects can be present (Supplementary Figure S1). In order to reduce 
the influence of such effects a sensitivity analysis was performed, which excluded all 
studies with a standard error above one. Based on this criterion, five studies remained, 
containing 1413 patients and 289 cases. The overall OR for neoplastic progression was 
4.15 (95% CI 1.96 to 8.81) in patients with an aberrant p53 expression (Table 2). 

































































































































































































































































































































































































































































































































expression in cases, in controls, or in both. In order to investigate this, the proportion 
of controls deemed aberrant was plotted against the OR of each study (Supplementary 
Figure S2). Studies with a higher point estimate of the OR appeared to have had less 
positive non-progressors. The same is seen if this is analyzed in individual studies where 
multiple cut-offs for positivity are described (32, 34). Using a more stringent cut off 
resulted in a higher OR. Further sub sensitivity analyses were performed excluding 
studies for which no adjusted ORs were available. Four studies remained, containing 
1322 patients and 278 cases. The overall OR for neoplastic progression was 3.18 (95% 
CI 1.68 to 6.03) in patients with an aberrant p53 expression (Table 2). Subsequently, 
individual studies were excluded from this analysis, and finally also studies presented 
as abstracts. These sensitivity analyses showed similar results with slightly lower point 
estimates compared to the main analysis (Table 2). For three studies both unadjusted 
and adjusted ORs were available, and all three adjusted ORs had a lower point estimate 
compared to the unadjusted ones, in line with the outcome of our meta-analyses.
p53 as independent predictor of neoplastic progression
For this analysis studies that did not adjust for histology at baseline were excluded. This 
led to the inclusion of six studies. These studies contained a total of 1340 BE patients, of 
which 282 cases. The overall OR, for aberrant p53 IHC on neoplastic progression, after 
stratification for histology, was 3.86 (95% CI 2.03 to 7.33) (Table 2).
p53 in non-dysplastic Barrett’s oesophagus 
Two studies were included for this analysis. These contained a total of 720 BE patients, 
of which 61 cases. Individual patient data of one study was re-analyzed to provide an 
OR for non-dysplastic BE patients only (35). The overall OR for neoplastic progression 
to HGD or EAC in non-dysplastic BE patients was 6.12 (95% CI 2.99 to 12.52) (Table 
2). 
Figure 2. Forest plot of studies investigating p53 as a predictor of progression. Twelve studies were included.
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p53 in low-grade dysplasia Barrett
For this analysis four studies were included. These contained a total of 182 BE patients, 
of which 37 cases. One study was re-analyzed to provide an OR for the LGD subgroup 
only (35). The overall OR for neoplastic progression to HGD or EAC was 8.64 (95% 
CI 3.62 to 20.62) (Table 2). 
AOL
Two studies were included in this meta-analysis. These contained 573 BE patients, of 
which 204 cases. The overall OR for neoplastic progression in BE patients with an 
aberrant AOL staining in 2 or 3 compartments, versus 0 or 1 compartments of the tissue 
was 3.04 (95% CI 2.05 to 4.49) (Table 3 and Supplementary Figure S3). Results of 
the two studies were consistent in their findings (I2=0%, p=0.85). 
Table 3. Summary of meta-analyses of studies investigating IHC biomarkers other than p53 as a predictor 
of neoplastic progression
Analysis Studies Cases Controls OR 95% CI I2
AOL 2 (Suppl. Fig. S3) 204 369 3.04 2.04-4.49 0%
Cyclin A 4 (Suppl. Fig. S3) 285 990 1.90 0.85-4.22 76%
Cyclin D 3 (Suppl. Fig. S3) 50 287 1.01 0.14-7.03 80%
AMACR 2 (Suppl. Fig. S3) 53 659 4.07 0.66-25.12 53%
CYCLIN A
Four studies were included in this meta-analysis. These contained 1275 patients, of 
which 285 cases. The overall OR for neoplastic progression in BE patients with cyclin 
A positivity was 1.90 (95% CI 0.85 to 4.22) (Table 3 and Supplementary Figure S3). 
Results of the three studies were inconsistent in their findings (I2=76%, p=0.005).
CYCLIN D 
Three studies were included in this meta-analysis. These contained 337 patients, of 
which 50 cases. The overall OR for neoplastic progression in BE patients with cyclin D 
positivity was 1.01 (95% CI 0.14 to 7.03) (Table 3 and Supplementary Figure S3). 
Results of the two studies were inconsistent in their findings (I2=80%, p=0.007).
Alpha-methylacyl-CoA racemase
Two studies were included in this meta-analysis. These contained 712 patients, of 
which 53 cases. The overall OR for neoplastic progression in BE patients with alpha-
methylacyl-CoA racemase positivity was 4.07 (95% CI 0.66 to 25.12) (Table 3 and 








Supplementary Figure S3). Results of the two studies were moderately consistent in 
their findings (I2=53%, p=0.14).
Studies on other IHC biomarkers
The following IHC biomarkers were investigated only once: β-catenin, CD1a, COX2, 
HER2, Ki67, Lewis, Mcm2, Sialyl Lewis, SOX2, and WGA. The same group published 
two studies on hERG1, both including patients from the same population (46, 48). 
Therefore, both studies were individually included without summary in a meta-analysis. 
In the CD1a study CLE without IM was used as baseline histology (45). When 
considering study size and point estimate, CD1a, SOX2, and hERG1 appeared most 
promising (Supplementary Figure S4).
Discussion
This is the first systematic review and meta-analysis to assess if IHC biomarkers can be 
used as an independent predictor for neoplastic progression in BE surveillance. Sixteen 
biomarkers have been investigated in this setting, of which five biomarkers have been 
investigated more than once. The meta-analysis showed that aberrant p53 expression 
was associated with a significantly increased risk of neoplastic progression. Moreover, 
aberrant p53 expression predicted neoplastic progression in both non-dysplastic BE 
patients and BE patients with LGD. Of the other four IHC biomarkers, AOL appeared 
to be most promising in predicting neoplastic progression, whereas Cyclin A, Cyclin D, 
and alpha-methylacyl-CoA racemase are still of limited value.
Current use of p53 IHC in BE patients differs in international guidelines. The guideline 
of the British Society of Gastroenterology recommends the addition of p53 IHC 
staining for the pathological assessment of BE to improve the diagnostic reproducibility 
of dysplasia (5). While the American Gastroenterological Association guideline states 
that: “data supporting the use of biomarkers to confirm the histologic diagnosis of 
dysplasia must be considered preliminary” (51). No guideline has yet adopted the 
use of IHC biomarkers to predict neoplastic progression. Two large population based 
studies confirmed that patients with LGD have an approximately 5 times higher risk 
of neoplastic progression compared to patients without LGD (15, 18). Our meta-
analysis is the first to show that BE patients, independent of the presence of LGD, 
with aberrant p53 IHC have a similar increased risk to develop cancer compared to 
patients with LGD. A recent publication claims to have investigated the predictive 
ability of immunohistochemical biomarkers (52). However, they reported on samples 
either obtained from a resection specimen or from cases and controls without follow-
up. Therefore, based on their current dataset, their current conclusion, i.e. that p53 
overexpression predicts malignant progression, is not justified (53). 
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Although routine p53 IHC will incur higher cost than histological assessment alone, 
application of this marker has the potential to reduce the overall costs related to BE 
surveillance by improved risk stratification using expression of p53 IHC in combination 
with other predictors of progression, such as histology, sex, age, and length of the BE 
segment. Better risk stratification could result in both earlier detection of lesions in 
patients at risk, and a reduction in endoscopic and pathology resources for patients 
that will never develop progression. The disparity in ORs of neoplastic progression 
found in the various studies may be explained by differences in staining methods, 
including antibodies used, antigen retrieval methods, definitions, and interpretations of 
aberrant staining used. Therefore, special consideration should be given to the protocol 
of staining and the definition and interpretation used for aberrant expression. Some 
studies did not consider loss of p53 staining aberrant, which might have contributed to 
the protocol being less predictive compared to other studies. By using a more stringent 
definition of aberrant expression, cases appeared to remain p53 aberrant, while controls 
were not considered aberrant (Supplementary Figure S2). Therefore, the use of more 
stringent definitions and interpretations for aberrant staining appears to lead to a higher 
predictive ability of p53 IHC. 
The strength of this paper is the focus on IHC biomarkers as a relatively easy applicable 
tool to improve risk stratification in BE surveillance. Additionally, we performed a broad 
search, and the extraction of ORs from text, tables and figures resulted in the inclusion of 
quite a large number of studies. The inclusion of abstracts results in an up to date overview 
of this field. Because meta-analysis is the synthesis technique that is most transparent and 
most likely valid also with small amount of studies included, some of the meta-analysis 
were performed with only two studies, as no more studies were available (27). This 
study also has its limitations, such as the confinement to English language publications, 
the apparent presence of publication bias, differences in baseline comparability within 
studies, and the various adjustments made for these baseline differences. Therefore, 
we performed sensitivity analyses of the p53 meta-analyses, these show that the point 
estimate of the OR decreased from 7.04 to 3.18 when we accounted for these limitations. 
Because aberrant p53 IHC co-occurs with LGD, separate analyses were performed in 
which we stratified for dysplastic and non-dysplastic patients. These analyses show that 
aberrant p53 expression is an independent prognostic factor for neoplastic progression. 
In conclusion, we show that sixteen IHC biomarkers in BE surveillance have been 
studied. Aberrant p53 expression is the most studied IHC biomarker and associated with 
a significantly increased risk to develop HGD or EAC, this association was independent 
of the presence of LGD. Consensus amongst pathologists concerning the appropriate 
staining method, definition, and interpretation of aberrant p53 expression is currently 
low, and more consensus is required. Other promising biomarkers such as AOL need 
further investigation. 
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Supplementary Figure S1. Funnel plot of all studies investigating p53 IHC as a predictor of progression. 
The exact patient numbers and the SE of these studies can be found in Figure 2.
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Supplementary Figure S2. Stringency of the definition and interpretation of aberrant p53 IHC. A more 
stringent definition of aberrant staining, and interpretation of that definition, may lead to loss of aberrant 
expression in cases, in controls, or in both. In order to investigate this, the proportion of controls deemed 
aberrant was plotted against the OR of each study with a standard error below 1. The use of a more 
stringent definition and interpretation for aberrant p53 staining appeared to result in a bigger reduction in 
the number of controls considered to have aberrant staining, compared to cases. Thus, by applying a more 
stringent definition and interpretation, the predictive value of p53 for neoplastic progression appears to 
increase. Formal statistical tests were not performed due to the limited number of data points and the post 
hoc nature of this analysis.
 

























Supplementary Figure S3. Forest plot of all studies investigating AOL, Cyclin A, Cyclin D, and AMACR 
as a predictor of progression. (A) Two studies were included in the forest plot for AOL. (B) Four studies 
were included in the forest plot for Cyclin A. (C) Three studies were included in the forest plot for Cyclin 
D. (D) Two studies were included in the forest plot for AMACR.
Supplementary Figure S4. Forest plot, without meta-analysis, of all studies investigating IHC biomarkers 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary information search 
Appendix 1: EMBASE search
(immunohistochemistry/exp OR Immunocytochemistry/exp OR histochemistry/
de OR 'biological marker'/exp OR 'disease marker'/de OR 'tumor marker'/de OR 
'molecular marker'/de OR marker/de OR staining/de OR 'antibody labeling'/exp OR 
(immunohistochem* OR Immunocytochemistr* OR Immunohistocytochemis* OR 
immunostain* OR stain* OR histochemist* OR Histocytochemist* OR marker* OR 
biomarker* OR (marking NEAR/3 agent*) OR ((antibod* OR immun*) NEAR/3 label*) 
OR immunolabel*):ab,ti) AND ('oncogenesis and malignant transformation'/exp OR 
'cancer risk'/de OR 'disease course'/de OR ('esophageal adenocarcinoma'/exp AND 
'risk assessment'/exp) OR (((malign* OR metasta* OR cancer* OR adenocarcinom* 
OR tumo* OR ac OR eac OR high-grade OR hgd OR neoplas*) NEAR/10 (potential* 
OR transformat* OR predict* OR progress* OR develop* OR risk OR growth OR 
progress*)) OR (risk NEAR/3 progress*) OR carcinogene* OR oncogene* OR (tumo* 
NEAR/3 promot*)):ab,ti) AND ('Barrett esophagus'/exp OR (Barret*):ab,ti) AND 
[english]/lim NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/
lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
Appendix 2: MEDLINE search
(exp immunohistochemistry/ OR Histocytochemistry/ OR "Biological Markers"/ OR 
"disease marker"/ OR exp "Tumor Markers, Biological"/ OR exp "Staining and Labeling"/ 
OR (immunohistochem* OR Immunocytochemistr* OR Immunohistocytochemis* 
OR immunostain* OR stain* OR histochemist* OR Histocytochemist* OR marker* 
OR biomarker* OR (marking ADJ3 agent*) OR ((antibod* OR immun*) ADJ3 label*) 
OR immunolabel*).ab,ti.) AND (exp "Carcinogenesis"/ OR "Disease Progression"/ OR 
("Esophageal Neoplasms"/ AND "Risk Assessment"/) OR (((malign* OR metasta* OR 
cancer* OR adenocarcinom* OR tumo* OR ac OR eac OR high-grade OR hgd OR 
neoplas*) ADJ10 (potential* OR transformat* OR predict* OR progress* OR develop* 
OR risk OR growth OR progress*)) OR (risk ADJ3 progress*) OR carcinogene* 
OR oncogene* OR (tumo* ADJ3 promot*)).ab,ti.) AND ("Barrett Esophagus"/ OR 
(Barret*).ab,ti.) AND english.la. NOT (exp animals/ NOT humans/) NOT (letter OR 
news OR comment OR editorial OR congresses OR abstracts).pt.
Appendix 3: Web of  Science search
((immunohistochem* OR Immunocytochemistr* OR Immunohistocytochemis* OR 
immunostain* OR stain* OR histochemist* OR Histocytochemist* OR marker* OR 
biomarker* OR (marking NEAR/3 agent*) OR ((antibod* OR immun*) NEAR/3 
label*) OR immunolabel*):ab,ti) AND ((((malign* OR metasta* OR cancer* OR 
adenocarcinom* OR tumo* OR ac OR eac OR high-grade OR hgd OR neoplas*) 








NEAR/10 (potential* OR transformat* OR predict* OR progress* OR develop* OR 
risk OR growth OR progress*)) OR (risk NEAR/3 progress*) OR carcinogene* OR 
oncogene* OR (tumo* NEAR/3 promot*)):ab,ti) AND ((Barret*):ab,ti) 
Appendix 4: CENTRAL search
TS=(((immunohistochem* OR Immunocytochemistr* OR Immunohistocytochemis* 
OR immunostain* OR stain* OR histochemist* OR Histocytochemist* OR marker* OR 
biomarker* OR (marking NEAR/2 agent*) OR ((antibod* OR immun*) NEAR/2 label*) 
OR immunolabel*)) AND ((((malign* OR metasta* OR cancer* OR adenocarcinom* 
OR tumo* OR ac OR eac OR high-grade OR hgd OR neoplas*) NEAR/10 (potential* 
OR transformat* OR predict* OR progress* OR develop* OR risk OR growth OR 
progress*)) OR (risk NEAR/2 progress*) OR carcinogene* OR oncogene* OR (tumo* 
NEAR/2 promot*))) AND ((Barret*)) NOT ((animal* OR rat OR rats OR mouse OR 
mice OR murine) NOT (human* OR patient*))) AND dt=(article)
Appendix 5: Pubmed publisher search
(immunohistochemistry[mh] OR Histocytochemistry[mh] OR "Biological Markers"[mh] 
OR "disease marker"[mh] OR "Tumor Markers, Biological"[mh] OR "Staining and 
Labeling"[mh] OR (immunohistochem*[tiab] OR Immunocytochemistr*[tiab] 
OR Immunohistocytochemis*[tiab] OR immunostain*[tiab] OR stain*[tiab] 
OR histochemist*[tiab] OR Histocytochemist*[tiab] OR marker*[tiab] OR 
biomarker*[tiab] OR (marking AND agent*[tiab]) OR ((antibod*[tiab] OR 
immunol*[tiab] OR immuni*[tiab]) AND label*[tiab]) OR immunolabel*[tiab])) 
AND ("Carcinogenesis"[mh] OR "Disease Progression"[mh] OR ("Esophageal 
Neoplasms"[mh] AND "Risk Assessment"[mh]) OR (((malign*[tiab] OR metasta*[tiab] 
OR cancer*[tiab] OR adenocarcinom*[tiab] OR tumor*[tiab] OR tumour*[tiab] OR 
ac OR eac OR high-grade OR hgd OR neoplas*[tiab]) AND0 (potential*[tiab] OR 
transformat*[tiab] OR predict*[tiab] OR progress*[tiab] OR develop*[tiab] OR risk OR 
growth OR progress*[tiab])) OR (risk AND progress*[tiab]) OR carcinogene*[tiab] OR 
oncogene*[tiab] OR ((tumor*[tiab] OR tumour*[tiab]) AND promot*[tiab]))) AND 
("Barrett Esophagus"[mh] OR (Barret*[tiab])) AND english[la] NOT (animals[mh] 
NOT humans[mh]) NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] 
OR congresses[pt] OR abstracts[pt]) AND publisher[sb]
Appendix 6: Google scholar search
immunohistochemistry|Immunocytochemistristry|immunostaining|histochemististry| 




S1 Standardized data extraction form
Appendix 7: standardized data extraction form
A standardized data extraction form was used, which contained the following items:
 - General information: title, authors, source, contact address, country, published/
unpublished, full paper / abstract, language, and year of publication.
 - Study design. 
 - Quality assessment: a difference at baseline between cases and controls of at least 
10% (concerning baseline histology, age, sex, length of BE segment, and follow –up 
time), adjustments in the form of regression for differences of known predictors of 
progression (such as baseline histology, age, sex, and length of BE segment), exclusion 
of prevalent cases, control stainings, number of pathologists, pathologist agreement 
and pathologist blinding. 
 - Patients: baseline histology, end-point histology, definition of BE used, age of the 
patients, proportion of male patients.
 - Staining characteristics: IHC biomarker studied, antibody used and dilution, cutoff 
value of IHC biomarker expression used, positive/negative control used. 
 - Outcomes: Numbers of IHC biomarker positive cases and controls and IHC 
biomarker negative cases and controls. ORs and the factors that were adjusted for.
With regard to the MOOSE and PRISMA checklists, these can be accessed through 
PLoS One. 
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Altaf and colleagues present an interesting systematic review and meta-analysis on the 
ability of biomarkers to predict the risk of malignant progression in Barrett’s oesophagus 
(1). This is particularly interesting as endoscopic interventions for Barrett’s oesophagus 
are widely available are increasingly being adopted (2). Some concerns however, arise 
about the methodology used in this meta-analysis (3). To assess the predictive ability 
of a biomarker, the biomarker status must have been established in tissue taken before 
the occurrence of the event. Therefore, prospective studies or case control studies, in 
which controls are representative for the population from which the cases are derived, 
are required (4). Most of the 40 studies that were included comparing P53 biomarker 
status in adenocarcinoma versus Barrett’s, reported on samples either obtained from a 
resection specimen or from cases and controls without follow-up. These studies should 
have been excluded from the analysis. Based on the current dataset, therefore, the current 
conclusion that p53 overexpression predicts malignant progression is not justified. 
Additionally, the paper included a series of funnel plots which showed the presence 
of small study effects, such as publication bias. The authors considered it unlikely that 
these effects would change the magnitude of the pooled estimates in prediction of the 
progression to OAC. However, this was not analyzed nor were efforts made to reduce the 
influence of small study effects. This may have led to an overestimation of the prognostic 
ability of the biomarkers investigated. We feel that the role of p53 as a biomarker of 
progression needs further investigation.
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DNA integrity as biomarker 
in pancreatic cyst fluid
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Abstract
Identification of pancreatic cysts with malignant potential is important to prevent 
pancreatic cancer development. Integrity of cell free DNA (cfDNA) has been described 
as tumor biomarker, but its potential for pancreatic cancer is unclear. While normal 
apoptotic cells release uniformly truncated DNA, malignant tissues release long 
fragments of cell free DNA (cfDNA). We measured 247 base pair (bp) and 115 bp 
DNA fragments of ALU repeats by qPCR in serum from healthy controls and pancreatic 
cancer patients, and in cyst fluid from pancreatic cyst patients. No differences in total 
cfDNA (ALU115) and cfDNA integrity (ALU247/115) were observed between sera 
from healthy controls (n=19) and pancreatic cancer patients (n=19). Although elevated 
as compared to serum, but no differences in cfDNA were found in cyst fluid from high 
risk (n=10) and low risk (n=20) cyst patients. We conclude that cfDNA integrity is not 
a useful marker to identify (pre)malignant pancreatic lesions.
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Pancreatic cystic neoplasms (PCN) can give rise to pancreatic cancer, with intraductal 
papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) showing 
a high malignant potential, whereas serous cystic adenomas and solid pseudopapillary 
neoplasms have a more favorable prognosis (1). Development of pancreatic cancer may 
be prevented by resection of the cysts with high risk malignant potential. Unfortunately, 
current imaging and diagnostic techniques have difficulty distinguishing low risk cysts 
from high risk and transformed cysts, which in some cases leads to unnecessary surgery (2). 
Thus, better diagnostic tools are urgently needed. Patients with neoplastic diseases 
often have an increased amount of free circulating, cell-free DNA (cfDNA) in their 
peripheral blood, which originates from the tumor (3–5). This cfDNA is not all of an 
equal length. While apoptotic cells release small, ~180 base pair (bp) DNA fragments, 
necrotic cells release larger fragments of irregular size (6). Whereas apoptosis is a normal 
physiological process occurring in all cells that need to be cleared from the body, necrosis 
is a potentially harmful form of cell death, which occurs under pathological conditions, 
including cancer. Thus, the presence of longer DNA fragments in serum is taken as a 
sign of enhanced necrosis taking place in the body and is thought to be indicative of 
disease (7). In order to reliably measure such DNA fragments, researchers have employed 
the abundant presence in the human genome of DNA ALU repeats - repetitive ~300 
bp sequences of retrotransposon origin found in genomic introns (8). Using different 
primers, fragments of these ALU repeats can be detected of either >200 bp (indicative of 
necrotic DNA), or of <200 bp (detecting both necrotic and apoptotic DNA). Detection 
of these longer cfDNA fragments and their relative abundance compared to short cfDNA 
fragments in sera appears to be a promising tool for diagnosis and prognostic prediction 
of malignancies (9,10). However, the percentage of cfDNA originating from tumor 
cells has been estimated to range from 10% to 90% of total cfDNA, and applicability 
of measuring cfDNA length (i.e. DNA integrity) in serum may therefore depend on 
the type of disease (6). Thus, while ALU-repeat measurements have been shown to 
adequately predict colorectal and breast cancer, the presence of pancreatic cancer could 
not be diagnosed by high length cfDNA fragments in serum (11). We speculated that 
pancreatic cyst fluid, coming from a small and enclosed environment, would provide 
a more suitable biological fluid in which to search for tumor markers. Therefore we 
compared DNA integrity in fluid from high risk and low risk cysts. 
Material and methods
Pancreatic cyst fluid acquirement
Pancreatic cyst fluid of patients undergoing surgery was collected from two separate 
biobanks (Erasmus MC Rotterdam, the Netherlands, MEC-2008-233 and MEC-2012-
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107, and Hôpital Beaujon, Clichy France; DEC-2009-938). Fluid was obtained by 
endoscopic ultrasound-fine needle aspiration (EUS-FNA) or post-resection and stored 
sterile at -80°C until analysis. Samples were selected so as to represent the different groups 
of pancreatic cyst based on malignant potential. Cysts with histologically confirmed low 
grade and intermediate dysplasia were grouped under ‘low grade dysplasia’, and cysts 
with high grade dysplasia or invasive carcinoma were considered ‘high grade dysplasia’.
Serum acquirement
Patients with pancreatic adenocarcinoma who were eligible for surgery were included at 
the EMC. Healthy controls (mean age 60±4 years) were collected from the biorepository 
of the Rotterdam arm of the ERSPC (12,13) (MEC 138.741/1994/152). Serum was 
obtained by whole blood centrifugation in serum separator tubes (BD-Vacutainer), 
aliquoted and stored at -80°C until analysis. 
Sample preparation and qPCR
To digest proteins that might confound results, both cyst fluid and serum were mixed 
with a buffer containing 25 ml/l Tween 20, 50 mmol/l Tris, 1 mmol/l EDTA, and 0.8 
mg/ml proteinase K in a 1:1 ratio. Subsequently, the mix was incubated at 50°C for 
20 minutes, followed by heat inactivation at 95°C for 5 minutes. Next, the samples 
were centrifuged at 10,000g for 5 minutes and 0.2 µl of the supernatant was used in 
the qPCR reaction. This protocol was also described earlier (14). After preparation of 
samples, DNA integrity was determined by measuring the presence of ALU repeat 
fragments of 115 bp size and of 247 bp size, using previously described primers (15). 
The ALU115 primers are designed to amplify both the shorter and the longer fragments, 
and are therefore indicative of total circulating cfDNA (including DNA released from 
both apoptotic and necrotic cells) whereas the ALU247 primers only amplify the longer 
DNA fragments, and thus detect of tumor DNA. To measure the absolute concentration 
of DNA in the samples, we constructed a calibration curve using genomic DNA derived 
from Huh7 cell lines at a concentration ranging from 2.97 pg/µl up to 297 ng/µl. 
The absolute concentration was measured (in the most concentrated sample) using the 
Nanodrop (Thermo Scientific). This was subsequently used in a serial dilution and used 
as a template in triplicate on each qPCR-plate measured. The same serial dilutions were 
used to produce standard curves for all qPCR runs. 
For the qPCR reaction of the ALU repeats, previously published primers were 
used: ALU115 forward, CCTGAGGTCAGGAGTTCGAG; ALU115 reverse, 
CCCGAGTAGCTGGGATTACA; ALU247 forward, GTGGCTCACGCCTGTAATC; 
ALU247 reverse CAGGCTGGAGTGCAGTGG. The total volume of the qPCR reaction 
mix was 25 µl, consisting of 12.5 µl SYBR Green (Life technologies), 2.5 µl 10 µM forward 
and reverse primer, 9.8 µl Microbial DNA-Free Water (Qiagen), and 0.2 µl template.







The qPCR was run at 95°C for 10 minutes, and subsequently at 95°C for 30 seconds, 
64°C for 30 seconds and 72°C for 30 seconds for 40 cycles using the StepOnePlus™ Real-
Time PCR System (Life technologies). ALU repeat expression levels were measured in 
duplicate. The genomic DNA used for the calibration curve and negative controls were 
measured in triplicate.
Analysis
Using the data obtained from the serial diluted genomic DNA, we constructed a 
calibration curve on each plate measured using the Graphpad Prism 5. From this, we 
derived the intercept and slope of the curve using a nonlinear regression model and 
recalculated the absolute concentration of the samples from measured Ct values using 
the following formula: Absolute concentration = 10^((Ct-intercept)/slope). Finally, 
to obtain ALU247/115 ratios, the absolute concentration of ALU247 was divided by 
the absolute concentration ALU115 measured in the samples. Mean differences were 
analysed using Mann-Whitney U test. A p value of <0.05 was considered statistically 
significant.
Results
While previous reports were unable to find a relationship between pancreatic cancer 
and cfDNA length in serum, we wanted to verify this in our own cohort (see Table 
1). The mean total circulating cfDNA, as represented by ALU115-qPCR values, 
was 20±3 pg/µl in control sera (n=19) vs 36±14 pg/µl in sera from pancreatic cancer 
patients (n=19) (p=0.559) (Figure 1A), whereas the mean amount of circulating tumor 
Table 1. Patient characteristics of the serum samples
Number of patients 19
Age, years  
Range 24-82
Mean (SD) 65 (13)
Gender, n (%)  
Male 11 (57.9)
Female 8 (42.1)
Disease location (%)  
Pancreas corpus 3 (15.8)
Pancreas head/uncinate 5 (26.3)
Pancreas head 7 (36.9)




DNA, as determined by ALU247-qPCR values, was 8±1 and 14±6 pg/µl (p=0.793). 
The ratio of ALU247/ALU115, allowing quantification of the integrity of the cfDNA, 
was 0.41±0.02 and 0.40±0.05 for healthy controls and pancreatic cancer patients, 
respectively (p=0.267). Thus, no increased total cfDNA or tumor-associated DNA was 
detected in sera from pancreatic cancer patients.
Next, we analysed cyst fluid obtained from 40 pancreatic cyst patients, 23 of which 
had low risk cysts, and 17 had high risk cysts. In 10 of these samples, we were unable 
to perform a reliable analysis due to the mucinous nature of the fluid. In the remaining 
samples (Table 2), we observed drastically higher levels of cfDNA as compared to sera, 
presumably due to the enclosed nature of these cysts. However, the mean amount of 
total and tumor circulating cfDNA did not differ between the high risk (n=10) and low 
risk (n=20) samples: 44,463±39,228 vs 33,021±20,004 pg/µl for ALU115 (p=0.10) and 
27,254±24, 2682 vs 22,118±13,774 pg/µl for ALU247 (p=0.18), respectively (Figure 
1B). Furthermore, no significant differences in ALU247/ALU115 ratio between high 
risk and low risk cysts (0.63±0.07 vs 0.66±0.06, p=0.34) was seen. Overall, ratios were 
higher than in serum, with some samples reaching almost 1. Thus, the nature of cyst 
fluid makes it a less suitable compartment to determine necrotic/apoptotic cfDNA 
ratios.
Figure 1. Levels of cfDNA in serum or pancreatic cyst fluid do not identify high risk/adenocarcinoma 
patients. PCRs detecting short, apoptotic cell-derived cfDNA (ALU115) and longer cfDNA fragments 
(ALU247) were performed on (A) serum from healthy donors (n=19) and patients with pancreatic 
adenocarcinoma (ADC, n=19) and (B) pancreatic cyst fluid from patients with low grade dysplasia (LGD, 
n=20) and high grade dysplasia (HGD and ADC, n=10). cfDNA was detected by ALU115 and ALU247, 
and DNA integrity was calculated (ALU247/ALU115). No differences in cfDNA levels and cfDNA 
integrity were observed.







Measurement of necrotic cell-derived long cfDNA fragments in serum has been suggested 
for the early detection of tumors. However, usefulness of this tool in pancreatic diseases 
has so far not been shown, and we were unable to find increased levels of necrotic cell-
derived cfDNA in sera from pancreatic cancer patients. As pancreatic cancer can derive 
from PCN, we speculated that cyst fluid would present the ideal biological fluid to detect 
premalignant lesions. Indeed, total levels of cfDNA observed in cyst fluid were almost 
1000 fold higher as compared to sera. Nevertheless, we did not observe differences in 
cfDNA length between high risk and low risk cysts. While the apoptotic process reduces 
DNA to 180-200 bp fragments, incomplete cleaving of the DNA may result of the 
presence of multimers of these fragments, which can subsequently also be detected by 
ALU247 primers. This background ‘noise’ of 180 bp multimers accounts for the fact 
that a signal is detected in the ALU247 PCR in samples were no necrotic cfDNA is 
expected (i.e. healthy serum), and detection of tumor-derived, necrotic DNA depends 
on a relative increase in the abundance of long cfDNA, and hence a shift in DNA 
integrity (ALU247/ALU115 ratio). It is conceivable that pancreatic tumor cells produce 
too little necrotic cfDNA to be detected above background levels. Additionally, in cyst 
fluid, high levels of total cfDNA levels present may preclude detection of additional 
long cfDNA fragments. 
We acknowledge several limitations to our study. Of the cystic fluid samples selected for 
this pilot study, 15 of 30 were obtained after resection, with ischemic damage potentially 
Table 2. Patient characteristics of the cyst fluid samples
 Total LGD HGD
Number of patients 30 20 10
Age, years    
Range 19-85 19-79 52-85
Mean (SD) 59.5 (15.3) 54.7 (15.4) 69.2 (10)
Gender    
Male 10 (33.3%) 3 (15%) 7 (70%)
Female 20 (66.7%) 17 (85%) 3 (30%)
Diagnosis    
IPMN 17 (56.7%) 8 (40%) 9 (90%)
MCN 13 (43.3%) 12 (60%) 1 (10%)
Disease location (%)    
Pancreas head 6 (20%) 2 (10%) 4 (40%)
Pancreas corpus 5 (16.7%) 3 (15%) 2 (20%)
Pancreas tail 18 (60%) 15 (75%) 3 (30%)
Unknown 1 (3.3) 0 (0%) 1 (10%)
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causing necrosis. However, subanalysis of the re-resection and post-resection obtained 
samples did not show significant differences in total cfDNA levels or ALU247/ALU115 
ratios (not shown). 
A second limitation is the low number of high risk cyst fluid samples in our analysis. The 
mucinous nature of the fluid prevented accurate analysis in ~25% of cases. As mucinous 
cysts show a higher malignant potential, it is not surprising that many of the excluded 
samples were high risk. This means that the intrinsic nature of high risk cyst fluid makes 
them less suitable for this type of analysis.
In conclusion, our data suggest that the use of cfDNA integrity in pancreatic cyst fluid 
is not suitable to distinguish low risk from high risk cysts.
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Abstract
Barrett’s esophagus (BE) is a premalignant condition caused by gastroesophageal reflux 
disease (GERD) where physiological squamous epithelium is replaced by columnar 
epithelium. Several in vivo and in vitro BE models were developed with questionable 
translational relevance when implemented separately. Therefore, we aimed to screen 
Gene Expression Omnibus 2R (GEO2R) databases to establish clinical BE molecular 
profile being comparable with animal and optimized human esophageal squamous 
cell lines-based in vitro models. The GEO2R tool and selected databases were used to 
establish human BE molecular profile. BE-specific mRNAs in human esophageal cell 
lines (Het-1A and EPC2) were determined after 1, 3 and/or 6-days treatment with 
acidified medium (pH 5.0) and/or 50 and 100 µM bile mixture (BM). Wistar rats 
underwent microsurgical procedures to generate esophagogastroduodenal anastomosis 
(EGDA) leading to BE. BE-specific genes (keratin (KRT)1, KRT4, KRT5, KRT6A, 
KRT13, KRT14, KRT15, KRT16, KRT23, KRT24, KRT7, KRT8, KRT18, KRT20, 
trefoil factor (TFF)1, TFF2, TFF3, villin (VIL)1, mucin (MUC)2, MUC3A/B, 
MUC5B, MUC6, and MUC13) mRNA expression was assessed by real-time PCR. Pro/
anti-inflammatory factors (interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-
13, tumor necrosis factor α, interferon γ, granulocyte-macrophage colony-stimulating 
factor) serum concentration was assessed by Luminex assay. Expression profile in vivo 
reflected about 45% of clinical BE with accompanied inflammatory response. 6-day 
treatment with 100 µM BM (pH 5.0) altered gene expression in vitro reflecting in 
73% human BE profile and making this the most reliable in vitro tool taking into 
account two tested cell lines. Our optimized and established combined in vitro and in 
vivo BE models can improve further physiological and pharmacological studies testing 
pathomechanisms and novel therapeutic targets of this disorder.
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Barrett’s esophagus (BE) is a complex, genetically predisposed, premalignant condition 
of the distal esophagus characterized as replacement of the esophageal squamous 
epithelium into an intestinal-type columnar epithelium with a crypt-like architecture 
(1-3). Epithelium in BE is usually composed of mucous-producing cells which aids in 
the protection of the esophagus from the constant insult of acid and bile (2). BE affects 
2% of the adult population in the Western world (4, 5). It has been confirmed that 
chronic gastroesophageal reflux disease (GERD) is one of the most important etiological 
component of BE (4, 5). 
Importantly, BE and GERD are closely associated with a high risk of developing 
esophageal adenocarcinoma (EAC). EAC has a very poor prognosis with a 9-15% 
5-year survival rate (4). The pattern of reflux is a significant factor that may influence 
the progression of BE towards advanced precancerous changes (6, 7). In contrast to 
the physiological esophageal epithelium, the BE development results in alternation of 
several individual molecular markers and signaling pathways. These changes include 
variety of mucins (MUC), mucin-associated trefoil factor family (TFF) peptides, and 
villin (VIL) (8-10). However, the physiological and pathophysiological aspects still 
require further investigation, especially in the context of the implementation of novel 
non-invasive methods of treatment of this disorder.
Both BE and GERD are related to inflammation of the esophageal epithelium. Chronic 
inflammation in BE has been linked to DNA damage, leading to mutations and genomic 
instability, and altered expression of genes that are involved in cellular proliferation 
and programmed cell death (11). The inflammatory response also includes increased 
oxidative stress, activation of several signaling pathways, and release of inflammatory 
cytokines (11). Moreover, chronic inflammation can lead to a higher rate of cellular 
turnover, which is typical for BE and can alter the pattern of gene expression in 
epithelial cells (11). For example, an analysis of keratin (KRT), a major constituent of 
the esophageal epithelium, revealed significant changes from those keratins normally 
expressed in squamous epithelia to those expressed in columnar epithelium (8, 12, 13). 
The diagnostic criteria for BE phenotype requires endoscopic identification of columnar 
mucosa and microscopic appearance of columnar epithelium with presence of goblet 
cells within the esophageal mucosa (3). The basic therapeutic options for patients with 
BE include pharmacological treatment with proton pump inhibitors or endoscopic 
procedures with surgical resection, and chemo- and radiotherapy (14). However, the 
evidence from randomized controlled trial shows that pharmacological and surgical 
therapies do not completely prevent or eliminate BE and existing dysplasia (14). Therefore, 
development of novel or alternative pharmacological therapeutic interventions seems to 
be justified, also taking into account recently published evidence (5). Current advances 
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in the understanding of the complex molecular mechanisms of BE development which 
came from experimental models of BE include overexpression of cyclooxygenase-2 
(COX-2) (15, 16), epidermal growth factor EGF (17-19), or mitogen-activated protein 
kinase (MAPK) and the protein kinase phosphorylation (PI3K) pathways (20, 21), as 
well as increased secretion of gastrin due to achlorhydria as complication of prolonged 
proton pomp inhibitors (PPI) therapy (22). However, many ongoing controversies and 
challenges and potential mediators responsible for the development of BE still remain 
unsolved. Additionally, the conversion process of normal squamous epithelium towards 
Barrett’s metaplasia is difficult to monitor directly under clinical conditions (23). Thus, 
over the last few years, several experimental models using various types of cell cultures 
and animal models have been published to investigate the mechanisms of bile and/or 
acid exposure in BE pathogenesis (1, 23). However, the relevance of each of the models 
implemented separately is considered to be questionable. 
Therefore, this study was designed to establish relevant experimental models for further 
studies underlying the effectiveness of possible protective treatment of BE esophageal 
metaplasia with pharmacological agents. Thus, we selected appropriate translational 
molecular markers such as KRT, MUC, TFF and VIL genes to compare expression 
profiles in clinical biopsies derived from BE patients with the animal surgical model and 
an in vitro model of BE involving two human derived primary immortalized esophageal 
cell lines. We put special emphasis on the optimization of this in vitro model with the 
aim to reflect the molecular events observed clinically as closely as possible. 
Material and methods
Analysis of  BE expression profile for selected genes in human biopsies based on 
GSE datasets
Expression profiles from human biopsies derived from patients with normal esophageal 
epithelium and with diagnosed BE epithelium were obtained from Gene Expression 
Omnibus datasets GSE13083 (7 patients with normal vs 7 patients with BE) (8), 
GSE34619 (8 patients with normal vs 10 patients with BE) (9) and GSE1420 (8 
patients with normal vs 8 patients with BE) (24). The results demonstrated on Table 
1 are shown based on the analysis of the part of the data derived from the previously 
published databases (8, 9, 24). Analyses were performed in silico using the NCBI Gene 
Expression Omnibus (GEO) database and the GEO2R tool (www.ncbi.nlm.nih.gov/
geo/geo2r/). The results were represented as a log2-fold change (logFC) in BE samples vs 
normal esophageal epithelium. For each logFC, an empirical Bayes moderated t-statistic 
was calculated by the software. Adjusted p values, corrected for multiple testing using 
the Benjamini & Hochberg false discovery rate method were taken for the results 
interpretation. P<0.05 was interpreted as statistically significant and marked in the 







table with asterisk (*) for the genes with logFC values higher than 2 or lower than -2, 
which was considered as biologically significant up- or downregulation, respectively. 
Additionally, we further analyzed genes that were included in all three GSE datasets and 
were significantly up-/downregulated in at least one database.
Cell cultures 
The human SV40-immortalized esophageal squamous (Het-1A) epithelial cell line was 
a gift of J. W. P. M. van Baal (Utrecht University, The Netherlands). Het-1A cells were 
cultured in serum-free EPM2 medium (AthenaES, Baltimore, Maryland, USA). Het-1A 
cells were grown on FNC Coating Mix® (AthenaES, Baltimore, MD, USA) containing 
fibronectin, collagen and albumin. The primary human telomerase reverse transcriptase 
(hTERT) immortalized esophageal epithelial (EPC2) cell line was a gift of K. K. 
Krishnadath (University of Amsterdam, Amsterdam, The Netherlands). EPC2 cells were 
cultured in Keratinocyte-SFM (Life Technologies, Paisley, UK) medium supplemented 
with 50 µg/ml Bovine Pituitary Extract (BPE) (Life Technologies, Paisley, UK) and 
1.0 ng/ml human recombinant Epidermal Growth Factor (EGF) (Life Technologies, 
Paisley, UK). Both culture media were supplemented with 100 U/ml penicillin and 50 
mg/ml streptomycin (Sigma-Aldrich, Saint Louis, MO, USA). Cells were maintained at 
37°C and 5% CO2 and detached from the flasks prior to subculturing by the removal of 
the medium and the addition of 0.25% trypsin (Sigma-Aldrich, Saint Louis, MO, USA) 
for 1 to 5 minutes. These cell lines were selected as the most appropriate to be tested in 
experimental model of BE as described previously (1, 25, 26).
Acid/bile mixture (BM) treatment
Het-1A and EPC2 epithelial cell lines were used to reflect the response of normal 
human esophageal epithelium to low pH and/or BM exposure. Both cell lines were 
seeded at a density of 105 cells/well in 6-well plates. The cells were cultured until they 
reached approximately 40–50% confluence. At this stage, the cells were subjected to 1, 
3 and 6 days of acid and/or BM treatment, with a 30-min period of exposure per day. 
The BM contained 25% deoxycholic acid, 45% sodium glycocholate hydrate and 30% 
sodium taurochenodeoxycholate (Sigma-Aldrich, Saint Louis, MO, USA); total BM 
concentration used in final experiments was 50 and 100 µM. The acidified medium 
consisted of appropriate culture medium adjusted to pH 5.0 in which pH was adjusted 
with 5 M HCl. Cells were also cultured in regular medium (pH 7.3 for EPM2 medium; 
pH 7.2 for Keratinocyte-SFM medium) with/or without co-incubation with BM. After 
acid/BM exposure, the cells were rinsed with PBS, and then regular medium was added. 
After the last day of exposure, cells were left for 24 h and then lysed for RNA extraction. 
Cells were approximately 90% confluent at this time. The type and the molar ratio of 
bile salts in the BM have been based on studies analyzing gastroesophageal refluxate 
of patients with erosive esophagitis and BE (27, 28). Daily exposure time to BM and 
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BM concentrations were selected based on cell viability assays data, cell morphology 
observations and previously published data (27).
Cell viability assays
Cell viability was evaluated by MTT colorimetric assay using thiazolyl blue tetrazolium 
bromide (MTT) (Sigma-Aldrich, St. Louis, MO, USA). Het-1A and EPC2 cells were 
plated in 5 replicates in 96-well plates at a density of 104 cells/well in a final volume 
of 100 µl medium. After overnight incubation at 37°C, 5% CO2, dilutions of BM 
in acidified (pH 5.0) or regular medium were added in 5 replicates for 30 minutes. 
Untreated cells (appropriate volumes of medium added) served as controls. After 24 
h, 50 µl of the MTT solution was added to each well and incubated for 4 h at 37°C. 
Medium was removed and the formazan product of MTT reduction was dissolved in 75 
µl of DMSO per well. The optical density was measured at 550 nm. 
Analysis of  mRNA expression by real-time polymerase chain reaction (PCR)
Total RNA was isolated using commercially available kit with spin-columns (Universal 
RNA/miRNA Purification Kit, EURx, Gdansk, Poland) according to manufacturer 
protocol. RNA concentration was measured using Qubit 4 Fluorometer (Thermo Fisher 
Scientific, Waltham, MA, USA). Reversed transcription to cDNA was performed using 
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA, USA) using 1.8 µg of RNA for each reaction well. 
Relative gene expression was determined by real-time PCR according to the MIQE 
guidelines. All reactions were performed in 96-well reaction plates in duplicates or 
triplicates via the Quant Studio 3 system (Applied Biosystems, Foster City, CA). 2X 
TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) 
and 20X TaqMan gene expression assays (Thermo Fisher Scientific, Waltham, MA, USA) 
were used according to the manufacturers protocol (see gene IDs in Supplementary 
Tables S1 and S2). PCR reaction conditions were as follows: i) an initial incubation 
at 50°C for 2 min, ii) denaturation at 95°C for 2 min, iii) 40 cycles of 95°C for 1 sec 
and 60°C for 20 sec. The relative quantitation of gene expression was performed using 
the 2-ΔΔCT method with cDNA derived from untreated cells or physiological esophageal 
epithelium of rat as reference samples. P<0.05 was interpreted as statistically significant 
for at least a two-fold up/downregulation in relative expression which was considered 
as biologically relevant. Barrett’s like samples were selected in the no of 5 for gene 
expression analysis in animal biopsies.







Animal model of  BE
The study was approved by the I Local Animal Care and Use Ethical Committee held on 
Jagiellonian University Medical College in Cracow and were run in compliance with the 
European Union regulations, ARRIVE guidelines and with implications for replacement, 
refinement or reduction (the 3Rs) principle regarding handling of experimental animals 
(Approval no 89/2017, permission date: 22 November 2017 and Approval no 23/2016, 
permission date: 20 July 2016).
Male Wistar rats (Rattus norvegicus) in the total number of 15 were used in the 
experiments. Animals were fasted for 24 h before surgery with free access to drinking 
water. An anastomosis between the gastroesophageal junction (GEJ) and the duodenum 
(esophagogastroduodenal anastomosis, EGDA) on its anterior mesenteric border was 
created to induce mixed duodenogastroesophageal reflux according to the method 
introduced by Nishijima et al. (29) and based on generation of a shortcut for the chronic 
mixed gastroduodenal contents reflux through the damaged lower esophageal sphincter 
(15). This surgical model with slight modifications has been widely described in scientific 
literature (30, 31). Briefly, under general isoflurane (2-4%) anesthesia, midline laparotomy 
was performed and followed by the longitudinal incision extending approximately 5 mm 
along the lower part of anterior esophagus wall, including GEJ area. Next, the second 
incision of 5 mm in length was generated 4 cm distally from Treitz ligament on the anterior 
mesenteric border of the duodenum. These incisions were side to side anastomosed using 
7-0 silk sutures. The abdomen muscles and skin were closed separately with 4-0 silk 
sutures. After surgical procedure during recovery phase, rats were infused s.c. with 5-10 
ml of isotonic sodium chloride. For the next 10 weeks, animals were fed standard diet 
with free access to the drinking water. After that period animals were sacrificed by i.p. 
administration of lethal dose of pentobarbital (Biowet, Pulawy, Poland). 
The esophagus and stomach were removed and opened longitudinally for macroscopic 
examination. For microscopic evaluation biopsies containing esophagus, GEJ and 
forestomach were sectioned. These segments were embedded in paraffin, cut into 4 µm 
sections and stained by haematoxylin/eosin (H&E) and alcian blue/periodic acid-Schiff 
(AB/PAS) for microscopic evaluation. Samples were evaluated using a light microscope 
(AxioVert A1, Carl Zeiss, Oberkochen, Germany). Digital documentation of histological 
slides was obtained using above mentioned microsope equipped with automatic scanning 
table and ZEN Pro 2.3 software (Carl Zeiss, Oberkochen, Germany) to collect multiple 
photographs of each histological sample and to stitch them into one picture; to obtain 
better quality of each picture, the background was subtracted and unified as white (32). 
Esophageal mucosal samples were collected for biochemical and molecular assessments 
on ice, snap-frozen in liquid nitrogen and stored at −80°C until further analysis (32). 




Macroscopic degree of the esophageal mucosa injury and disease progression was assessed 
based on following criteria (lesion score):
0 physiological normal esophageal mucosa with squamous epithelium,
1 inflammation without ulcers reaching up to 1.5 cm of the esophagus as measured 
from GEJ,
2 inflammation without ulcers reaching beyond 1.5 cm of the esophagus as 
measured from GEJ,
3 inflammation with macroscopic ulceration and papillomatosis of the esophageal 
mucosa surface reaching up to 1.5 cm of the esophagus as measured from GEJ,
4 inflammation with macroscopic ulceration and papillomatosis of the esophageal 
mucosa surface reaching beyond 1.5 cm of the esophagus as measured from GEJ.
Presence or absence of the following criteria was included in microscopic and histological 
analysis of the disease progression within esophageal mucosa: 
1. hyperplasia of squamous epithelium, 
2. fibrosis of lamina propria, 
3. esophagitis: 1- thickening of squamous epithelium with basal cell layer occupying 
up to 30% of its height; elongation of connective tissue papillae, 2- regeneration 
layer occupying 50% of the epithelium thickness; hyperemia and scanty 
inflammatory infiltrate are present in connective tissue papillae, 3- expansion of 
the regeneration zone to 75% of the epithelial height; moderate inflammatory 
infiltrate in connective tissue papillae, 4- ulceration or massive inflammatory 
infiltrate,
4. Barrett’s-like lesion with the presence of goblet cells.
Determination of  serum content of  pro- and anti-inflammatory factors by Lumi-
nex microbeads fluorescent assays
Serum concentration of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, TNF-α, 
IFN-γ, GM-CSF was assessed using Luminex microbeads fluorescent assays (Bio-Rad, 
Hercules, CA, USA) and Luminex MAGPIX System (Luminex Corp., Austin, TX, 
USA). Results were calculated from calibration curves and expressed in pg/ml, according 
to the manufacturers protocol, as described previously (32).
Statistical analysis
Analyses were performed using GraphPad Prism 5 (GraphPad Prism Software Inc., 
San Diego, CA, USA). Results are presented as mean ± SEM. Statistical analysis was 
performed with Student’s t-test or ANOVA with Dunnett’s multiple comparison if more 
than two experimental groups were compared. For all statistical analyses, the level of 
significance was set as p<0.05. 








Analysis of  BE expression profi le for selected genes in human biopsies based on 
GSE datasets
Expression of mRNA for squamous epithelium-specifi c genes such as KRT1, KRT4, KRT5, 
KRT6A-C, KRT13, KRT14, KRT15, KRT16, KRT23, and KRT24 was signifi cantly decre-
ased in human Barrett’s esophagus biopsies as compared with expression of these specifi c 
genes in samples collected from normal squamous epithelium and observed in at least one 
out of three analyzed databases (p<0.05, Table 1). Expression of mRNA for columnar and 
intestinal epithelium-specifi c genes such as KRT7, KRT8, KRT18, KRT20, TFF1, TFF2, 
TFF3, VIL1, MUC2, MUC3A/B, MUC5B, MUC6, and MUC13 was signifi cantly upre-
gulated in human BE biopsies as compared with gene expression in samples collected from 
normal squamous epithelium in at least one out of three analyzed databases (p<0.05, Table 
1). Genes such as KRT10, KRT17, KRT19, MUC1, MUC5ac, MUC12, MUC15, MUC17, 
and MUC21 did not fulfi l our selection criteria and were not interpreted (Table 1). 
The effect of  exposition to various bile mixture (BM) concentrations and pH values 
on the viability of  esophageal epithelial cell lines
To determine the eff ect of the exposure to BM on cell viability, cells were incubated for 
30 min with various BM concentrations (0-800 µM) in regular or low pH (pH 5.0) 
cell culture medium (Figure 1A and 1B). Figures 1A-B show no signifi cant changes in 
cell viability when BM (0-800 µM) was applied in regular medium in both cell lines as 
compared with control cells not exposed to BM. In contrast, when Het-1A and EPC2 
cells were incubated with BM in the concentrations ≥200 µM and at low pH, a dose-
dependent and signifi cant decrease in cell viability was observed in comparison to the 
respective doses of BM applied in regular medium (p<0.05, Figure 1A and 1B).
Figure 1. Th e eff ect of exposure to various concentrations of bile mixture (BM) and diff erent pH on the 
viability of esophageal epithelial cell lines. Het-1A (A) and EPC2 (B) cells were treated for 30 min with BM 
at concentrations ranging from 0 to 800 µM. After 24 h, MTT assay was used to determine cell viability. 
Signifi cant changes (p<0.05) in cell viability after BM treatment at pH 5.0 as compared to the treatment 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Optimization of  the experimental procedure duration
To identify the optimal duration of acidic BM treatment in the establishment of an in 
vitro model of BE type molecular profi le development, based on the analysis of GSE 
datasets, two squamous (KRT4, KRT15) and two columnar (KRT8, KRT18) epithelium-
specifi c genes were randomly selected. For this purpose, Het-1A (Figure 2, A-D) and 
EPC2 (Figure 3, A-D) cell lines were daily exposed for 30 min to acidifi ed medium 
(pH 5.0) and/or 100 µM of bile mixture (BM) for 1, 3 or 6 consecutive days. Th e 
concentration of 100 µM of BM (pH 5.0) was selected based on previous experiments 
documenting that this concentration was the highest concentration at which the cells 
viability was not signifi cantly aff ected (Figure 1A and 1B).
No amplifi cation of KRT4 gene was observed in Het-1A cell line (Figure 2A) but Figure 
3A shows that at 100 µM BM in acidifi ed medium, a signifi cant downregulation of the 
Figure 2. Th e eff ect of treatment with bile mixture (BM), acidifi ed medium alone or acidic BM for 1, 3 
and 6 consecutive days on KRT4, 15, 8 and 18 mRNA expression in Het-1A cell line. Het-1A cell line 
underwent 30 min of daily incubation with BM at concentration of 100 µM, acidifi ed medium to pH 5.0 
alone or BM (100 µM) in acidifi ed medium (pH 5.0) for 1, 3 or 6 consecutive days and expression of KRT4, 
KRT15, KRT 8 and KRT18 mRNA was analyzed by real-time PCR (A-D). PCR reaction was performed 
in duplicates and quantifi ed using ACTB/GAPDH as reference genes. Data from three independent 
experiments are shown as the mean ± SEM. An asterisk (*) indicates a signifi cant change as compared with 
untreated control cells (p<0.05). Signifi cant change (p<0.05) in gene expression as compared with 1 day 
exposure to respective treatment regime is indicated by a hash (#). A cross (+) indicates a signifi cant change 
as compared with cells after 3 days of treatment for respective treatment regime (p<0.05).







expression of squamous epithelium-specifi c KRT4 mRNA in EPC2 cells was observed 
after 1, 3 and 6 days of treatment in comparison to untreated control cells (p<0.05). 
Moreover, KRT4 mRNA level in EPC2 cells was signifi cantly decreased after 6 days in 
comparison to 1 and 3 days of treatment (p<0.05; Figure 3A). Additionally, the low 
pH and 100 µM BM applied separately to EPC2 cells for 6 but not 3 days signifi cantly 
inhibited KRT4 mRNA expression in comparison to untreated control cells and to 
respective experimental group after 1 day treatment (p<0.05; Figure 3A). 
Figure 2B and Figure 3B show signifi cant downregulation of KRT15 mRNA expression 
in both cell lines after 6 days as compared to untreated control cells and to 1 and 3 
days of treatment with BM at pH 5.0 (p<0.05). Additionally, in Het-1A cells low pH 
alone decreased level of KRT15 mRNA after 6 days in comparison to untreated control 
cells and to cells after 1 and 3 days of treatment (p<0.05; Figure 2B). Moreover, we 
Figure 3. Th e eff ect of treatment with bile mixture (BM), acidifi ed medium alone or acidic BM for 1, 3 and 
6 consecutive days on KRT4, 15, 8 and 18 mRNA expression in EPC2 cell line. EPC2 cell line underwent 
30 min of daily incubation with BM at concentration of 100 µM, acidifi ed medium to pH 5.0 alone 
or BM (100 µM) in acidifi ed medium (pH 5.0) for 1, 3 or 6 consecutive days and expression of KRT4, 
KRT15, KRT 8 and KRT18 mRNA was analyzed by real-time PCR (A-D). PCR reaction was performed 
in duplicates and quantifi ed using ACTB/GAPDH as reference genes. Data from three independent 
experiments are shown as the mean ± SEM. An asterisk (*) indicates a signifi cant change as compared with 
untreated control cells (p<0.05). Signifi cant change (p<0.05) in gene expression as compared with 1 day 
exposure for respective treatment regime is indicated by hash (#). A cross (+) indicates a signifi cant change 
as compared with cells after 3 days of treatment (p<0.05).
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have noticed that 100 µM BM applied at regular medium to Het-1A cells for 6 days 
significantly downregulated KRT15 mRNA expression in comparison to untreated 
control cells and to cells after 1 day of treatment (p<0.05; Figure 2B). In EPC2 cells low 
pH alone inhibited KRT15 mRNA expression after 6 days in comparison to untreated 
control cells and to cells after 1 day of treatment (p<0.05; Figure 3B). BM applied 
in concentration 100 µM (regular pH 7.2) for 6 days significantly decreased KRT15 
mRNA level in EPC2 cells in comparison to respective untreated control cells (p<0.05; 
Figure 3B).
Our time sequence determination revealed that a significant upregulation of KRT8 
mRNA was observed exclusively in Het-1A but not in EPC2 cells after 6 days as 
compared with 1 and 3 days of treatments or with untreated control cells (p<0.05; 
Figure 2C and 3C). KRT18 mRNA was significantly upregulated in EPC2 but not 
in Het-1A cell line after 3 and 6 days as compared with 1 day of treatment or with 
untreated control cells (p<0.05; Figure 2D and 3D).
To summarize two out of three and three out of four genes from the BE molecular 
profile, in Het-1A and EPC2 respectively, show a significantly higher fold change after 6 
days of acidic BM treatment, compared to 1 or 3 days of treatment. As the fold change 
in expression between BE and squamous epithelium is most resembled by the model 
using 6 days of acidic BM treatment, this condition was selected for further study. 
Squamous and columnar epithelium-specific genes expression in in vitro model
Figures 4A-J show changes in mRNA expression for squamous epithelium-specific genes 
selected based on Table 1 analysis as characteristic for human BE biopsies, determined 
in Het-1A and EPC2 cells treated for 30 minutes per day with 0 µM, 50 µM, and 100 
µM BM at either pH 7.2/3 or pH 5.0, for 6 consecutive days. Incubation of EPC2 
cells with 100 µM BM at pH 5.0 resulted in a significant decrease in expression of all 
investigated squamous epithelium-specific KRT (KRT1, KRT4, KRT5, KRT6, KRT13, 
KRT14, KRT15, KRT16, KRT23, KRT24) genes as compared to untreated control cells 
(p<0.05; Figure 4, A-J). Significant downregulation of KRT1 (4A), KRT4 (4B), KRT5 
(4C), KRT6 (4D), KRT14 (4F), KRT16 (4H) and KRT24 (4J) mRNA as compared to 
EPC2 cells incubated with low pH alone was observed (p<0.05). Incubation of EPC2 
cells with lower concentration of BM (50 µM) at pH 5.0 significantly downregulated 
mRNA expression of KRT1 (4A), KRT4 (4B), KRT6 (4D), KRT13 (4E), KRT15 (4G) 
KRT23 (4I) and KRT24 (4J) in comparison to untreated control cells (p<0.05). Exposure 
of EPC2 cells to 100 µM of BM at regular medium resulted in a significant decrease of 
KRT1 (4A), KRT4 (4B), KRT15 (4G) and KRT23 (4I) mRNA levels as compared to 
untreated control cells (p<0.05). In turn, 50 µM of BM applied alone inhibited mRNA 
expression of KRT1 (4A) and KRT4 (4B) in comparison to untreated control EPC2 
cells (p<0.05). The mRNA expression of KRT1 (4A), KRT4 (4B), KRT13 (4E), KRT15 







Figure 4. Squamous epithelium-specifi c mRNA expression upon incubation of Het-1A and EPC2 cells 
with bile mixture (BM) at pH 5.0. Het-1A and EPC2 cell lines were incubated with BM (50 µM and 100 
µM) in acidifi ed medium (pH 5.0) or regular medium for 6 consecutive days and squamous epithelium-
specifi c mRNA expression was analyzed by real-time PCR (A-J). PCR reaction was performed in duplicates 
and quantifi ed using ACTB/GAPDH as reference genes. Data from three independent experiments are 
shown as the mean ± SEM. Signifi cant change in gene expression after 6 days treatment as compared with 
untreated control cells is indicated by an asterisk (*) (p<0.05). A cross (+) indicates a signifi cant change as 
compared with cells incubated with pH 5.0 alone (p<0.05).
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(4G) and KRT23 (4I) in EPC2 cells cultured in acidified medium (pH 5.0) without BM 
was significantly inhibited as compared to untreated control cells (p<0.05). In Het-1A 
cells, no mRNA amplification of KRT1 (4A), KRT4 (4B), KRT5 (4C), KRT13 (4E), 
KRT14 (4F), KRT23 (4I) and KRT24 (4J) and no changes in mRNA expression of KRT 
6 (4D) and KRT16 (4H) was observed in all experimental groups. Only KRT15 mRNA 
expression was significantly downregulated in Het-1A cells after the treatment with BM 
(100 µM) at pH 5.0, as compared to untreated control cells (p<0.05; Figure 4G). 
Figures 5A-G show mRNA expression of columnar epithelium-specific genes, selected 
based on Table 1 analysis, altered in patients with BE, and determined in Het-1A and 
EPC2 cells. In EPC2 cells treated with 100 µm BM at pH 5.0, significant upregulation of 
KRT7 (5A), KRT18 (5C) and TFF3 (5D) mRNA expression in comparison to untreated 
control cells and cells treated with low pH alone was observed (p<0.05). In contrast, 
exposure to 50 µM BM at pH 5.0 significantly elevated only TFF3 mRNA expression in 
EPC2 cells (p<0.05; Figure 5D). When BM (100 µm) at pH 5.0 was co-incubated with 
Het-1A cells, the upregulation of KRT8 (5B), TFF3 (5D), MUC2 (5E), MUC13 (5F) 
and VIL1 (5G) mRNA was detected as compared to untreated control cells (p<0.05). 
In turn, BM applied at the concentration of 50 µM at pH 5.0 significantly elevated 
only TFF3 (5D) and MUC13 (5F) mRNA expression over the mRNA expression levels 
obtained in untreated control Het-1A cells (p<0.05). Likewise, BM (100 µM) applied 
at regular medium significantly increased mRNA expression of TFF3 as compared to 
untreated control Het1A cells (p<0.05; Figure 5D). In Het-1A cells cultured in acidified 
medium (pH 5.0) without BM significant upregulation of KRT8 (5B), TFF3 (5D), 
MUC2 (5E), MUC13 (5F) and VIL1 (5G) mRNA was determined as compared to 
untreated control cells (p<0.05). No amplification was observed for either KRT20, 
TFF1, TFF2, MUC6, MUC5B and MUC3A/B mRNA in all experimental groups for 
both cell lines (data not shown).
Morphology of  esophageal mucosa, gastroesophageal junction (GEJ), and gastric 
cardia in rats with esophagogastroduodenal anastomosis (EGDA)
Table 2 shows that in rats with 10 weeks of EGDA, the lesion score assessed 
macroscopically reached 3 in 70% of cases (7 out of 10 animals). In 20% of rats, disease 
progression reached score 4 and only 10% of animals reached lesion score 2 (Table 2).
Table 2. Incidence of the particular macroscopic lesion score in esophageal mucosa of rats 10 weeks after 
esophagogastroduodenal anastomosis (EGDA)-inducing surgery











Figure 5. Columnar epithelium-specifi c mRNA expression upon incubation of Het-1A and EPC2 cells 
with bile mixture (BM) at pH 5.0. Het-1A and EPC2 cell lines were incubated with BM (50 µM and 100 
µM) in acidifi ed medium (pH 5.0) or regular medium for 6 consecutive days and squamous epithelium-
specifi c mRNA expression was analyzed by real-time PCR (A-G). PCR reaction was performed in duplicates 
and quantifi ed using ACTB/GAPDH as reference genes. Data from representative three independent 
experiments are shown as the mean ± SEM. Signifi cant change in gene expression after 6 days treatment 
as compared with untreated control cells is indicated by an asterisk (*) (p<0.05). A cross (+) indicates a 
signifi cant change as compared with cells incubated with pH 5.0 alone (p<0.05).
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Figure 6. Macroscopic appearance of esophageal mucosa, gastroesophageal junction and gastric cardia in 
representative rats without (Intact, A) or with esophagogastroduodenal anastomosis (EGDA, B). Table 3 
shows that all 10 animals with EGDA developed hyperplasia of squamous epithelium and fi brosis of the 
lamina propria at 10 weeks after surgery. In 80% of the rats esophagitis with ulceration was observed (Table 
3). Barrett’s metaplasia was present in 60% of the rats (Table 3).
Figure 6 shows the macroscopic appearance of esophageal mucosa, GEJ, and gastric cardia 
of representative rats with or without EGDA (Figure 6A and 6B, respectively). After 
exposure to chronic refl ux due to EGDA, thickening of esophageal wall with ulceration 
and papillomatosis of the esophageal mucosa surface was observed (Figure 6B).
Figure 7A1 and 7A2 shows the microscopic appearance of the esophageal mucosa, GEJ, 
and gastric mucosa obtained from representative intact rats. Th e typical morphology 
manifestation of hyperplasia, fi brosis or infl ammation of experimental BE was not 
observed in esophageal epithelium and submucosa attached to the GEJ of intact rats 
(Figure 7A1) and the AB/PAS staining did not show any pathological changes within 
the tissue of these rats (Figure 7A2). In contrasts, Figure 7B1 and 7B2 show that in 
rats with EGDA, the GEJ architecture is altered. Esophageal mucosa is characterized by 
Table 3. Incidence of the selected microscopic criteria in esophageal mucosa of rats 10 weeks after 
esophagogastroduodenal anastomosis (EGDA)-inducing surgery
Assessed microscopic criteria
Number of animals with EGDA with presence 
of the criteria (%) (N=10)
Hyperplasia of squamous epithelium 10 (100%)
Fibrosis of lamina propria 10 (100%)
Barrett’s metaplasia 6 (60%)
Esophagitis with ulceration 8 (80%)







Figure 7. Microscopic appearance of esophageal mucosa, gastroesophageal junction (GEJ) and gastric cardia 
stained with H&E or AB/PAS in representative rats without (A1, A2) or with an esophagogastroduodenal 
anastomosis (B1-B6). Grey arrow points out gastric mucosa, blue arrow points out GEJ, red arrow indicates 
esophageal mucosa, yellow arrow indicates esophageal ulceration, orange frame shows Barrett’s-like lesions 
(A1, A2, B1, B2). (B3, B4) show high resolution images of Barrett’s-like lesions where yellow arrows indicate 
goblet cells and green arrows indicate fi brosis. Yellow arrows indicate epithelial hyperplasia (B5, B6).
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evident ulceration and fi brosis as demonstrated at high resolution image (Figure 7B3). 
Moreover, Barrett’s-like lesions metaplasia with presence of AB-positive goblet cells is 
observed proximally from the GEJ (Figure 7B3 and 7B4). Figure 7B5 and 7B6 present 
photomicrographs of esophageal tissue section collected separately from the same rate 
as shown in Figure 7B3 and 7B4. In animals with EGDA, the esophageal squamous 
mucosa shows pronounced epithelial hyperplasia (Figure 7B5 and 7B6). 
Figure 8. Serum concentration of interleukin (IL)-1β (A), IL-2 (B), IL-4 (C), IL-5 (D), IL-6 (E), IL-10 
(F), IL-12 (G), IL-13 (H), interferon (IFN)-γ (I), tumor necrosis factor (TNF)-α (J), and granulocyte-
macrophage colony-stimulating factor GM-CSF (K) in rats without (intact) and with esophagogastroduodenal 
anastomosis (EGDA). Results are mean ± SEM of fi ve samples per each experimental group. Asterisk (*) 
indicates a signifi cant change as compared with respective values obtained in rats without EGDA (p<0.05).







Alterations in serum content of  pro- and anti-inflammatory cytokines in rats with 
EGDA
Figures 8A-K show that serum contents of interleukin (IL)-1β (8A), IL-2 (8B), IL-4 
(8C), IL-5 (8D), IL-6 (8E), IL-10 (8F), IL-12 (8G), IL-13 (8H), interferon (IFN)-γ (8I), 
tumor necrosis factor (TNF)-α (8J), and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (8K), respectively, were significantly increased in rats with EGDA as 
compared with intact animals (p<0.05). 
Squamous and columnar epithelium-specific mRNA expression in esophageal 
mucosa of  rats with EGDA
Figure 9 shows expression of squamous epithelium-specific (A-G) genes in esophageal 
mucosa of rats with EGDA. In esophageal mucosa of rats with EGDA, KRT4 (9A), 
KRT13 (9D) and KRT15 (9F) mRNA expression was significant downregulated in line 
with in vitro model and KRT1 (9A), KRT5 (9C) and KRT14 (9E) mRNA fold changes 
were significantly increased not in line with in vitro model as compared to intact rats 
(p<0.05). EGDA did not significantly affect mRNA expression of KRT23 (9G). 
Figure 10 shows that the mRNA expression of columnar epithelium-specific genes 
KRT7 (10A), KRT8 (10B), KRT18 (10C), KRT20 (10D), TFF3 (10F), MUC2 (10H) 
and MUC13 (10I) was significantly upregulated in rats with EGDA in comparison 
to intact rats (p<0.05). Only TFF1 (10E) mRNA was downregulated after EGDA. 
EGDA did not lead to any significant changes in VIL1 (10G) mRNA expression. No 
amplification was observed for KRT6, KRT16, KRT24, TFF2, MUC3A, MUC5B and 
MUC6 mRNA in rats (data not shown).
Discussion
Human BE is a pathological condition associated with longstanding GERD and is 
defined as metaplasia of the flat, layered esophageal squamous epithelium into a tall 
intestinal columnar epithelial cells (23, 33). It is important to highlight that Barrett’s 
metaplasia may originate from GEJ stem cells (34, 35).
In our study, we have aimed to establish an appropriate experimental model which 
enables the evaluation of the effectiveness of novel pharmacological tools in the 
pathophysiology of Barrett’s metaplasia development at the microscopic, systemic, and 
especially molecular levels. For this purpose, we have chosen three datasets GSE13083 
(8), GSE34619 (9) and GSE1420 (24) from Gene Expression Omnibus (GEO) and 
applied them for GEO2R online tool to select the commonly expressed genes in BE 
epithelium. We observed significant downregulation in mRNA expression for squamous 
epithelium-specific genes such as KRT1, KRT4, KRT5, KRT6A-C, KRT13, KRT14, 
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Figure 9. Expression of mRNA for squamous epithelium-specifi c genes in rats without (intact) and with 
esophagogastroduodenal anastomosis (EGDA). Results are expressed as mRNA expression of squamous 
epithelium-specifi c genes (A-G) normalized to ACTB/GAPDH expression and are mean ± SEM for n=5 
samples per each experimental group. Asterisk (*) indicates a signifi cant change as compared with respective 
values obtained in rats without EGDA (p<0.05).







Figure 10. Expression of mRNA for columnar epithelium-specifi c genes in rats without (intact) and with 
esophagogastroduodenal anastomosis (EGDA). Th e results are expressed as mRNA expression of columnar 
epithelium-specifi c genes (A-I) normalized to ACTB/GAPDH expression and are the mean ± SEM for n=5 
Barrett’s-like samples per experimental group. Asterisk (*) indicates a signifi cant change as compared with 
respective values obtained in rats without EGDA (p<0.05).
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KRT15, KRT16, KRT23 and KRT24 in human BE biopsies as compared with samples 
collected from normal squamous esophageal epithelium. In turn, expression of mRNA 
for columnar and intestinal epithelium-specific genes such as KRT7, KRT8, KRT18, 
KRT20, TFF1, TFF2, TFF3, VIL1, MUC2, MUC3A/B, MUC5B, MUC6 and MUC13 
was significantly upregulated. We assume that the alterations in the mRNA expression 
of above mentioned specific genes reflect the development of metaplasia within the 
epithelium on molecular level.
There have been several attempts to develop experimental in vivo models of GERD 
leading to BE and/or EAC which attempt to mimic the clinical course of this disorder. 
The most widely described model in literature is the surgical animal model with rats 
(36). Attwood et al. divided existing reflux models into three categories depending on 
the production of esophagitis alone (rat pyloric ligation, Wendel esophagogastroplasty, 
or external esophageal perfusion), esophagitis and BE but not EAC (total gastrectomy 
or mucosal excision with hiatal hernia creation), and esophagitis, BE, and EAC 
(esophagojejunostomy, esophagoduodenal anastomosis, or esophagogastroduodenal 
anastomosis) (37). Interestingly, Quante et al. demonstrated that genetically modified 
mice overexpressing IL-1β also develop Barrett’s-like lesions (34). 
We have selected and implemented the well-known surgical rat model based on 
generation of an appropriate anastomosis between the GE and EGDA according to 
the method described previously by Nishijima et al. (29). Microscopic and histological 
analysis confirmed BE metaplasia with the presence of goblet cells in 60% of rats with 
10 weeks of EGDA. 
Additionally, we have demonstrated an evident increase in expression of pro/anti-
inflammatory cytokines in rats with experimental gastroduodenoesophageal reflux. This 
is corroborative with previous findings that chronic inflammation of esophageal mucosa 
may occur as the secondary consequence of multiple exposures of esophageal structure 
to the acidic and alkaline content. Thus, there is no doubt that this gastroduodenal 
content may represent a common risk factors in the BE pathogenesis and its further 
progression (7, 15, 29, 30, 38). 
Moreover, based on the analysis of the BE expression profile in human biopsies, we 
sought to identify alterations in mRNA expression of selected genes including squamous 
epithelium-specific (KRT1, KRT4, KRT5, KRT6, KRT13, KRT14, KRT15, KRT16, 
KRT23, KRT24) and columnar epithelium-specific (KRT7, KRT8, KRT18, KRT20) 
keratins together with secretory (MUC2, MUC5B, MUC6) and epithelial membrane-
bound (MUC3A/B) mucins, trefoil factor family (TFF1, TFF2, TFF3) and villin (VIL1) 
genes in the esophageal mucosa of rats with EGDA in comparison to intact rats without 
EGDA. We found that expression of squamous epithelium-specific KRT4, KRT13 and 
KRT15 mRNA was significantly downregulated in esophageal mucosa of rats with 







EGDA. These findings seem to closely correlate with changes in mRNA expression as 
demonstrated in mucosal biopsies collected from patients with BE. In addition, among 
investigated columnar epithelium-specific genes KRT7, KRT8, KRT18, KRT20, TFF3, 
MUC2 and MUC13 mRNA expression was significantly upregulated reflecting changes 
observed in BE patients (Table 5). In contrary, KRT1, KRT5, KRT14, TFF1 and VIL1 
mRNA expression was increased in animal biopsies which is not in line with these 
genes expression observed in human BE biopsies. This phenomenon can be explained by 
species-specific discrepancy between humans and rodents, especially taking into account 
that KRT1, KRT5 and KRT14 are expressed in human squamous epithelium. The direct 
translational character of the scientific data derived from animal studies related to BE 
and compared with human BE can be doubtful when considering e.g. the variability in 
the structure and physiology between the rodent and human esophagus (Table 4) (26, 
39). 
Our data accumulated in this study may support the notion proposed by Attwood et 
al. that results from animal models cannot be always translated to clinical settings [35]. 
Thus, if the results are achieved without the solid pathology background, experimental 
as well as molecular evidences, the results of subsequent work must be interpreted 
carefully (37). Therefore, there is a great need for alternative methods that will be more 
available, will not depend on the presence of BE patients, and strive to mimic the 
human in vivo microenvironments in an in vitro setting (40). For instance, Bus et al. 
reviewed a large variety of in vitro models and incubation conditions for studying BE 
development (1). In their in vitro studies, bile salts at either a low or neutral pH were 
required to induce expression of BE-specific factors (1). Moreover, they proposed that 
the esophageal squamous epithelium cell lines, such as the Het-1A cells appear to be the 
most appropriate models for studying of BE pathogenesis (1). In contrary, according 
to Underwood et al., Het-1A cell line does not possess the characteristics of normal 
Table 4. Major differences between human and rat esophagus physiology and Barrett’s esophagus (BE) 
pathophysiology
Human Rat
Esophageal epithelium Non-keratinized Keratinized
Esophageal submucosal glands and papillae Present Absent
Stratum corneum Absent Present
Squamocolumnar transition at GEJ Yes No
 Natural reflux Yes No
Natural BE to EAC progression Yes No
Compartmentalized stomach 
(forestomach and distal stomach)
No Yes
BE progression time 10 years Around 2-3 months
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esophageal squamous cells and should be studied with caution in translational research 
on BE (41). Thus, besides commonly used Het-1A cell line, we have implemented 
human esophageal keratinocytes EPC2 cell line to investigate their molecular response 
to acid and/or BM exposures.
Since the major constituent of the esophageal epithelium are the keratins (40, 42), we 
chose them as a focal point to investigate the molecular pattern of Barrett’s metaplasia 
and to identify the optimal duration of acid and/or BM treatment to establish an in 
vitro model of BE development. Based on cell viability analysis we have selected BM 
at the concentration of 100 µM applied in medium adjusted to pH 5.0 as the highest 
concentration, which did not affect esophageal cell lines survival. We have further 
assessed possible time-dependent alterations in the expression of two squamous (KRT4, 
KRT15) and two columnar (KRT8, KRT18) epithelium-specific KRT genes in Het-1A 
and EPC2 cell lines after exposing the cells for 30 min per day to desired BM (100 µM) 
at pH 5.0 for 1, 3 and 6 consecutive days. In majority of cases investigated KRT genes 
revealed the most efficient changes in mRNA expression reflecting these observed in 
human biopsies only when treatment was repeated for 6 consecutive days in contrast 
to those recorded at 1 or 3 days. Thus, we conclude that six days of treatment seems to 
be the most optimal for both tested cell-lines to induce a specific BE molecular pattern 
and these conditions have been chosen for further analysis of a broader spectrum of 
genes. Interestingly, for EPC2 cells three days of treatments were sufficient to induce 
this molecular pattern. Thus, to determine whether and how low pH and/or BM 
exposure can affect mRNA expression of squamous and columnar epithelium-specific 
genes observed in humans (Table 2), both Het-1A and EPC2 cells were exposed for 
30 minutes daily in 6 consecutive days with BM (50 µM and 100 µM) at pH 5.0, or 
with BM (50 µM and 100 µM) and medium adjusted to pH 5.0 applied separately. 
We found that in EPC2 and Het-1A cells, BM at the concentration 50 µM at pH 5.0, 
as well as BM and acidified medium (pH 5.0) applied separately were less effective in 
induction of gene expression changes characteristic for BE patients in comparison to 
the experiments in which BM in higher concentration of 100 µM has been applied at 
pH 5.0. This clearly indicates that changes in the specific gene expression are dependent 
on bile concentration and acidic environment. Moreover, we observed that incubation 
of EPC2 cells with 100 µM of BM at pH 5.0 downregulated mRNA expression of all 
investigated squamous epithelium-specific KRT genes as compared to untreated control 
cells. Interestingly, in Het-1A cells only KRT15 mRNA expression was significantly 
downregulated. This is in accordance with observation by Mari et al. (25), who claimed 
that Het-1A cells lacked the expression of majority of squamous epithelium-specific 
KRT genes, confirming that this cell line has an incomplete squamous phenotype. 
In addition, in our study, more columnar epithelium-specific genes were upregulated 
in Het-1A in comparison to EPC2 under optimized experimental conditions. For 
instance, when Het-1A cells were treated with 100 µM BM at pH 5.0, the expression of 







columnar epithelium-specific KRT8, TFF3, VIL1, MUC2 and MUC13 was upregulated 
in comparison to untreated control cells. The same experimental conditions in EPC2 
cells provoked upregulation of columnar epithelium-specific KRT7, KRT18 and TFF3 
mRNA as compared to untreated control cells.
Summarized, alterations in BE-specific gene expression observed in human biopsies and 
in vitro and in vivo models were presented in Table 5.
Table 5. Summary of alterations in expression of squamous and columnar epithelium-specific genes 
observed in human biopsies and in vitro using Het-1A and EPC2 cells and in vivo EGDA rat model. A 
vertical up arrow (↑) indicates upregulation of mRNA expression in Barrett’s metaplasia as compared with 
samples without Barrett’s metaplasia/untreated control cells/intact rats; a vertical down arrow (↓) indicates 
downregulation of mRNA expression in Barrett’s metaplasia as compared with samples without Barrett’s 
metaplasia/untreated control cells/intact rats; a horizontal left right arrow (↔) indicates no changes in 
mRNA expression; n.a. indicates no amplification; n.d. not determined.
Gene symbol Type of epithelium
In vitro models
In vivo model Human biopsiesHet-1A EPC2
KRT1 squamous n.a. ↓ ↑ ↓
KRT4 squamous n.a. ↓ ↓ ↓
KRT5 squamous n.a. ↓ ↑ ↓
KRT6 squamous ↔ ↓ n.d. ↓
KRT13 squamous n.a. ↓ ↓ ↓
KRT14 squamous n.a. ↓ ↑ ↓
KRT15 squamous ↓ ↓ ↓ ↓
KRT16 squamous ↔ ↓ n.a. ↓
KRT23 squamous n.a. ↓ ↔ ↓
KRT24 squamous n.a ↓ n.a. ↓
KRT7 columnar ↔ ↑ ↑ ↑
KRT8 columnar ↑ ↔ ↑ ↑
KRT18 columnar ↔ ↑ ↑ ↑
KRT20 columnar n.a. n.a. ↑ ↑
TFF1 columnar n.a. n.a. ↓ ↑
TFF2 columnar n.a. n.a. n.a. ↑
TFF3 columnar ↑ ↑ ↑ ↑
VIL1 columnar ↑ n.a. ↔ ↑
MUC2 columnar ↑ n.a. ↑ ↑
MUC3 columnar n.a. n.a. n.a. ↑
MUC5B columnar n.a. n.a. n.a. ↑
MUC6 columnar n.a. n.a. n.a. ↑
MUC13 columnar ↑ ↔ ↑ ↑
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Based on our data, EPC2 and Het-1A cells react diff erently to the implemented chronic 
mixed acid and bile treatment. Interestingly, when we took a deeper look into the 
outcome of our investigations in vitro, we fi nd that the expression pattern of analyzed 
genes demonstrated around 57% of similarities between the human biopsies and the 
EPC2 cells treated with acidic BM (Figure 11, Table 5). In turn, in Het-1A model only 
26% of genes refl ected the expression pattern similar to that obtained in biopsies from 
BE patients (Figure 11, Table 5). 
Additionally, we have found that in animal BE model 45% of assessed genes were 
expressed in a pattern characteristic for human BE metaplasia (Figure 12, Table 5). In 
turn, when expression profi le of both cell lines within the optimized in vitro BE model 
were analyzed together, 73% of genes refl ected alterations observed in human biopsies 
(Figure 12, Table 5).
Taken together, we conclude that our optimized in vitro model based on two primary 
immortalized human esophageal squamous cell lines is suitable to observe an effi  cient 
induction markers specifi c for human BE epithelium. However, it is worth to mention 
that cell cultures apparently lack of systemic infl ammatory response, the infl uence 
of esophageal microcirculation, microenvironmental factors, neural components, 
neuropeptides and cellular interactions characteristic for esophageal cells functioning 
in vivo (26, 43). Th erefore, these doubts could be, at least in part, solved by studies 
in animal models of BE in vivo providing additional information about macroscopic, 
microscopic, functional and biochemical alterations. Th e animal model, applied 
Figure 11. Venn diagram displaying numbers of up/downregulated genes in human biopsies derived from 
patients with Barrett’s metaplasia as compared with in vitro Het-1A and EPC2 model of Barrett’s esophagus. 
Overlap area shows the number of the same up/downregulated genes in the appropriate groups. Graphs 
were obtained through Venn diagrams software (available online: http://bioinformatics.psb.ugent.be/
webtools/Venn/). Diff erent color meant diff erent datasets.







simultaneously with the optimized in vitro model could off er the opportunity to the 
evaluation of the molecular response and the eff ectiveness of possible drugs candidates 
targeting BE prevention and/or treatment.
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Supplementary Table S1. The list of selected human genes (and reference genes) and the corresponding 
TaqMan assays
No. Gene name and symbol Assay ID
NCBI gene 
reference
1 β-actin, ACTB Hs99999903_m1 NM_001101.3
2 Glyceraldehyde-3-phosphate dehydrogenase, GAPDH Hs99999905_m1 NM_002046.5
3 Keratin 1, KRT1 Hs00196158_m1 NM_006121.3
4 Keratin 4, KRT4 Hs00361611_m1 NM_002272.3
5 Keratin 5, KRT5 Hs00361185_m1 NM_000424.3
6 Keratin 6A, KRT6A Hs01699178_g1 NM_005554.3
7 Keratin 7, KRT7 Hs00559840_m1 NM_005556.3
8 Keratin 8, KRT8 Hs01670053_m1 NM_001256282.1
9 Keratin 13, KRT13 Hs00999762_m1 NM_153490.2
10 Keratin 14, KRT14 Hs00265033_m1 NM_000526.4
11 Keratin 15, KRT15 Hs00267035_m1 NM_002275.3
12 Keratin 16, KRT16 Hs00373910_g1 NM_005557.3
13 Keratin 18, KRT18 Hs02827483_g1 NM_000224.2
14 Keratin 20, KRT20 Hs00300643_m1 NM_019010.2
15 Keratin 23, KRT23 Hs01119992_m1 NM_015515.4
16 Keratin 24, KRT24 Hs00962561_m1 NM_019016.2
17 Mucin 2, oligomeric mucus/gel-forming, MUC2 Hs00159374_m1 NM_002457.3
18 Mucin 3A/B, cell surface associated, MUC3A/B Hs03649367_mH NM_005960.1
19 Mucin 6, oligomeric mucus/gel-forming, MUC6 Hs01674026_g1 NM_005961.2
20 Mucin 5B, oligomeric mucus/gel-forming, MUC5B Hs00861588_m1 NM_002458.2
21 Mucin 13, cell surface associated, MUC13 Hs00217230_m1 NM_033049.3
22 Trefoil factor 1, TFF1 Hs00170216_m1 NM_003225.2
23 Trefoil factor 2, TFF2 Hs00193719_m1 NM_005423.4
24 Trefoil factor 3, TFF3 Hs00173625_m1 NM_003226.3




Supplementary Table S2. The list of selected rat genes (and reference genes) and the corresponding 
TaqMan assays
No. Gene name and symbol Assay ID
NCBI gene 
reference
1 β-actin, ACTB Rn00667869_m1 NM_031144 
2 Glyceraldehyde-3-phosphate dehydrogenase, GAPDH Rn01462662_g1 NM_017008   
3 Keratin 1, KRT1 Rn02346048_m1 NM_001008802 
4 Keratin 4, KRT4 Rn02346072_m1 NM_001008806 
5 Keratin 5, KRT5 Rn01533116_gH NM_183333  
6 Keratin 6, KRT6 not available
7 Keratin 7, KRT7 Rn01533141_m1 XM_003750407
8 Keratin 8, KRT8 Rn01532759_g1 NM_199370    
9 Keratin 13, KRT13 Rn01464231_m1 NM_001004021    
10 Keratin 14, KRT14 Rn01467684_m1 NM_001008751   
11 Keratin 15, KRT15 Rn01460389_m1 NM_001004022  
12 Keratin 16, KRT16 Rn02345941_g1 NM_001008752
13 Keratin 18, KRT18 Rn01533362_g1 NM_053976  
14 Keratin 20, KRT20 Rn00687576_m1 NM_173128
15 Keratin 23, KRT23 Rn01773106_m1 NM_001008753 
16 Keratin 24, KRT24 Rn01471287_m1 NM_001004131
17 Mucin 2, oligomeric mucus/gel-forming, MUC2 Rn01498197_m1 XM_008760048  
18 Mucin 3A, intestinal, MUC3a Rn01481134_m1 XM_008769185
19 Mucin 5B, oligomeric mucus/gel-forming, MUC5B Rn01502008_m1 XM_006230608
20 Mucin 6, oligomeric mucus/gel-forming, MUC6 Rn01759814_m1 XM_008760036 
21 Mucin 13, cell surface associated, MUC13 Rn01647776_g1 XM_008768788 
22 Trefoil factor 1, TFF1 Rn01428805_m1 NM_057129   
23 Trefoil factor 2, TFF2 Rn00587721_m1 NM_053844 
24 Trefoil factor 3, TFF3 Rn00564851_m1 NM_013042 
25 Villin 1, VIL1 Rn01400773_g1 NM_001108224
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Abstract
Almost half of people with esophageal or gastroesophageal junction cancer have metastatic 
disease at the time of diagnosis. Chemotherapy and targeted therapies are increasingly used 
with a palliative intent to control tumor growth, improve quality of life, and prolong survival. 
To date, and with the exception of ramucirumab, evidence for the efficacy of palliative 
treatments for esophageal and gastroesophageal cancer is lacking. Our objective was to 
assess the effects of cytostatic or targeted therapy for treating esophageal or gastroesophageal 
junction cancer with palliative intent. We searched the Cochrane Central Register of 
Controlled Trials (CENTRAL), MEDLINE, Embase, the Web of Science, PubMed 
Publisher, Google Scholar, and trial registries up to 13 May 2015, and we hand searched the 
reference lists of studies. We did not restrict the search to publications in English. Additional 
searches were run in September 2017 prior to publication, and they are listed in the ‘Studies 
awaiting assessment’ section. We included randomized controlled trials (RCTs) on palliative 
chemotherapy and/or targeted therapy versus best supportive care or control in people 
with esophageal or gastroesophageal junction cancer. Two authors independently extracted 
data. We assessed the quality and risk of bias of eligible studies according to the Cochrane 
Handbook for Systematic Reviews of Interventions. We calculated pooled estimates of 
effect using an inverse variance random-effects model for meta- analysis. We identified 41 
RCTs with 11,853 participants for inclusion in the review as well as 49 ongoing studies. 
For the main comparison of adding a cytostatic and/or targeted agent to a control arm, 
we included 11 studies with 1347 participants. This analysis demonstrated an increase in 
overall survival in favor of the arm with an additional cytostatic or targeted therapeutic 
agent with a hazard ratio (HR) of 0.75 (95% confidence interval (CI) 0.68 to 0.84, high-
quality evidence). The median increased survival time was one month. Five studies in 750 
participants contributed data to the comparison of palliative therapy versus best supportive 
care. We found a benefit in overall survival in favor of the group receiving palliative 
chemotherapy and/or targeted therapy compared to best supportive care (HR 0.81, 95% 
CI 0.71 to 0.92, high-quality evidence). Subcomparisons including only people receiving 
second-line therapies, chemotherapies, targeted therapies, adenocarcinomas, and squamous 
cell carcinomas all showed a similar benefit. The only individual agent that more than one 
study found to improve both overall survival and progression-free survival was ramucirumab. 
Palliative chemotherapy and/or targeted therapy increased the frequency of grade 3 or higher 
treatment-related toxicity. However, treatment-related deaths did not occur more frequently. 
Quality of life often improved in the arm with an additional agent. In conclusion, people 
who receive more chemotherapeutic or targeted therapeutic agents have an increased overall 
survival compared to people who receive less. These agents, administered as both first-line 
or second-line treatments, also led to better overall survival than best supportive care. With 
the exception of ramucirumab, it remains unclear which other individual agents cause the 
survival benefit. Although treatment associated toxicities of grade 3 or more occurred more 
frequently in arms with an additional chemotherapy or targeted therapy agent, there is no 
evidence that palliative chemotherapy and/or targeted therapy decrease quality of life. Based 
on this meta-analysis, palliative chemotherapy and/or targeted therapy can be considered 
standard care for esophageal and gastroesophageal junction carcinoma.
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This review aimed to investigate the effectiveness of adding cytostatic or targeted therapy 
to supportive care in people with esophageal or gastroesophageal junction cancer. 
Esophageal cancer is the eighth most common cancer in the world. Many people are 
diagnosed only after the disease has spread to other parts of the body, when cure is 
rarely possible. These people can be treated with palliative chemotherapy or targeted 
therapy (a drug directed against a specific component of the tumor). The aim of this 
treatment is to control tumor growth and increase survival, without a significant 
decrease in quality of life. We searched reference lists, biomedical databases (Cochrane 
Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, the Web of 
Science, PubMed Publisher, and Google Scholar), and trial registries up to 13 May 
2015. Additional searches were run in September 2017 prior to publication, and they 
are listed in the ‘Studies awaiting assessment’ section. We identified 41 randomized 
controlled trials (RCTs) that met our inclusion criteria for inclusion in the review, as 
well as 49 ongoing studies. This review and meta-analysis shows that people who receive 
more chemotherapeutic or targeted therapeutic agents live longer and with less disease 
progression than people who receive best supportive care or less therapy. The only 
individual agent that more than one study found to improve survival was ramucirumab. 
We found severe treatment-associated toxicities (grade 3 or above) more frequently in 
the arms with an additional chemotherapy or targeted therapy agent. However, there is 
no evidence that palliative chemotherapy and/ or targeted therapy decreases quality of 
life. Our meta-analysis indicates that chemotherapy and targeted therapy are effective 
palliative treatments for people with esophageal and gastroesophageal junction cancer. 
The evidence that more chemotherapeutic or targeted therapeutic agents increase 
survival is of high quality, as is the evidence for improved survival compared to best 
supportive care. The evidence for the increased occurrence of severe treatment-related 
toxicities is of very low quality, while the evidence showing no decrease in quality of life 




See Appendix 1 for a glossary of key terms.
Description of  the condition
Epidemiology
Esophageal cancer is the eighth most common cancer worldwide (Arnold 2015), 
with approximately 398,000 people diagnosed with squamous cell carcinoma (SCC) 
and 52,000 with adenocarcinoma in 2012. This corresponds with incidence rates of 
5.2 and 0.7 per 100,000 population, respectively. Adenocarcinomas develop from 
metaplastic Barrett mucosa located in the lower esophagus, while SCC develops from 
the squamous epithelium (Enzinger 2003). Both histological types have dysplasia as 
their precursor. Recent epidemiological data indicate that 79% of SCCs worldwide 
occur in Southeastern and Central Asia, whereas 46% of people with adenocarcinomas 
are diagnosed in Northern and Western Europe, North America, and Oceania. In 
general, incidence of esophageal cancer is higher in men than in women, especially in 
adenocarcinoma, for which the male to female ratio is 4.4:1, compared to 2.7:1 for SCC 
(Arnold 2015). In the past few decades, developed countries have seen an increase in 
the incidence of adenocarcinoma (Edgren 2013), attributed to the higher prevalence of 
obesity. On the other hand, the decreasing incidence of SCC in these contexts correlates 
with the decline in smoking (Cook 2009). SCC remains most common in low- and 
middle-income countries, including in Africa and Eastern Asia (Lin 2013, Ocama 2008, 
Somdyala 2010, White 2009). Almost half of people with esophageal carcinoma have 
distant disease at the time of diagnosis (Howlader 2014).
Prognosis and management options
Endoscopic therapy may be an option for early oesophageal cancers, but a Cochrane 
Review found no randomized controlled trials (RCTs) comparing management options 
for this early stage (Bennett 2012). Surgical resection is the potentially curative treatment 
for esophageal cancer, but it is only feasible in people who are fit for surgery, have locally 
resectable disease, and show no signs of distant metastases. Unfortunately, most people 
develop recurrent tumor growth within the first few years after surgery. Palliative care is 
the only option for metastatic disease, with a five year survival rate of less than three per 
cent (Hur 2013). Palliative therapy aims to control tumor growth and increase survival 
without significantly decreasing quality of life.
Description of  the intervention
In daily practice, clinicians often offer palliative chemotherapy to control tumor 
growth, increase quality of life, and increase life expectancy. Clinicians have the option 







to choose from cytostatic therapy, which is directed at fast dividing cells in general, or 
from targeted therapies directed against specific molecules needed for carcinogenesis 
and tumor growth. The most extensively used agents for this disease are 5-fluorouracil 
(5-FU) and cisplatin, which are included in most combination chemotherapy regimens. 
However, the chemotherapy agents used in RCTs are very heterogeneous. Researchers 
have examined targeted therapies as palliative treatment for a decade (Lorenzen 2009). 
People treated with these anti-neoplastic agents experience fewer side effects compared 
to people treated with classic cytotoxic chemotherapies. The most common targets 
studied are the epidermal growth factor receptor (EGFR) and the vascular endothelial 
growth factor receptor two (VEGFR2). Most targeted therapies studied are monoclonal 
antibodies, except for the tyrosine kinase inhibitor, gefitinib (Dutton 2014).
Why it is important to do this review
Palliative chemotherapy and/or targeted therapies are widely accepted treatment 
options. However, except for ramucirumab, evidence for the efficacy of palliative 
treatment for esophageal and gastroesophageal cancer is lacking. To assess whether 
a benefit exists, there is a need for large randomized studies assessing the effects of 
chemotherapy or targeted therapy for treating people with esophageal and GE-junction 
cancer with palliative intent. In a randomized gastric cancer study, (Thuss-Patience 
2011) reported that accrual for first-line studies is very difficult because most people 
refuse randomization, so new data from large randomized studies investigating first-
line chemotherapy or targeted therapy versus best supportive care (BSC) will probably 
not become available. On the other hand, interesting new data have become available 
regarding targeted therapies and second line therapies. Due to the limited availability of 
relevant data, summarizing the available evidence could increase insight into whether 
chemotherapy and targeted therapies are justifiably being prescribed to people with 
advanced or metastatic esophageal or gastroesophageal (GE)-junction cancer.
We have chosen to construct the main meta-analysis in a way that summarizes the 
largest number of studies. The downside of this approach is the heterogeneity of the 
included studies in terms of intervention and participant groups. Because this approach 
complicates the straightforward translation of results to individuals, we performed 
subgroup analyses wherever possible to investigate whether the overall result was 
consistent across subsets of treatments and participants.
Objectives
To assess the effects of cytostatic or targeted therapy for treating esophageal or 




Criteria for considering studies for this review 
Types of studies 
We included RCTs with or without blinding. We included abstracts that met the inclusion 
criteria and that reported data on review outcomes as studies awaiting classification. If 
the abstract was a study protocol, we included it as an ongoing study. 
We excluded all non-randomized and quasi-randomized studies, as we considered they 
did not provide sufficiently high-quality evidence.
Types of participants
People with advanced (T3-T4NxM0 non-resectable; and all TxNxM1), recurrent, 
or metastatic carcinoma of the esophagus and GE-junction. We included only 
studies involving participants with advanced or non-resectable disease who received 
chemotherapy with palliative intent. We did not consider studies including participants 
receiving chemotherapy for locally advanced cancer in order to assess resectability. We 
included people with both SCC and adenocarcinoma, as well as people who had received 
prior chemotherapy.
We included in the qualitative synthesis studies involving only a subset of eligible 
participants, for instance studies including participants with both GE-junction cancer 
and gastric cancer, if they described the results for GE-junction cancer separately and 
included at least 15 eligible participants. We evaluated these studies for inclusion in the 
quantitative synthesis under certain circumstances (see Sensitivity analysis).
Types of interventions
We included treatments with systemic intravenous and single oral chemotherapy 
or targeted therapy, as well as combination regimens in all doses and schedules. We 
defined ‘control arm’ as BSC or treatment with at least one chemotherapy agent whose 
composition, dose, and schedule were equal in both arms. Dose defining RCTs were not 
eligible for this review. Chemotherapy encompassed all cytotoxic and anti-neoplastic 
drug treatment, and targeted therapy encompasses all anti-neoplastic drug treatment 
targeting a specific protein or small group of proteins. We did not consider combined 
radiochemotherapy or radio-targeted therapy interventions for this review.
Our main comparison was chemotherapy or targeted therapy agent(s) plus any control 
intervention versus control intervention alone. We also performed a sensitivity analysis 
to assess the effect of the intervention in people with esophageal and GE-junction cancer 
versus gastric cancer.







Finally, we performed several subgroup analyses.
a. Chemotherapy or targeted therapy plus BSC versus BSC.
b. Effect of intervention in participants who had received previous chemotherapy 
(versus control intervention alone).
c. Chemotherapeutic agent plus control intervention versus control intervention alone.
d. Targeted therapeutic agent plus control intervention versus control intervention 
alone.
i. Epidermal growth factor receptor (EGFR)-targeting agent plus control 
intervention versus control intervention alone.
ii. Cetuximab plus control intervention versus control intervention alone.
iii. Ramucirumab plus control intervention versus control intervention alone.
e. Chemotherapy or targeted therapy agent(s) plus control intervention versus control 
intervention alone in people with adenocarcinoma of the esophagus.
f. Chemotherapy or targeted therapy agent(s) plus control intervention versus control 
intervention alone in people with SCC of the esophagus. 
Types of outcome measures
We did not use the outcome measures mentioned below as inclusion criteria but as a list 
of outcome measures of interest to this review.
Primary outcomes
Median overall survival (OS) (time to death) and hazard ratio (HR) with 95% confidence 
interval (CI).
Secondary outcomes
•	 Median progression-free survival (PFS) (time to disease progression and/or death) 
and HR with 95% CI.
•	 Toxicity (type, severity, and percentage of acute and chronic toxic effect, including 
toxic death), classified according to World Health Organization (WHO) or National 
Cancer Institute Common Toxicity Criteria (NCI-CTC). The focus was on toxicities 
of grade 3 or higher. Grade 3 toxicities are described in the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.0 as “severe or medically significant but 
not immediately life-threatening; hospitalization or prolongation of hospitalization 
indicated; disabling; limiting self-care activities of daily living” (Common Toxicity 
Criteria 4.0).
•	 Quality of life (including all validated outcome measures). 
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Search methods for identification of  studies 
Electronic searches 
We identified records by searching the following electronic databases using the search 
strategies detailed in the appendices. 
1. Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 9) in the 
Cochrane Library (searched 19 September 2017; Appendix 2).
2. MEDLINE (1950 to 19 September 2017; Appendix 3).
3. Embase (1980 to 19 September 2017; Appendix 4).
4. Web of Science (1900 to 19 September 2017; Appendix 5).
5. Pubmed Publisher (1950 to 19 September 2017; Appendix 6).
6. Google Scholar (1592 to 19 September 2017; Appendix 7).
7. Clinicaltrials.gov (searched 19 September 2017; Appendix 8).
8. WHO International Clinical Trials Registry Platform (ICTRP) (searched 19 
September 2017; Appendix 9).
We constructed the search strategy by applying a sensitivity maximizing approach, using 
a combination of MeSH subject headings and text words related to chemotherapy or 
targeted therapy with a palliative intent for cancer of the esophagus and GE-junction. 
We adapted the MEDLINE search strategy for use in the other databases. We did not 
confine the search to English-language publications. We placed studies identified after 
the search of 13 May 2015 in ‘Studies awaiting classification’ or ‘Ongoing studies’. In 
the next version of the review, we will screen these and incorporate them as appropriate.
Searching other resources
We hand-searched reference lists from studies included in the qualitative assessment to 
identify further relevant studies. Additionally, within the retrieved records, we identified 
and selected reviews based on title and abstract, extracting relevant references and 
including them as retrieved records.
Data collection and analysis
Selection of studies
Two review authors (VJ, MS) independently scanned the title and abstract of every 
record retrieved during the search. If the information given suggested that the RCT 
included participants with advanced (T3-T4NxM0 non-resectable; and all TxNxM1), 
recurrent, or metastatic carcinoma of the esophagus or GE-junction and used random 
allocation to generate the comparison groups, or if there was any doubt regarding these 
criteria, we retrieved the full text for detailed assessment. We resolved differences in data 
extraction through discussion.







Data extraction and management
Two review authors (VJ, MS) independently extracted details on study population, 
interventions, and outcomes by using a standardized data extraction form, which 
included the following items.
•	 General information: title, authors, source, contact address, country, publication 
status, full paper/abstract, language, and year of publication.
•	 Study characteristics: design, allocation concealment, blinding, number of arms, 
phase, and duration of follow-up.
•	 Participants: inclusion and exclusion criteria, sample size, baseline characteristics, 
similarity of groups at baseline, dropouts described, and ITT performed.
•	 Intervention: which comparison was performed, type, dose, route, and schedule of 
drug administration.
•	 Outcomes: as specified above: median OS and PFS, HRs and their 95% CIs, toxicity, 
and quality of life.
We contacted authors of all eligible studies to provide us with individual participant data.
Assessment of risk of bias in included studies
Two review authors (VJ, MS) independently assessed the risk of bias and the quality 
of the eligible studies according to the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins). In case of disagreements, they consulted a third review author 
to reach consensus. We extracted data using the assessment form designed for this review.
We assessed each study taking into account the following points (Higgins); (Jadad 1996).
•	 Was the allocation random?
•	 Was the concealment of treatment allocation adequate?
•	 Was the study blinded?
•	 Was there selective reporting?
•	 Were the groups similar at baseline?
•	 Were the number of withdrawals, dropouts, and losses to follow-up described?
•	 Was intention-to-treat analysis performed?
We rated each study as being at low, high, or unclear risk of bias for these domains.
We defined baseline comparability as follows: we considered the most important 
prognostic factors to be tumor stage (advanced versus metastatic disease), performance 
index (Eastern Cooperative Oncology Group (ECOG) status 0 to 1 versus 2 to 3), and 
the number of organs involved in metastatic disease (one versus more than one). We 
considered a difference of more than 15% between study arms to be clinically relevant. 
For the median age of participants in treatment arms, we considered baseline differences 
of five years to be clinically relevant. 
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We defined intention-to-treat analysis as either randomized analysis restricted to 
participants who received at least one cycle of chemotherapy or targeted therapy and 
for which survival data were available, or methodologies that included all participants at 
randomization in the analysis.
Measures of treatment effect
We extracted or directly or indirectly estimated HRs and 95% CIs from the given data 
in each included study (Altman 2001). If we could not extract the data directly from 
the text, we determined them indirectly. For example, we estimated HRs from ratios 
of median survival times, from observed to expected event ratios and from time point 
survival ratios (Machin 1997); (Parmar 1998). Sometimes, we had to read these ratios 
from a Kaplan-Meier graph provided in the paper. We extracted median overall and 
progression-free survival times if available.
Dealing with missing data
Where studies did not report outcomes directly, we calculated them if possible (see 
Measures of treatment effect) and reported them narratively if not.
Assessment of heterogeneity
For each data synthesis, we calculated pooled estimates of effect and investigated results for 
statistical heterogeneity. We assessed forest plots for heterogeneity by visual inspection. To 
quantify inconsistency across studies, we calculated the I2 statistic as ((Q − df)/Q) × 100%, 
where Q is the Chi2 statistic and df its degrees of freedom. See also Sensitivity analysis.
Assessment of reporting biases
We assessed small study effects such as publication bias in a qualitative manner using a 
funnel plot if enough studies were present (i.e. at least 10).
Data synthesis
In the meta-analyses, we aimed to combine data from different RCTs reporting similar 
comparisons. Therefore, only RCTs in which treatments were added to BSC or a control 
arm were included. Given the amount of variation in the interventions studied in the 
included studies, we calculated pooled estimates of effect using an inverse variance 
random-effects model for the meta-analyses. We did not include all studies in the 
quantitative synthesis. Under Included studies, subheading ‘Interventions’, we give a 
summary of which agents are included in the analyses. 
We synthesized data on OS and PFS in meta-analyses, and we summarized data on 
toxicity and quality of life. We present the results on toxicity and quality of life narratively 
for the main comparison but not for the subcomparisons.







Subgroup analysis and investigation of heterogeneity
For the main objective, we identified six subcomparisons. In subcomparison 1, 
we investigated chemotherapy or targeted therapy plus BSC versus BSC alone. In 
subcomparison 2, we investigated the effect of the intervention for second-line 
chemotherapy or targeted therapy. For subcomparison 3, we included only interventions 
with a chemotherapy drug. For subcomparison 4, we included only interventions with a 
targeted therapy agent. For subcomparison four, we identified three further subgroups. 
The first subgroup, 4a, consisted of studies that investigated regimens containing EGFR-
targeting agents versus those containing a non-EGFR-targeting agent. The second 
subgroup, 4b, consisted of studies that investigated cetuximab versus non-cetuximab 
containing regimens. The third subgroup, 4c, consisted of studies that investigated 
regimens that contained ramucirumab versus those that did not. In subcomparison 5, 
we investigated chemotherapy or targeted therapy agent(s) plus control intervention 
versus control intervention alone in people with adenocarcinoma of the esophagus. 
In subcomparison 6, we assessed the same comparison for people with SCC of the 
esophagus. 
Sensitivity analysis
A potential effect modifier in the meta-analyses was the inclusion of studies that included 
participants with gastric cancer. If the effect of the interventions investigated in the 
included studies were similar for both participants with esophageal or GE-junction 
cancer versus participants with gastric cancer, it would have been reasonable to include 
studies involving participants with any of these cancers and which did not report results 
separately for these groups. Thereto, we investigated eligibility for inclusion into the 
quantitative synthesis by assessing the effect of the interventions on both the esophageal 
and GE-junction versus the gastric cancer subgroups. We compared all studies included 
in the meta-analysis of the main comparison for OS (including only esophageal and 
GE-junction) to a group of studies that had included participants with esophageal, GE-
junction, and gastric cancer, through a random-effects meta-regression analysis using 
the R statistical computing software (R 2014). In this meta-regression analysis, the 
interventions in both groups of studies were not similar. Therefore, we performed a second 
meta-regression analysis that focused on studies reporting the effect of the intervention on 
OS for esophageal and GE-junction cancer groups and gastric cancer groups separately. If 
non-significant heterogeneity existed between the two groups of participants, we included 
studies containing a subset of eligible participants for the main analysis. 
Summary of findings tables
We used the GRADE system to assess the quality of evidence for each analysis (Guyatt 
2008), presenting our assessments in ‘Summary of findings’ tables using Review Manager 
5 (RevMan 2014). The GRADE system describes the quality of evidence based on how 
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confident the authors are that an estimate of effect reflects the comparison being assessed. 
The quality of evidence considers study limitations, inconsistent results, indirectness of 
evidence, imprecision, and publication bias. We present the synthesized data and these 
assessments in ‘Summary of findings’ tables, using Review Manager 5 (RevMan 2014). 
Results
Description of  studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics 
of studies awaiting classification; Characteristics of ongoing studies. 
Results of the search
We retrieved 5786 unique records and excluded 5571 after screening title and abstract. 
We excluded 69 (see Excluded studies and Figure 1). The quantitative synthesis includes 
41 studies. We added a total of 46 and 49 potential new studies of interest to a list of 
‘Studies awaiting classifications’ and ‘Ongoing studies’, respectively. We will assess these 
and incorporate as appropriate in the next version of this review. 
Included studies
Eleven studies in 1347 participants contributed data to the meta-analysis of the main 
comparison: chemotherapy or targeted therapy agent(s) plus control intervention 
versus control intervention alone. For more details about the included studies, see 
Characteristics of included studies. We performed six subcomparisons, described below.
Participants
The median age of participants in the population included in the meta-analyses was 60 
years (range 53 to 72 years). The proportion of participants reported as having metastatic 
disease ranged from 69% in (Al-Batran 2013) to 100% in (Nicolaou 1982). We could 
not extract the percentage of people with metastasis in 5 out of 19 studies included in 
the meta-regression analyses. For information on individual studies, see Characteristics 
of included studies. 
With regard to baseline differences, we saw a five-year difference in median age between 
the study arms in one trial (Rao 2010). In another, the proportion of the metastatic 
sites involved per participant was not similar at baseline: 29% of participants in the 
intervention group had one site involved, compared to 58% in the BSC group (Thuss-
Patience 2011). Performance status was well balanced in all studies, with no differences 
greater than 15% between study arms. The percentage of participants with ECOG-2 or 
-3 was in the range of 0% to 35%.







Figure 1. Study fl ow diagram: review update.
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Seven studies included in the meta-analyses took place completely or partially in Asia 
(Bang 2010); (Fuchs 2014); (Huang 2009); (Lordick 2013); (Ohtsu 2011); (Shen 2014); 
(Wilke 2014), (Xu 2013). One study was translated from Chinese (Huang 2009).
Two studies selected participants based on biomarker expression. The effect of a targeted 
therapeutic can be expected to depend on the presence of the target in the tumor. The 
first included only EGFR-positive participants (Lorenzen 2009). The second included 
only participants that were eligible if their tumor samples, stained with HER2, were 
scored as 3 or more on immunohistochemistry or if they tested positive using fluorescent 
in situ hybridization (FISH) analysis (HER2:CEP17 ratio X 2) (Bang 2010). The results 
of these studies cannot be extrapolated to people that do not have biomarker expression 
as defined by these studies.
Comparisons
Main comparison
Eleven studies contributed data to the meta-analysis for the main comparison: 
chemotherapy or targeted therapy agent(s) plus control intervention versus control 
intervention alone in people with esophageal and GE-junction cancer. Trials used the 
following agents: 5-FU (Bleiberg 1997), 5-FU and cisplatin (Levard 1998), cetuximab 
(Lordick 2013); (Lorenzen 2009), cyclophosphamide and doxorubicin (Nicolaou 
1982), docetaxel (Ford 2014), gefitinib (Dutton 2014), ramucirumab (Fuchs 2014); 
(Wilke 2014), Shenyi Capsule (Huang 2009), and trastuzumab (Bang 2010). Six 
studies were first-line therapy regimens (Bang 2010); (Bleiberg 1997); (Levard 1998); 
(Lordick 2013); (Lorenzen 2009); (Nicolaou 1982), one was a mixed therapy (Huang 
2009), and the others were second-line treatments. Three studies were included in the 
main comparison but did not provide enough detail for inclusion in the meta-analysis 
(Eatock 2013); (Wilkes 2011); (Xu 2013).
Sensitivity analysis
We compared the effect of the intervention in the studies of the main comparison to the 
effect of intervention in the studies that also included gastric cancer participants. These 
studies investigated: bevacizumab (Ohtsu 2011); (Shen 2014), cetuximab (Richards 
2013), docetaxel (Al-Batran 2013), irinotecan (Thuss-Patience 2011), matuzumab 
(Rao 2010), mitomycin (Tebbutt 2002), and rilotumumab (Iveson 2014). Six studies 
were first-line therapies (Al-Batran 2013); (Iveson 2014); (Ohtsu 2011), (Rao 2010); 
(Shen 2014); (Tebbutt 2002), and two were mixed or unclear (Richards 2013); 
(Thuss-Patience 2011). The subsequent meta-regression analysis focused on studies 
that reported the effectiveness of the intervention for GE-junction and gastric cancer 
participants separately. We made a direct comparison with regard to the effectiveness 
of treatment on these two subgroups in five studies: (Bang 2010) (trastuzumab), (Ford 







2014) (docetaxel), (Fuchs 2014) (ramucirumab), (Lordick 2013) (cetuximab), and 
(Wilke 2014) (ramucirumab). Two studies focused on first-line therapy regimens (Bang 
2010); (Lordick 2013), and three used second-line therapies (Ford 2014); (Fuchs 2014); 
(Wilke 2014). SCCs were not included in any of these studies.
Subcomparison 1
Five studies investigated chemotherapy or targeted therapy plus BSC versus BSC, using 
the following agents: cyclophosphamide plus doxorubicin (Nicolaou 1982), 5-FU 
plus cisplatin (Levard 1998), docetaxel (Ford 2014), ramucirumab (Fuchs 2014), and 
gefitinib (Dutton 2014). Two studies were first-line therapy regimens (Nicolaou 1982); 
(Levard 1998), and the others were second-line regimens.
Subcomparison 2
Four studies investigated second-line therapy regimens. (Dutton 2014) investigated 
gefitinib in participants with progression after chemotherapy and excluded participants 
receiving either cytotoxic chemotherapy, immunotherapy, hormonal therapy, or 
radiotherapy to the site of measurable or evaluable disease within the four weeks prior 
to inclusion. (Ford 2014) investigated docetaxel in a participant population with 
documented disease progression during or within six months of treatment with platinum 
and fluoropyrimidine-based treatment. These participants were not allowed to have had 
previous chemotherapy with a taxane. (Fuchs 2014) investigated ramucirumab in a 
participant population with disease progression either within four months of the last 
dose of first-line platinum-containing or fluoropyrimidine-containing chemotherapy 
for metastatic disease, or within six months of the last dose of platinum-containing 
or fluoropyrimidine-containing adjuvant treatment. (Wilke 2014) investigated 
ramucirumab with participants that had disease progression during or within four 
months of the last dose of first-line platinum and fluoropyrimidine doublet.
Subcomparison 3
Five studies compared a chemotherapy agent(s) plus control intervention versus control 
intervention, using the following agents: 5-FU (Bleiberg 1997), 5-FU plus cisplatin (Levard 
1998), docetaxel (Ford 2014), cyclophosphamide plus doxorubicin (Nicolaou 1982), and 
Shenyi Capsule (Huang 2009). Three studies were first-line therapy regimens (Bleiberg 
1997); (Levard 1998); (Nicolaou 1982), one used mixed therapies (Huang 2009), and 
one a second-line regimen (Ford 2014). One study included in the subcomparison did not 
provide enough detail for inclusion in the meta-analysis (Wilkes 2011).
Subcomparison 4
Six studies compared a targeted therapeutic agent plus control intervention versus 
control intervention alone, testing the following agents: cetuximab (EGFR) (Lordick 
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2013); (Lorenzen 2009), gefitinib (tyrosine kinase inhibitor for EGFR) (Dutton 2014), 
ramucirumab (VEGFR2) (Fuchs 2014); (Wilke 2014), and trastuzumab (HER2) 
(Bang 2010). Three studies focused on first-line regimens (Bang 2010); (Lordick 2013); 
(Lorenzen 2009), and the others used second-line therapies. One study was included in 
the subcomparison but did not provide enough detail for inclusion in the meta-analysis 
(Xu 2013).
Subgroup 4a. Three studies investigated EGFR-targeting agents plus control intervention 
versus control intervention alone (Dutton 2014); (Lordick 2013); (Lorenzen 2009). 
Two studies were first-line therapies (Lordick 2013); (Lorenzen 2009), and one was a 
second-line regimen (Dutton 2014). One study was included in the subgroup but did 
not provide enough detail for inclusion in the meta-analysis (Xu 2013).
Subgroup 4b. Two studies investigated the EGFR-targeting agent cetuximab plus control 
intervention versus control intervention alone, both with first-line therapy regimens 
(Lordick 2013); (Lorenzen 2009).
Subgroup 4c. Two studies compared VEGFR2-targeting agent ramucirumab plus 
control intervention versus control intervention alone, both with second-line therapies 
(Fuchs 2014); (Wilke 2014).
Subcomparison 5
Five studies investigated chemotherapy or targeted therapy agent(s) plus control 
intervention versus control intervention alone in participants with adenocarcinoma of 
the esophagus, using the following agents: trastuzumab (Bang 2010), docetaxel (Ford 
2014), ramucirumab (Fuchs 2014), cetuximab (Lordick 2013), and ramucirumab 
(Wilke 2014). Two studies were first-line therapy regimens (Bang 2010); (Lordick 
2013), and three were second-line therapies (Ford 2014); (Fuchs 2014); (Wilke 2014). 
One study was included in the subcomparison but did not provide enough detail for 
inclusion in the meta-analysis (Eatock 2013).
Subcomparison 6
Five studies investigated chemotherapy or targeted therapy agent(s) plus control 
intervention versus control intervention alone in participants with SCC of the esophagus, 
using 5-FU (Bleiberg 1997), 5-FU and cisplatin (Levard 1998), cetuximab (Lorenzen 
2009), doxorubicin (Nicolaou 1982), and gefitinib (Dutton 2014). Four studies were 
first-line therapy regimens (Bleiberg 1997); (Levard 1998); (Lorenzen 2009), (Nicolaou 
1982), and one was a second-line therapy (Dutton 2014). One study was included in 
the subcomparison but did not provide enough detail for inclusion in the meta-analysis 
(Xu 2013).







We describe all interventions in detail, along with the type and location of the tumors, 
in the Characteristics of included studies. We defined second-line therapy studies as 
including only participants that had received previous chemotherapy or targeted therapy 
within six months of starting the study regimen, including adjuvant therapy.
Studies excluded from the comparisons
Five studies included only eligible participants, however, these studies were not eligible 
for inclusion in any of our comparisons. (Waddell 2013) studied panitumumab 
and adjusted the control regimen of epirubicin, oxaliplatin, and capecitabine in the 
experimental arm. One study was not eligible because it compared leucovorin and 
5-FU versus S-1 on a background of cisplatin (Pang 2014). Three studies used an equal 
number of agents in each arm. These studies compared: atofluding versus Morafur on a 
background of either mitomycin C plus etoposide, cisplatin plus hydroxycamptothecin, 
cisplatin plus vindesine, or mitomycin C plus adriamycin (Li 2002), epirubicin versus 
mitomycin on a background of cisplatin plus 5-FU (Ross 2002), and adriamycin versus 
methotrexate or 5-FU (Ezdinli 1980).
There were 15 studies that also included participants with gastric cancer that we excluded 
from the comparisons because they did not compare the addition of an agent to an 
unaltered control regimen. These studies compared: S1 versus 5-FU on a background 
of cisplatin (Ajani 2010); oxaliplatin versus cisplatin on a background of 5-FU plus 
leucovorin (Al-Batran 2013); cisplatin versus oxaliplatin on a background of epirubicin 
plus 5-FU or capecitabine, and 5-FU versus capecitabine on a background of epirubicin 
plus cisplatin or oxaliplatin (Cunningham 2008); irinotecan plus folinic acid versus 
cisplatin on a background of 5-FU (Dank 2008); continuous 5-FU plus cisplatin 
versus bolus 5- FU plus leucovorin (Duffour 2006); irinotecan versus cisplatin on a 
background of capecitabine (Moehler 2010); 5-FU versus cisplatin on a background 
of irinotecan (Pozzo 2004); irinotecan versus 5- FU on a background of docetaxel 
(Roy 2012); and epirubicin plus cisplatin versus doxorubicin plus methotrexate on a 
background of 5-FU (Waters 1999). Five studies did add an agent to a control regimen 
but adjusted their control regimens in the experimental arm. They investigated docetaxel 
plus cisplatin (Ajani 2005); docetaxel plus oxaliplatin, either with or without 5-FU (Van 
Cutsem 2015); lapatinib (Lorenzen 2009); docetaxel plus oxaliplatin with or without 
capecitabine (Van Cutsem 2015); or cisplatin and 5-FU with or without docetaxel (Van 
Cutsem 2006). One study was not eligible for inclusion because it tested two agents 
(cisplatin, 5-FU) versus one agent (capecitabine) (Tebbutt 2010).
In order to analyze the data from studies with a mixed participant population, including 
both eligible and ineligible participants, we requested individual participant data from 
authors of studies that we included after the search round of 3 October 2013. Only one 
author responded and provided individual participant data. Subsequently, we decided 
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to investigate the information from the studies that included both esophageal and/or 
GE-junction, mixed with gastric cancer participants, in a sensitivity analysis to assess the 
influence of gastric cancer participants on the outcome of the individual studies.
Outcomes
OS and toxicity were the most commonly described outcomes, followed by PFS, time to 
progression (TTP), and objective response rate. Studies did not always classify toxicity 
according to NCI-CTC or WHO. Studies published before 2010 did not report quality 
of life with validated methods, and where reported, authors did not always report this 
outcome separately for esophageal and GE-junction cancer subgroups.
Excluded studies
See Characteristics of excluded studies. We updated and revised the search for this 
version of the review. We excluded 5571 records based on their title and abstract as well 
as another 69 articles after reading the full text. The most frequent reason for exclusion 
was because the study turned out not to involve esophageal of GE-junction cancer 
participants. The reasons for exclusion are further specified in Figure 1 according to the 
recommendations of the PRISMA statement (Moher 2009). We included studies that 
contained non-eligible participants as well as eligible participants. However, we excluded 
two studies that contained only nine and four eligible participants (Cascinu 2011); (Li 
2011), respectively), as they did not provide sufficient data. We also excluded (Koizumi 
2014) because authors did not specify the number of participants with GE-junction 
cancer. Additionally, we excluded several studies currently published as abstracts only, 
because full information on risk of bias and/or data on the esophageal and GE-junction 
cancer subgroup were unavailable. We classified these as ‘Studies awaiting classification’.
Risk of  bias in included studies
For details on the included studies see Characteristics of included studies and the 
summary figure of the quality assessment (Figure 2). Investigators performed and 
described blinding in 8 out of 41 studies. This poses a certain risk of bias in many of the 
included studies.
Allocation
Studies frequently failed to describe allocation concealment, and six studies did not 
describe the method of random sequence generation.
Blinding
Two studies evaluated progression using a blinded independent review board (Lordick 
2013); (Rao 2010). We did not downgrade the GRADE level of evidence for the primary 







Figure 2. Risk of bias summary: review authors’ judgements 
about each risk of bias item for each included study.
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outcome, OS, due to lack of binding or mentioning of blinding in the study report. 
This because we assume knowledge of allocation has limited effect on survival and the 
detection of survival and would, thus, not induce performance or detection bias. Seven 
studies described use of an external review board but did not describe blinding (Ajani 
2005); (Ajani 2010); (Duffour 2006); (Pozzo 2004); (Roy 2012); (Tebbutt 2010); (Van 
Cutsem 2006).
Incomplete outcome data
Incomplete outcome data with risk of attrition bias was present in a few included 
studies, either because there was no intention to- treat analysis (Li 2002); (Moehler 
2010); (Pang 2014); (Pozzo 2004); (Van Cutsem 2006); (Xu 2013), or because authors 
did not describe dropouts (Li 2002); (Xu 2013).
Selective reporting
Risk of reporting bias was present in one study (Ross 2002), where authors reported 
the data in esophageal participants separately for overall response rate but not for other 
outcomes. We did not consider studies that reported overall survival for esophageal 
participants separately and did not report on other outcome measures to be at high risk 
of reporting bias, as overall survival was the primary endpoint of analysis in this review. 
Other potential sources of bias
We considered that four studies had groups that were not similar at baseline. This was 
due to age difference (Rao 2010), number of organs involved in metastatic disease 
(Lorenzen 2009, Thuss-Patience 2011), or both (Ezdinli 1980). We assessed small study 
effects, such as publication bias, in a qualitative manner using a funnel plot for the main 
analysis, but we found no evidence that these effects were present.
Effects of  interventions
See: Summary of findings for the main comparison Summary of findings table: 
chemotherapy or targeted therapy agent(s) plus control intervention versus control 
intervention alone for palliative treatment of esophageal and GE-junction carcinoma; 
Summary of findings 2 Summary of findings table (sensitivity analysis): interventions 
esophageal and GE-junction carcinoma versus gastric carcinoma; Summary of findings 
3 Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus 
best supportive care (BSC) versus BSC for palliative treatment of esophageal and GE-
junction carcinoma; Summary of findings 4 Summary of findings table (subcomparison 
2): second-line chemotherapy or targeted therapy agent(s) plus control intervention 
versus control intervention alone for palliative treatment of esophageal and GE-
junction carcinoma; Summary of findings 5 Summary of findings table (subcomparison 







3): chemotherapy agent(s) plus control intervention versus control intervention 
alone for palliative treatment of esophageal and GE-junction carcinoma; Summary 
of findings 6 Summary of findings table (subcomparison 4): targeted therapy agent 
plus control intervention versus control intervention alone for palliative treatment of 
esophageal and GE-junction carcinoma; Summary of findings 7 Summary of findings 
table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control 
intervention versus control intervention alone in participants with AC of the esophagus; 
Summary of findings 8 Summary of findings table (subcomparison 6): chemotherapy or 
targeted therapy agent(s) plus control intervention versus control intervention alone in 
participants with SCC of the esophagus
Main analysis: chemotherapy or targeted therapy agent(s) plus control intervention versus control 
intervention alone
Overall survival
Eleven studies in 1347 participants contributed data to this meta-analysis (Bang 2010); 
(Bleiberg 1997); (Dutton 2014); (Ford 2014); (Fuchs 2014); (Huang 2009); (Levard 
1998); (Lordick 2013); (Lorenzen 2009); (Nicolaou 1982); (Wilke 2014). These studies 
included only people with esophageal and/or GE-junction cancer, or they reported the 
results separately for this group. The overall HR in favor of the arm with the additional 
agent was 0.75 (95% CI 0.68 to 0.84, high-quality evidence), showing an OS benefit 
(Analysis 1.1; Figure 3). On average, participants in the arm with the additional 
chemotherapy or targeted therapy agent received 2.1 chemotherapy or targeted therapy 
Figure 3. Forest plot of the main analysis: chemotherapy or targeted therapy agent(s) plus control arm 
versus control arm, outcome: 1.1 Overall survival.
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Figure 4. Funnel plot of the main comparison: chemotherapy or targeted therapy agent(s) plus control arm 
versus control arm, outcome: 1.1 Overall survival.
agents, versus an average of 1.0 agents in the control arms. Median OS, weighted for 
study size, in the arm with the additional agent was 6.7 months versus 5.7 months in 
the control arm. We could not include two studies because they did not report median 
overall survival data (Bang 2010); (Huang 2009). Cochrane’s Q test for heterogeneity 
showed a non-significant amount of heterogeneity (I2=5%, p=0.40), which indicated 
that results of the different studies were consistent in their findings. We did not note any 
small study effects such as publication bias (Figure 4). 
Two studies included in the meta-analysis selected participants based on biomarker 
expression (Lorenzen 2009, Bang 2010). We could not include three studies under this 
comparison in the meta-analysis because of insufficient information. (Eatock 2013) 
investigated trebananib. Median OS times at the time of analysis were 9.1 months, 
9.4 months, and 12.8 months for the 10.0 mg/ kg, 3.0 mg/kg, and control arms, 
respectively. (Wilkes 2011) studied thalidomide and reported that survival was not 
affected by group allocation. (Xu 2013) found higher, statistically significant (p<0.05) 
OS in the nimotuzumab group relative to the control group.
Progression-free survival
Of all studies included in this comparison, only studies that investigated a targeted 
therapy agent reported PFS. Therefore, we describe the results of this analysis in more 







detail under subcomparison 4, ‘Progression-free survival’. The analysis contained five 
studies in 883 participants. The addition of a targeted therapeutic agent probably leads 
to an HR of 0.64 (95% CI 0.45 to 0.92, moderate-quality evidence; Analysis 1.2; Figure 
5). (Eatock 2013) investigated trebananib in esophageal adenocarcinoma participants 
but did not provide enough detail for inclusion in the meta-analysis. Median PFS times 
at the time of analysis were 4.2 months, 4.9 months, and 5.2 months for the 10.0 mg/
kg, 3.0 mg/kg, and control arms, respectively.
Toxicity
All 11 studies included in the main analysis reported on toxicity. All studies reported 
the frequency of toxic effects, although not all used WHO or NCI-CTC guidelines. 
Five studies did not report toxicity for the esophageal and GE-junction cancer subgroup 
separately (Bang 2010); (Ford 2014); (Fuchs 2014); (Lordick 2013); (Wilke 2014). 
Therefore, in this review, we only compared toxicity between study arms, not between 
studies. (Nicolaou 1982) and (Levard 1998) did not use WHO or NCI-CTC guidelines. 
All other studies used NCI-CTC, except for two that used WHO guidelines (Bleiberg 
1997); (Huang 2009).
In (Bang 2010), the most common grade 3 and 4 adverse events reported with tras-
tuzumab plus chemotherapy versus chemotherapy alone were neutropenia (27% 
versus 30%), anemia (12% versus 10%), and diarrhea (9% versus 4%). Treatment-
related mortality was 3% in the trastuzumab plus chemotherapy arm, versus 1% in the 
chemotherapy alone arm. (Bleiberg 1997) reported that grade 3 and 4 adverse events 
occurred most frequently in the 5-FU cisplatin arm versus the cisplatin alone arm. These 
were nausea or vomiting (27% versus 11%) and leukocytopenia and thrombocytopenia 
(both 12% versus 0%). Seven (16%) treatment related deaths occurred in the treatment 
arm. (Dutton 2014) reported that any grade 3, 4, or 5 toxicities occurred in 45% of 
Figure 5. Forest plot of the main analysis: chemotherapy or targeted therapy agent(s) plus control arm 
versus control arm, outcome: 1.2 Progression free survival.
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participants in the gefitinib plus control arm versus 39% of participants in the control 
arm. Two treatment-related deaths occurred in the placebo group and one in the gefitinib 
group. (Ford 2014) found that grade 4 toxicities occurred more frequently in participants 
treated with docetaxel compared to participants in the control arm (21% versus 4%). 
Neutropenia, infections, and febrile neutropenia were the toxicities that differed most 
between the study arms. None of the deaths were attributed to the treatment. In 
both arms of (Fuchs 2014), 2% of the participants died due to drug-related toxicity. 
Ramucirumab was not associated with increased rates of fatigue, decreased appetite, 
vomiting, anemia, or other notable toxic effects. (Huang 2009) used WHO guideline 
classifications but did not specify the grade of the side effects that occurred. In (Lordick 
2013), any grade 3 or 4 adverse events occurred in 83% of participants in the cetuximab 
plus control arm versus 77% in the control arm. Nine per cent of participants in the 
chemotherapy plus cetuximab arm and eight per cent of participants in the control 
arm had an adverse event leading to death. (Lorenzen 2009) reported that grade 3 
and 4 adverse events, which occurred more frequently in the cetuximab group, were 
diarrhea (16% versus 0%), neutropenia (22% versus 13%), and rash (6% versus 0%). 
Additionally, they reported one (3%) treatment related death in the control arm and 
none in the experimental arm. (Wilke 2014) found that the most frequently occurring 
grade 3, 4, and 5 adverse events in the ramucirumab arm versus the control arm were 
neutropenia (41% versus 19%), leukopenia (18% versus 7%), and hypertension (15% 
versus 3%). In both arms, 2% of participants had adverse events leading to death with 
a causal relation to the study drugs.
Overall, palliative chemotherapy and/or targeted therapy appears to increase the 
frequency of treatment-related toxicity of at least grade 3. Treatment-related deaths were 
rare in most studies, and there is no clear evidence that treatment-related deaths occur 
more frequently in the study arms with an additional chemotherapy or targeted therapy 
agent.
Quality of life
Five studies included in the main analysis did not report on quality of life (Bleiberg 
1997); (Lordick 2013); (Lorenzen 2009); (Nicolaou 1982); (Wilkes 2011). Four 
studies did not report quality of life separately for the esophageal and GE-junction 
cancer subgroup (Bang 2010); (Ford 2014); (Fuchs 2014); (Wilke 2014). Two studies 
reported on quality of life but did not use validated methods (Huang 2009); (Levard 
1998). (Huang 2009) used improvement after treatment in the treatment arm versus 
the control arm for the Karnofsky score (33% versus 10%) and body weight (27% 
versus 6.7%). (Levard 1998) studied dysphagia in order to judge the quality of life 
during the survival of their participants. (Bang 2010), see (Satoh 2014) reported that 
trastuzumab plus chemotherapy versus chemotherapy alone prolonged time to 10% 
definitive deterioration in all QLQ-C30 and QLQ-STO22 scores (Aaronson 1993); 







(Blazeby 2004), including QLQ-C30 global quality of life score, from 6.4 months to 
10.2 months. (Dutton 2014) reported no differences between the gefitinib and placebo 
groups in global quality of life measured with QLQC30. However, odynophagia 
worsened for participants on placebo and improved significantly for participants on 
gefitinib. (Ford 2014) reported that the mean quality-adjusted life weeks (QLQ-C30) 
were 12.1 weeks (standard deviation (SD) 0.84) for the docetaxel group and 9.3 weeks 
(SD 0.73) for the control group. (Fuchs 2014) reported a trend toward better quality 
of life (QLQ-C30) at six weeks for participants in the ramucirumab group compared 
to those in the placebo group (p=0.23). Median time of deterioration to a score of 2 or 
worse in ECOG performance status was 2.4 months (95% CI 1.3 to not reached) in the 
placebo group and 5.1 months (95% CI 1.9 to 16.8) in the ramucirumab group. (Wilke 
2014) reported that baseline and end-of-treatment results for global quality of life from 
the QLQ-C30 and index scores from the EQ-5D-3L were similar in the treatment 
groups (EuroQol 1990). Overall, the studies reporting quality of life did so in different 
ways. Although recent studies often use the QLQ-C30, the outcomes were reported 
in the form of either mean values with SD, change from the baseline, proportions 
improved, or mean area under the curve. This prohibited a meta-analysis of quality of 
life outcomes. The five studies were not representative for all the studies in this analysis, 
as four of them tested a targeted agent, and four did not report data separately for the 
esophageal and GE-junction cancer subgroup. However, the quality of life improved in 
the arms with the additional agent. 
Sensitivity analysis: effect of the intervention in participants with esophageal and GE-junction cancer 
versus gastric cancer 
We conducted this sensitivity analysis to investigate whether there was a significant 
difference in the effect of the intervention between both the participants with esophageal 
and GE-junction cancer and the participants with gastric cancer. The sensitivity analysis 
consisted of two parts, both regarding OS. Firstly, we compared the group of studies 
that included participants with both esophageal/GE-junction and gastric cancer to the 
group of studies that included only participants with esophageal and GE-junction cancer 
through a meta-regression analysis. In this meta-regression analysis, the interventions 
between groups of studies were not similar, making the comparison indirect. Therefore, 
we performed a second sensitivity analysis, also by meta-regression, which focused on 
five studies that reported the effect of the intervention on OS for participant groups 
with both GE-junction and gastric cancer separately. 
For the first part of the sensitivity analysis, we meta-analyzed the group of studies that 
included participants with both esophageal/ GE-junction and gastric cancer. This group 
contained eight studies and 1755 participants, 459 of whom had esophageal or GE-
junction cancer (Al-Batran 2013); (Iveson 2014); (Ohtsu 2011); (Rao 2010); (Richards 
2013); (Shen 2014); (Tebbutt 2002); (Thuss-Patience 2011). (Iveson 2014) investigated 
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rilotumumab at two concentrations, 7.5 mg/kg and 15 mg/kg. The HR that we used in 
the meta-analysis was derived from both groups versus the control arm. In this analysis, 
the overall HR, in favor of the arm with the additional agent was 0.94 (95% CI 0.83 
to 1.05), showing a trend toward a survival benefit in the arm with the additional agent 
versus the control arm (Analysis 2.1). Cochrane’s Q test for heterogeneity showed a 
considerable amount of heterogeneity (I2=54%, p=0.03), which indicated that results of 
the different studies were somewhat inconsistent in their findings.
We performed a meta-regression analysis to compare the effect of the intervention in 
studies involving participants with esophageal and GE-junction cancer (main analysis 
group, HR 0.75, 95% CI 0.68 to 0.84, high-quality evidence), versus studies in 
participants with both gastric and esophageal/GE-junction cancer (HR 0.94, 95% CI 
0.83 to 1.05). This meta-regression analysis showed that there was a difference in the 
effect of intervention between the two groups of studies (p=0.004).
For the second part of the sensitivity analysis, we assessed the group of studies reporting 
the effect of the intervention on OS for participants with both GE-junction and gastric 
cancer separately in two meta-analyses, each containing five studies (Bang 2010); 
(Ford 2014); (Fuchs 2014); (Lordick 2013); (Wilke 2014). The meta-analysis of the 
participant subgroups with GE-junction cancer contained 538 participants. The meta-
analysis of the participant subgroups with gastric cancer contained 2093 participants. 
The effect of adding a chemotherapeutic or targeted therapeutic agent in the participant 
subgroups with GE-junction cancer on OS in these studies was HR 0.66 (95% CI 0.54 
to 0.81; Analysis 3.1). The effect of adding a chemotherapeutic or targeted therapeutic 
agent to the participant subgroups with gastric cancer in these studies was HR 0.89 
(95% CI 0.76 to 1.04; Analysis 3.2). That said, this was a selected group of participants 
with gastric cancer, so this meta-analysis might not accurately reflect the effect of 
adding a chemotherapeutic or targeted agent to the control regimen of participants 
with gastric cancer in general. This meta-analysis was not meant to be exhaustive with 
regard to the effect of chemotherapy or targeted therapy in people with gastric cancer. 
For more information, see Wagner 2010. We performed a meta-regression analysis 
between these groups, which indicated that both participant subgroups responded 
significantly differently to the investigated interventions (p=0.03), in line with the first 
part of the sensitivity analysis. This meta-regression analysis indicated that the studied 
interventions appeared to result in an increased beneficial effect on OS in participants 
with GE-junction cancer compared to participants with gastric cancer. Therefore, we 
excluded the studies that also included participants with gastric cancer and did not 
report outcomes separately from the meta-analyses of this review.







Subcomparison 1: chemotherapy or targeted therapy plus BSC versus BSC
Overall survival
Five studies in 750 participants contributed data to this meta-analysis (Dutton 2014); 
(Ford 2014); (Fuchs 2014); (Levard 1998); (Nicolaou 1982). For overall survival, we 
found an HR of 0.81 (95% CI 0.71 to 0.92, high-quality evidence; Analysis 4.1; Figure 
6) in favor of the chemotherapy or targeted therapy arm. Median OS, weighted for 
study size, in the chemotherapy arm was 4.7 months versus 4.2 months in the BSC 
arm. Only two studies used first-line therapies (Levard 1998); (Nicolaou 1982), while 
the others used second-line. Cochrane’s Q test for heterogeneity was non-significant 
(I2=0%, p=0.56), which indicated that results of the five studies were consistent in their 
findings. 
Figure 6. Forest plot of subcomparison 1: chemotherapy or targeted therapy agent(s) plus BSC versus BSC, 
outcome 4.1: overall survival.
Progression-free survival
Two studies in 540 participants contributed data to this meta-analysis (Dutton 2014); 
(Fuchs 2014)). Both studies assessed a targeted therapeutic agent. The other three 
studies did not report on PFS. The overall HR of 0.58 (95% CI 0.28 to 1.18, very low 
quality evidence; Analysis 4.2; Figure 7) in favor of targeted therapy demonstrated that 
there was a larger, non-significant effect estimate toward a PFS benefit when participants 
received targeted therapy; however, we are uncertain of these findings due to the very low 
quality of evidence. Median progression-free survival was only available from (Dutton 
2014) and was 1.6 months in the targeted therapy arm versus 1.2 months in the BSC 
arm. Cochrane’s Q test for heterogeneity showed significant heterogeneity (I2=85%, 
p=0.01), which indicated that results of the two studies were not consistent. 
Subcomparison 2: participants who had received previous chemotherapy
We intended for this subcomparison to investigate whether chemotherapy or targeted 
therapy for participants that had previously received chemotherapy resulted in a benefit 
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for overall survival, progression-free survival, or both. We did not include studies if only 
some of the participants had received previous chemotherapy. For a description of criteria 
used for including studies with regard to previous chemotherapy, see Characteristics of 
included studies, ‘Partipants’ section.
Overall survival
This meta-analysis included four studies in 769 participants (Dutton 2014); (Ford 
2014); (Fuchs 2014); (Wilke 2014). Three studies included participants with GE-
junction cancer only. In (Dutton 2014), 24% of the esophageal cancers were SCC. 
Two studies investigated ramucirumab (Fuchs 2014); (Wilke 2014), which we analyzed 
separately in subgroup analysis 4b. The overall HR of 0.71 (95% CI 0.54 to 0.94, 
moderate-quality evidence; Analysis 5.1) in favor of the arm with the additional agent 
demonstrated that an additional chemotherapeutic or targeted agent leads to a survival 
benefit. Median OS, weighted for study size, was 5.1 months in the chemotherapy 
arm versus 4.4 months in the BSC arm. Cochrane’s Q test for heterogeneity showed 
significant heterogeneity (I2=57%, p=0.07), indicating that results of the three included 
studies were quite inconsistent in their findings.
Progression-free survival
Three studies in 677 participants contributed data to this meta-analysis (Dutton 2014); 
(Fuchs 2014); (Wilke 2014). All three studies investigated targeted agents. Two studies 
(both of ramucirumab) included participants with GE-junction cancer only. In the third 
study, 24% of the esophageal cancers were SCC. The overall HR of 0.51 (95% CI 
0.29 to 0.90, low-quality evidence; Analysis 5.2) in favor of the targeted therapy arms 
demonstrated that there may be a PFS benefit for people receiving targeted therapy 
agents. Cochrane’s Q test for heterogeneity showed substantial heterogeneity (I2=83%, 
p<0.001), which indicated that results of the three studies were inconsistent in their 
findings.
Figure 7. Forest plot of subcomparison 1: chemotherapy or targeted therapy agent(s) plus BSC versus BSC, 
outcome 4.1: progression free survival.







Subcomparison 3: chemotherapy agent(s) plus control intervention versus control intervention alone
Overall survival
Five studies in 358 participants contributed data to this meta-analysis (Bleiberg 1997); 
(Ford 2014); (Huang 2009); (Levard 1998); (Nicolaou 1982). The overall HR of 0.73 
(95% CI 0.63 to 0.85, moderate-quality evidence; Analysis 1.1; Figure 3, subcomparison 
3) in favor of the arm with the additional chemotherapy agent demonstrates that there 
is probably a significant survival benefit in people receiving an additional chemotherapy 
agent. Median survival time, weighted for study size, was 6.9 months in the chemotherapy 
arm versus 5.8 months in the control arm. We could not include (Huang 2009) in 
the median OS analysis because it did not report this outcome. Cochrane’s Q test for 
heterogeneity showed non-significant heterogeneity (I2=0%, p=0.50), which indicated 
that results of the five studies were consistent in their findings. Considering the limited 
number of studies and the low heterogeneity in the model, we consider that the quality 
of evidence is moderate.
One study included in the comparison did not contribute to the meta-analysis for 
subcomparison 3 for OS because the publication did not provide enough information. 
(Wilkes 2011) only reported that survival was not affected by group allocation or 
whether the participant was able to complete the protocol.
Progression-free survival
None of the four studies reported on PFS.
Subcomparison 4: targeted agent plus control intervention versus control intervention alone
Overall survival
Six studies with 989 participants contributed to this meta-analysis (Bang 2010); (Dutton 
2014); (Fuchs 2014); (Lordick 2013); (Lorenzen 2009); (Wilke 2014). The overall 
HR in favor of the arm containing a targeted agent was 0.75 (95% CI 0.63 to 0.90, 
high-quality evidence. This analysis demonstrated a survival benefit for participants 
randomized to the arm with the additional targeted agents (Analysis 1.1; Figure 3, 
subcomparison 4). Median OS in the arm with the additional targeted agent, weighted 
for study size, was 6.7 months versus 5.7 months in the control arm. We could not 
include (Bang 2010) because it did not report median OS data. Cochrane’s Q test for 
heterogeneity showed low heterogeneity (I2=24%, p=0.25), indicating that results of the 
different studies were quite consistent in their findings.
Two studies included in the meta-analysis selected participants based on biomarker 
expression (Lorenzen 2009, Bang 2010). (Xu 2013) found higher PFS and OS in the 
nimotuzumab group. However, the study did not provide enough information to extract 
HRs, so we could not include it in the analyses.
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Subgroup analysis 4a: EGFR-targeting agent plus control intervention versus control intervention 
alone
Three studies in 655 participants contributed data to this meta-analysis (Dutton 
2014); (Lordick 2013); (Lorenzen 2009). The overall HR of 0.86 (95% CI 0.73 to 
1.01, moderate-quality evidence; Analysis 6.1) in favor of the arms that contained 
an EGFR-targeting agent showed that there is probably a survival benefit in the arm 
with the additional EGFR-targeting agent. Cochrane’s Q test for heterogeneity showed 
no significant heterogeneity (I2=0%, p=0.56), which indicated that results of the four 
studies were very consistent in their findings. Median OS, weighted for study size, 
was 6.4 months in the treatment arm containing an EGFR-targeting agent versus 5.5 
months in the control arm.
One study included in the meta-analysis selected participants based on biomarker 
expression (Lorenzen 2009). (Xu 2013) found higher PFS and the OS in the 
nimotuzumab group. However, the study did not provide enough information to extract 
HRs, so we could not include it in the meta-analysis.
(Waddell 2013) investigated panitumumab. We could not formally include this study in 
the comparison because the control regimen was adjusted in the arm with the additional 
EGFR-targeting agent. This study found that the addition of panitumumab resulted in 
an HR for OS of 1.37 (95% CI 1.07 to 1.76), but readers should interpret these results 
with caution.
Subgroup analysis 4b: cetuximab plus control intervention versus control intervention alone
Two studies in 206 participants contributed data to this meta-analysis (Lordick 2013); 
(Lorenzen 2009). (Lordick 2013) investigated the addition of cetuximab to a control 
arm of capecitabine plus cisplatin; (Lorenzen 2009) used cisplatin plus 5-FU as a control 
regimen. The overall HR of 0.76 (95% CI 0.55 to 1.04, low-quality evidence; Analysis 
7.1) in favor of the cetuximab arm showed that there may be a non-significant survival 
benefit for participants randomized to receive cetuximab. Median OS, weighted for 
study size, was 12.2 months in the cetuximab arm versus 9.4 months in the control 
arm. Cochrane’s Q test for heterogeneity showed nonsignificant heterogeneity (I2=0%, 
p=0.58), which indicated that results of the two studies were consistent in their findings. 
One study included in the meta-analysis selected participants based on biomarker 
expression (Lorenzen 2009).
Subgroup analysis 4c: ramucirumab plus control intervention versus control intervention alone
Two studies in 228 participants contributed data to this meta-analysis (Fuchs 2014); 
(Wilke 2014). (Fuchs 2014) investigated ramucirumab versus BSC, while (Wilke 2014) 
added ramucirumab to paclitaxel. The two studies included only people with GE-
junction cancer who had previously received chemotherapy, so the results of this meta-







analysis are not generalizable to other patient populations. The overall HR of 0.62 (95% 
CI 0.43 to 0.88, moderate quality evidence; Analysis 8.1) in favor of the ramucirumab 
arm showed that there is probably an overall survival benefit. Median OS, weighted for 
study size, was 7.5 months in the ramucirumab arm versus 6.3 months in the control 
arm. Cochrane’s Q test for heterogeneity showed non-significant heterogeneity (I2=28%, 
p=0.24), which indicated that results of the two studies were consistent in their findings.
Progression-free survival
Five studies in 883 participants contributed data to this meta-analysis (Dutton 2014); 
(Fuchs 2014); (Lordick 2013); (Lorenzen 2009); (Wilke 2014). The five studies 
investigated targeted therapies. In this analysis, the overall HR, in favor of the treatment 
arm that contained a targeted therapy agent, was 0.64 (95% CI 0.45 to 0.92, moderate-
quality evidence). This showed that there is probably a PFS benefit for people treated 
with the targeted therapy agent (Analysis 1.2; Figure 5). Median progression-free 
survival, weighted for study size, was 2.9 months in the arm with the additional targeted 
therapy agent versus 2.4 months in the control arm. We could not include two studies 
in the analysis because they did not report median PFS data (Fuchs 2014); (Wilke 
2014). Cochrane’s Q test for heterogeneity showed substantial heterogeneity (I2=79%, 
p<0.001), which indicated that results of the individual studies were quite inconsistent 
in their findings. One study included in the meta-analysis selected participants based on 
biomarker expression (Lorenzen 2009).
Subgroup analysis 4a: EGFR-targeting agent plus control intervention versus control intervention 
alone
Three studies in 655 participants contributed data to this meta-analysis (Dutton 2014); 
(Lordick 2013); (Lorenzen 2009). The overall HR of 0.85 (95% CI 0.73 to 1.00, low-
quality evidence; Analysis 6.2) in favor of the arm with the EGFR-targeting agent 
demonstrated that there may be a non-significant PFS benefit in the arms with the 
EGFR-targeting agents. Cochrane’s Q test for heterogeneity showed non-significant 
results (I2=2%, p=0.36), which indicated that results of the three studies were consistent 
in their findings. Median progression-free survival, weighted for study size, was 2.9 
months in the treatment arm that contained an EGFR-targeting agent versus 2.4 
months in the control arm.
One study included in the meta-analysis selected participants based on biomarker 
expression (Lorenzen 2009). (Waddell 2013) investigated panitumumab, but we could 
not formally include it in the comparison because the control regimen was adjusted in 
the panitumumab arm. The addition of panitumumab resulted in an HR for PFS of 
1.22 (95% CI 0.98 to 1.52), but readers should interpret these results with caution.
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Subgroup analysis 4b: cetuximab plus control intervention versus control intervention alone
Two studies in 206 participants contributed data to this meta-analysis (Lordick 2013); 
(Lorenzen 2009). The overall HR of 0.90 (95% CI 0.59 to 1.37, very low-quality 
evidence; Analysis 7.2) shows a small and very uncertain PFS benefit in favor of the 
cetuximab arm. Median progression-free survival, weighted for study size, was 5.7 
months in the cetuximab arms versus 5.0 months in the control arms. Cochrane’s Q test 
for heterogeneity showed a considerable amount of heterogeneity (I2=53%, p=0.14), 
which indicated that results of the two studies were not very consistent in their findings. 
One study included in the meta-analysis selected participants based on biomarker 
expression (Lorenzen 2009).
Subgroup analysis 4c: ramucirumab plus control intervention versus control intervention alone
Two studies in 228 participants contributed data to this meta-analysis (Fuchs 2014); 
(Wilke 2014). This meta-analysis only applies to GE-junction participants, the only 
participants included. The overall HR of 0.39 (95% CI 0.28 to 0.54, moderate-quality 
evidence; Analysis 8.2) in favor of the ramucirumab arm demonstrated that there was 
probably a PFS benefit in the ramucirumab group. We could not determine median 
PFS, as neither study reported this outcome. Cochrane’s Q test for heterogeneity showed 
nonsignificant heterogeneity (I2=0%, p=0.99), which indicated that results of the two 
studies were very consistent in their findings.
Subcomparison 5: chemotherapy or targeted therapy agent(s) plus control intervention versus con-
trol intervention alone in participants with adenocarcinoma of the esophagus
Overall survival
Five studies in 538 participants contributed data to this meta-analysis (Bang 2010); 
(Ford 2014); (Fuchs 2014); (Lordick 2013); (Wilke 2014). For overall survival, we 
found an HR of 0.66 (95% CI 0.54 to 0.81, high-quality evidence; Analysis 9.1) in 
favor of the experimental arm. Median OS, weighted for study size, was 7.1 months 
in the added agent arm versus 6.0 months in the control arm. We could not include 
(Bang 2010) because it did not report median overall survival data. Two studies were 
first-line therapy regimens (Bang 2010); (Lordick 2013), and three were second-line 
therapies (Ford 2014); (Fuchs 2014); (Wilke 2014). Cochrane’s Q test for heterogeneity 
was non-significant (I2=0%, p=0.55), which indicated that results from the five studies 
were consistent in their findings. (Eatock 2013) investigated trebananib in participants 
with esophageal adenocarcinoma but did not provide enough detail for inclusion in the 
meta-analysis. Median OS at the time of analysis were 9.1 months, 9.4 months, and 
12.8 months for the 10.0 mg/kg, 3.0 mg/kg, and control arms, respectively.








Four studies in 713 participants contributed data to this meta-analysis (Dutton 2014); 
(Fuchs 2014); (Lordick 2013); (Wilke 2014). For progression-free survival, we found an 
HR of 0.62 (95% CI 0.38 to 1.00, very low-quality evidence; Analysis 9.2) in favor of 
the experimental arm; however, we are uncertain of these results due to the low-quality 
evidence. Median OS, weighted for study size, was 1.8 months in the added agent arm 
versus 1.7 months in the control arm. We could not include two studies in the analysis 
because they did not report median PFS data (Fuchs 2014); (Wilke 2014). One study 
was on first-line therapy regimens (Lordick 2013), and three were second-line therapies 
(Dutton 2014); (Fuchs 2014); (Wilke 2014). Cochrane’s Q test for heterogeneity was 
non-significant (I2=84%, p<0.001), which indicated that results of the four studies were 
very inconsistent in their findings. (Eatock 2013) investigated trebananib in participants 
with esophageal adenocarcinoma but did not provide enough detail for inclusion in the 
meta-analysis. Median PFS times at the time of analysis were 4.2 months, 4.9 months, 
and 5.2 months for the 10.0 mg/kg, 3.0 mg/kg, and control arms, respectively.
Subcomparison 6: chemotherapy or targeted therapy agent(s) plus control intervention versus con-
trol intervention alone in participants with SCC of the esophagus
Overall survival
Four studies in 268 participants contributed data to this meta-analysis (Bleiberg 1997); 
(Levard 1998); (Lorenzen 2009); (Nicolaou 1982). For overall survival, we found an 
HR of 0.76 (95% CI 0.65 to 0.90, high-quality evidence; Analysis 10.1) in favor of 
the experimental arm. Median OS, weighted for study size, was 8.0 months in the 
added agent arm versus 6.5 months in the control arm. All studies were first-line therapy 
regimens. Cochrane’s Q test for heterogeneity was non-significant (I2=0%, p=0.95), 
which indicated that results of the four studies were consistent in their findings. (Xu 
2013) found that the OS of the nimotuzumab group was increased relative to the 
control group.
Progression-free survival
Two studies in 168 participants contributed data to this meta-analysis (Dutton 2014); 
(Lorenzen 2009). For overall survival, an HR of 0.72 (95% CI 0.55 to 0.96, low-quality 
evidence; Analysis 10.2) showed that there may be a benefit in favor of the experimental 
arm. Median OS, weighted for study size, was 1.7 months in the added agent arm versus 
1.2 months in the control arm. All studies were first-line therapy regimens. Cochrane’s 
Q test for heterogeneity was non-significant (I2=0%, p=0.97), which indicated that 
results of the four studies were consistent in their findings. (Xu 2013) found that the 
PFS of the nimotuzumab group was higher than in the control group.
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Studies excluded from the meta-analysis
(Li 2002) did not detect a difference between the response rates of participants with 
esophageal cancer who received atofluding (20.0%) versus Morafur (24.6%). (Ross 
2002) reported that the overall response rate with epirubicin, cisplatin, and 5-FU was 
37.5% for participants with esophageal cancer and 54.8% for participants with GE-
junction cancer versus an overall response rate with mitomycin, cisplatin, and 5-FU of 
49.5% for participants with esophageal cancer and 41.5% for participants with GE-
junction cancer. (Ezdinli 1980) reported median overall survival of 8.1 months for the 
adriamycin arm, 13.7 months for the methotrexate arm, and 15.4 months for the 5-FU 
arm. (Pang 2014) reported that the median OS of the intervention (leucovorin, 5-FU, 
and cisplatin) was 12 months versus 9 months in the control group (cisplatin and S-1) 
(p=0.045). (Waddell 2013) found that the addition of panitumumab resulted in an 
HR for OS of 1.37 (95% CI 1.07 to 1.76) and an HR for PFS of 1.22 (95% CI 0.98 
to 1.52). This study adjusted the dose of the control regimen in the experimental arm. 
Our analysis did not include the information from studies that contain participants with 
esophageal and/or GE-junction cancer alongside that from participants with gastric 
cancer. A meaningful sensitivity analysis was not possible, and we could not quantify 
the influence of the participants with gastric cancer on the outcome of the individual 
studies.
Discussion
Summary of  main results
This review and meta-analysis included only RCTs. Eight of the included studies 
reported details on adequate blinding. Apart from blinding, the most common 
methodological weakness in the included studies was the lack of description regarding 
allocation concealment. Palliative chemotherapy and/or targeted therapy significantly 
increased OS compared to BSC in participants with esophageal or GE-junction 
carcinoma. Additionally, participants who received multiple chemotherapeutic 
or targeted therapeutic agents had an increased OS and PFS. Although treatment 
associated toxicities of at least grade 3 occurred more frequently in the arms with an 
additional chemotherapy or targeted therapy agent, there was no evidence that palliative 
chemotherapy and/or targeted therapy decreased quality of life.
Main comparison: chemotherapy or targeted therapy agent(s) plus control intervention versus con-
trol intervention alone
The meta-analysis focused on the addition of a chemotherapeutic or targeted agent to 
the regimen or BSC treatment provided in the control arm. This meta-analysis provided 
evidence of an OS benefit for participants treated with an additional chemotherapy or 







targeted therapy agent (Analysis 1.1; Figure 3). Results of the different studies were 
consistent in their findings. Median OS, weighted for study size, was longer in the arm 
with the additional agent versus the control arm, and we did not find small study effects.
The meta-analysis for PFS provided evidence of a benefit for participants who had 
received an additional targeted agent (Analysis 1.2; Figure 5). Median progression-free 
survival, weighted for study size, was longer in the arm with the additional agent versus 
in the control arm. Palliative chemotherapy and/or targeted therapy appears to increase 
the frequency of treatment-related toxicity of at least grade 3. However, treatment-
related deaths did not appear to occur more frequently. Five studies included in this 
analysis measured quality of life with validated methods. Although the five studies were 
not representative of all the studies in this analysis, as four out of five tested a targeted 
agent and four did not report data separately for the esophageal and GE-junction cancer 
subgroup, the quality of life improved in the arms with the additional agent.
Sensitivity analysis: effect of the intervention in participants with esophageal and GE-junction cancer 
versus gastric cancer
We included the group of studies that also included gastric cancer participants in a 
separate meta-analysis. Subsequently, we performed a meta-regression analysis between 
these studies and those including only esophageal and GE-junction cancer participants. 
This analysis showed significant heterogeneity between groups of studies. Studies that 
included participants with esophageal or GE-junction cancer only showed a larger OS 
risk reduction compared to studies that also included participants with gastric cancer. In 
this sensitivity analysis, the interventions between the groups of studies were not similar, 
complicating a straightforward comparison. Therefore, we performed a second sensitivity 
analysis that focused on five studies reporting the effect of the intervention on OS for 
participants with GE-junction and gastric cancer separately. This meta-regression analysis 
indicated that the studied interventions appeared to result in an increased beneficial 
effect on OS in participants with GE-junction cancer compared to participants with 
gastric cancer. Therefore, we excluded the studies involving participants with gastric 
cancer from the meta-analyses of this review. We did not perform any further meta-
regression analyses because a comparison between participant groups exposed to the 
same intervention was not possible. Additionally, the sample size was too small for meta-
regression analyses of responses in different participant groups across interventions.
Subcomparison 1: chemotherapy or targeted therapy plus BSC versus BSC
This analysis showed that palliative chemotherapy or targeted therapy for participants 
with esophageal of GE-junction cancer in the palliative setting increased OS (Analysis 4.1; 
Figure 6). We are uncertain whether PFS increased when participants with esophageal or 
GE-junction cancer received chemotherapy or targeted therapy in the palliative setting 
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(Analysis 4.2; Figure 7). Considering the data available, toxicity levels were similar in 
both arms of the studies, except for in (Levard 1998). Only (Dutton 2014) described 
quality of life, showing a trend toward improvement for the chemotherapy arm for one 
domain.
Subcomparison 2: participants who had received previous chemotherapy
In the main analysis, we analyzed first- and second-line palliative chemotherapy together. 
In subcomparison 2, we investigated the effect of the intervention in participants who 
had received previous chemotherapy, i.e. second-line palliative therapy studies. This 
subanalysis showed a probable OS benefit even in participants with prior chemotherapy 
who received additional chemotherapy or targeted therapy (i.e. second-line therapy). 
Regarding PFS, there may be a benefit for participants treated with an additional 
targeted therapy agent.
Subcomparison 3: chemotherapy agent(s) plus control intervention versus control intervention alone
The meta-analyses of subcomparison 3 on OS demonstrated that there is probably an 
effect with regard to OS in favor of the arm with the additional chemotherapy agent, 
(Analysis 1.1; Figure 3, subcomparison 3). Median OS in the arm with the additional 
chemotherapy agent, weighted for study size, was longer than in the control arm.
Subcomparison 4: targeted therapy agent plus control intervention versus control intervention alone
The meta-analyses of subcomparison 4 regarding OS demonstrated the presence of an 
effect with regard to OS in favor of the arm with the additional targeted agent (Analysis 
1.1; Figure 3, subcomparison 4). Median overall survival in the arm with the additional 
targeted agent, weighted for study size, was longer than in the control arm. We performed 
a subgroup analysis with three studies investigating agents targeting EGFR signaling, 
finding that these agents probably prolong OS. Subsequently, cetuximab, an EGFR-
targeting agent, may decrease the hazard of death. We performed another subgroup 
analysis that focused on studies investigating ramucirumab and found that this agent 
also probably decreases the hazard of death. The two studies included only GE-junction 
participants. The meta-analyses of subcomparison 4 regarding PFS was identical to the 
meta-analysis of comparison one for PFS as described above. We performed a subgroup 
analysis investigating EGFR-targeting agents plus control intervention versus control 
intervention alone, finding a possible reduction of the HR of PFS. Subsequently, we 
analyzed cetuximab plus control intervention versus control intervention alone; results 
showed uncertainty with regard to whether this agent reduces the HR for PFS. We 
performed a third subgroup analysis that focused on studies investigating ramucirumab 
plus control intervention versus control intervention alone. This resulted in a probable 
reduction of the HR in favor of the ramucirumab arm, indicating a probable PFS benefit 
in the ramucirumab group. This meta-analysis only applied to participants with GE-







junction cancer. Regarding quality of life, (Wilke 2014) and (Dutton 2014) reported no 
differences between groups. Furthermore, (Fuchs 2014) reported a trend toward better 
quality of life for the arm with the addition of the targeted therapy, ramucirumab in 
this case.
Subcomparison 5: chemotherapy or targeted therapy agent(s) plus control intervention versus con-
trol intervention alone in participants with adenocarcinoma of the esophagus 
The meta-analyses of subcomparison 5 regarding OS demonstrated the presence of an 
effect in favor of the arm with the additional chemotherapy or targeted therapy agent 
(Analysis 9.1). Median OS in the arm with the additional chemotherapy agent, weighted 
for study size, was longer than in the control arm.
Subcomparison 6: chemotherapy or targeted therapy agent(s) plus control intervention versus con-
trol intervention alone in participants with SCC of the esophagus
The meta-analyses of subcomparison 6 regarding OS demonstrated the presence of an 
effect with regard to OS in favor of the arm with the additional chemotherapy or targeted 
therapy agent (Analysis 10.1). Median OS in the arm with the additional chemotherapy 
agent, weighted for study size, was longer than in the control arm.
Overall completeness and applicability of  evidence
In most of the included studies, the participants were only partially representative of 
all people with esophageal and GE-junction cancer. For instance, they were generally 
younger, with a median age of 60 years, compared to the overall population of people 
with esophageal and GE-junction cancer. The proportion of participants with metastatic 
disease was 69% to 100%, which is roughly comparable to the population normally 
seen in the clinic. The percentage of participants with ECOG-2 or -3 was in the range 
of 0% to 35% in the included studies. Two studies selected participants based on tumor 
biomarker expression, and their results cannot be extrapolated to people that do not have 
biomarker expression as defined by these studies. The effect of a targeted therapeutic can 
be expected to depend on the presence of the target in the tumor. (Lorenzen 2009) 
included only people with EGFR-positive cancer, and (Bang 2010) included only people 
with HER2-positive cancer. It is therefore not possible to apply these studies’ findings to 
all people, and it is unclear whether they are equally generalizable to everyone with both 
esophageal and GE-junction cancer. Furthermore, it was not feasible to differentiate 
between participants with esophageal SCC and adenocarcinoma or investigate their 
response to various treatments individually because of insufficient availability of data.
Palliative therapy that shows increased survival but without evidence of its effect on 
quality of life has unclear applicability. Therefore, the preservation of quality of life is 
an important goal and should be an outcome measure in clinical studies of palliative 
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treatment modalities (Blazeby 2001). Because not all included studies reported on 
quality of life in a validated manner, we can only conclude that there is no evidence 
that palliative chemotherapy and/or targeted therapy decreases quality of life. Various 
validated measures are available to assess generic as well as disease-specific quality of life. 
The most commonly used measure for esophageal cancer is the EORTC QLQ-C30 
(Aaronson 1993). This measure is specifically designed to measure quality of life in people 
diagnosed with cancer. A worthwhile addition to this questionnaire is the EORTC QLQ-
OES18, a measure specifically designed for people with esophageal cancer that contains 
more specific questions on dysphagia, chest pain, and reflux symptoms (Blazeby 2003). 
Only (Rao 2010) used this last measure. More recent studies often use the QLQ-C30 
to measure quality of life.
The median absolute survival gain found in the above described analyses, weighted for 
study size, is limited. For the main analysis, this survival gain applies to the addition 
of 1.1 agents on average. Adding three agents to BSC, for instance, will likely increase 
the absolute survival gain. In addition, this analysis also included second-line studies 
for which the potential survival gain is likely less in absolute terms when compared to 
first-line palliative care regimens. Except for these limitations, readers may consider the 
evidence cited above as complete and applicable.
Quality of  the evidence
We generally considered the analyzed RCTs to be at low risk of bias in most domains. 
However, studies were frequently at unclear or high risk of bias with regard to blinding 
and allocation concealment. More recent RCTs often contained more useful information 
for determining risk of bias in their descriptions of methodology when compared to 
older RCTs. For more details about risk of bias, see Risk of bias in included studies.
Various chemotherapy and targeted therapy regimens have been applied for esophageal 
and GE-junction cancer in a palliative setting. As the regimens in the included RCTs of 
this review are very heterogeneous, it was often not feasible to make a direct comparison 
between the various chemotherapeutic agents. The only agents that more than one trial 
investigated by adding them individually to a control regimen were cetuximab and 
ramucirumab. Because of the heterogeneity of the agents used, most information can 
be extracted from an analysis in the form of the main comparison. However, it remains 
largely unclear which agents lead to a survival benefit. Moderate-quality evidence supports 
the effectiveness of ramucirumab, and targeting EGFR signaling appears promising. The 
same heterogeneity is present in the agents that make up the control arms of the studies. 
Today, some of these agents are no longer or rarely used. Studies testing agents on a 
background of more popular regimens, for instance containing platinum-based agents 
and 5-FU, could influence the added effect of the tested agent on survival.







Potential biases in the review process
One significant threat to the validity of the review was the possibility of publication bias, 
that is, studies that did not find the treatments to have been effective may not have been 
published. We investigated small study effects such as publication bias in a qualitative 
manner using a funnel plot (Figure 4) but found no evidence of its presence.
Agreements and disagreements with other studies or reviews 
(Mohammad 2015) investigated whether a triplet regimen was superior to a doublet 
regimen in terms of overall survival, progression-free survival, and objective response 
rate in participants receiving first-line chemotherapy for advanced or metastatic 
esophagogastric carcinoma. They found a significant improvement in OS in favor of a 
triplet regimen (HR 0.90, 95% CI 0.83 to 0.97). Additionally, they found that toxicity 
grades 3 and 4 were significantly higher in the triplet regimens. Both of these conclusions 
are in line with our findings.
(Amdal 2013) investigated the effect of palliative radiotherapy and/ or chemotherapy on 
symptoms and quality of life, as assessed by person-reported outcomes and measurement 
of toxicity for people with esophageal cancer. They had included mixed populations, 
including those with gastric, GE-junction, or esophageal cancer. They found no clear 
association between quality of life and treatment toxicity. Interestingly, two of the RCTs 
included in our review, which investigated chemotherapy, reported better quality of life 
despite more treatment toxicity in the experimental arm versus the standard arm (Van 
Cutsem 2006); (Waters 1999).
Differences in risk factors, gene expression, and tumor biology exist between 
adenocarcinoma of the stomach, GE-junction, and esophagus (Marsman 2005); (Shah 
2011). In this review, we found a difference in chemotherapy and targeted therapy efficacy 
between GE-junction adenocarcinoma and gastric adenocarcinoma. We found a similar 
trend in a study by (Chau 2009) using individual participant data from four studies 
(Cunningham 2008); (Ross 2002); (Tebbutt 2002); (Waters 1999). They concluded 
that response rates in participants were 44.1% in esophageal, 41.1% in GE-junction, 
and 35.6% in gastric cancer. Regarding chemotherapeutic treatment of advanced gastric 
carcinoma, a Cochrane Review has been published (Wagner 2010).
Authors’ conclusions
Implications for practice
Palliative chemotherapy and targeted therapy increase overall survival in people with 
esophageal or GE-junction carcinoma compared to BSC. With regard to PFS, we saw a 
probable trend in the same direction. Additionally, adding chemotherapeutic or targeted 
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agents increases OS, and adding a targeted agents lengthens PFS. However, the median 
survival benefit is limited. Of all the individual chemotherapeutic and targeted agents 
studied, only cetuximab and ramucirumab were investigated more than once. Only 
ramucirumab significantly prolonged OS and PFS in people with GE-junction cancer 
that had previously been treated with chemotherapy. Palliative chemotherapy and/or 
targeted therapy appear to increase the frequency of treatment-related toxicity of at least 
grade 3. However, treatment-related deaths did not occur more frequently. Five studies 
measured quality of life with validated methods in this analysis. Although they were not 
perfectly representative of all the studies in this analysis, they did show that quality of 
life improved in the arms with the additional agent. Overall, palliative chemotherapy 
and/or targeted therapy can be considered as standard care for esophageal and GE-
junction carcinoma.
Implications for research
There is a need for well-designed, adequately powered, phase III studies on chemotherapy 
and targeted therapy for metastatic esophageal and GE-junction carcinoma. The main 
objective should be increased survival, with an additional emphasis on quality of life. 
These future studies comparing palliative treatment modalities should assess quality of 
life with validated measures. Studies should be designed in such a way that they enable 
the comparison of different individual agents on a meta-analysis level. Our results suggest 
that the participants with GE-junction cancer respond differently to chemotherapy and 
targeted therapy when compared to the participants with gastric cancer. We do not 
suggest excluding either group from studies. However, it is advisable to report outcomes 
separately for these and other subgroups of participants. Additionally, studies pooling 
these plausibly differently reacting populations might underestimate the number 
of participants necessary to reach definitive conclusions for each subgroup. Separate 
reporting for SCC, adenocarcinoma of the esophagus, and adenocarcinoma of the GE-
junction would further increase the understanding of the effectiveness of chemotherapies 
and targeted therapies in these groups.
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With regard to the characteristics of the excluded studies, studies awaiting assessment, 
and ongoing studies, these can be accessed through the Cochrane Library.
With regard to the comparisons and analyses, these can be accessed through the 
Cochrane Library.
Appendix 1. Glossary
 - Chemotherapy: a drug treatment that uses chemicals to kill fast-growing cells in the 
body in a fairly aspecific manner.
 - Dysphagia: the symptom of difficulty in swallowing.
 - Metastatic: the spread of cancer from one part of the body to another without being 
directly connected to it.
 - Non-resectable: not able to be removed by surgery. This can have multiple possible 
causes, for instance, the cancer has grown into a vital organ which cannot be 
removed, or the removal of the cancer would not cure the person because metastases 
are present, or the person is in such physical condition that exposure to surgery 
would cause a significant risk of dying.
 - Palliative care: treatment that reduces the effects or symptoms of a medical condition 
without curing it.
 - Cytostatic therapy: a drug treatment that is directed at fast-dividing cells in general.
 - Targeted therapy: a drug treatment, often a monoclonal antibody or a small molecule, 
to block the growth and spread of cancer by interfering with specific molecules.
 - Toxicity: any unfavourable event, symptom, or disease associated with the use of a 
treatment that may or may not be considered related to the treatment.
Appendix 2. CENTRAL search strategy
(((esophag* OR oesophag* OR gastroesophag* OR gastrooesophag* OR junction*) 
NEAR/6 (neoplas* OR cancer* OR tumo* OR metasta* OR meta-stasis OR meta-
static OR malign* OR carcinom* OR adenocarcinom*)):ab,ti)AND ((chemotherap* 
OR chemoradi* OR radiochemo* OR photochemo* OR ((drug* OR chemo*) 
NEAR/6 (radi* OR therap*))):ab,ti) AND ((palliat* OR unresect* OR irresect* OR 
nonresect* OR inopera* OR unopera* OR nonopera* OR advanced OR (non NEAR/1 
(opera* OR resect*)):ab,ti)) NOT ((preopera* OR ((pre OR post) NEAR/1 opera*) OR 
postopera*):ab,ti)
Appendix 3. MEDLINE OvidSP
(“Esophageal Neoplasms”/ OR (exp “Esophagogastric Junction”/ AND exp “Digestive 
System Neoplasms”/) OR ((esophag* OR oesophag*OR gastroesophag* OR 
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gastrooesophag* OR junction* ) ADJ6 (neoplas* OR cancer* OR tumo* OR metasta* 
OR meta-stasis OR meta-static OR malign* OR  carcinom* OR adenocarcinom*)).
ab,ti.) AND (exp “drug therapy”/ OR exp “digestive systemcancer”/dt OR (chemotherap* 
OR chemoradi* OR radiochemo* OR photochemo* OR ((drug* OR chemo*) ADJ6 
(radi* OR therap*))).ab,ti.) AND (“PalliativeCare”/ OR (palliat* OR unresect* OR 
irresect* OR  nonresect* OR inopera* OR unopera* OR nonopera* OR advanced OR 
(non ADJ1 (opera* OR resect*)).ab,ti.)) AND (“randomized controlled trial”.pt. OR 
“evaluation studies”.pt. OR “comparative study”.pt. OR “ Follow-Up Studies”/ OR 
“Prospective Studies”/ OR (random* OR factorial* OR crossover* OR (cross ADJ over*) 
OR placebo* OR ((doubl* OR singl* OR tripl*) ADJ (mesk* OR blind*)) OR assign* 
OR allocat* OR volunteer* OR comparat* OR evaluat* OR follow-up OR followup OR 
prospectiv* OR control*).ab,ti.) NOT (“preoperative period”/ OR exp “postoperative 
period”/ OR (preopera* OR ((pre OR post) ADJ1 opera*) OR postopera*).ab,ti.)
Appendix 4. Embase search strategy
(’esophagus cancer’/exp OR (’lower esophagus sphincter’/de AND ’digestive system 
cancer’/exp) OR ((esophag* OR oesophag* OR gastroesophag* OR gastrooesophag* OR 
junction*) NEAR/6 (neoplas* OR cancer* OR tumo* OR metasta* OR meta-stasis OR 
meta-static OR malign* OR carcinom* OR adenocarcinom*)):ab,ti) AND (’drug therapy’/
exp OR ’digestive system cancer’/exp/dm˙dt OR (chemotherap* OR chemoradi* OR 
radiochemo* OR photochemo* OR ((drug* OR chemo*) NEAR/6 (radi* OR therap*))): 
ab,ti) AND (’advanced cancer’/de OR ’palliative therapy’/exp OR (palliat* OR unresect* 
OR irresect* OR nonresect* OR inopera* OR unopera* OR nonopera* OR advanced OR 
(non NEAR/1 (opera* OR resect*)):ab,ti)) AND (’crossover procedure’/de OR ’doubleblind 
procedure’/de OR ’randomized controlled trial’/de OR ’single-blind procedure’/de OR 
evaluation/de OR ’comparative study’/ exp OR ’follow up’/de OR ’prospective study’/
de OR (random* OR factorial* OR crossover* OR (cross NEXT/1 over*) OR placebo* 
OR ((doubl* OR singl* OR tripl*) NEXT/1 (mesk* OR blind*)) OR assign* OR allocat* 
OR volunteer* OR comparat* OR evaluat* OR follow-up OR followup OR prospectiv* 
OR control*):ab,ti) NOT (’preoperative period’/exp OR ’postoperative period’/exp OR 
(preopera* OR ((pre OR post) NEAR/1 opera*) OR postopera*):ab,ti)
Appendix 5. Web of  Science
TS=((((esophag* OR oesophag* OR gastroesophag* OR gastrooesophag* OR junction*) 
NEAR/6 (neoplas* OR cancer* OR tumo* OR metasta*OR meta-stasis OR meta-static OR 
malign* OR carcinom* OR adenocarcinom*))) AND ((chemotherap* OR chemoradi* OR 
radiochemo* OR photochemo* OR ((drug* OR chemo*) NEAR/6 (radi* OR therap*)))) 
AND ((palliat* OR unresect* OR irresect* OR nonresect* OR inopera* OR unopera* 
OR nonopera* OR advanced OR (non NEAR/1 (opera* OR resect*)))) NOT ((preopera* 
OR ((pre OR post) NEAR/1 opera*) OR postopera*)) AND (random* OR factorial* OR 







crossover* OR (cross NEAR/ 1 over*) OR placebo* OR ((doubl* OR singl* OR tripl*) 
NEAR/1 (mesk* OR blind*)) OR assign* OR allocat* OR volunteer* OR comparat* 
OR evaluat* OR follow-up OR followup OR prospectiv* OR control*)) Appendix 6. 
PubMed publisher (((esophag*[tiab] OR oesophag*[tiab] OR gastroesophag*[tiab] OR 
gastrooesophag*[tiab] OR junction*[tiab] ) AND (neoplas*[tiab] OR cancer[tiab] OR 
cancers[tiab] OR tumor[tiab] OR tumors[tiab] OR tumor*[tiab] OR metasta*[tiab] OR 
meta-sta*[tiab] OR malign*[ tiab] OR carcinom*[tiab] OR adenocarcinom*[tiab]))) 
AND ((chemotherap*[tiab] OR chemoradi*[tiab] OR radiochemo*[tiab] OR 
photochemo*[tiab] OR ((drug[tiab] OR drugs[tiab] OR chemo[tiab]) AND (radio[tiab] 
OR radiother[tiab] OR therapy[tiab] OR therapies[tiab])))) AND ((palliat*[tiab] OR 
unresect*[tiab] OR irresect*[tiab] OR nonresect*[tiab] OR inopera*[tiab] OR unopera*[ 
tiab] OR nonopera*[tiab] OR advanced OR non opera*[tiab] OR non resect*[tiab])) 
AND ((random*[tiab] OR factorial*[tiab] OR crossover*[tiab] OR cross over*[tiab]OR 
placebo*[tiab] OR ((doubl*[tiab] OR singl*[tiab] OR tripl*[tiab]) AND (mesk*[tiab]OR 
blind*[tiab])) OR assign*[tiab] OR allocat*[tiab] OR volunteer*[tiab] OR comparat*[tiab] 
OR evaluat*[tiab] OR follow-up OR followup OR prospectiv*[tiab] OR control[tiab] 
OR controlled[tiab])) NOT ((preopera*[tiab] OR pre opera*[tiab] OR post opera*[tiab] 
OR postopera*[tiab])) AND publisher[sb]




(esophageal OR esophagus OR gastresophageal) AND (neoplasm OR neoplasms 
OR cancer OR tumors) AND (chemotherapy OR chemoradiotherapy OR 
radiochemotherapy) AND (palliative OR unresectable OR irresectable OR nonresectable 
OR inoperable OR advanced)
Appendix 8.WHO International Clinical Trials Registry Platform (ICTRP) search 
strategy
Esophag* AND neoplas* AND palliat* OR Oesophag* AND neoplas* AND palliat* 
OR Esophag* AND cancer* AND palliat* OR Oesophag* AND cancer* AND palliat* 
OR Esophag* AND neoplas* AND unresectable* OR Oesophag* AND neoplas* AND 
unresectable* OR Esophag* AND cancer* AND unresectable* OR Oesophag* AND 
cancer* AND unresectable*
The sections: what’s new, history, contributions of authors, declarations of interest, 
sources of support, differences between protocol and review, and index terms can be 
accessed through the Cochrane Library.

Chapter 10
Cost-effectiveness of  cetuximab for 
advanced esophageal squamous 
cell carcinoma
Vincent T. Janmaat · Marco J. Bruno · Suzanne Polinder · Sylvie Lorenzen · 
Florian Lordick · Maikel P. Peppelenbosch · Manon C.W. Spaander
PLoS One. 2016;11(4):e0153943
Abstract
Costly biologicals in palliative oncology are emerging at a rapid pace. For example, in 
patients with advanced esophageal squamous cell carcinoma addition of cetuximab to a 
palliative chemotherapy regimen appears to improve survival. However, it simultaneously 
results in higher costs. We aimed to determine the incremental cost-effectiveness ratio 
of adding cetuximab to first-line chemotherapeutic treatment of patients with advanced 
esophageal squamous cell carcinoma, based on data from a randomized controlled 
phase II trial. A cost effectiveness analysis model was applied based on individual 
patient data. It included only direct medical costs from the health-care perspective. 
Quality-adjusted life-years and incremental cost-effectiveness ratios were calculated. 
Sensitivity analysis was performed by a Monte Carlo analysis. Adding cetuximab to 
a cisplatin-5-fluorouracil first-line regimen for advanced esophageal squamous cell 
carcinoma resulted in an incremental cost-effectiveness ratio of €252,203 per quality-
adjusted life-year. Sensitivity analysis shows that there is a chance of less than 0.001 
that the incremental cost-effectiveness ratio will be less than a maximum willingness 
to pay threshold of €40,000 per quality-adjusted life-year, which is representative for 
the threshold used in The Netherlands and other developed countries. In conclusion, 
the addition of cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced 
esophageal squamous cell carcinoma is not cost-effective when appraised according to 
currently accepted criteria. Cost-effectiveness analyses using outcome data from early 
clinical trials (i.c. a phase II trial) enable pharmaceutical companies and policy makers 
to gain early insight into whether a new drug meets the current eligibility standards for 
reimbursement and thereby potential admittance for use in regular clinical practice.
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The use of biologicals in palliative oncology is expanding at a rapid pace. These new 
therapeutic agents may improve patients’ survival and quality of life. However, the 
money spend on biologicals is expected to increase at a faster rate than the overall 
spending growth on pharmaceuticals and is projected to represent roughly one fifth of 
the total costs by 2017 (1). It would be beneficial for drug companies, policy makers, 
physicians and patients alike when the cost-effectiveness of these biologicals would 
become apparent at an early stage of development.
A good example of a carcinoma for which biologicals are being studied in palliative phase 
II trials is esophageal squamous cell carcinoma (ESCC). ESCC is the predominant form 
of esophageal carcinoma worldwide, and most patients are diagnosed in advanced stages 
not amenable to curative treatment (2-4). Palliative therapy consists of chemotherapy 
or (chemo-)radiation therapy, management of pain, and achieving optimal nutrition. 
Currently survival in these patients receiving palliative care remains poor. 
Lorenzen et al. conducted a phase II trial in 62 patients with non-resectable epidermal 
growth factor receptor (EGFR)-expressing ESCC (5). This trial showed that addition 
of cetuximab (Erbitux, Merck Serono, Geneva, Switzerland) in palliative treatment of 
ESCC is likely to prolong survival. The median progression-free survival increased from 
3.6 months (95% confidence interval (CI) 1.0-6.2) to 5.9 months (95% CI 3.8-8.0). 
The median overall survival increased from 5.5 months (95% CI 1.9-9.1) to 9.5 months 
(95% CI 8.4-10.6). The three adverse events that occurred more often in the cetuximab 
arm were neutropenia (22% vs 13%), diarrhea (16% vs 0%), and nausea (13% vs 3%), 
while fatigue decreased (3% vs 10%) (5).
The cost-effectiveness of cetuximab as palliative treatment has not been investigated 
in ESCC, but has been assessed for other malignancies. Hannouf et al. (6) estimated 
that adding cetuximab to platinum-based chemotherapy for squamous cell carcinoma 
of the head and neck (SCCHN) resulted in a cost-utility ratio of €249,888 per 
quality adjusted life year (QALY). In addition an incremental cost-effectiveness ratio 
(ICER) of €242,494 per QALY was reported by the National Institute for Care and 
health Excellence (NICE) after exploratory analysis using alternative assumptions and 
parameters in the economic model of the treatment of SCCHN with cetuximab (7). In 
metastasized KRAS wild type colorectal carcinomas, an ICER of €112,707 per QALY 
was reported (8). All these studies with incurable patients receiving cetuximab show 
ICERs above a maximum willingness to pay threshold of €40,000. This threshold is 
representative for The Netherlands and other developed countries (9-14).
Phase III trials investigating the effectiveness of adding cetuximab to palliative therapy of 
ESCC were started after the publication of Lorenzen et al. (15). Although the addition 
of cetuximab seems to offer a health benefit, it might have an ICER above the current 
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maximum willingness to pay threshold. Early estimation of the ICER would give early 
insight into the costs of the therapy regimen and hence the probability that the drug will 
be reimbursed. If there is too much of a gap between effectiveness and costs, informed 
decision-making could question the costly development of a drug that will have a hard 
time to be commercially viable and, importantly, early information sharing would spare 
the public from developing false expectations.
This paper aims to calculate the expected mean ICER of adding cetuximab to the standard 
palliative treatment of ESCC in a Dutch health-care setting, based on published data 
from a phase II trial (5). It shows that the addition of cetuximab is not cost-effective. 
Methods
Framework of  cost-effectiveness analysis
The cost-effectiveness analysis was based on data from the study performed by Lorenzen 
et al. (5). A linear model was used. Two clinical outcome measures, namely mean 
progression free survival (PFS) and mean overall survival (OS), were used in addition 
to an approximation of overall costs, in order to calculate ICERs. The cost-effectiveness 
analysis assumed the health-care perspective, including only direct medical costs. 
Modelling was done using Microsoft Excel (Microsoft Corporation, Redmond, WA). 
One-way sensitivity analysis
A one-way sensitivity analysis was conducted by taking all input variables of the model 
and varying them by 10% in both directions. When varying one input variable, other 
input variables were kept constant. 
Probabilistic sensitivity analysis 
The probabilistic sensitivity analysis was performed using a Monte Carlo simulation 
using Microsoft Excel (Microsoft Corporation, Redmond, WA). For this analysis, 1000 
simulated trials were run, where the values for the OS and PFS of both arms were 
sampled at random from normalized probability distributions based on the trial sample 
means and their standard deviation. By using the standard deviation of the mean values 
the variation of the sample means estimate of the population mean was taken into 
account. Other parameters of the model were kept constant. This generated the mean 
costs and mean survival benefit for 1000 simulated trials. 
Patients
In the study of Lorenzen et al. (5), 62 patients were randomly assigned to the cetuximab, 
cisplatin, and fluorouracil arm (n=32) or to the cisplatin and fluorouracil arm (n=30). The 







protocol of the study of Lorenzen et al. was approved by the ethics committee for human 
research at the Technische Universität München, Munich, Germany, and conformed 
to the principles of the Declaration of Helsinki and its subsequent amendments. The 
analyses presented in this study fall under the same protocol. All patients gave written 
informed consent. Patient records/information was anonymized and de-identified prior 
to analysis. The patients were at least 18 years of age, had histologically confirmed and 
EGFR-expressing advanced non-resectable ESCC. They had not received (neo)adjuvant 
chemotherapy within six months of enrollment into the study and had not had prior 
chemotherapy for recurrent or metastatic disease. Their Eastern Cooperative Oncology 
Group performance status (ECOG PS) had to be one or less, creatinine clearance had 
to be above 70 ml/min. They had to have adequate hepatic function, bone marrow 
function, and a lesion measurable in one dimension of at least one cm in diameter 
detected by computed tomography (CT) scan was required. Exclusion criteria were a 
second malignancy, uncontrolled infection, a neuropathy grade more than one, and 
pregnancy or lactation. Median follow-up time was 21.5 months. Both groups were well 
balanced with respect to age, tumor differentiation, and intensity of EGFR staining. 
However, there was a marked difference in the gender balance between the arms with 
the cetuximab arm containing more female patients. More than 30% of patients in each 
arm had either prior surgery, radiotherapy, or both. In contrast, only 13% of patients in 
each arm had received prior systemic chemotherapy (5).
Therapy regimen
For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 
fluorouracil 1000 mg/m2, days 1-5, either alone or in combination with cetuximab. 
Cetuximab was initially dosed at 400 mg/m2, followed by 250 mg/m2 weekly thereafter 
(5). The modelled therapy regimen was constructed to take treatment discontinuation 
into account, the level of treatment discontinuation was chosen so as to assume a mean 
cetuximab use equal to that calculated for the phase II trial (see results section). 
Determination of  QALYs
PFS and OS figures were used from the study of Lorenzen et al. The authors reported 
median OS and PFS times. Using individual patient data, mean OS and PFS times were 
calculated, as these data were necessary to calculate the ICER of the proposed therapy 
regimen. The utility score during PFS was calculated. Asymptomatic adenocarcinoma of 
the esophagus was associated with a utility score of 0.77, symptomatic adenocarcinoma 
of the esophagus was associated with a utility score of 0.675 (16, 17). Since most patients 
were diagnosed because they presented themselves with symptoms, the utility score of 
symptomatic disease was used, i.e. 0.675. The utility score during disease progression 
was defined as the average of the utility score at death, which is zero, and the utility score 
during PFS. This approach reflects the assumption that the utility score linearly declines 
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from the point of progression to the point of passing away, see Figure 1 for a schematic 
representation of the assumptions used. QALYs were calculated by: PFS * utility score 
during PFS + (OS – PFS) * utility score during disease progression: PFS  0.675 + (OS 
– PFS)  0.675. The amount of QALYs gained was calculated by taking the amount of 
QALYs calculated for the intervention group minus the amount of QALYs calculated 
for the control group.
Figure 1. Schematic representation of the health states and utility scores used in the linear model. At 
diagnosis a utility score of 0.675 was assumed. This utility score remains stable during progression free 
survival. During progressive disease, it was assumed that the utility score declines linearly from 0.675 to 0 
at the time of death.
Determination of  costs
An estimate was made of the medical resource usage that resulted from the incremental 
cost of adding cetuximab to the standard treatment. Unless otherwise specified, unit costs 
were obtained from the Dutch manual for cost-effectiveness research 2010 (18). The cost 
of cetuximab for an average patient was calculated. The cost of cetuximab in 2007 was 
€207 per 100 mg in the Netherlands, and €237.20 in 2009 (19). The model accounted 
for: value attributed tax, duration of treatment, the increased dose for the first treatment 
(400 versus 250 mg), the male female difference in dosage, the relative proportion of 
both sexes affected by ESCC, and the amount of treatment discontinuation. The cost 
of an outpatient visit was estimated to be €251 (18). The number of outpatient clinic 
visits was calculated. Duration of therapy and the number of outpatient visits that can 
be combined with visits for chemotherapy were accounted for. The incremental cost 
of these combined visits was estimated. Lorenzen et al. screened for EGFR expressing 
tumor patients (5). Screening for a subset of eligible patients significantly contributes 
to therapy cost, increasing with decreasing biomarker frequencies (16). The cost of 







evaluation of EGFR expression (€750) was based on the reimbursement for such a 
test in the Dutch healthcare system. It was assumed that 60% of patients have EGFR 
expressing tumors (20-22). Although all patients have to be screened. Incremental cost 
for housing and depreciation of goods (6.5%) and overhead (35.5%) were accounted 
for. Possible costs associated with an increase in adverse events were not accounted for. 
All costs and effects were converted to the price level of 2009 according to the general 
Dutch consumer price index (23). Results of other studies, reported in CAD and Pound 
Sterling, were converted to euros using the purchasing power parity index of the year 
closest to the year in which the study outcome was reported (24). A cost-effectiveness 
ratio below €40,000 per gained QALY was assumed to be acceptable. This threshold 
is representative for the willingness to pay threshold in The Netherlands and other 
developed countries (9-14). The time horizon of the base case model was 0.9 years. 
Because of this short time horizon, neither costs nor clinical outcomes were discounted.
Results
Lorenzen et al. reported a median OS of 5.5 and a median PFS of 3.6 months for the 
CF arm as well as a median OS of 9.5 and a median PFS of 5.9 months for the CET 
CF arm. This translates into a mean OS of 8.6 and a mean PFS of 5.6 months for the 
CF arm as well as a mean OS of 10.8 and a mean PFS of 7.1 for the CET CF arm. 
The median cumulative dose of cetuximab per patient was reported to be 8 690mg. 
The mean cumulative dose of cetuximab per patient was recalculated. This resulted in 
a mean cumulative dose of 6,443mg cetuximab per patient. Subsequently, the level of 
treatment discontinuation was chosen so as to assume a mean cetuximab use of 6,444 
mg.
The mean survival gained by the addition of cetuximab to standard chemotherapy was 
0.187 life years and 0.105 QALYs. The mean incremental cost was calculated to be 
€26,459 per treated patient. The incremental costs included the costs of cetuximab, 
additional day treatment facilities, and the cost of evaluation EGFR status, in order of 
impact. Adding cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced 
ESCC resulted in a mean ICER of €252,203 per QALY.
A one-way sensitivity analysis was conducted by taking all input variables of the model 
and varying them by 10% in both directions. The resulting ICERs were depicted in a 
tornado plot, see Figure 2. The input extracted from the phase II trial, had most effect 
on the determination of the ICER. Other factors of influence were the quality of life 
assumption used, the amount of cetuximab used, and the price of cetuximab.
A probabilistic sensitivity analysis was performed by conducting a Monte Carlo analysis, 
results are shown in Figure 3. Each point represents one of the 1000 trials runs. The data 
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Figure 2. Tornado plot of a one-way sensitivity analysis. Input variables were tested in a one-way sensitivity 
analysis. These variables were either decreased by 10% of the value used in the base case model, or increased 
10% from their original value. The bars represent the range of the ICER if the variable lies between -10% 
and +10% of its assumed value in the base case model. The ICER form the base case model was indicated 
by the vertical dotted line.
Figure 3. Scatter plot of Monte Carlo sensitivity analysis. One thousand repeated random samplings from 
the model described are depicted in the figure. Each sampling is depicted by one dot and represents the 
average QALY gained and the incremental cost of that sampling from the model. The vertical line separates 
the plane (to the left), for which the intervention is not effective. With the plane to the right for which the 
intervention is effective. The inclining line depicts the maximum willingness to pay threshold at an ICER of 
€40,000 per QALY gained. This line separates the plane above it, for which the intervention is effective but 
not cost effective, with the plane below, for which the intervention is effective and cost effective.







extracted from the phase II trial had most influence on the determination of the ICER 
in the one-way sensitivity analysis. Therefore, with respect to the input data for the OS 
and PFS of both arms, each input was assigned a random value. This was based on the 
mean and standard deviation extracted from the individual patient data. Other input 
data was kept constant. The solid diagonal line indicates the €40,000 per QALY gained 
willingness to pay threshold. Trial points that fall to the left and above this diagonal 
line indicate a cost-effectiveness of that trial run above the given maximum willingness 
to pay threshold level. This analysis shows that p<0.001 of the ICER being below a 
maximum willingness to pay threshold of €40,000.
Discussion
The mean ICER of adding cetuximab to a cisplatin-5-fluorouracil first-line palliative 
regimen for ESCC, is €252,203 per QALY gained. By performing a Monte Carlo analysis 
we showed that there’s a chance of less than 0.001 that the ICER would be below a 
threshold of acceptable cost per QALY of €40,000. This threshold is representative for 
the willingness to pay threshold in the Netherlands. Thus, the therapy regimen will at 
present not be considered cost-effective by decision makers and, in all probability, will 
not be reimbursed within the regulated Dutch health insurance system.
In the United Kingdom, the NICE uses an unpublished threshold of £30,000 (€36,997) 
in 2012 (12, 13). In Japan the willingness to pay threshold is 5,000,000 JPY (€43,014) 
in 2010. In the United States of America the threshold is US$ 62,000 (€46,617) in 2010 
(14). This indicates the threshold used, of €40,000, is representative for a willingness 
to pay threshold used in many developed countries (9, 10). The price of cetuximab is 
the dominant driver of the overall costs. Although biosimilars are expected to become 
available at a 15% to 30% lower prices, substitution of cetuximab with a biosimilar 
would not make the therapy regimen cost effective (25). In fact, due to testing of EGFR 
overexpression and the need for additional day treatments, the ICER was modelled to 
become €45,907 if cetuximab would be available for free. The ICER that we calculated 
is in line with previous findings for SCCHN, which has similarities in etiology and 
pathology (6, 7, 26), and for KRAS wild type colorectal carcinomas (8, 27). Cost-
effectiveness studies after phase II trials have been previously performed (28). This 
method has been discussed related to the topic of streamlining the drug development 
process and early estimation and decision making for reimbursement in 2001 and 2003 
(29, 30). However, no widespread adaptation has taken place. 
This study has certain limitations. Quality of life of the patients receiving cetuximab 
could be affected negatively by side effects. This has not been accounted for in the 
model. Other limitations of this study are the lack of data on utility scores, both during 
PFS and after progression of ESCC, therefore data for adenocarcinoma of the esophagus 
Chapter 10
366
was used. Vial wastage and possible discounts negotiated by hospitals have not been 
accounted for. Since we did not have access to actual cost data from patient enrolled in 
this phase II study, another limitation is the use of costs that were taken from a manual 
for cost-effectiveness. 
The results of the phase II trial remain promising despite the considered lack in cost 
effectiveness. Selecting patients for whom the drug has the most effect will increase 
treatment effectiveness and remove the burden of side effects from unselected patients. 
The EGFR staining pattern could be used as a criterion for selection. It has been correlated 
with poor prognosis in ESCC in a western European population (20). Tumor specific 
EGFR downstream signaling mutations in KRAS (8, 31), BRAF (31, 32), PTEN (33), 
and PIK3CA (31, 34) cause reduced benefit of cetuximab therapy in colon carcinoma 
patients. Germ line polymorphisms could also predict response to treatment, as has 
been studied in colorectal cancer (35-38). These options for selection of patients are still 
speculative and should be investigated further.
Conclusions
Addition of cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced 
ESCC is not cost-effective when appraised according to currently accepted criteria. 
Cost-effectiveness analyses using outcome data from early clinical trials (i.c. a phase II 
trial) enable pharmaceutical companies and policy makers to gain early insights into 
whether a new drug meets the current eligibility standards for reimbursement and 
thereby potential allowance for use in clinical practice.
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Summary and general discussion









The overall aim of this thesis is to gain better understanding of the etiology, the detection, 
and the palliative treatment of gastrointestinal (GI) cancer. This thesis is divided into 
five parts. 
Part 1 contains the introduction to this thesis. In Chapter 1.1, GI is described as a 
type of disease characterized by increased cell growth combined with the ability of these 
cells to spread to or invade other parts of the body. GI is one of the leading causes of 
morbidity and mortality worldwide. Esophageal cancer is the eighth most common 
cancer worldwide, with approximately 398,000 people diagnosed with esophageal 
squamous cell carcinoma (ESCC) and 52,000 with esophageal adenocarcinoma (EAC) 
in 2012. Barrett’s esophagus (BE) is an intestinal metaplasia of the esophagus and can 
give rise to EAC. In the past few decades, developed countries have seen an increase 
in the incidence of BE and EAC, attributed to the higher prevalence of obesity. As 
various infectious diseases can be treated, or managed, better than before and the patient 
population is aging, oncological conditions become more and more prevalent in the 
gastroenterological patient population. Without profound understanding of the causes 
of cancer of the GI-tract, prevention, detection, and treatment are impossible. Chapter 
1.2 describes the outline of this thesis. 
In Part 2 of this thesis, we aim to increase our fundamental understanding on oncogenesis 
in the GI-tract through study of HOX gene signaling in (pre)malignant lesions of the 
GI tract. In Part 3, we investigate several approaches to improve the prediction of the 
development of malignant lesions and develop models for translational studies. In Part 4, 
we study the palliative treatment of esophageal cancer. Our findings will be summarized 
in this chapter. Part 5 consists out of the summary, discussion, and appendices.
Part 2: HOX genes in (pre)malignant lesions of  the GI-tract
In Chapter 2, HOXA13 was studied in esophageal carcinogenesis, because the biology 
and early events of metaplasias in the GI tract remain elusive. Here, we showed that 
HOX gene collinearity exists in great detail in the GI tract of adult humans and mice. 
In metaplasias, EAC, and heterotopias of the upper GI tract, a colon-like HOX gene 
expression was observed, with marked upregulation of the, in physiology, classically 
thought of as distally expressed HOXA13. ISH of HOXA13 showed it was expressed 
mainly epithelial and confirmed its expression in metaplasia of the upper GI tract and 
its sequela. These HOX gene aberrations are paralleled in the stem cell component of the 
GI epithelium and BE. This supports a role for HOX gene expression in stem cells in 
the development of metaplasia. Data from a mouse model showed physiological Hoxa13 
expression was crypt clonal and expression along the baso-luminal axis was location 
specific. The proximal expression border was located between the proximal and distal 
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colon, this was conserved in humans. Strikingly, physiological HOX collinearity was 
interrupted by expression of the distal HOXA13 in the upper GI-tract. This was detected 
just distally from the gastroesophageal junction and in the esophageal submucosal 
glands of adult humans and in the glandular stomach epithelium of adult mice. In fetal 
humans, high and specific HOXA13 expression was observed at the gastric cardia, while 
more distal stomach and epithelium of esophagus were less positive. In a gut progenitor 
cell model, HOXA13 reduced differentiation efficiency and, consequently, increased 
proliferation. In definitive endoderm, HOXA13 supports caudal epithelial functions and 
appears to promote proliferation. Thus, HOXA13-positive cells at the gastroesophageal 
junction may outcompete other cell clones through a reduction in differentiation and an 
increase in proliferation. HOXA13 downregulates the epidermal differentiation complex, 
which is an example of the capacity of a clustered multigene family member to regulate 
other clustered multigene families. In a BE cell culture model, HOXA13 downregulates 
the epidermal differentiation complex and increases proliferation. In an in vivo tissue 
reconstitution model, parental cells of a BE cell line produce both intestinal-type 
columnar epithelium and stratified squamous epithelium from the same clone, suggesting 
this cell line has dual potential. In this model, HOXA13 knock-out impaired epithelial 
proliferation and counteracted formation of the intestinal-type columnar epithelium. 
Thus, HOXA13 emerges as a critical gene mediating BE pathophysiology.
In Chapter 3, the oncogenic hallmarks which HOXA13 confers to esophageal 
keratinocytes were studied. To this end, HOXA13 was overexpressed in a non-transformed 
human esophageal cell line EPC2-hTERT, gene expression profiling was performed 
to identify key processes and functions, and functional experiments were performed. 
We found that HOXA13 expression confers oncogenic hallmarks to esophageal 
keratinocytes. It provides proliferation advantage to keratinocytes, reduces sensitivity 
to chemical agents, downregulates MHC class I expression, alters differentiation status, 
and promotes cellular migration. Our data indicate a crucial role of HOXA13 in early 
stages of esophageal carcinogenesis.
In Chapter 4, HOXA9 overexpression in premalignant colonic lesions was studied. 
Colorectal cancer is an important contributor to cancer deaths worldwide. It follows 
an adenoma-to-carcinoma sequence. Thus, identifying the molecular aberrations at the 
premalignant adenoma stage may help to understand its malignant potential. HOXA9 
acts as an oncogene in the hematopoietic system. However, its role in the colonic adenoma 
is unknown. Therefore, the aim of this study was to assess the expression of HOXA9 in 
colonic adenoma tissue and its involvement in carcinogenesis. HOXA9 mRNA levels are 
increased in colonic adenomas compared to location matched healthy tissue (p<0.0001). 
It inhibits cellular migration, which appears to be mediated by decreased PAK activity. 
This is the first mechanistic study into the effect of HOXA9 in a premalignant solid 
lesion. Strikingly, the pro-oncogenic phenotype of HOXA9 alteration in hematologic 







malignancies was also found in this study as HOXA9 stimulates cell growth. This 
phenotype appears to be mediated through increased IGF1, FLT3, PTGS2, p-4E-BP1, 
and p-ERK1/2. In conclusion, HOXA9 has a pro-oncogenic effect on colon adenomas 
suggesting its importance for the adenoma-to-carcinoma sequence in particular and 
solid tumors in general.
Part 3: predicting the development of  malignant lesions
If the progression of BE to EAC could be predicted, therapies are available to effectively 
and safely remove the BE. Therefore, good screening and surveillance have the potential 
to reduce the disease burden for EAC significantly. 
In Chapter 5, vitamin D receptor (VDR) polymorphisms were studied in relation to 
esophageal VDR expression and EAC risk. Epidemiological studies indicate that vitamin 
D exerts a protective effect on the development of various solid cancers. However, 
concerns have been raised regarding the potential deleterious role of high vitamin D 
levels in the development of EAC. This study investigated genetic variation in the VDR 
in relation to its expression and risk of BE and EAC. VDR mRNA expression was higher 
in BE compared with squamous epithelium. VDR protein was located in the nucleus in 
BE. A rs1989969T/rs2238135G haplotype was identified in the 5´regulatory region of 
the VDR gene. It was associated with an approximately halved risk of RE, BE, and EAC. 
Analysis of a replication cohort was done for BE which confirmed this. Rs1989969T 
causes a GATA-1 transcription factor binding site to appear. The signaling of GATA-1, 
which is regarded as a negative transcriptional regulator, could explain the findings for 
rs1989969. Rs2238135G was associated with a significantly reduced VDR expression 
in BE, for the rs1989969T allele a trend in reduced VDR expression was observed. We 
identified a VDR haplotype associated with reduced esophageal VDR expression and a 
reduced incidence of RE, BE, and EAC. This VDR haplotype could be useful to identify 
individuals who benefit most from vitamin D chemoprevention. 
In Chapter 6.1, immunohistochemical (IHC) biomarkers for risk stratification of 
neoplastic progression in BE were systematically reviewed and a meta-analysis was 
performed. The low incidence of EAC in BE patients reinforces the need for risk 
stratification tools to make BE surveillance more effective. Therefore, we have undertaken 
a systematic review and meta-analysis of published studies on IHC biomarkers in BE 
to determine the value of IHC biomarkers as neoplastic predictors in BE surveillance. 
Sixteen different IHC biomarkers were studied in 36 studies. These studies included 
425 cases and 1835 controls. A meta-analysis was performed for p53, aspergillus oryzae 
lectin (AOL), Cyclin A, Cyclin D and alpha-methylacyl-CoA racemase. Aberrant p53 
expression was significantly associated with an increased risk of neoplastic progression 
with an odds ratio of 3.18 (95% CI 1.68 to 6.03). This association was confirmed for 
both non-dysplastic BE and BE with low-grade dysplasia. Another promising biomarker 
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to predict neoplastic progression was AOL, with an odds ratio of 3.04 (95% CI 2.05 
to 4.49). Use of p53 IHC staining may improve risk stratification in BE surveillance. 
In Chapter 6.2, we responded to a review and meta-analysis in which studies were 
included without follow-up. However, these studies were used to assess the value of p53 
as a predictor of malignant progression. 
In Chapter 7, DNA integrity was investigated as a biomarker in pancreatic cyst fluid. Iden-
tification of pancreatic cysts with malignant potential is important to prevent pancreatic 
cancer development. Integrity of cell free DNA (cfDNA) has been described as a tumor 
biomarker, but its potential for pancreatic cancer is unclear. Normal apoptotic cells release 
uniformly truncated DNA, whereas malignant tissues release long fragments of cell free 
DNA. We measured 247 base pair and 115 base pair DNA fragments of ALU repeats by 
qPCR in serum from healthy controls and pancreatic cancer patients, and in cyst fluid from 
pancreatic cyst patients. No differences in total cfDNA (ALU115) and cfDNA integrity 
(ALU247/115) were observed between sera from healthy controls (n=19) and pancreatic 
cancer patients (n=19). Though elevated as compared to serum, no differences in cfDNA 
were found in cyst fluid between high risk (n=10) and low risk (n=20) cyst patients.
In Chapter 8, we studied and optimized BE models. The formation of a Barrett’s 
esophagus is difficult to monitor directly under clinical conditions. Thereto, experimental 
models have been published to investigate the mechanisms of BE pathogenesis. However, 
either the technical possibilities or the translational relevance of these models, or both, 
is limited. We analyzed Gene Expression Omnibus 2R (GEO2R) databases to establish 
a clinical BE molecular profile. Subsequently, by using keratin markers we were able 
to optimize an in vitro BE model based upon two immortalized squamous esophageal 
epithelial cell lines. Finally, we compared this optimized model and a rat surgical model 
to the BE molecular profile. The in vitro model reflected 73% of the human BE profile 
while the in vivo model reflected about 45% of the human BE profile. 
Part 4: Palliative treatment of  esophageal cancer
Despite increasing understanding of the biology of GI-tract cancer and efforts to prevent 
cancer the incidence of EAC has been rising in Western countries. Despite efforts to 
detect cancer at an early stage almost half of patients are diagnosed with esophageal 
cancer at a palliative stage. However, it was unclear whether palliative chemotherapy or 
targeted therapies are effective for esophageal cancer. 
In Chapter 9, palliative chemotherapy and targeted therapies for esophageal and GEJ 
cancer were systematically reviewed and a meta-analysis was performed. Chemotherapy 
and targeted therapies are increasingly used with a palliative intent to control tumor 
growth, improve quality of life, and prolong survival. Our aim was to assess the effects 
of cytostatic or targeted therapy for treating esophageal or GEJ cancer with palliative 







intent. We identified 41 randomized controlled trials with 11,853 participants for 
inclusion in the review. We demonstrated an increase in overall survival in favor of 
the arm with an additional cytostatic or targeted therapeutic agent with a hazard ratio 
(HR) of 0.75 (95% confidence interval (CI) 0.68 to 0.84, high-quality evidence). The 
median increased survival time was one month. We found a benefit in overall survival in 
favor of the group receiving palliative chemotherapy and/or targeted therapy compared 
to best supportive care (HR 0.81, 95% CI 0.71 to 0.92, high-quality evidence). 
Subcomparisons including only people receiving second-line therapies, chemotherapies, 
targeted therapies, EAC, and SCC all showed a similar benefit. Palliative chemotherapy 
and/or targeted therapy increased the frequency of grade 3 or higher treatment-related 
toxicity. However, treatment-related deaths did not occur more frequently. Quality of 
life often improved in the arm with an additional agent. In conclusion, people who 
receive more chemotherapeutic or targeted therapeutic agents have an increased overall 
survival compared to people who receive less, which appeared not to negatively affect 
quality of life in the studies included. 
In Chapter 10, the cost-effectiveness of giving cetuximab for advanced esophageal SCC, 
based on phase II trial data was investigated. In patients with advanced esophageal SCC, 
the addition of cetuximab to a cisplatin-5-fluorouracil first-line palliative chemotherapy 
regimen appears to improve survival. However, it results in an incremental cost-
effectiveness ratio of €252,203 per quality-adjusted life-year. Sensitivity analysis shows 
that there is a chance of less than 0.001 to one that the incremental cost-effectiveness 
ratio will be less than a maximum willingness to pay threshold of €40,000 per quality-
adjusted life-year. Adding cetuximab to palliative regimen for advanced esophageal 
SCC is not cost-effective. Cost-effectiveness analyses using outcome data from early 
clinical trials (i.c. a phase II trial) enable pharmaceutical companies and policy makers 
to gain early insight into whether a new drug meets the current eligibility standards for 
reimbursement and thereby potential admittance for use in regular clinical practice.
In Part 5, we summarize and discuss of the main findings of this thesis in Chapter 11. 
Chapter 12 contains a Dutch summary and Chapter 13 consists out of the appendices.
General discussion
In this general discussion we aim to discuss the research firstly per chapter and secondly 
for the thesis as a whole.
Part 1: HOX genes in (pre)malignant lesions of  the gastrointestinal tract
Metaplasia is a common occurrence in the adult gut. Metaplasia acquires a caudal 
phenotype in a rostral location, and can thus be termed a homeotic transformation. 
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Therefore, positional misspecification is likely involved. Regulation of rostral-caudal 
patterning of specialized tissue in embryology and adulthood is largely dependent on the 
concerted action of two evolutionary highly conserved gene systems, the Caudal-related 
Homeobox (CDX) transcription factor gene family and the genes of the Homeobox 
(HOX) cluster. The function of CDX genes has been studied extensively (1, 2), but HOX 
genes less so in this context. HOX genes are linked to homeotic transformations and 
neoplasia (3, 4). 
Chapter 2 HOXA13 in etiology and oncogenic potential of Barrett’s esophagus
We have shown the adult gut is characterized by HOX collinearity. In Barrett’s 
esophagus (BE) HOX expression is reprogrammed to a distal pattern in stem and 
differentiated cells, with prominent HOXA13 expression. HOXA13 expression appears 
mediated by lncRNA HOTTIP. Strikingly, HOXA13 was found to be expressed in the 
gastroesophageal junction. In a model of the cell of origin of BE, HOXA13 confers a 
relative competitive advantage and a pro-oncogenic expression profile. In BE models, 
HOXA13 downregulates the epidermal differentiation complex, increases proliferation, 
and conveys phenotypical aspects of BE. Recently, the thesis that the origin of BE lies 
in the GEJ has been gaining influence. Jiang et al. describes p63+KRT5+KRT7+ basal 
cells at the murine GEJ as the origin of a BE-like lesion while a similar human basal cell 
population has also been postulated (5). In apparent agreement, murine Lgr5+ gastric 
cardia stem cells that lineage trace into an early BE-like lesion have been described (6). 
Furthermore, Wang et al. show that a discrete population of embryonic cells persists in 
adult mice and humans at the SCJ. These embryonic cells migrate upwards and form 
a BE-like lesion upon epithelial damage (7). We could learn more from attempting to 
lineage trace HOXA13-positive cells to a Barrett’s (like) lesion in a mouse, rat, or naturally 
occurring human model. On the other hand, in esophagogastrostomy patients BE can 
reoccur, proving the involvement of the GEJ is not a prerequisite for the development 
of BE (8). In the latter study submucosal glands of the esophagus were hypothesized 
to contain a BE progenitor cell. This fits with our analysis of single cell RNA-seq data 
published by Owen et al. (44). This analysis shows a small population of HOXA13-positive 
cells is present in the normal squamous esophagus of BE patients. These HOXA13-
positive cells express designated esophageal submucosal gland markers indicating that 
the small population of HOXA13-positive cells resides in the submucosal glands in the 
physiological adult human squamous esophageal epithelium. The submucosal gland as 
a potential origin of Barrett’s esophagus is also supported by the canine study of Gillen 
et al. (9). In this study, squamous barriers were employed to prevent proximal migration 
of columnar epithelium from the stomach to the mucosal defect. Despite this barrier, 
the regenerated epithelium was frequently found to have a columnar morphology. In 
another canine study performed by Li et al. (10) acid suppression resulted in squamous 
islands to appear in the epithelium that would otherwise regenerate in a columnar 







morphology. This aligns with the potential cell of origin model, which we illustrated 
in figure 6E. This model of cellular identity in BE suggest that HOXA13 expressing 
clones in the GEJ may outcompete clones with another positional identity, depending 
on local circumstances. When taking into account our finding of HOXA13-positive 
gastric inlet patches this is in line with an hypothesis postulated in 1923 by Nicholson 
(11) whom proposes that local differentiation of existing pluripotent cells might result 
in heterotopic gastric mucosa. He describes this as an example of a heteromorphosis. 
A later hypothesis, which aligns with this thought, states that esophageal submucosal 
glands might become clogged, form cysts and finally erupt to form a gastric inlet patch. 
As gastric IM expresses HOXA13, positive cells at the GEJ are insufficient explanation 
for the existence of gastric IM in other parts of the stomach. One explanation might 
be the presence, potentially dependent on developmental stage, of multiple positional 
misspecified microcompartments, or single HOXA13-positive cells, throughout the 
GI tract. Our immunohistochemical data of mouse glandular stomach tissue shows 
dispersed HOXA13-positive cells in the stomach of that species. It would be interesting 
to attempt a more detailed characterization of cell populations based on their positional 
identity in various parts of the GI tract. This study could have translational meaning if 
areas of the gut were chosen with a higher cancer risk. Additionally, studying junction 
areas between gut segments would be interesting, for instance the junction between the 
proximal and distal ileum, regardless of the presence of a Meckels diverticulum. The 4 
cells depicted on the Y-Z plane in figure 6E represent multiple potential cells of origin 
of metaplasia or rather heteromorphosis of the GI tract. The thought that multiple 
potential origins might exist is recognized in the literature (12). While evidence for 
some of the, above mentioned, previously proposed model appears convincing, none 
of these proposed model can explain the formation of BE in all circumstances. Often, 
these models do not clearly show a link between the proposed cell of origin and the 
characteristic morphology of BE. Additionally, some models depend almost solely on 
evidence from mouse models, while the mouse models have translational issues in the 
case of BE research. 
Only one previous study has been published on HOX genes in BE. In this study 
HOXA cluster gene expression partially contrasts with our findings (13). Employing 
the Affymetrix HuGene-1_0-st-v1 microarray, this study describes HOXA6 and 11 
upregulation in BE. Our study, however, documents modest upregulation of HOXA11 
but strong HOXA13 expression in BE. This discrepancy may be due to the highly 
homologous nature of different HOX genes, thus probe-based array technology might 
not be ideally suited. We do confirm their qPCR based findings regarding HOXB6 and 
7, show their involvement in IM of the stomach, and the establishment of deregulation 
in the deep stem cell in BE. A second study shows a germline variant of Msh homeobox 
1 (MSX1) in a Dutch family with clustering of BE and EAC. Loss of the wild type allele 
was found in the tumor DNAs of the affected family members. This shows the relevance 
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of homeobox genes in this disease characterized by homeotic transformation (14). 
Germline variants of HOXA13 have been described, but not for BE or EAC. The pro-
oncogenic characteristics of HOXA13 have been shown before in different contexts (15). 
Decreased wild type Hoxa13 protein in the early developing chick caudal endoderm 
results in endoderm-specific atresia of the hindgut rostral to the cloaca in line with our 
observations (16). In pancreatic cancer, it was shown by in vitro assays that HOTTIP 
alterations affected stemness, tumorigenesis, and levels of stemness related genes LIN28, 
NANOG, OCT4, and SOX2 in pancreatic stem cells. HOTTIP regulating HOXA13 
levels is supported by our data. Knowing this, our observation that HOXA13 increased 
NANOG signaling in the definitive endoderm context is in line with these findings. The 
present study highlights the importance of regional patterning by HOX genes in gut 
epithelium. It would be interesting to perform functional experiments with other HOX 
paralogues potentially involved in BE pathophysiology, candidates would be HOXA10, 
11, B13, and C10. GATA genes could be of interest as well as GATA4 was found to be 
involved in establishing jejunal versus ileal identity (17). 
Chapter 3 Forced expression of HOXA13 confers oncogenic hallmarks to esophageal keratinocytes 
The disease etiology of esophageal squamous cell carcinoma (ESCC) is still poorly 
understood. HOXA13 appears to be involved as it is overexpressed, high protein 
expression is correlated with a shorter median survival time, and poor clinicopathological 
characteristics in ESCC (18-20). How these effects are exerted was largely unclear. We 
overexpressed HOXA13 in a squamous esophageal cell line and performed functional 
experiments. Our data show that HOXA13 expression confers oncogenic hallmarks to 
esophageal keratinocytes. It provides proliferation advantage to keratinocytes, reduces 
sensitivity to chemical agents, regulates MHC class I expression and differentiation 
status, and promotes cellular migration. The down-regulated expressions of HLA class 
I in ESCC is correlated with tumor grade and lymph node status (60). Our results 
indicate that HOXA13 expression may drive the immune escape of neoantigen-bearing 
transformed keratinocytes. Whether the correlation found is an effect of immune 
escape, which allows for local and distant spread is unclear. Possibly, more advanced 
malignancies have had more and longer immune pressure under which the clones 
with more immune escape are selected for. In this second case immune escape also 
appears to provide the lesion with more opportunity to progress, but might not be 
obligatory for this process. Reduced HLA class I expression makes cells vulnerable for 
NK cell-mediated killing. Multiple malignancies are associated with reduced HLA 
class I expression (21). It appears likely that there is an optimum in the amount of 
HLA class I expression which provides immune escape but avoids NK cell-mediated 
killing. In a series of 143 cases of ESCC 36.4% were found to be negative for HLA 
class I by immunohistochemistry (60). This indicates that NK-escape mechanisms 
are more complex that just expression levels of this complex (22). In this study, we 







found HOXA13 overexpression did not significantly affect 2D growth of esophageal 
cells as measured with an MTT assay, although a trend towards increased cell pool 
growth was seen. However, when assessed as growth in spheroid form the HOXA13 
overexpression does increase the size of spheroids. This points to the importance of 
being conservative in interpreting the results of a single model system. Our model shows 
HOXA13 overexpression makes these cells more resistant to paclitaxel-induced death. 
Previously, high HOXA13 expression was found to be associated with inferior tumor 
regression grade and poor overall survival in 131 ESCC patients treated with cisplatin 
and paclitaxel. Caution is warranted while interpreting this result as the HOXA13 
expression was assessed by immunohistochemistry (32). HOXB7 has recently also been 
found to mediate Cisplatin resistance in ESCC by mechanism of DNA damage repair 
(23).
Chapter 4 HOXA9 mediates and marks premalignant compartment size expansion in colonic 
adenomas
Our data shows HOXA9 mRNA levels are increased in colonic adenomas compared to 
location matched healthy tissue. HOXA9 inhibits cellular migration, which appears to 
be mediated by decreased PAK activity. This is the first mechanistic study into the effect 
of HOXA9 in a premalignant solid lesion. Strikingly, the pro-oncogenic phenotype of 
HOXA9 alterations in hematologic malignancies was also found in this study as HOXA9 
stimulates cell growth. This phenotype appears to be mediated through increased IGF1, 
FLT3, PTGS2, p-4E-BP1, and p-ERK1/2. Forced HOXA9 expression upregulates IGF1 
and FLT3, this stimulates cell proliferation and inhibit apoptosis (24, 25). PTGS2 
was overexpressed while it is known that inhibition of PTGS2 with nonsteroidal anti-
inflammatory drugs (NSAIDs), decreases the risk of developing adenomas and colorectal 
carcinoma (CRC) (26-29). CYBB was downregulated in line with CYBB levels in 
stomach cancer (30). It is known that HOXA10, which is closely related to HOXA9, 
represses CYBB during inflammation (31). CYBB forms reactive oxygen species, which 
are important for death receptor activation and induction of apoptosis (32-34). CYBB 
downregulation is in line with an increase in cell pool size. In acute myeloid leukemia, 
HOXA9 upregulates FGF2, in contrast to our findings (35). Increased WNT5a is in 
line with its levels in colonic adenomas and CRC (36). In CRC it acts as a tumor 
suppressor and attenuates EMT (37). Wnt genes have, apart from a role in oncogenesis, 
also a role in cell fate and patterning during embryogenesis, related to the role of HOX 
genes (38). Interestingly, Wnt5a and its target gene CCND2, both upregulated, have 
a higher expression in the proximal colon versus the distal colon (39). HOXA9 might 
thus affect positional identity of the colon epithelium. A recent study reports HOXA9 
overexpression in CRC with a similar fold change, their main message is that HOXA9 
expression level in CRC is associated with the presence of lymph node metastasis (40). 
These authors could not find a relation to overall survival (OS) which might have been 
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due to differences in tumor stage, as the population studied contained mostly stage 2 
and 3 patients. In contrast to our findings, HOXA9 knock down with a siRNA, after 
which cells were counted after 24 and 48 hours, did not reveal a statistically significant 
effect of HOXA9 expression on the cell pool size. Based on data from the publically 
available cBioPortal database, gene amplification appears not to be involved in the 
increase of HOXA9 levels in CRC. Assuming that gene amplifications are rare in colonic 
adenomas, this is in line with our findings. Another study reports overexpression of 
nucleus accumbens-associated protein 1 confers chemotherapy resistance via HOXA9 in 
CRC cells (41). Bhatlekar et al. found HOXA4 and HOXA9 are up-regulated in CRC 
stem cells (42). Their data indicate that HOXA9 aids self-renewal and overpopulation of 
stem cells in CRC. Multiple reports have described HOXA9 as a pro-oncogenic factor 
in other solid tumors (43-50). HOXA9 was not differentially methylated in CRC (51). 
Recently, it was suggested that hsa_circ_0079662, as a covalently closed circular RNA, 
might be a hsa-mir-324-5p sponge, and it was suggested that HOXA9 is a direct target of 
has-mir-324-5p. High HOXA9 contributed to chemotherapy drug oxaliplatin resistance 
in CRC through the TNF‐α pathway in human colon cancer (52). 
Part 2: predicting the development of  malignant lesions
The incidence of esophageal adeno carcinoma (EAC) rises to date despite screening 
and surveillance strategies. BE provides the opportunity to prevent the development 
of BE related adenocarcinoma (AC) by stratifying BE patients at risk for neoplastic 
progression.
Chapter 5 Vitamin D receptor polymorphisms are associated with reduced esophageal vitamin D 
receptor expression and reduced esophageal adenocarcinoma risk
Vitamin D supplementation is likely to convey a level of chemo preventive properties 
against oncogenic transformation in for instance the colon. However, there is evidence 
some BE patients are likely to respond negatively to vitamin D. We identified a 
rs1989969 T/rs2238135 G haplotype in the 5´regulatory region of the vitamin D receptor 
(VDR) gene which is associated with a lower VDR expression and an approximately 
halved risk of reflux esophagitis, BE, and EAC. Since then, a nonrandomized inter-
ventional study assessed the effects of vitamin D supplementation in BE. However, 
despite improved vitamin D status with supplementation, no significant alterations in 
gene expression profiles were noted (53). This is in contrast with other cancers (54, 55). 
Obviously, a longer duration or higher dose of supplementation might be able to show an 
effect. Evidence from epidemiological studies mimicking true long-life effects of vitamin 
D are required to endorse the idea of personalized recommendations for vitamin D 
supplementation. A recent study concluded that population-wide screening for vitamin 
D deficiency and supplementation should not be recommended for cancer prevention 
(56). For CRC they found an odds ratio of 0.92 (95% confidence interval 0.76 to 1.10) 







per 25 nmol/l increase in genetically determined 25(OH)D concentrations. This might 
indicate a modest protective effect with respect to CRC. A Mendelian randomization 
study found no association with BE or EAC and low genetically estimated 25(OH)D 
concentrations (57). Unfortunately, both alleles studied in our paper were not included. 
Chapter 6 Use of immunohistochemical biomarkers as independent predictor of neoplastic progres-
sion in Barrett’s oesophagus surveillance: a systematic review and meta-analysis
We show that sixteen immunohistochemical (IHC) biomarkers in BE surveillance 
have been studied. Aberrant p53 expression is the most studied IHC biomarker and 
associated with a significantly increased risk to develop high grade dysplasia (HGD) or 
EAC, this association was independent of the presence of low grade dysplasia (LGD). 
There has been a case published in which a p53 mutation was shown to have occurred 
in cardia type metaplastic tissue, thus whithout goblet cells (58). Therefore, although 
difficult to study, it is plausible that p53 is a more biologically relevant identifier of 
progression risk compared to the better known risk factor, being the presence of goblet 
cells. More consensus is required amongst pathologists concerning the appropriate 
staining method, definition, and interpretation of aberrant p53 expression. Our research 
group previously reported in a large case-control study that aberrant p53 expression was 
significantly associated with an increased risk of neoplastic progression in BE. However, 
only 40% of the BE patients with progression to HGD or EAC showed an aberrant 
p53 protein expression during surveillance, indicating that additional biomarkers are 
needed (59). One such promising biomarker is aspergillus oryzae lectin. Other types 
of biomarkers could also contribute, an interesting protocol has appeared investigating 
DNA methylation, histone modification, chromatin remodeling, micro and non-
coding RNAs of all types for their value of predicting progression from BE to EAC 
(60). A recently published study claimed to have investigated the predictive ability 
of IHC biomarkers (61). However, they reported on samples obtained either from a 
resection specimen or from cases and controls without follow-up. Therefore, based on 
their current dataset, their current conclusion, i.e. that p53 overexpression predicts 
malignant progression, is not justified (62). This case shows the fragility of the current 
peer review system and emphasizes caution is warranted when interpreting conclusions 
from published studies. Although routine p53 and other IHC biomarker staining incur 
higher costs, application of a panel of biomarkers has the potential to reduce the overall 
costs of BE surveillance. Patients at low-risk of neoplastic progression, i.e. the majority 
of the patients with LGD, might be followed-up less intensively. A recent study into 
the “Use of Ancillary Stains in the Diagnosis of BE and BE-associated LGD and HGD 
on p53 IHC” concluded: “Although p53 is a promising marker for identifying high-
risk BE patients, it is not recommended for routine use at present; additional studies 
are needed to address questions regarding case selection, interpretation, integration 
with morphologic diagnosis, and impact on clinical outcome” (63). Recently, Snyder 
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et al. (64) performed a separate meta-analyses of case-control and cohort studies. They 
expressed the results of their meta-analysis as RRs instead of ORs, deeming this easier 
to compare with other studies of risk stratification techniques. Their results are similar 
to ours as they found an OR of 4 to 6 for case-control studies and a RR of 14 to 17 
for cohort studies. They align with the BSG recommendations, as do we, and state that 
IHC assessment of p53 in BE should be investigated as a risk stratification tool (65). 
The next step would be a randomized controlled trial (RCT) with implementation of 
p53 IHC in a risk stratification tool which also contains simple clinical parameters 
(66), randomizing patients to both ways of surveillance, i.e. with or without the risk 
stratification tool. Knowledge on rs1989969 and rs2238135 as well as knowledge from 
genome wide association studies could contribute to this risk stratification tool. After 
sufficient time, clinical, social, and economic outcomes of the intervention could be 
investigated. Such a trial would provide the level of evidence and practical tools necessary 
for widespread implementation. 
Chapter 7 DNA integrity as biomarker in pancreatic cyst fluid
The integrity of cell free DNA (cfDNA) was studied in serum of patients with pancreatic 
carcinoma and controls. We did not observe any significant differences between patients 
and controls. Previous studies were also unable to show cfDNA fragments in serum 
from pancreatic cancer patient. We analyzed pancreatic cyst fluids and found DNA 
levels are roughly a thousand fold higher in cyst fluids. However, no differences in 
DNA integrity were found in high versus low risk cysts. As tumor size determines the 
amount of necrosis, the size of these premalignant lesions might be to small for this 
assay. Extrapolating these findings to BE it seems unlikely that integrity of cfDNA in 
serum will provide enough information for risk stratification. However, a recent study 
has shown loss of heterozygosity analysis in cfDNA could be valuable in BE (67). 
Receiver operating characteristic curve analysis showed an area under the curve of 0.79. 
Interestingly, loss of heterozygosity (LOH) frequencies near or within TP53 showed a 
trend towards discrimination between BE and dysplastic samples. This shows interesting 
markers from LOH studies and IHC studies could be valuable in the other modality 
as well. IHC markers have the advantage that they can be performed and analyzed 
concurrently with the histological analysis. LOH markers, if multiple would be found 
with additional predictive power, could (partially) obviate the need for surveillance 
endoscopies. A question that remains is if other lesions would not interfere with this 
analysis as surveillance is often done in an older patient group. Analysis of biopsy 
specimens is not subject to this uncertainty.







Chapter 8 Molecular profile of Barrett’s esophagus and gastroesophageal reflux disease in the 
development of translational physiological and pharmacological studies
The process of conversion of normal squamous epithelium towards Barrett’s metaplasia 
is difficult to monitor directly under clinical conditions. This has impeded the progress 
of the field. Thus, over the years, several experimental models have been published 
to investigate the mechanisms of BE pathogenesis. However, either the technical 
possibilities or the translational relevance of these models, or both, is limited. Animal 
models generally do not offer a good representation of the situation in humans. The 
most used animal models are variants of surgical rat models, which are physiologically 
not similar to humans and require long time periods to develop BE and EAC. The 
benefit of the rat models is the relative ease of performing surgical procedures on rats 
when compared to mice. Mice have the advantage of being much easier to manipulate 
genetically. Anatomic differences, i.e. the presence of a squamous forestomach, the lack 
of esophageal submucosal glands, and the fact that BE or reflux does not occur naturally 
in rodents are also important drawbacks. Higher order animals such as dogs, pigs, and 
primates do offer a similar anatomy compared to humans. However, the development of 
BE takes very long, due to their size these animals are difficult to handle in a laboratory 
setting, and, in general, the use mammals for these experiments is increasingly seen as 
unethical which is especially the case for higher animals (68). Our data appears to suggest 
that results from animal models should be interpreted carefully when clinical translation 
is sought (36). The observation that the proximal expression border of HOXA13 and the 
presence of HOXA13-positive cells at the upper GI tract were made in both mice and 
humans, leads us to conclude that mice appear a reasonable in vivo model for studies 
into the role of HOX genes in the GI tract. Given the downsides of these animal models, 
the development of suitable in vitro models is important. Downsides of these models 
are that these cell lines are usually transformed in order to keep the cells continuously 
growing. These models lack a microenvironment consisting out of immune cells and 
stroma and the factors that these cell secrete (69). We found 57% similarity between 
the human biopsies and the EPC2 cell model and only 26% similarity for the Het-1A 
model. This indicates a lot of heterogeneity, which is surprising as both cell lines are 
derived from the squamous esophageal epithelium. Combining both expression profiles 
resulted in 73% overlap with the human biopsy data. This indicates the importance of 
combining multiple model systems to study a research question especially in the setting 
of BE. The development of organotypic culture models using spheroids or differentiated 
embryonic stem cells could offer model systems that offer possibilities not met with 
either cell line models or animal models alone. These models would offer a higher 
throughput and less ethical constraints compared to animal models. While offering 
more of the microenvironment lacking in the cell line models. Finally, given the debate 
on the cell of origin of Barrett’s esophagus, the choice for the correct model system is 
not always straightforward. Whether a cell line, organotypic culture, or animal model is 
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chosen adequately does not only depend on the research question but will often depend 
on the theoretical framework with which the researcher(s) are aligned.
Part 3: Palliative treatment of  esophageal cancer
Almost half of patients with esophageal cancer present themselves in the palliative stage. 
This emphasizes the need for screening and surveillance. However, this is hindered by 
the high incidence of BE, the low progression rates from BE to EAC, and the invasive 
procedures necessary for surveillance. As these obstacles will not be easy to overcome, 
improvement of palliative therapy remains an important research goal.
Chapter 9 Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal 
junction cancer
We have shown that people who receive more chemotherapeutic or targeted therapeutic 
agents live longer compared to people who receive less therapy or best supportive care. 
There was no evidence that palliative chemotherapy and targeted therapy decreased 
quality of life (QoL). A triplet regimen was superior to a doublet regimen with regard 
to OS in participants receiving first-line chemotherapy for advanced or metastatic 
esophagogastric carcinoma (70). This is in line with our findings. We did not expect 
to find an increase in toxicities without a decrease in QoL. Interestingly, two included 
RCTs reported better QoL despite more toxicity in the experimental arm versus the 
control arm (71, 72). A previous study also found no clear association between QoL 
and toxicity (73). Differences in risk factors, gene expression, and tumor biology exist 
between AC of the stomach, the GE-junction, and EAC (74, 75). In this chapter, we 
found a difference in efficacy of chemotherapy and targeted therapy between gastro 
esophageal (GE)-junction AC and gastric AC. We found a similar trend in a previous 
study (76). This study used individual participant data from four studies (72, 77-79). 
They concluded that response rates in participants were 44.1% in esophageal, 41.1% in 
GE-junction, and 35.6% in gastric cancer. We included studies awaiting classification 
to update our search but did not include these in the analysis. There were several studies 
eligible for inclusion identified amongst these studies. Most study targeted therapeutic 
agents and most of them present results in line with our current main conclusion. In 
this chapter, we used the GRADE approach to assess the quality of the evidence per 
analysis. Recently, a new tool has been developed to quantify the magnitude of clinical 
benefit of anti-cancer therapies. This tool is called the European Society for Medical 
Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (80). The aim of this 
tool is to assign grades to trials based on adequate power for a relevant magnitude of 
clinical benefit. The magnitude of effect in our main analysis is only one month of 
additional OS for the addition of one agent. The mean OS of this patient group is about 
half a year. Even though we have shown a statistically significant difference in survival, 
the magnitude of effect is limited. Future use of the ESMO-MCBS might reflect this 







more accurately compared to the reporting of mean OS times as we did in this chapter. 
It also emphasizes the search for adequate therapies is long from over. Recently a quality 
of life study was performed in Denmark by interviewing patients with oesophageal 
cancer. Their conclusions are that the main issues these patients face are loneliness and 
lack of continuity. Patients feel banished from their normal lives (81). This provides 
an important perspective on the palliative phase of treatment for esophageal cancer 
patients. 
Chapter 10 Cost-effectiveness of cetuximab for advanced esophageal squamous cell carcinoma
We found the mean incremental cost effectiveness ratio (ICER) of adding cetuximab to 
a cisplatin-5-fluorouracil (5-FU) first-line palliative regimen for esophageal squamous 
cell carcinoma (ESCC), is €252,203 per QALY gained. By performing a Monte Carlo 
analysis, we showed that there is a chance of less than 0.001 that the ICER could be 
below a threshold of acceptable cost per QALY of €40,000. The ICER that we calculated 
is in line with previous findings for squamous cell carcinoma of the head and neck 
(SCCHN), which has similarities in etiology and pathology, (82-84) and for KRAS 
wild type CRC (85, 86). A study showed prolonged OS (49.0 vs. 29.3 months) for 
patients who receive cetuximab added to the comparator radiotherapy for locally 
advanced SCCHN (87). A recent cost-effectiveness study based on that dataset showed 
probabilities between 0.76 and 0.87 of radiotherapy with cetuximab being cost-effective 
compared to radiotherapy alone (88). This indicates that for other indications, where 
more clinical effectiveness is observed, cetuximab does seem to be cost effective. Cost-
effectiveness studies after phase II trials have been previously performed (89). This 
method has been discussed related to the topic of streamlining the drug development 
process and early estimation and decision making for reimbursement in 2001 and 
2003 (90, 91). However, no widespread adaptation has taken place. The reluctance 
of adopting these methodologies by pharmaceutical companies can be explained, as 
they know decision makers do not base themselves solely on cost effectiveness studies. 
Many see these studies as controversial and using them to make policy decisions is 
seen as a form of health care rationing. These concerns have affected policy makers in 
the United States to such an extent that the Senate Finance Committee in writing The 
Patient Protection and Affordable Care Act of 2010 forbade the newly created Patient-
Centered Outcomes Research Institute from using “dollars-per-quality adjusted life year 
(or similar measure that discounts the value of a life because of an individual’s disability) 
as a threshold to establish what type of health care is cost effective or recommended”. 
However controversial, cost effectiveness will have to be assessed as unlimited access to 
all therapies cannot be afforded by society. The NICE is the most progressive institute in 
the world in this regard and their policies could serve as an example for other societies. 
Classic chemotherapeutic agents do not appear to be less effective for esophageal cancer 
compared to targeted agents and do not seem to reduce QoL. As targeted agents are 
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more expensive, chemotherapeutic agents are probably the more sensible class to use 
from a cost effectiveness perspective. A higher level of clinical benefit might reasonably 
be expected for targeted agents before choosing to prescribe them.
Discussion
Considering the data on VDR polymorphisms, weight loss in palliative esophageal cancer 
patients may cause fast liberation of excessive amounts of vitamin D from its adipose 
storage. This might contribute to the dismal prognosis of these patients and stresses the 
need for optimal nutritional support. Endocrine regulation of HOX genes is known. The 
regulatory region of HOXA10 is known to contain a vitamin D responsive element and 
has been shown to be regulated by 1,25-dihydroxycholecalciferol in both hematopoietic 
and endometrial cells (92). Hoxa13 is not regulated by the sex steroids in vivo (92-
94). Estrogens regulate expression of the 5′ Hox paralogs such as Hoxa9, Hoxa10, and 
Hoxa11, in posterior and distal domains of the body axis (94). Additionally, retinoic 
acid treatment also up-regulates expression of Hoxa1 and Hoxb1 (95). 
In our studies of HOXA13 EPC2-hTERT and HET-1A were used alongside each other 
for bile and acid exposure experiments. In these experiments a one time exposure of a 
bile and acid mixture was chosen, the results of Chapter 8 suggest that 6 consecutive 
days of exposure results in an effect, or a larger effect, with regard to the expression of 
keratins, which alters in parallel with their expression in BE. For our overexpression 
experiments with esophageal keratinocytes EPC2-hTERT was chosen, as this cell line 
was immortalized using hTERT whereas the HET-1A cell line was immortalized using 
the SV40 large T antigen. The latter was deemed more likely to influence the biology 
of the cell line. The results of Chapter 8 show that exposure of a bile and acid mixture 
induced a gene expression profile in EPC2-hTERT which was more comparable with 
a BE gene signature, when compared with the gene expression profile that was induced 
in HET-1A. 
There are several reports of HOXA13 expression as a predictor of survival in gastric 
cancer (96), HCC (97-99), ESCC (44, 100), and pancreatic cancer (101). Outside 
of the GI tract similar results have been found in cervical cancer, ovarian cancer, and 
prostate carcinoma (102-104). Some of these studies are based on IHC which we deem 
not to be very trustworthy. To our knowledge, it has never been shown that HOXA13 is 
also useful as a predictor of survival in EAC. We inspected the data available through the 
cBioPortal database (www.cbioportal.org) in 2015. Using a linear regression approach no 
correlation was seen between mRNA expression of HOXA13 and survival. Repeating the 
analysis using the online tool on the website provided the same results. Experimentally, 
we performed RNA-ISH for HOXA13 on roughly 20 patients. No correlation between 
HOXA13 and survival was found for the whole group. However, there was a correlation 







if all patients surviving beyond 1.5 years were excluded under the assumption these 
patients were not palliative, leaving only ten patients in the analysis. We were able to 
confirm previous reports that HOXA13 expression in HCC negatively correlates with 
survival as we found a correlation in the same direction with recurrence of HCC in 
a patient group that was resected with curative intention (98, 99). This opens up the 
possibility for improving the determination of the prognosis of individual patients based 
on their HOXA13 status, amongst other factors.
In pancreatic ductal AC (PDAC) HOTTIP was shown to be one of the most significantly 
upregulated lncRNAs. Knockdown of HOXA13 showed HOTTIP promoted 
proliferation, invasion, and resistance to gemcitabine of PDAC cells, at least partly 
through regulating HOXA13. High HOXA13 expression was correlated with lymph 
node metastasis, poor histological differentiation, and decreased OS in PDAC patients. 
(101). Inhibition of HOTTIP potentiated the antitumor effects of gemcitabine in vitro 
and in vivo. In CRC overexpression of nucleus accumbens-associated protein 1 confers 
chemotherapy resistance via HOXA9 (41). This shows HOX gene signaling appears 
capable of interfering with chemotherapy response. A role for HOTTIP and HOXA13 
as markers for chemotherapy resistance in EAC is conceivable. As both gemcitabine and 
5-FU are nucleoside analogues, response to 5-FU might also be predicted by HOXA13 
and HOTTIP status in the esophagus. This could be very relevant, particularly for ESCC 
chemotherapy where 5-FU is one of the primary building blocks of therapy. In ESCC 
HOXA13 was shown to have tumorigenic effects in vivo. A significant association between 
HOXA13 and OS was described (44). Co-expression of HOXA13 with annexinA2 and 
SOD was shown to be significantly associated with poor prognosis (105). In gastric 
cancer HOXA1, 4, 10, and 13, and HOXB7, and HOXC10 were previously found to be 
overexpressed. HOXA13 overexpression was associated with T stage, M stage, histologic 
differentiation, relapse, and a decrease in OS (106). Concerning HOXB7, in vitro studies 
have shown overexpression of HOXB7 in gastric cancer cells promotes cellular invasion 
and migration, and inhibited apoptosis, whereas silencing HOXB7 showed the opposite 
effects (107, 108). 
Although we have shown a decrease in methylation and an increase in hydroxymethylation 
of the HOXA9 promotor in BE versus squamous esophagus, in CRC HOXA9 was not 
found to be differentially methylated (51). 
In conclusion, this thesis has shown HOX genes play an important role in (pre)malignant 
lesions of the-GI tract. Vitamin D receptor polymorphisms and p53 IHC can predict 
progression from BE to EAC. Palliative chemotherapy and targeted therapies increase 
the survival of esophageal and gastroesophageal junction cancer patients and cost 
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Het doel van dit proefschrift is het verkrijgen van een beter begrip van de etiologie, de 
detectie en de palliatieve behandeling van gastro-intestinale kanker. Dit proefschrift is 
onderverdeeld in vijf delen. 
Deel 1 bevat de introductie van het proefschrift. In Hoofdstuk 1.1 wordt gastro-
intestinale kanker beschreven. Deze ziekte kenmerkt zich door een toename van celgroei 
in het maagdarmkanaal gecombineerd met het vermogen van deze cellen om zich te 
verspreiden buiten het weefsel van origine. Gastro-intestinale kanker is één van de 
hoofdoorzaken van morbiditeit en mortaliteit in de wereld. Slokdarmkanker is de op 
zeven na meest voorkomende vorm van kanker ter wereld. In 2012 werden ongeveer 
398.000 patiënten gediagnosticeerd met plaveiselcelkanker van de slokdarm en 52.000 
met kliercelkanker van de slokdarm. Barrett slokdarm is een intestinale metaplasie 
van de slokdarm en deze aandoening kan aanleiding geven tot kliercelkanker van de 
slokdarm. In de afgelopen decennia hebben ontwikkelde landen een toename gezien 
van de incidentie van zowel Barrett slokdarm als kliercelkanker van de slokdarm. Deze 
toename van Barrett slokdarm wordt toegeschreven aan de toenemende prevalentie van 
obesitas. Met een diepgaand inzicht in de mechanismen van het ontstaan van kanker 
in het maagdarmkanaal zijn preventie, detectie en behandeling effectiever toe te passen. 
Hoofdstuk 1.2 beschrijft de opbouw van dit proefschrift. 
In Deel 2 van dit proefschrift proberen we het fundamentele inzicht in het mechanisme 
van het ontstaan van kanker in het maagdarmkanaal te vergroten. Hiervoor bestuderen 
we HOX-gen signalering in (pre)maligne laesies van het maagdarmkanaal. In Deel 3 
bestuderen we verschillende methodieken om te voorspellen welke afwijkingen maligne 
zullen ontaarden en bestuderen we modellen om het mechanisme van het ontstaan van 
kanker te kunnen onderzoeken. In Deel 4 bestuderen we de palliatieve behandeling van 
slokdarmkanker. Deel 5 bestaat uit de samenvatting, discussie en appendices. Hieronder 
zullen we dit proefschrift in het Nederlands samenvatten.
Deel 2: HOX-genen in (pre)maligne laesies van het maagdarmkanaal
In Hoofdstuk 2 werd de rol van HOXA13 in de vorming van Barrett slokdarm en 
uiteindelijk de ontaarding in kliercelkanker van de slokdarm bestudeerd. De biologie 
van Barrett slokdarm en meer algemeen, metaplasie in het maagdarmkanaal, is namelijk 
nog slechts beperkt bekend. We hebben aangetoond dat de volgorde waarin HOX-genen 
gecodeerd zijn in het genoom parallel loopt met de volgorde waarin zij tot expressie komen 
langs de lengteas van het maagdarmkanaal van volwassen mensen en muizen. Bij Barrett 
slokdarm, kliercelkanker van de slokdarm, heterotopie van de slokdarm, metaplasie van 
de maag, en het Meckels divertikel werd een HOX-gen expressiepatroon waargenomen 
dat vergelijkbaar is met het patroon dat werd waargenomen in de dikke darm en afwijkt 
van het patroon dat kenmerkend is voor de proximale gastro-intestinale tractus. Dit 
patroon wordt gekenmerkt door een sterk verhoogde expressie van HOXA13 ten opzichte 
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van het omliggende weefsel. In de embryologisch ontwikkeling komt HOXA13 distaal in 
orgaansystemen tot expressie. RNA In situ hybridisatie van HOXA13 toont aan dat het 
voornamelijk epitheliaal tot expressie komt en bevestigde de expressie van HOXA13 in 
Barrett slokdarm en de overige metaplastische en heterotopische weefsels van het bovenste 
gedeelte van het maagdarmkanaal. Deze afwijkende expressie van HOX-genen wordt 
ook gezien in de stamcellen van zowel fysiologisch slijmvlies van het maagdarmkanaal 
alsook in Barrett slokdarm. Dit wijst op betrokkenheid van zowel epitheliale stamcellen 
als HOX-genen tijdens de ontwikkeling van metaplasie. Bevindingen afkomstig van een 
muismodel lieten zien dat Hoxa13 expressie in de fysiologie nauwkeurig gereguleerd is. 
De proximale expressiegrens bevond zich tussen het proximale en het distale colon van 
de muis. Deze expressiegrens is op dezelfde locatie aanwezig bij mensen. Opvallend was 
dat het expressiepatroon van HOX-genen werd onderbroken door expressie van HOXA13 
in de proximale gastro-intestinale tractus. HOXA13 werd gedetecteerd net distaal van de 
overgang van de slokdarm naar de maag en in submucosale klieren van de slokdarm in 
volwassen mensen, en in het klierepitheel van de maag van volwassen muizen. In humane 
foetussen werd veel HOXA13-expressie gezien in de proximale maag en minder expressie 
in de slokdarm en de distale maag. In een model van maagdarmkanaal voorlopercellen, 
zijnde definitief endoderm, verminderde HOXA13 de differentiatie efficiëntie van 
deze cellen. Een remmende werking op de differentiatie zou kunnen verklaren hoe 
een HOXA13-positieve klonale populatie van cellen sneller zou kunnen uitgroeien na 
beschadiging van het slokdarmslijmvlies in vergelijking met andere klonale populaties van 
cellen aanwezig op dezelfde locatie. Kunstmatige toename van HOXA13-expressie zorgt 
voor toename van expressie van genen in de Nanog-signaaltransductieroute. Dit verklaart 
het mechanisme waarop HOXA13 de differentiatie remt. In de definitieve endoderm 
cellen bevordert HOXA13 de expressie van genen kenmerkend voor distaal darmepitheel 
en stimuleert het de groeisnelheid van de celpopulatie. HOXA13 onderdrukt de expressie 
van het epidermale differentiatiecomplex dat tot expressie komt vanaf chromosoom 
1q21.3 en stimuleert de groeisnelheid van de celpopulatie in een Barrett celmodel en 
een celmodel van plaveiselcellen van de slokdarm. In een levend model waarin door 
cellijnen een slijmvlies kan worden gevormd, produceert een normale Barrett cellijn 
zowel kliertype slijmvlies met kolomvormige cellen alsook plaveiseltype slijmvlies. 
Dit laat zien dat een enkele cellijn zich kan ontwikkelen in twee typen epitheel. Het 
uitschakelen van HOXA13 in deze cellijn zorgt voor een afname van de ontwikkeling van 
het kliertype epitheel. Concluderend, kennis van de expressie en functie van HOXA13 
geeft informatie over de oorsprong, het uiterlijk en het risico op progressie van Barrett 
slokdarm tot slokdarmkanker.
In Hoofdstuk 3 werden de oncogene kenmerken bestudeerd die HOXA13 geeft aan 
slokdarmkeratinocyten. HOXA13 werd verhoogd tot expressie gebracht in een celmodel 
van plaveiselcellen van de slokdarm. Genexpressieprofielen werden vervaardigd en 








bleek oncogene kenmerken over te brengen op de cellen. HOXA13 zorgt voor een 
toename van de groeisnelheid van de celpopulatie, het vermindert de gevoeligheid voor 
chemische stoffen, het vermindert de expressie van het MHC-klasse 1 eiwitcomplex, het 
verandert de mate van differentiatie en het bevordert de migratie van cellen. Deze data 
wijst op een cruciale rol van HOXA13 in een vroeg stadium van maligne ontaarding van 
het plaveiselcelepitheel van de slokdarm.
In Hoofdstuk 4 wordt de verhoogde expressie van HOXA9 in poliepen van het colon 
bestudeerd. Kanker van de dikke darm komt relatief vaak voor. Deze kanker ontstaat 
uit een poliep. Meer kennis over afwijkingen in signaaloverdrachtketens die in cellen 
van deze poliepen plaatsvinden, kan helpen bij het begrijpen welke personen risico 
lopen op het krijgen van dikke darmkanker. HOXA9 gedraagt zich als een oncogen in 
het bloedvormend orgaansysteem. De expressie van HOXA9 in poliepen van de dikke 
darm en de rol van HOXA9 bij de ontwikkeling van poliepen naar dikke darmkanker 
waren tot op heden onbekend en werden bestudeerd. HOXA9-expressie blijkt hoger te 
zijn in poliepen van de dikke darm in vergelijking met naastgelegen controle slijmvlies. 
HOXA9 vermindert celmigratie wat wordt gemedieerd door PAK. HOXA9 bevordert 
de groei van de celpopulatie in parallel met de rol van HOXA9 in het bloedvormend 
orgaansysteem. Hierbij vindt een toename plaats van expressie van de genen IGF1, 
FLT3, PTGS2, p-4E-BP1 en p-ERK1/2. Concluderend kunnen we stellen dat HOXA9 
verhoogd tot expressie komt in poliepen van de dikke darm en groei van de celpopulatie 
stimuleert voordat maligne ontaarding optreedt.
Deel 3: Voorspellen van de ontwikkeling van kwaadaardige laesies
Als de progressie van Barrett slokdarm naar slokdarm kliercelkanker kon worden 
voorspeld, zouden we weten welke patiënten actiever moeten worden vervolgd of zelfs 
preventief moeten worden behandeld. Een goede voorspelling van het risico op maligne 
ontaarding van Barrett slokdarm heeft daarom het potentieel om de ziektelast door 
slokdarm kliercelkanker aanzienlijk te verminderen.
In Hoofdstuk 5 werden vitamine D-receptor (VDR) polymorfismen bestudeerd 
in relatie tot VDR expressie in de slokdarm. Daarnaast werd de invloed van VDR 
polymorfismen op het risico op het ontwikkelen van slokdarm kliercelkanker onderzocht. 
Epidemiologische studies hebben laten zien dat vitamine D de kans vermindert dat 
bepaalde vormen van kanker zich ontwikkelen. Er zijn echter aanwijzingen dat hoge 
vitamine D-spiegels bij de ontwikkeling van slokdarm kliercelkanker een schadelijke 
rol kunnen spelen. Deze studie onderzocht genetische variatie in het gen dat codeert 
voor de VDR in relatie tot de expressie van dit gen en het risico op de ontwikkeling van 
Barrett slokdarm en slokdarm kliercelkanker. VDR-mRNA kwam verhoogd tot expressie 
in Barrett slokdarm slijmvlies in vergelijking met plaveiselcel slijmvlies van de slokdarm. 
VDR-eiwit bevond zich in de kern van de cellen in het Barrett slokdarm slijmvlies. 
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Een rs1989969 T/rs2238135 G haplotype werd geïdentificeerd in het 5’ regulerende 
gebied van het VDR gen. Dit haplotype ging gepaard met een ongeveer tweevoudige 
verlaging van het risico op de aanwezigheid van reflux oesofagitis, een Barrett slokdarm 
en/of slokdarm kliercelkanker. Analyse van een replicatiecohort werd uitgevoerd voor 
Barrett slokdarm en deze analyse bevestigde bovenstaande bevinding. Het Rs1989969 T 
polymorfisme zorgt voor het verschijnen van een GATA-1 transcriptiefactor 
bindingsplaats. GATA-1 wordt beschouwd als een negatieve regulator van transcriptie. 
Dit zou de bevindingen voor rs1989969 kunnen verklaren. Het allel Rs2238135 G was 
geassocieerd met een significant verminderde VDR-expressie in Barrett slokdarm. Voor 
het allel rs1989969 T werd een trend in verminderde VDR-expressie waargenomen. 
Concluderend identificeerden we een VDR-haplotype dat is geassocieerd met een 
verminderde VDR-expressie in de slokdarm en een verminderde incidentie van reflux 
oesofagitis, Barrett slokdarm en slokdarm kliercelkanker. Dit VDR-haplotype kan 
nuttig zijn om individuen te identificeren die het meest baat hebben bij vitamine 
D-chemopreventie.
In Hoofdstuk 6.1 werden immunohistochemische biomarkers voor risicostratificatie 
van maligne progressie in de Barrett slokdarm systematisch beoordeeld en werd een meta-
analyse uitgevoerd. De kans is klein dat een patiënt slokdarm kliercelkanker ontwikkelt 
vanuit een Barrett slokdarm. Daarom is er behoefte aan methoden om het risico op 
het ontstaan van slokdarm kliercelkanker te kunnen bepalen. Zo zouden patiënten met 
een hoger risico vaker kunnen worden gesurveilleerd en patiënten met een lager risico 
minder vaak. Daarom hebben we een systematische review en meta-analyse uitgevoerd 
van gepubliceerde studies over immunohistochemische biomarkers die zijn toegepast 
op biopten uit Barrett slokdarm slijmvlies. 16 verschillende immunohistochemische 
biomarkers uit 36 studies werden bestudeerd. Deze studies bevatten samen 425 patiënten 
die slokdarm kliercelkanker of hooggradige dysplasie ontwikkelden en 1835 patiënten 
waarbij geen sprake was van maligne progressie. Meta-analyses werden uitgevoerd 
voor de immunohistochemische biomarkers p53, aspergillus oryzae lectine, cycline A, 
cycline D en alfa-methylacyl-CoA racemase. Afwijkende p53-expressie was significant 
geassocieerd met een verhoogd risico op het ontwikkelen van kanker. Deze associatie 
werd bevestigd voor zowel niet-dysplastische Barrett slokdarm als Barrett slokdarm met 
laaggradige dysplasie. Een andere veelbelovende biomarker om maligne ontaarding te 
voorspellen was aspergillus oryzae lectine. Gebruik van p53 immunohistochemische 
kleuring, op biopten afgenomen tijdens controle endoscopische onderzoeken, kan de 
risico-inschatting op maligne ontaarding van een Barrett slokdarm verbeteren. 
In Hoofdstuk 6.2 hebben we een reactie geschreven op een review en meta-analyse 
waarin tevens studies werden geïncludeerd zonder follow-up. Deze studies werden wel 
gebruikt om uitspraken te doen over de waarde van p53 als een voorspeller van maligne 








In Hoofdstuk 7 werd DNA-integriteit afkomstig uit cysten van de alvleesklier 
onderzocht als mogelijke voorspeller van het risico op maligne ontaarding van deze 
cysten. Identificatie van cysten in de alvleesklier met een hoge kans om zich te 
ontwikkelen tot kanker is belangrijk om de cysten goed te kunnen vervolgen en op tijd 
in te grijpen indien noodzakelijk. Cellen die op een gecontroleerde manier sterven geven 
uniform in stukken gebroken DNA af, terwijl bij sterfte van kwaadaardige cellen langere 
fragmenten DNA vrijkomen. We maten de hoeveelheid van beide DNA-fragmenten 
van ALU-herhalingen, één van 247 en één van 115 basenparen. Dit deden we door 
middel van een kwantitatieve polymerase kettingreactie. Als monsters gebruikten we het 
serum van gezonde controle patiënten en patiënten met alvleesklierkanker, en vloeistof 
uit cysten in de alvleesklier. Er werden geen verschillen in totaal cel vrij DNA (ALU115) 
of cel vrij DNA integriteit (ALU247 / 115) waargenomen tussen sera van gezonde 
controle patiënten (n=19) en patiënten met alvleesklierkanker (n=19). De hoeveelheid 
cel vrij DNA was verhoogd in cysten van de alvleesklier. Er werd geen verschil in cel vrij 
DNA-integriteit gevonden tussen vloeistof uit cysten van de alvleesklier van hoog risico 
patiënten (n=10) versus laag risico patiënten (n=20). Concluderend blijkt uit onze data 
dat cel vrij DNA-integriteit in cyste vloeistof niet geschikt is om laag versus hoog risico 
cystes van elkaar te onderscheiden.
In Hoofdstuk 8 hebben we Barrett slokdarm modellen bestudeerd en geoptimaliseerd. 
De reden hiervoor was dat de formatie van een Barrett slokdarm moeilijk is om direct 
te monitoren in de kliniek. Derhalve zijn er experimentele modellen gepubliceerd om 
het mechanisme van Barrett slokdarm pathogenese te bestuderen. Echter zijn ofwel de 
technische mogelijkheden ofwel de vertaalbaarheid naar de klinische situatie, of beiden, 
beperkt. We hebben genexpressie gegevensbestanden geanalyseerd om een klinisch 
moleculair profiel van Barrett slokdarm vast te kunnen stellen. Vervolgens hebben we 
een in vivo model geoptimaliseerd door gebruik te maken van keratine markers. Dit 
model was gebaseerd op twee geïmmortaliseerde cellijnen. Tenslotte hebben we dit 
model en het chirurgische ratten model vergeleken met het klinische moleculaire profiel 
van Barrett slokdarm. Het in vitro model kwam overeen met 73% van het moleculaire 
profiel terwijl het in vivo model overeenkwam met 45% van het moleculaire profiel. 
Deel 4: Palliatieve behandeling van slokdarmkanker
Ondanks het toenemende begrip van de biologie van kanker van het maagdarmkanaal 
en de inspanningen om kanker te voorkomen, is de incidentie van slokdarm 
kliercelkanker in westerse landen toegenomen over de laatste decennia. Ondanks 
pogingen om kanker in een vroeg stadium op te sporen, wordt bijna de helft van 
de patiënten met slokdarmkanker in een palliatieve fase gediagnosticeerd. Het was 
voorheen echter onduidelijk of chemotherapieën of gerichte therapieën effectief zijn 
tegen slokdarmkanker in de palliatieve fase.
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In Hoofdstuk 9 werden palliatieve chemotherapie en gerichte therapieën voor 
slokdarmkanker en kanker van de overgang van slokdarm naar maag systematisch 
beoordeeld en werd een meta-analyse uitgevoerd. Chemotherapie en gerichte therapieën 
worden steeds meer gebruikt met als doel controle van de tumorgroei, verbetering van de 
kwaliteit van leven en verlenging van het leven. We identificeerden 41 gerandomiseerde 
studies met controlegroepen. Deze studies bevatten samen 11.853 deelnemers die konden 
worden opgenomen in de beoordeling. We hebben een toename van de totale overleving 
aangetoond ten gunste van de arm met een extra cytostatisch of gericht therapeutisch 
agens met een risicofactor ratio van 0,75 (95% betrouwbaarheidsinterval 0,68 tot 0,84). 
De mediaan van de toename in overlevingstijd was één maand. We vonden een voordeel 
in overleving ten gunste van de groep die palliatieve chemotherapie en/of gerichte 
therapie kreeg in vergelijking met patiënten die ondersteunende zorg ontvingen met een 
risicofactor ratio van 0,81 (95% betrouwbaarheidsinterval 0,71 tot 0,92). Deel analyses, 
die alleen deelnemers bevatten die tweedelijnstherapieën, chemotherapie, of gerichte 
therapieën kregen, en slokdarm kliercelkanker ofwel plaveiselcel kanker van de slokdarm 
hadden, lieten allemaal een vergelijkbaar voordeel zien. Palliatieve chemotherapie en/
of gerichte therapie verhoogden de frequentie van aan de behandeling gerelateerde 
toxiciteit van graad drie of hoger. Aan de behandeling gerelateerde sterfgevallen 
kwamen echter niet vaker voor. De kwaliteit van leven was vaak verbeterd in de arm 
met een extra middel. Concluderend, deelnemers die meer chemotherapeutische of 
gerichte therapeutische middelen krijgen, hebben een verhoogde algehele overleving in 
vergelijking met deelnemers die minder middelen krijgen, wat de kwaliteit van leven van 
de deelnemers in de opgenomen studies niet negatief leek te beïnvloeden.
In Hoofdstuk 10 werd de kosteneffectiviteit van het geven van cetuximab voor gevorderde 
plaveiselcel kanker van de slokdarm onderzocht op basis van een fase twee studie. Bij 
patiënten met gevorderde plaveiselcel kanker van de slokdarm lijkt de toevoeging van 
cetuximab aan een cisplatinum 5-fluorouracil, eerstelijns, palliatief chemotherapie 
regime de overleving te verbeteren. Het resulteert echter in een incrementele 
kosteneffectiviteitsratio van € 252.203 per voor kwaliteit gecorrigeerd levensjaar. Een 
gevoeligheidsanalyse toont aan dat er een kans van minder dan 0,001 op 1 is dat de 
incrementele kosteneffectiviteitsratio voor deze therapie lager zal zijn dan € 40.000 per voor 
kwaliteit gecorrigeerd levensjaar. Dit is de maximale drempel voor betalingsbereidheid 
per voor kwaliteit gecorrigeerd levensjaar. Het is dus niet kosteneffectief om cetuximab 
toe te voegen aan een palliatieve behandeling voor gevorderde plaveiselcel kanker van de 
slokdarm. Uit deze studie blijkt dat kosteneffectiviteitsanalyses met behulp van gegevens 
uit fase twee studies farmaceutische bedrijven en beleidsmakers in staat kunnen stellen 
om vroegtijdig inzicht te krijgen in de vraag of een nieuw geneesmiddel voldoet aan 
de huidige standaarden voor vergoeding. Daarmee kan worden afgewogen of er een 









In Deel 5 vatten we de belangrijkste bevindingen van dit proefschrift samen. We 
bediscussiëren deze bevindingen in Hoofdstuk 11. Hoofdstuk 12 bevat een Nederlandse 
samenvatting. Hoofdstuk 13 bestaat uit meerdere bijlagen, te weten, het dankwoord, 













Dit proefschrift was niet tot stand gekomen zonder de hulp, inzet en aanmoedigingen 
van vele collega’s, vrienden en familie. De volgende personen wil ik graag in het bijzonder 
bedanken. 
Als eerst dank ik graag de promotiecommissie voor hun bereidheid zitting te nemen in 
de commissie. 
Prof. Peppelenbosch, beste Maikel, dank voor de steun en de vrijheid het onderzoek deels 
zelf vorm te geven. Dit heeft ertoe geleid dat we veel interessante experimenten hebben 
kunnen doen, waarvan sommigen met interessante en onverwachte resultaten. Onze 
gesprekken ontaarden vaak in politieke, biologische, geografische en geschiedkundige 
chaos maar bleven altijd van hoog niveau.
Prof. Bruno, beste Marco jij hebt me vaak voorgehouden: “in der beschränkung zeigt 
sich erst der meister”. Ondanks dat het me niet altijd gelukt is, heeft de geachte hieraan 
me wel geholpen om de projecten af te ronden. Veel dank voor je steun en begeleiding. 
Prof. Spaander, beste Manon, dank voor je bereidheid om mij aan te nemen op een 
grotendeels experimenteel onderzoek. Je hebt me altijd welkom laten voelen in de 
klinische wereld en in de persoonlijke sfeer. Hieruit ontstond een unieke kans om het 
basale onderzoek te combineren met mooie klinische projecten. 
Dr. Fuhler, beste Gwenny, dank voor je kritische blik en je passie voor basaal onderzoek. 
Je hebt me altijd scherp weten te houden en ik ben blij dat ik veel van je heb mogen 
leren. 
Anouk, jij bent begonnen met het HOX onderzoek op de afdeling. Het heeft mij een 
aantal jaar van de straat gehouden en ik denk dat er nog veel meer in het vat zit. Zeker 
met betrekking tot het hoofdstuk over vitamine D receptor polymorfismen heb je zeer 
genereus het stokje overgedragen. 
Prof. Kuipers, beste Ernst, dank voor jouw tomeloze energie en enthousiasme bij 
de initiatie van drie hoofdstukken. Het was een voorrecht om elkaar in Chicago te 
ontmoeten tijdens het James W. Freston conference on metaplasia.
Kateryna, I take off my hat to you for completing some of our complex projects. You 
are conscientious and have your priorities straight. It has been inspiring to see your 
development into a great researcher and I am very happy you are my paranimf. 
Auke, dank voor al je hulp en natuurlijk de samenwerking bij de begeleiding van 
studenten. Onze discussies over het onderzoek hielden mij scherp en ik heb daarnaast 
veel praktische kennis van je mogen overnemen. Je hebt me welkom geheten op het 
laboratorium en gevormd als onderzoeker. 
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Ron, te pas en te onpas liep ik bij je binnen, jij kan diep en kritisch op de theorie 
ingaan en hebt tegelijkertijd veel praktische kennis. Dank dat je bleef aandringen op het 
gebruik van een tweede techniek die mij naar Dresden heeft gebracht. Met jouw hulp 
heb ik mooie experimenten kunnen uitvoeren onder andere resulterend in de cover van 
dit boekje.
Prof van der Laan, beste Luc, dank dat je me de ruimte hebt gegeven om door te bouwen 
op het werk van Anouk en voor al jouw hulp om verder te komen.
André en Jun, dank, specifiek voor de hulp met de verwerking van de RNA-Seq data.
Hanneke, dank dat je alle biobanken bijhoudt, ik heb een paar keer juweeltjes van 
materiaal kunnen gebruiken. 
Leendert, Katharina, Arjun, Jan, Bas, Sjoerd en Fiebo, de Barrett club stafleden, dank 
voor jullie feedback en inspiratie. Leendert en Katharina daarnaast ook veel dank voor 
jullie hulp bij het verkrijgen van weefsels en het doen van kleuringen.
Dr. Ewout Steyerberg, dr. Ate van der Gaast en dr. Ron Mathijssen dank voor de hulp 
en het advies omtrent de Cochrane review over palliatieve chemotherapie voor slokdarm 
en slokdarm maag overgangs tumoren.
Sophie, het was erg leuk om te kunnen samenwerken en van elkaar te leren, zeker omdat 
ons studieonderwerp klinisch toepasbaar is. Veel succes in Utrecht. 
Dr. Cros, dr. Lévy, dr. Ruszniewski, dr. van den Berg, dr. Jenster en dr. Braat thank 
you for collaborating on the pancreatic cyst and cancer biomarker study. A special thanks 
for dr. Utomo, it was really nice to work together!
Dr. Lorenzen and prof. dr. Lordick, your generosity to share the individual patient 
data on cetuximab from the phase II trial enabled us to publish a paper with firm 
conclusions. Ook dr. Polinder erg bedankt voor de hulp bij het schrijven van deze 
paper. Het was erg leerzaam voor mij.
Dr. Uitterlinden, dr. Pourfarzad, dr. Tilanus, dr. Rygiel, dr. Moons, dr. Arp en dr. 
Krishnadath, veel dank van al jullie bijdragen aan de paper over vitamine D receptor 
polymorfismen.
Prof. dr. Wayne Phillips and dr. Nick Clemons, thank you so much, firstly for the 
discussions we had in San Diego, later in Chicago and finally for performing the 
experiments in your unique model system. You are an inspiration and your willingness 
to collaborate is an example for all. 
Dr. Stadler and dr. Sandoval-Guzmán, many thanks for the opportunity to work 
with the Hoxa13-GFP mouse model. Our collaboration has provided us with beautiful 








Hui and Timo, your assays have provided relevant insight into the biology of HOXA9 
and HOXA13. Thank you for all your efforts and interesting discussions.
Rodrigo, your unstoppable energy was of great benefit to our projects but also an 
inspiration to be around. Knowing your positive nature, I am sure you will overcome 
all obstacles on your path and have a bright future. Karla, thank you for all your efforts 
with regard to the HOXA9 project. It was a very positive experience.
Marcin, it has been a lot of fun to collaborate with such an ambitious researcher. The 
cell models we made have already resulted in a nice paper. I am looking forward to 
celebrating with you in The Netherlands, Poland or beyond. I hope to continue our 
collaboration in the future. 
Marieke, zonder al jouw hulp met de FACS zouden we onze cel modellen niet kunnen 
hebben gemaakt. 
Max, Pamela, Ilona, Mark, Chantal, Pieter, Eveline, Wendy, Eva en Jessica, zonder 
jullie hulp was het onderzoek nooit zover gekomen en was het bovendien een stuk 
minder leuk geweest. Heel veel dank voor al jullie inzet en doorzettingsvermogen. 
Leonie, het is niet verantwoord om je ooit met pensioen te laten gaan. 
Rik, Wesley, Martijn, Evelyn, Michelle en Elmer, team BOTM, ik was laat van de 
partij maar kwam binnen in een rijdende trein die bestond uit borrels, strandweekenden, 
kamperen, themafeesten en meer. Dank voor een heerlijke tijd!
Lauke, wat heb ik genoten van onze discussies, juist omdat we het meestal niet met 
elkaar eens zijn. Ik hoop dat we dit in de toekomst kunnen voortzetten, al dan niet 
tijdens het vissen.
Michiel, prachtig hoe jij mensen op het verkeerde been kan zetten met een subtiele 
vorm van sarcasme. Jouw ambitieuze verbouwing heeft me geïnspireerd en Ivonne is je 
dankbaar.
Wen, Hakim, Thijmen, Suk-Yi, Yingying, Pauline, Adriaan, Sunrui, Rachid, 
Ruby, Jorke, my roommates, I had a wonderful time with you and a special thanks for 
organizing the goodbye lunch! 
Maren, Evelien en Daphne, het was geweldig om de “diamond edition” skireis met 
jullie te mogen organiseren. 
Alle collega’s van het lab: Hugo, Andrea, Thomas, Wanlue, Kan, Hester, Juan, Pengyu, 
Xiaolei, Eelke, Wenhui, Wenshi, Estella, Yijin, Lei, Yuebang, Guoying, Xinying, 
Paula, Aniek, Frances, Jan, Anthonie, Kim, Shanta, Gertine, Martine, Buddy, Petra, 
Lisanne, Patrick, Jaap, Marcel, Abdullah, Sonja, Lucia, Jun, Noe, Diahann, Qiuwei, 
Henk, Monique V, Yik, Floris, Emmeloes, Renee, Cynthia, Ishaku, Monique de B, 
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Wouter, Sunrui, Aafke, Yingying, Janine, Gijs, Gülce, Yunlong, Meng, Shan, Yiaye, 
Pengyu, Buyun, Xmin, Changbo, Shaojun, Ling, Qin, Shaoshi, Kelly, Sharida, 
Effie, Cindy, Amy, Natascha en alle collega’s van het vroegere dak en uit de kliniek: 
Heng, Anniek, Willem Pieter, Margo, Anne, Esmee, Jihan, Shannon, Ingrid, Joany, 
Mitchell, Wim, Alison, Gwen, Raoel, Lisanne, Priscilla, Eline, Kostas, Loes, Evelien, 
Louisa, Jorn, Stella, Rosalie, Kasper, Renske, Arjan, Carlijn, Marjolein, Fanny, 
Sophia, Alison, Ad, Jerome, Angela, en Vera, wat hebben jullie de afgelopen jaren tot 
een onvergetelijke tijd gemaakt!
Prof. van der Woude dank voor het in mij gestelde vertrouwen door mij op te leiden tot 
Maag-, Darm-, en Leverarts. Dr. Schrama, en alle collega arts-assistenten en medisch 
specialisten van het Franciscus Gasthuis en Vlietland, mede door het hechte team heb 
ik een mooie tijd gehad. Tegen mijn verwachting in waren de nefrologie stage en de 
coronatijd hoogtepunten van mijn vooropleiding.
Veel dank aan Dencher, Sluijsmans, Franzen, van der Kemp, Rauwé, van Lidth 
de Jeude, Spaan, Vink, en Siregar, mijn clubgenoten. Van der Torren, het is al even 
geleden dat je me het goede voorbeeld gaf. Hafkamp, ik hoop je weer te zien. Van 
Dullemen, het was bijzonder om samen op het lab te kunnen werken, ik ben blij dat jij 
druk bent met je opleiding en gezin en trots dat je mijn paranimf wil zijn! Bij jullie is 
het echt thuiskomen, ik vraag me af of we ooit helemaal op zullen groeien en een deel 
van mij hoopt van niet. 
Marja, dank je voor al je initiatieven. Ik hoop er ook in de toekomst deelgenoot van te 
zijn, ga zo door. Eduard, ik hoop dat je op je ouders gaat lijken. 
Jan, Gijs en Sander wat een mooie wedstrijden, tochten en hachelijke momenten 
hebben we meegemaakt. Ik hoop dat er nog vele zullen volgen. 
Navin, Marthe, Nadia, LIMSCers, wat mooi om te zien hoe jullie gegroeid zijn in jullie 
carrières en wat fijn om contact te kunnen houden na ons geweldige avontuur.
Jack en Kate, mijn schoonouders, dank dat jullie me altijd hebben verwelkomd en in 
slechte tijden voor een slaapplaats en lekker eten hebben gezorgd.  
Theo en Cobie, mijn ouders, zonder jullie was ik nooit zover gekomen. Cobie, dank 
dat je altijd vertrouwen in me had en me hebt gesteund toen ik dat nodig had. Theo, we 
lijken meer op elkaar dan goed voor ons is. Dank voor al je hulp en in het bijzonder de 
laatste jaren, ik heb ontzettend veel van je geleerd. Cynthia en Simone, mijn zussen, ik 
ben ontzettend trots op jullie, hetgeen jullie nu al hebben bereikt en hoop dat ik in de 
toekomst meer rust kan vinden om jullie vaker te zien. Kevin, ik haal veel steun uit het 
feit dat we hetzelfde doormaken en hoop dat ook jij na jouw promotie meer tijd krijgt 
voor ontspanning. Lune, blijf vrolijk, niet te veel naar je ouders luisteren en ik ben ervan 








Fantastische Ivonne, mijn verloofde, jij hebt veel met mij te stellen gehad de afgelopen 
jaren. Initieel vooral omdat de cellen verzorgd moesten worden en jouw weekenden 
daarvan het slachtoffer werden. Vervolgens omdat we een paar jaar zijn gaan verbouwen. 
Je hebt mijn afwezigheid, vermoeidheid, stof en kabaal moeten verwerken. Door jouw 
eigen grenzeloze ambitie en het vertrouwen dat we samen altijd een weg zullen vinden, 
was het allemaal mogelijk. Dank je voor de ruimte die je me hebt gegeven. Wat hebben 
we het toch fijn samen. Ik hou van je en je weet dat je nooit van me af zult komen!
Chapter 13
418
List of  publications
1. Gurnani N, van Deurzen DF, Janmaat VT, van den Bekerom MP. Tenotomy or 
tenodesis for pathology of the long head of the biceps brachii: a systematic review 
and meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2016;24(12):3765-71.
2. Janmaat VT, Bruno MJ, Polinder S, Lorenzen S, Lordick F, Peppelenbosch MP, 
et al. Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell 
Carcinoma. PLoS One. 2016;11(4):e0153943.
3. Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, 
Peppelenbosch MP, et al. Palliative chemotherapy and targeted therapies for 
esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 
2017;11:CD004063.
4. Janmaat VT, Van De Winkel A, Peppelenbosch MP, Spaander MC, Uitterlinden 
AG, Pourfarzad F, et al. Vitamin D Receptor Polymorphisms Are Associated with 
Reduced Esophageal Vitamin D Receptor Expression and Reduced Esophageal 
Adenocarcinoma Risk. Mol Med. 2015;21:346-54.
5. Janmaat VT, van Olphen SH, Biermann KE, Looijenga LHJ, Bruno MB, Spaander 
MCW. Use of immunohistochemical biomarkers as independent predictor of 
neoplastic progression in Barrett’s oesophagus surveillance: A systematic review 
and meta-analysis. PLoS One. 2017;12(10):e0186305.
6. Utomo WK, Janmaat VT, Verhaar AP, Cros J, Levy P, Ruszniewski P, et al. DNA 
integrity as biomarker in pancreatic cyst fluid. Am J Cancer Res. 2016;6(8):1837-
41.
7. Janmaat VT, Kortekaas KE, Moerland TM, Vereijken MWC, Schoones JW, 
van Hylckama Vlieg A, et al. Research-Tutored Learning: An Effective Way for 
Students to Benefit Research by Critical Appraisal. Medical Science Educator. 
2013;23(2):269-77.
8. da Silva RA, Fuhler GM, Janmaat VT, da C Fernandes CJ, da Silva Feltran G, 
Oliveira FA, et al. HOXA cluster gene expression during osteoblast differentiation 
involves epigenetic control. Bone. 2019;125:74-86.
9. Janmaat VT, Liu H, da Silva RA, Wisse PHA, Spaander MCW, Ten Hagen TLM, 
et al. HOXA9 mediates and marks premalignant compartment size expansion in 
colonic adenomas. Carcinogenesis. 2019;40(12):1514-24.
10. Keijser WA, Handgraaf HJM, Isfordink LM, Janmaat VT, Vergroesen PA, Verkade 
J, et al. Development of a national medical leadership competency framework: the 
Dutch approach. BMC Med Educ. 2019;19(1):441.
11. Nesteruk K, Janmaat VT, Liu H, Ten Hagen TLM, Peppelenbosch MP, Fuhler 
GM. Forced expression of HOXA13 confers oncogenic hallmarks to esophageal 








12. Korbut E, Janmaat VT, Wierdak M, Hankus J, Wójcik D, Surmiak M, Magierowska 
K, et. al. Molecular profile of Barrett’s esophagus and gastroesophageal reflux 
disease in the development of translational physiological and pharmacological 
studies. Int J Mol Sci 2020;21:6436.
13. Janmaat VT, Nesteruk K, Spaander MCW, Verhaar AP, Yu B, Silva RA, Phillips 








31-03/04-04-2014 BROK course 1.5
27-02-2014 The Workshop on Microsoft Excel 2010: Advanced. 27-02-2014/ 
27-02-2014
0.4
25-03/27-05-2014 The course on Biomedical English Writing Course for MSc and 
PhD-students
1.3
14-01-2014 Scientific integrity course 0.3
15-10/29-10-2013 Workshops Systematic Literature Retrieval and EndNote. (Grade 
8.0)
2.0
30-06/ 02-07-2016 UEGW basic science course with travel grant 0.7
Oral presentations at attended conferences
20/21-03-2014 Overexpression of HOXA13 in Barrett’s esophagus is a potential 
mediator of its posterior phenotype.
Spring meeting of the Dutch Society for Gastroenterology 
(NVGE), Veldhoven, The Netherlands.
1.0
17/18-03-2016 HOX gene expression in Barrett’s esophagus resembles that of the 
colon, can be modulated by acid and bile exposure, and induces 
Barrett’s specific gene products. 
Day of the Molecular Medicine Postgraduate School, Rotterdam, 
The Netherlands.
1.0
17/18-03-2016 Palliative chemotherapy and targeted therapies for esophageal and 
gastroesophageal junction cancer.
Spring meeting of the Dutch Society for Gastroenterology 
(NVGE), Veldhoven, The Netherlands.
1.0
17/18-03-2016 Cost-effectiveness of Cetuximab for advanced esophageal squamous 
cell carcinoma. 
Spring meeting of the Dutch Society for Gastroenterology 
(NVGE), Veldhoven, The Netherlands.
1.0
21/24-04-2016 HOX Gene Expression in Barrett's Esophagus Resembles That of 
the Colon, Can Be Modulated by Acid and Bile Exposure, and 
Induces Barrett's Specific Gene Products.
Digestive Diseases Week, San Diego, USA.
1.0
15/19-10-2016 Palliative chemotherapy and targeted therapies for esophageal and 
gastroesophageal junction cancer.
United European Gastroenterology Week, Vienna, Austria.
1.0
20/24-10-2018 Barrett’s metaplasia originates from HOXA13-positive cells in the 
gastroesophageal junction.













Poster presentations at attended conferences
04/06-04-2014 Hoxa Cluster Expression along the Gastrointestinal Tract.
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18/22-10-2014 HOXA13 overexpression in Barrett’s esophagus is a potential 
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21/24-04-2016 Palliative Chemotherapy and Targeted Therapies for Esophageal 
and Gastroesophageal Junction Cancer.
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1.0
19/20-08-2016 HOX gene expression in Barrett’s esophagus resembles that of the 
colon, can be modulated by acid and bile exposure, and induces 
Barrett’s specific gene products.
James W. Freston conference on intestinal metaplasia, Chicago, 
USA.
1.0
07/11-10-2016 Immunohistochemical biomarkers for risk stratification of 
neoplastic progression in Barrett esophagus.
European Society for Medical Oncoloy, Copenhagen, Denmark
1.0
15/19-10-2016 HOX gene expression in Barrett's esophagus resembles that of the 
colon, can be modulated by acid and bile exposure, and induces 
Barrett's specific gene products.
United European Gastroenterology Week, Vienna, Austria.
1.0
28-10/01-11-2017 Gastric cardia glands manifest apparent broad differentiation 
potential, as evidenced by HOXA13 expression, implications for the 
origin of Barrett’s esophagus.
United European Gastroenterology Week, Barcelona, Spain. 
1.0
Attended conferences
2014 Daniel den Hoed symposium 0.4
2016 Sattelite symposium Amsterdam 1.0
2017 Spring meeting of the Dutch Society for Gastroenterology 
(NVGE), Veldhoven, The Netherlands.
0.5
Scientific awards and grants
2014 HOXA13 overexpression in Barrett’s esophagus is a potential 
mediator of its posterior phenotype.
United European Gastroenterology Week, Vienna, Austria, Poster 
of excellence.
2014 Dutch Society for Gastroenterology (NVGE) “Gastrostart” grant
2014 UEGW travel grant
2016 UEGW travel grant
2016 ESMO travel grant






2016 NVGE travel grant
2016 Erasmus Trustfonds travel grant
2016 Immunohistochemical biomarkers for risk stratification of 
neoplastic progression in Barrett esophagus.
European Society for Medical Oncoloy, Copenhagen, Denmark, 
best poster prize.
2016 HOX gene expression in Barrett's esophagus resembles that of the 
colon, can be modulated by acid and bile exposure, and induces 
Barrett's specific gene products.
United European Gastroenterology Week, Vienna, Austria, best 
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2016 HOX Gene Expression in Barrett's Esophagus Resembles That of 
the Colon, Can Be Modulated by Acid and Bile Exposure, and 
Induces Barrett's Specific Gene Products.
Digestive Diseases Week, San Diego, USA, Acknowledgement for 
achievements as a young researcher.
2017 Erasmus Trustfonds travel grant
2017 “Meer Kennis met Minder Dieren - module Maatschappelijke 
partners” grant
Seminars
2014-2018 Weekly MDL seminar program in experimental gastroenterology 
and hepatology (attending)
9.0
2014-2018 Weekly MDL seminar program in experimental gastroenterology 
and hepatology (presenting)
2.25
2014-2018 Weekly research group education (attending) 9.0
2014-2018 Weekly research group education (presenting) 9.0
2014-2018 Weekly Gastroenterology and Hepatology journal club 4.5
Teaching activities
2014 Chantal Govaart, 3rd year MLO student. 5.7
2015 Max van Dullemen, 4th year medical student. 2.1
2015 Pieter Wisse, 4th year medical student. 2.8
2015 Mark van der Lee, 2nd year HBO student. 2.8
2016 Ilona Edelijn, 2nd year HBO student. 3.6
2016 Eveline Zwalua, 2nd year HBO student. 3.6
2016 Wendy van Dam, 2nd year HBO student. 2.8
2017 Pamela Vasic, 2nd year HBO student. 3.2
2017 Eva Zielhuis, 3rd year Biomedical Sciences student. 4.4
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